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Abstract 
Dual specificity phosphatase 1 (DUSP1) limits the expression of pro-inflammatory gene 
products by dephosphorylating and inactivating mitogen-activated protein kinases 
(MAPKs), in particular p38 MAPK and cJun N-terminal kinase. In many mouse and 
human cell types, glucocorticoids (GCs) increase the expression of DUSP1. The 
resulting inhibition of intracellular signalling pathways is thought to contribute to the 
powerful anti-inflammatory effects of GCs. The purpose of this project was to define 
mechanisms by which GCs control expression of mouse and human DUSP1 genes. 
Orthologous genes of distantly related species often respond to GCs via regulatory 
elements that are evolutionarily conserved in sequence and position. Therefore inter-
species sequence comparison was used as one tool to identify GC-responsive regions 
(GRRs) of mouse and human DUSP1 genes. Functional assays of GRRs were carried 
out by transient and stable transfection of mouse and human cells. Interactions of these 
cis-acting elements with transcription factors (including the GC receptor itself, GR) 
were assessed by in vitro DNA-binding assays and chromatin immunoprecipitation. 
 
A number of conserved, putative GRRs were identified up to 29 kb upstream of the 
DUSP1 transcription start site (TSS). Surprisingly, some of these were found to be 
differently utilised by mouse and human DUSP1 genes, in spite of their sequence 
similarity. Strongly GC-responsive elements were found 4.6 and 1.3 kb upstream of the 
human DUSP1 TSS. The corresponding regions of the mouse DUSP1 gene were 
unresponsive or very weakly responsive to GC. Instead the mouse gene appeared to be 
regulated via an element 29 kb upstream of the TSS, the corresponding human element 
being unresponsive. GC responsiveness correlated with the ability to recruit GR in vivo, 
but could not be explained on the basis of differences in the sequences of GR binding 
sites. These observations suggest that recruitment of GR to DUSP1 loci and 
transcriptional activation in response to GC are critically dependent on “accessory” 
transcription factors. GC responses of mammalian DUSP1 genes appear to have 
evolved via gain and/or loss of binding sites for accessory factors, whilst maintaining 
overall output. GC regulation of DUSP1 genes involves atypical GR binding sites and, 
unusually, does not appear to require dimerisation of GR. 
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1. INTRODUCTION 
 
1.1. Transcriptional regulation in Eukaryotes 
Cells are well equipped with different mechanisms that allow them not only to detect 
continuous environmental changes but also adapt in response to them. The homeostasis 
and survival of the organism are ultimately dependent on adequate responses of 
individual cells to changes in their micro-environment. At any given moment only some 
genes in a eukaryotic cell are being expressed, varying with the life cycle, type of cell 
and external stimuli (Wray, et al., 2003). Physiological and environmental inputs reach 
the cell and can trigger changes in the level and pattern of genes being expressed. 
Infection by external agents for example is sensed by the cells and induces several 
signalling cascades that mediate changes in gene and protein expression to levels more 
adequate to the new status. This can be achieved by intervening at the level of mRNA 
synthesis or degradation and protein synthesis or degradation. mRNA synthesis, or 
transcription, has been the focus of many studies and can be regulated by events acting 
on the chromatin remodelling, transcriptional initiation and elongation. Transcriptional 
initiation is considered the primary mechanism determining the gene expression profile, 
and will be given emphasis here. First, the different elements involved in regulation of 
transcription and its initiation will be addressed and a brief insight into chromatin 
remodelling and regulation at the elongation step will be given. 
 
In eukaryotes transcription of genes encoding proteins is performed by RNA 
polymerase II (RNA pol II) and originates from the transcription start site (TSS). 
However, to recognize the TSS and initiate the process of transcription, RNA pol II 
requires the presence of additional general transcription factors (GTFs) to bind to DNA 
in a region known as the core promoter. GTFs include transcription factor (TF) IIA, 
TFIIB, TFIID, TFIIE, TFIIF and TFIIH. This then promotes the binding of the enzyme, 
forming the transcription initiation complex (TIC) (Lewin, 2004; Narlikar and 
Ovcharenko, 2009). TIC is only sufficient to drive low levels of correctly initiated 
transcription in vitro, a phenomenon known as basal transcription. Additional factors 
and DNA regions are required to further increase the levels of successful transcription. 
In fact, TIC formation, activity and stability can be regulated by two types of elements: 
cis-regulatory elements which are regions along the DNA and trans-regulatory elements 
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comprising proteins directly or indirectly interacting with the cis-elements. A brief 
definition of elements classified as trans- and cis-regulatory will follow. 
 
1.1.1. Trans-regulatory elements 
Trans-regulatory elements comprise DNA-binding proteins (transcription factors) and 
non-DNA-binding proteins (cofactors). Transcription factors are proteins which contain 
DNA-binding domains that recognize and bind specific short DNA sequences of 5-15 
base pairs (bp). The short sequences bound by each transcription factor are in fact 
degenerate and are consequently described by a consensus sequence where each 
position can correspond to a variable or more constrained residue. Recognition sites for 
transcription factors can be found in the core and proximal promoter, enhancers and 5’ 
untranslated regions (UTRs) (Wray, et al., 2003). Most transcription factors contain one 
or more discrete transcriptional activation domains, the function of which may be 
modulated by post-transcriptional modifications, permitting the fine-tuning of gene 
expression. Transcription factors such as nuclear receptors, can bind as homo or 
heterodimers and their binding sites are normally composed of two half sites. 
Interestingly, the sequence itself can determine what partners are binding, the level of 
affinity with which the activator binds, and can also alter the structure of a bound factor, 
all of which will affect the transcription factor activity (Claessens and Gewirth, 2004; 
Lefstin and Yamamoto, 1998; Maston, et al., 2006; Ptashne and Gann, 1997). 
 
The function of transcription factors can depend on the interaction with other 
transcription factors before or as they bind to DNA, for example the requirement for 
binding as dimers described above. Transcription factors can function through many 
different processes. They can, for example, promote the assembly of the transcriptional 
machinery through direct interactions with the GTFs or promote subsequent steps such 
as elongation and reinitiation (Maston, et al., 2006; Ptashne and Gann, 1997). 
Transcription factors have also been shown to directly or indirectly modify chromatin 
structure through activities such as addition/removal of acetyl groups, methyl groups 
and phosphates or by stabilizing the bending or looping of DNA (Wray, et al., 2003). 
Transcription factors that repress gene transcription are commonly designated as 
repressors. Modes of action include binding to DNA and physically inhibiting the 
binding of a different transcription factor to a nearby site or binding to cis-regulatory 
regions that have a repressing effect such as silencers (Wray, et al., 2003). Cofactors are 
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non-DNA binding proteins that modulate the activity of transcription factors, 
determining if they act positively or negatively on transcription. Normally they work 
through protein-protein interactions with one or more transcription factors and can 
function as a bridge between them and the GTFs. They are also known to influence 
transcription through their enzymatic activities that allow them to modify chromatin 
(such as histone acetyltransferases and methyltransferases) and can integrate 
information from signalling pathways (Lonard and O'Malley, 2005). 
 
1.1.2. Cis-regulatory elements 
Promoters, enhancers, insulators, silencers, locus control regions and matrix (or 
scaffold) attachment regions are all designated as cis-regulatory elements, which in turn 
are part of the functional non-coding DNA.  
 
Promoters can be divided into core promoters and proximal promoters. Core promoters 
are located generally -40 to +40 relatively to the TSS and are the docking sites for the 
assembly of the TIC. Proximal promoters are the region immediately upstream of the 
core promoter, normally up to 200 bp from TSS. This region contains binding sites for 
transcription factors interacting with GTFs, often including stimulating protein 1 (Sp1), 
nuclear factor-I (NF-I) and nuclear factor-Y (NF-Y) (Blackwood and Kadonaga, 1998; 
Maston, et al., 2006).  
 
Enhancers were firstly identified as DNA sequences that could strikingly increase 
transcription independently from their distance and orientation from the TSS. Enhancers 
are normally seen as modules in the sense that a single gene can contain several 
enhancers that can contribute in a somewhat cumulative manner to the spatial, temporal 
and stimulus dependent regulation of a gene (Atchison, 1988). These modules can vary 
from 50 bp to 1.5 kb, comprising binding sites for transcription factors that cooperate to 
enhance transcription and can be located upstream or downstream of a gene and even 
within introns (Blackwood and Kadonaga, 1998). A few mechanisms have been 
proposed to explain enhancer activity. The looping theory is the most popular, in which 
the binding of activators and co-activators to the enhancer leads to the formation of a 
loop in the DNA that brings the enhancer close to the proximal and core promoter and 
allows for direct interaction between them (Fig. 1.1A) . The contact can be direct or
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Figure 1.1. Mechanisms proposed for enhancer action  White and black circles indicate enhancer and promoter bound proteins, respectively. Brackets contain the 
intermediate complexes formed during enhancer action.   
A – Looping: Enhancer-protein directly interacts with proteins bound to the promoter or searches the DNA 
by hopping or scanning; B – Tracking: Proteins bind the enhancer and then track along the DNA until they 
find the promoter; C- Spreading/Looping: An activator bound to the enhancer induces highly cooperative 
binding of other proteins (grey circles) to several closely spaced sites positioned between the enhancer and 
promoter. Spreading is accompanied by DNA looping. Cooperative binding could involve stabilization by 
cofactors (white ovals). Figure copied from Bondarenko et al., 2003 
 
 
 
  
 
 
 
 
 
23 
 
Chapter 1- Introduction 
alternatively the enhancer-proteins complex can “search” the linker DNA through either 
hopping or scanning through the DNA until it reaches the proximal promoter. In a 
different model, activators first bind to the enhancer but then track along the DNA until 
they encounter their target promoter without formation of loops (Fig. 1.1B). More 
complex models suggest the binding of an activator which induces the cooperative 
binding of other proteins to different modules. This can happen by spreading or linking 
of several enhancer-protein complexes along the chromosome or a “facilitated tracking” 
where protein interactions with enhancers are maintained while tracking or hopping 
along the DNA and progressively looping the linker DNA (Fig. 1.1C) (Blackwood and 
Kadonaga, 1998; Bondarenko, et al., 2003; Cockerill, 2008). 
 
Silencers are specific sequences with a silencing or repressing effect on the target gene. 
They share features with enhancers such as acting independently of distance and 
orientation from the core and proximal promoter. They can be located within the 
proximal promoter, within enhancers or as independent modules, and normally contain 
binding sites for transcription factors acting as repressors (Ogbourne and Antalis, 1998). 
Insulators are regulatory regions containing binding sites for transcription factors, which 
act in a position- and orientation- dependent manner to suppress the activity of 
enhancers and silencers. They are determinants in maintaining enhancer selectivity for 
the appropriate targets. This can be achieved by being positioned between the enhancer 
and the promoter and therefore blocking their interaction. A different way of action is 
by forming a barrier to prevent one region of chromatin from being influenced by 
another and for example prevent the spread of repressive histone modifications 
(Gaszner and Felsenfeld, 2006).  
 
1.1.3. Regulation at the level of chromatin remodelling 
A nucleosome consists of 147 bp of DNA wrapped around a complex of four different 
proteins present in duplicates. These proteins are histones, namely H2A, H2B, H3 and 
H4 (Shahbazian and Grunstein, 2007). Nucleosomes play an important regulatory role 
in transcriptional regulation which results from covalent modifications of their 
components or through modifications of their structure. In the first case, histones are 
post-translationally regulated, normally in their N-terminal, through modifications such 
as methylation, acetylation, ubiquitylation, phosphorylation and sumoylation. The 
second example is associated with chromatin remodelling complexes which can change 
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the positions of nucleosomes, remove histones or change the position of the DNA 
wrapped around them (Varga-Weisz, 2001). All of these processes are associated with 
remodelling of the chromatin between more and less condensed states, which in turn are 
associated with repression or activation of gene expression, respectively (Shahbazian 
and Grunstein, 2007). More details about the elements involved in the processes of 
histone acetylation/deacetylation and chromatin remodelling by chromatin remodelling 
complexes will be described.  
 
1.1.3.1. Histone acetylation and transcription 
Histone acetylation is strongly associated with gene transcription by favouring more 
relaxed chromatin conformation that enables the binding of transcription factors and the 
transcriptional machinery. Histone acetyl transferases (HATs) can transfer acetyl groups 
from coenzyme A onto the ε-amino group of lysine residues (Shahbazian and Grunstein, 
2007). HAT activity has been discovered to be a property of some cofactors such as 
cAMP response element binding protein (CREB) binding protein (CBP) and p300 
(Janknecht and Hunter, 1996). HATs, such as the ones previously mentioned, are 
recruited by transcriptional activators and by prior methylation to histones. The 
presence of acetylation in histones reduces the electrostatic interactions between DNA 
and histones, allowing loosening of the chromatin structure. Additional transcription 
factors can bind directly to the HATs or to the relaxed chromatin, and exert their 
transcriptional activity (Shahbazian and Grunstein, 2007).  HATs can also function in 
an untargeted manner by increasing the basal transcription throughout the genome or by 
preactivating uninduced genes for later activation.  
 
1.1.3.2.  Histone deacetylation and transcription 
On the other hand, histone deacetylases (HDACs) remove acetyl moieties from the 
lysine residues of histones, a process which has been associated with the repression of 
gene transcription. HDACs work by reversing the effect of HATs, through restoring the 
positive charge on lysines which favours a more compacted structure of chromatin, 
reducing the binding of additional required transcription factors and co-activators. 
However, it appears that HDAC activity might also be required for proper transcription, 
highlighted by the fact that HDACs and HATs are normally recruited to the same sites 
and influence each other’s substrate specificity and lysine preference (Shahbazian and 
Grunstein, 2007).  
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Treatment with trichostatin A (TSA) and other HDAC inhibitors can reduce expression 
of many genes in mammalian cells, suggesting HDACs might be important for 
transcriptional activation. Specific examples have been described for the deacetylases 
Hos2 and Rpd3 in yeast. In genome wide-studies it has been shown that knocking down 
of Rpd3 results in downregulation of more genes than are upregulated (Bernstein, et al., 
2000). Interestingly, it seemed that Rpd3 deletion downregulated 40% of the genes 
located within 20 kb of the telomeres. Many of the genes downregulated by depletion of 
Rdp3 were also affected when treating cells with TSA. Because the effect could be seen 
with treatment of cells for periods as short as 15 min, it seemed a direct effect. Hos2, 
another deacetylase has been shown to bind to the GAL1 gene only when this was being 
expressed. Additionally, genome-wide binding of Hos2 has been shown to correlate 
with active transcription (Wang, et al., 2004).  
 
1.1.3.3.  Chromatin remodelling complexes 
Chromatin-remodelling complexes alter chromatin structure by modifying DNA-histone 
contacts within nucleosomes, with the concomitant requirement for ATP (Martens and 
Winston, 2003). These complexes are normally composed by several subunits with an 
ATPase as the catalytic centre. They can be divided into four classes, the Switch 
2/sucrose nonfermentable 2 (SWI2/SNF2)-, the nucleosome remodeling and 
deacetylation (NuRD)/Mi-2/ chromodomain, helicase, DNA binding (CHD), the inositol 
requiring 80 (INO80)- and the imitation switch (ISWI)-ATPases (Wang, et al., 2007a). 
The complexes can be composed of several subunits, for instance the SWI/SNF 
complex, which is part of  the SWI2/SNF2 class, contains eleven or more subunits and 
was first identified in yeast, but has homologues in all eukaryotes (Varga-Weisz, 2001). 
Chromatin remodelling complexes are recruited to DNA by direct interaction with 
transcription factors and can additionally cooperate with HDACs and HATs. They act 
by changing the position of nucleosomes along DNA, which render the DNA accessible 
or not for transcription factors and transcriptional machinery to bind. Hence, the action 
of chromatin remodelling complexes can result in both repression and activation of 
transcription (Varga-Weisz, 2001). 
 
1.1.4. Control of gene expression at the level of transcriptional elongation 
Recently, evidence has suggested that gene expression can also be regulated at a 
subsequent step after RNA pol II recruitment to the proximal promoter. This process, 
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which might be more common than initially thought, was first shown in the promoter of 
heat-shock protein 70 (Hsp70) genes (Lis, 1998). Chromatin immunoprecipitation 
(ChIP) experiments showed that RNA pol II was present at unstimulated Hsp70 genes 
and that it synthesizes 20-50 nucleotides of transcript before pausing (Nechaev and 
Adelman, 2008). Pausing by RNA pol II was previously believed to result from the 
enzyme sliding back a few nucleotides and misaligning the catalytic centre with the 
RNA transcript, but recent studies seem to indicate that it could be due to structural 
rearrangements within the enzyme and DNA sequences, which leads to an “unactivated” 
intermediate (Sims, et al., 2004). Pausing is reversible which means that in the right 
circumstances the RNA pol II can continue the synthesis of the transcript. In fact gene 
induction dramatically decreased the duration of RNA pol II stalling, which increased 
again after the stimulus was removed. This process has since been correlated with the 
ability to rapidly alter the levels of gene expression. It appears that the presence of 
stalled RNA pol II preloaded on a gene marks it for future activation when the 
appropriate stimulus is present. This probably occurs because it stabilizes a scaffold of 
transcription factors and the transcriptional machinery near the proximal promoter and 
maintains the chromatin in a permissive state, all of which allow for a rapid increase in 
the transcriptional levels once the induction signal arrives (Nechaev and Adelman, 
2008). Several factors seem to be involved in the regulation of elongation. Examples are 
the negative elongation factor (NELF), 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole 
(DRB), DRB-sensitivity-inducing factor (DSIF) and positive transcription elongation 
factor b (P-TEFb). DSIF binds to RNA pol II after initiation and NELF binds DSIF 
promoting pausing. P-TEFb suppresses pausing by phosphorylating Ser2 in the C-
terminal end of RNA pol II and also DSIF. DRB enhances pausing by inhibiting P-
TEFb kinase activity (Sims, et al., 2004). 
 
Genome-wide analyses of RNA Pol II distribution in Drosophila and mammalian 
systems have shown that a significant number of genes contain stalled RNA Pol II in 
their promoters, increasing the suspicion that this mechanism of regulation might be 
wide spread (Kim, et al., 2005; Law, et al., 1998; Muse, et al., 2007; Rougvie and Lis, 
1990). In fact, regulation of transcriptional elongation has been described for the 
promoters of several genes including TNF-α, c-Fos and JunB (Adelman, et al., 2009; 
Nechaev and Adelman, 2008). 
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1.2. Immune Response 
Activation and repression of transcription are events integrated in the assessment and 
response to “disturbances” received by the cells. Infection by external agents is one 
example of an event triggering specific signalling pathways within a cell that aim to 
overcome this situation. The sum of years of evolution has given rise to an 
extraordinary defence system for protecting animals from pathogenic infections and 
cancer. The immune system, through the use of a wide variety and number of cells and 
molecules, has built up a dynamic network of enormous complexity that exploits 
mechanisms, such as regulation of gene expression, to recover homeostasis.  
 
Immunity is the state of protection from foreign organisms or substances and can be 
divided into two major components: innate immunity and adaptive immunity. The 
innate immunity constitutes the first line of defence to infection and comprises four 
main defensive barriers: anatomic, physiologic, phagocytic, and inflammatory (Kuby, et 
al., 2000). The mechanisms of innate immunity discriminate between pathogen and 
host, by using receptors that recognize features characteristic to foreign agents, the so 
called pathogen-associated molecular patterns (PAMPS) such as microbial DNA, 
polysaccharides and proteins from bacterial flagella. Therefore it stands out as a non 
specific, immediate and antibody-independent response. The adaptive immunity, 
exclusive to vertebrates, is characterised as a pathogen-specific response that only starts 
after an antigenic challenge is presented, requiring the cooperation between 
lymphocytes and antigen-presenting cells. This type of response exhibits four 
immunologic attributes: antigenic specificity, diversity, immunologic memory and 
self/non-self recognition. 
 
1.3. Inflammation 
Infection, antigen challenge or tissue injury are events leading to a physiologic response 
designated inflammation. This response, also designated as acute inflammation, induces 
a complex cascade of non-specific events occurring expeditiously and for a short period 
of time and orchestrated by a vast set of cells and molecules. The physiological 
manifestations arising from this process are usually described as heat, redness, swelling, 
pain and loss of function. Being the first direct response of the organism to an injury or 
infection, it particularly aims at removing or destroying the offending agent, restraining 
the spread of the infection and initiating the preparations for the process of healing. 
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These purposes are achieved by phenomena occurring at both a localised and systemic 
level. Vasodilatation, increase in vascular permeability, cellular influx, production and 
release of soluble inflammatory factors and increase in circulating leukocytes are among 
those.  
 
Controlling the mechanisms involved in inflammation is extremely important. It can 
occur by several agents, including pro-inflammatory effectors which themselves trigger 
negative feedback loops and allow to tune the strength and duration of inflammation. In 
normal circumstances, inflammation will cease once the initiating element has been 
eliminated. However, sometimes the infectious agent persists, and inflammation 
becomes chronic with cytokine and other pro-inflammatory agents being produced and 
causing continuous tissue damage. Histological features of chronic inflammation 
include accumulation of macrophages and leukocytes and the growth of fibroblasts and 
vascular tissue, the latter two resulting in characteristic tissue scarring seen at sites of 
chronic inflammation (Paul, 2003). Inflammation becomes pathological for instance in 
allergic asthma where repeated exposure to the same environmental agent leads to an 
exaggerated activation of the immune response. Sustained inflammation can also occur 
when the immune system is unable to eradicate the infectious agent, for example 
Mycobacterium tuberculosis. Continuous inflammation activation is also the basis of 
autoimmune diseases, such as rheumatoid arthritis. In autoimmune diseases self-
molecules are no longer recognized as self and will activate the immune system causing 
continuous inflammation and tissue damage. Here, immune cells release inflammatory 
mediators in the absence of any infection. Since in autoimmune diseases the triggering 
event is endogenous the resulting inflammatory process can be designated as “sterile 
inflammation”.  Sterile inflammation is thought to be triggered by ligands derived from 
damaged cells such as Hsp, β-defensins and oxidized lipids and possibly involves 
recognition by Toll-like receptors (TLR) (Barton, 2008). It can occur when trauma and 
cell death happen and does not have to end in chronic inflammation, but it likely 
increases the probability of dysregulation and disease. For example, inappropriate 
activation of TLR7 and TLR9 by endogenous DNA and RNA might have an important 
role in the onset of autoimmune diseases such as systemic lupus erythematosus (Barrat 
and Coffman, 2008) 
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Many of the events initiated in the inflammation process require changes in gene 
expression. Two transcription factors have a crucial role in regulating these changes: 
nuclear factor κB (NF-κB) and activator protein 1 (AP-1). 
 
1.3.1. NF-κB 
NF-κB represents a group of five proteins in mammals: NF-κB1 (p50 and its precursor 
p105), NF-κB2 (p52 and its precursor p100), c-Rel, RelA (p65) and RelB (Wietek and 
O'Neill, 2007). NF-κB proteins are widely expressed, though the pattern of expression 
of each one is different, and retained in the cytoplasm of unstimulated cells in a 
complex with inhibitory IκB proteins (IκBα, IκBβ and IκBε). Inhibitor of NF-κB kinase 
(IKK) complex contains IKKα and IKKβ (catalytic activity subunits) and IKKγ 
(scaffold subunit) and is also in the cytoplasm. When the IKK complex is activated by 
phosphorylation, IKKα and IKKβ phosphorylate IκB leading to its polyubiquitination 
and ultimately to degradation by the proteasome (Li and Verma, 2002). The NF-κB 
proteins are then translocated into the nucleus. In response to external stimuli such as 
pro-inflammatory cytokines, pathogens and stress signals, cell-surface receptors are 
activated modulating signalling pathways that converge in activation of the IKK 
complex, subsequent inactivation of IκBs and NF-κB translocation into the nucleus (Li 
and Verma, 2002). Tumour necrosis factor (TNF)-α, lipopolysaccharide (LPS) and 
interleukin (IL)-1 are examples of different signals inducing different pathways that 
activate NF-κB (Fig. 1.2). TNF-α engages TNF receptor (TNFR) inducing receptor 
trimerisation and recruitment of the adaptor protein TNF receptor associated via death 
domain (TRADD). TRADD in turn interacts with TNF-receptor-associated-factor 2 
(TRAF2), another adaptor protein that has affinity for several other downstream 
signalling effectors such as MAP/ERK kinase kinase 3 (MEKK3), receptor interacting 
serine/threonine kinase (RIP), TGF-activated kinase 1 (TAK1) and NF-κB-inducing 
kinase (NIK) which will lead to activation of the IKK complex. LPS will bind the 
TLR4-myeloid differentiation-2 (MD-2)/ cluster of differentiation-14 (CD14) initiating 
a signalling pathway that involves recruitment of myeloid differentiation primary 
response gene 88 (MyD88), TIR domain-containing adapter-inducing interferon (IFN) β 
(TRIF), MyD88 adapter like protein (Mal) and IL-1-receptor-associated kinase (IRAK). 
Activation of IRAK results in recruitment and phosphorylation of TRAF6, which then 
signals through TAK1 complex to activate the IKK complex. Alternatively, IL-1β
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Figure 1.2. NF-κB activation 
TNF-α, IL-1 and LPS induced activation of NF-κB signalling. Activation of receptors signals to downstream 
adaptors and effectors leading to TAK1 activation and IKK phosphorylation. IKKα and IKKβ phosphorylate 
IκB leading to its ubiquitination and degradation by the proteasome. NF-κB proteins are then translocated 
into the nucleus where they can activate gene expression. Adapted from Alberts, et al., 2002 and Beck, et al., 
2009.  
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engages with the type I IL-1 receptor (IL-1RI) and then signals through MyD88, IRAK, 
TRAF6 and TAK1. For the three pathways TAK1 activation results in IKK activation, 
which leads to phosphorylation of IκB and consequently NF-κB proteins are rapidly 
translocated into the nucleus where they can regulate gene expression (Beck, et al., 
2009; Jimi and Ghosh, 2005; Li and Verma, 2002). The importance of TAK1 for the 
three pathways is explicit in studies employing TAK1-deficient cells, since these cells 
displayed no activation of the NF-κB pathway after stimulation with IL-1β, LPS and 
TNF-α (Sato, et al., 2005; Shim, et al., 2005). 
 
Alternatively, NF-κB can be activated by the non-classical pathway. More specifically 
this pathway is involved in the processing of precursor protein p100, which unlike the 
processing of p105 is not constitutive and requires a signal to occur. Some members 
from the TNF receptor superfamily once activated can lead to the sequential activation 
of NIK and IKKα (the only IKK required for this pathway) and the latter can 
phosphorylate p100. This protein which is complexed in the cytoplasm with RelB, is 
then polyubiquitinated and processed into p52. p52/RelB can then translocate into the 
nucleus and activate transcription (Hayden and Ghosh, 2004; Moynagh, 2005). 
 
The rel family comprises proteins which are expressed and are important for regulatory 
mechanisms in several species, for example in Drosophila melanogaster (Dushay and 
Eldon, 1998). NF-κB has been demonstrated to play an evolutionary conserved and 
crucial role in the inflammatory response by upregulating a plethora of inflammatory 
genes including cytokines (e.g., TNF-α, IL-1β, IL-2, IL-6, IL-12, granulocyte-
macrophage colony-stimulating factor [GM-CSF]), chemokines (e.g., IL-8, chemokine 
[C-C motif] ligand 5, CCL5), inducible effector enzymes (inducible nitric oxide 
synthase, iNOS, and cyclooxygenase-2, COX-2) and adhesion molecules (e.g., E-
selectin, inter-cellular adhesion molecule 1, ICAM) among others (Ghosh and Karin, 
2002). Once inside the nucleus, NF-κB is believed to bind as a dimer to a 9-bp 
consensus DNA sequence GGGACTTCC within target genes (Wietek and O'Neill, 
2007). Additionally, NF-κB recruits HATs, such as CBP and p300. This leads to 
acetylation on histone H4 and H3, which induces chromatin remodelling associated 
with induction of gene transcription (Hayashi, et al., 2004). Surprisingly, NF-κB was 
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shown to also interact with HDAC1 and HDAC2 to negatively regulate gene expression 
(Li and Verma, 2002).  
 
Initially it was thought that NF-κB was only regulated by signal-induced degradation, 
but evidence has been gathered claiming that NF-κB can be directly phosphorylated and 
acetylated, which influences its activity by altering the interactions with DNA and 
additional transcription factors (Hayashi, et al., 2004; Li and Verma, 2002). p65 can be 
phosphorylated at multiple sites with different effects. Kinases such as protein kinase A 
(PKA) and mitogen and stress-activated protein kinase 1 (MSK1), which can be 
activated by mitogen activated protein kinases (MAPK) p38 and extracellular signal 
regulated kinase (ERK), can phosphorylate p65 at Ser276 and this influences the 
activation of inflammatory gene expression, though not all gene expression depends on 
this modification. This phosphorylation is required for the interaction of p65 with 
cofactors CBP/p300 and P-TEFb (Beck, et al., 2009; Jamaluddin, et al., 2007; Nowak, 
et al., 2008; Okazaki, et al., 2003; Vermeulen, et al., 2003; Zhong, et al., 1998). p65 
Ser536 can be phosphorylated by IKKα, IKKβ and IKKε resulting in an increase of the 
transactivation function of p65, possibly by enabling the interaction with p300 or 
decreasing the interaction with IκB. The same phosphorylation by TANK binding 
kinase-1 (TBK1) results in a decrease of p65 nuclear export (Neumann and Naumann, 
2007). Ser311 phosphorylation by protein kinase C ζ (PKC ζ) can also potentiate the 
interaction between p65 and cofactor CBP. This phosphorylation is also related to 
increase in p65 recruitment to κB sites. Ser529 is phosphorylated by IKKβ and casein 
kinase II (CKII) and though it is still unclear it appears to influence its transactivation 
properties (Beck, et al., 2009; Li and Verma, 2002; Neumann and Naumann, 2007). 
Also, p65 phosphorylation status influences the interaction with HDAC1. The model 
proposes that in unstimulated cells p65 is unphosphorylated and interacts with HDAC1 
leading to histone deacetylation and gene repression; in stimulated cells p65 becomes 
phosphorylated and interacts with CBP/p300 leading to histone acetylation and gene 
activation (Zhong, et al., 2002). Interestingly, phosphorylation of Thr505 seems to 
potentiate p65-HDAC1 interaction, decreasing p65 transcriptional activity. The same 
seems to happen when IKKβ or glycogen synthase kinase (GSK) 3β phosphorylate 
Ser468 (Beck, et al., 2009; Li and Verma, 2002). p65 acetylation leads to a marked 
decrease in interaction with IκB, whereas deacetylation promotes this interaction 
resulting in export of p65 to the cytoplasm (Chen, et al., 2001). 
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Another interesting study proposed that p38 signalling was required to mark promoters 
of pro-inflammatory genes for NF-κB recruitment. This was achieved through 
modifications such as phosphorylations and phosphoacetylation of histone H3, which 
render binding sites for NF-κB more accessible (Saccani, et al., 2002). 
 
The importance of NF-κB signalling is highlighted by its implication in inflammatory 
diseases such as rheumatoid arthritis, multiple sclerosis, asthma and inflammatory 
bowel disease. Moreover, knockout of p65 subunit in mice is embryonic lethal whereas 
mice lacking each of the other four members are immunodeficient (Li and Verma, 
2002). 
 
1.3.2. AP-1 
AP-1 is the collective term used to refer to a family of transcription factors which act as 
dimers composed of Jun (v-Jun, c-Jun, JunB, JunD), Fos (v-Fos, c-Fos, Fos-B, Fra1, 
Fra2), activation transcription factor (ATF2, ATF3, b-ATF) and MAF (MAFA, MAFb, 
c-MAF, NRL, MAFF, MAFG and MAFK) proteins (Beck, et al., 2009; Karin, et al., 
1997). AP-1 activity is induced by numerous stimuli such as growth factors, cytokines, 
T-cell activators and UV radiation through the activation of several signalling cascades 
such as c-Jun N-terminal Kinase (JNK) and other MAPK pathways (Adcock and 
Caramori, 2001; Karin, 1996). Activity is influenced by the differential expression of 
each individual member, for example through direct effects on the transcription of their 
genes, which will influence the composition of the dimer. The type of cell, DNA 
binding sequences, other transcriptional partners will also influence their role as will 
different phosphorylations. For example, phosphorylations of activation domains of its 
members can decrease their ubiquitination and render the transcription factors active 
and allow binding to DNA (Karin, et al., 1997; Su and Karin, 1996). Each factor has 
different affinities to bind DNA and at the same time composition of the dimers is 
associated with different transcriptional activities; for example c-Fos and c-Jun 
containing dimers are related to strong transcriptional activity, whereas Fra and JunD 
are associated with weak transcriptional activity (Kaminska, et al., 2000).  
 
AP-1 complex has been reported to be involved in the upregulation of many genes 
coding for cytokines and enzymes such as collagenase-1, IL-2 and GM-CSF (Macian, et 
al., 2001; Manning and Davis, 2003). AP-1 is one of many transcription factors that are 
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able to recruit co-activators involved in histone modifications, such as p300, and 
influence the transcription of genes, such as IL-5 (Lee, et al., 1996; Liu, et al., 2004). 
Interesting is the fact that AP-1 and NF-κB pathways seem to influence each other. 
First, NF-κB is known to interact with AP-1 (Wietek and O'Neill, 2007). Second, there 
seems to be an increase in AP-1 and NF-κB activity arising from the presence and 
cooperation of proteins from both classes of transcription factors. This suggests a 
combinatorial mechanism of gene regulation dependent on simultaneous activation of 
both pathways (Stein, et al., 1993). 
 
1.4. Glucocorticoids 
Cortisol, an example of an endogenous glucocorticoid (GC), is a hormone produced by 
the adrenal cortex under the control of the hypothalamic-pituitary-adrenal axis. GCs 
have an important role in metabolic processes, since they promote gluconeogenesis and 
the formation of glycogen, and enhance the catabolism of fat and protein (Berg, et al., 
2002). Therefore these hormones are released in the body during periods of starvation or 
intense physical activity. Interestingly, they also play a pivotal role in the immune 
system thanks to their anti-inflammatory and immunosuppressive actions. 
 
1.4.1. Glucocorticoid Receptor 
GCs exert their effect by means of a member of the nuclear hormone receptor 
superfamily, the glucocorticoid receptor (GR). This transcription factor has multiple 
isoforms due to different translation sites and alternative splicing (Revollo and 
Cidlowski, 2009). GR-α, with 777 amino acids, is the most predominant and is 
expressed throughout the body, whilst GR-β does not bind GCs and is not ubiquitously 
expressed (Beck, et al., 2009; Newton, 2000). GR is known to be involved in both the 
therapeutic and the deleterious effects of GC. This receptor is described as having three 
different domains paired with specific functions: the N-terminal domain presenting 
transactivation functions (activation function 1, AF-1), a central DNA-binding domain 
(DBD) that contains the zinc finger motif responsible for the DNA-protein interactions, 
and a ligand-binding domain (LBD) with 12 α-helices implicated in the formation of the 
hydrophobic ligand-binding pocket and with a transactivation function (activation 
function 2, AF-2) (Wikstrom, 2003).  
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The standard model describes this 94 kDa protein as being retained in the cytoplasm 
and complexed with several proteins such as immunophilins (e.g. FKBP51, FKBP52 
and Cyp44) and heat shock proteins (e.g. Hsp90 and Hsp70) (Rhen and Cidlowski, 
2005). This complex is not only important to retain GR in the cytoplasm but also to 
ensure the correct folding of GR, without which the ligand binding does not occur 
(Ricketson, et al., 2007). GR becomes an activated transcription factor after the binding 
of its ligand, which disrupts the complex and exposes the nuclear localization signal 
inducing the translocation of GR to the nucleus. 
 
1.4.2. Glucocorticoids and Inflammation 
The anti-inflammatory function of glucocorticoids was discovered by Hench and co-
workers almost 60 years ago (Hench, et al., 1949). Hench first realised that remission of 
rheumatoid arthritis occurred in his patients when they became pregnant or jaundiced.  
Understanding that steroids were responsible for this improvement of the symptoms was 
a major breakthrough, later confirmed with the Nobel Prize for Physiology and 
Medicine awarded to Hench, Kendall and Reichstein. Glucocorticoids are still currently 
used as an immunosuppressive and anti-inflammatory treatment for chronic 
inflammatory diseases such as asthma, systemic lupus erythematosis, Crohn’s disease 
and rheumatoid arthritis. In fact, despite being reasonably inexpensive, glucocorticoids 
are estimated to have a market size of about US$ 10 billion per year (Schacke, et al., 
2002), since they are the most important and widely prescribed anti-inflammatory type 
of drug. Nonetheless, the use of this treatment is limited as it is known to be associated 
with a wide variety of side effects such as osteoporosis, diabetes, hypertension, growth 
retardation in children, immunosupression, cataracts and suppression of the 
hypothalamic-pituitary-adrenal axis (Rhen and Cidlowski, 2005; Saklatvala, 2002; 
Schacke, et al., 2002). 
 
1.4.3. Glucocorticoid’s side effects and resistance 
All of the side effects mentioned above seem to result from several, sometimes, 
independent events all triggered by GCs. For example, metabolic dysregulation and 
diabetes can arise through several different processes. GCs can decrease the insulin-
induced glucose uptake in skeletal muscle by interfering with the insulin signalling and 
inducing insulin resistance or by altering protein and lipid metabolism in these cells and 
reducing their sensitivity to insulin. They can also act directly on the liver where they 
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increase production of glucose through induction of metabolic enzymes such as 
phosphoenolpyruvate carboxykinase (PEPCK), tyrosine aminotransferase (TAT) and 
glucose-6-phosphatase (G6Pase). GCs have been shown to play a role in adipose tissue 
metabolism and differentiation through upregulation of enzymes such as hormone-
sensitive lipase (HSL). Prolonged steroid treatment promotes an increase in body fat 
content and a change in its distribution, insulin resistance and changes in the secretion 
of multiple metabolically active hormones and peptides. In yet another example, GCs 
can impair insulin secretion in pancreatic beta-cells (Schacke, et al., 2002; van Raalte, 
et al., 2009). 
 
Additionally to the side effects, there have also been reported cases of patients who are 
resistant to treatment with steroids. Several different explanations of glucocorticoid 
resistance have been put forward (DeRijk and Sternberg, 1997; Loke, et al., 2002; 
Smoak and Cidlowski, 2004). The molecular mechanisms suggested to be the basis of 
this phenomenon are diverse and can vary between patients. GR abnormalities can be at 
the centre including decrease in GRα protein levels (Pazirandeh, et al., 2000; Reichardt, 
et al., 2000), increased expression of GRβ, decrease in GR nuclear translocation 
(Matthews, et al., 2004), altered affinity of the ligand for the receptor and decrease in 
GR transcriptional activity (Ito, et al., 2006). Mutations of the GR itself (Charmandari 
and Kino, 2007) are sometimes related with these abnormalities, but so far no 
polymorphism has been associated with GC-insensitivity in inflammatory diseases 
(Barnes and Adcock, 2009). Other explanations include impairment of histone 
acetylation and deacetylation events associated with GC action, increase of the drug 
efflux pump P-glycoprotein 170 which transports drugs out of the cell, including GCs 
and increase in pro-inflammatory transcription factors expression and activity (Barnes 
and Adcock, 2009). One of these transcription factors is AP-1. Briefly, it appears that 
patients with GC-resistant asthma presented increased levels of c-Fos and increased 
activation of c-Jun, which could be related to overexpression of cytokines IL-2 and IL-
4. This accounts for the increased activity of AP-1 and probably correlates with the 
increased activation of JNK pathway, suggesting that the inability of GCs to inactivate 
this MAPK might be the basis of the GC-insensitivity presented by these patients. At 
the same time it has been shown that p38 and JNK can phosphorylate GR and 
consequently decrease its transcriptional activity (Barnes and Adcock, 2009). It is 
difficult to understand what the main primary event leading to GC insensitivity is, since 
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GR acts upon so many pathways that act on each other and are regulated by negative 
feedback loops.  
 
1.4.4. Glucocorticoids - Classical model of regulation of gene expression 
As previously described, GR is retained in the cytoplasm and only when bound to its 
ligand, it translocates into the nucleus. Once there, the GR can dimerise and bind the 
major groove of DNA, selectively targeting the glucocorticoid binding site consensus 
sequence (GBS), a consensus DNA sequence defined as two inverted and imperfect 
palindromic hexanucleotides separated by any three residues (GGTACANNNTGTTCT) 
(Beato, et al., 1989). Dimer binding occurs by the initial binding of one GR monomer to 
one of the hexanucleotides, followed by binding of the second monomer, which is 
promoted and stabilized by protein-protein interactions through a dimerisation interface 
within the DBD (Dahlman-Wright, et al., 1991). This particular mechanism accounts 
for GC induction of gene expression, also known as transactivation. Among these genes 
are several involved in gluconeogenesis such as TAT and PEPCK (Hanson and Reshef, 
1997; Jantzen, et al., 1987).  
 
Inhibition of gene expression has also been attributed to GR action following GC 
binding. Accordingly to previous studies, the GR uses transrepression as a means of 
negatively regulating the expression of pro-inflammatory genes. Transrepression will be 
referred to throughout this thesis exclusively as the process by which GR directly or 
indirectly interacts with transcriptional factors, inhibiting their action. As previously 
described, AP-1 and NF-κB transcription factors are directly involved in the 
upregulation of a vast list of pro-inflammatory genes. To achieve that, they not only 
directly bind to the promoter of target genes, but also interact with chromatin 
remodelling agents. Since these two transcription factors are activated by pro-
inflammatory stimuli and involved in the activation of many pro-inflammatory genes, it 
was widely accepted that the majority of the anti-inflammatory actions of GCs occur by 
the mechanism of transrepression, where GR interferes with the transcriptional activity 
of these factors. The discrimination between the mechanisms of transrepression and 
transactivation and their effects was fruit of a few studies carried out more than 10 years 
ago. In cells transfected with a mutant GR that carries a single amino acid mutation 
(Ala458 → Thr458 :GRdim) which impairs dimerisation, the inhibition of NF-κB and AP-1 
remained unaltered (Heck, et al., 1997; Heck, et al., 1994). In mice that only expressed 
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the dimerisation defective GR, GCs were still able to exert their anti-inflammatory 
effects (Heck, et al., 1994; Reichardt, et al., 1998), but were unable to induce the 
activation of PEPCK, which depends upon dimerisation. These observations lead to the 
hypothesis that the side effects and the anti-inflammatory features of the treatment with 
glucocorticoids could be uncoupled: the deleterious effects would be dependent upon 
dimerisation of the GR and binding to GBS and the suppression of the inflammatory 
response would be related to dimerisation-independent mechanisms. The classical 
model for the GCs gene regulation was then established (Stahn, et al., 2007). 
 
The exact molecular mechanism of transrepression is still subject of some controversy, 
though numerous experiments have been done. The interaction between the C-terminal 
activation domain of p65 and GR has been shown to be crucial for repression of NF-κB-
driven gene regulation (Caldenhoven, et al., 1995; De Bosscher, et al., 1997; Liden, et 
al., 1997). ChIP experiments have shown that GR is recruited to the regions where NF-
κB and AP-1 are binding, even when there are no GBS present (Caldenhoven, et al., 
1995; De Bosscher, et al., 1997; Liden, et al., 1997). The mechanism of transrepression 
excludes the direct binding of GR to DNA and relies instead on tethering mechanisms 
between the receptor and NF-κB and AP-1. However the GR-DBD has been shown to 
be important to inhibit NF-κB and AP-1-driven transcription (Heck, et al., 1994; Liden, 
et al., 1997; McKay and Cidlowski, 1998; Schule, et al., 1990). One explanation 
describes the GR-DBD as playing a part in the protein-protein tethering interactions 
between GR and their targets, which can occur through co-repressors such as 
glucocorticoid receptor-interacting protein 1 (GRIP-1) (Rogatsky, et al., 2002). GR-
DBD involvement in this mechanism is supported by experiments showing that GR-
DBD alone is sufficient for interactions with p65. Only some mutations of this domain 
impair transrepression, which means that those residues are involved in the interaction 
between protein-protein and the other residues involved in DNA binding are not 
important for transrepression (Heck, et al., 1997; Kassel and Herrlich, 2007; Nissen and 
Yamamoto, 2000).  
 
One interesting hypothesis states that GR represses the NF-κB and AP-1-dependent 
transcriptional activation by decreasing the acetylation of histone tails by recruiting an 
histone deacetylase or by preventing the action of an histone acetyltransferase (Kassel 
and Herrlich, 2007). In support of this, GCs have been shown to increase the expression 
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of HDAC2 and promote its recruitment to NF-κB/CBP complexes (Islam and 
Mendelson, 2008; Ito, et al., 2000; Ito, et al., 2001) and to reduce the level of H3 and 
H4 acetylation in the promoter of surfactant protein-A (SP-A) and IL-8, respectively 
(Islam and Mendelson, 2008; Tsaprouni, et al., 2007). Additionally, GCs can repress the 
TNF and IL-1β induced histone acetylation in the promoter of pro-inflammatory genes 
through reduction of CBP HAT activity and recruitment of HDAC2 (Ito, et al., 2000). It 
is also interesting that a mutation in the first zinc-finger of GR will inhibit the 
transrepression of NF-κB but not AP-1, whereas a different GR mutation inhibits the 
transrepression upon AP-1 but not NF-κB (Bladh, et al., 2005; Tao, et al., 2001). This 
further increases the evidence that multiple molecular mechanisms might be operating 
to produce the final outcome observed by GCs transrepression. Still, evidence 
converges in observations that in the mechanism of transrepression GR, does not 
directly bind DNA and it does not interfere with the recruitment of NF-κB or AP-1 to 
the promoter but can in fact be recruited with them. GR directly or indirectly interacts 
with these transcription factors leading to repression possibly by also interfering with 
the recruitment of co-activators, preventing the release of co-repressors or recruiting 
repressor elements. Ultimately in this mechanism of transrepression GR interacts with 
AP-1 and NF-κB interfering with their capacity to induce gene expression and 
consequently repressing several cytokines involved in the inflammatory response such 
as TNF-α, IL-1β, IL-2, IL-3 IL-6, IL-8, IL-11 and GM-CSF (Almawi and Melemedjian, 
2002).  
 
1.4.5. Dissociated Glucocorticoids 
The possibility of dissociating the side effects from the anti-inflammatory actions of 
GCs became a rather interesting idea for pharmaceutical companies. The search began 
for novel GR ligands which render the receptor unable to activate gene expression 
(transactivation), but still potently repress gene expression (transrepression). This would 
create compounds with the anti-inflammatory profile of GCs but deprived of their side 
effects. These compounds are known as dissociated compounds or selective GR 
agonists (SEGRAs) or modulators (SEGRMs). They were first identified in screens 
using reporter gene assays, more specifically by verifying their ability to repress AP-1 
and NF-κB reporter constructs and concomitant inability to activate reporter constructs 
driven by palindromic GBS. One of the first dissociated ligands described was 
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RU24858, a steroidal compound which was able to repress AP-1 and NF-κB-dependent 
transcription and presented anti-inflammatory properties in vivo (Belvisi, et al., 2001; 
Vanden Berghe, et al., 1999; Vayssiere, et al., 1997). However, loss of bone mass and 
body weight, part of the side effects displayed by GCs, were still observed (Belvisi, et 
al., 2001). Two other non-steroidal compounds AL-438 (Coghlan, et al., 2003) and 
ZK216348 (Schacke, et al., 2004) have been described. Both were able to abrogate the 
production of inflammatory mediators and exhibited impaired activity in transactivation 
assays, a dissociation phenomenon also shown in vivo. They were also shown to not 
affect osteoblasts in vitro (Humphrey, et al., 2006; Owen, et al., 2007) or induce 
hyperglycemia (Coghlan, et al., 2003; Schacke, et al., 2004). A series of betamethasone 
17α-carbamates have also been shown to present a dissociated profile in 
transactivation/transrepression in functional assays, and at least one of them was 
associated with decrease of TNF-α production in rats as well as little effects on glucose, 
insulin and triglyceride levels (Ali, et al., 2008). ZK245186, a different non-steroidal 
compound, has also been described as having anti-inflammatory properties in irritant 
contact dermatitis and T-cell-mediated contact allergy models, and diminished side 
effects, such as growth inhibition and induction of skin atrophy (Schacke, et al., 2009). 
In two separate studies it was shown that its anti-inflammatory properties in several 
primary human ocular cells were equivalent to the ones presented by dexamethasone 
(dex), a synthetic glucocorticoid. Additionally, expression of myocilin, which is linked 
to steroid-induced glaucoma, was reduced comparing to the expression induced by dex 
(Pfeffer, et al., 2010; Zhang, et al., 2009). LGD-5552 is another example of a non-
steroidal dissociated compound recently described. It possesses anti-inflammatory 
effects in vivo, exemplified by successfully treating adjuvant-induced arthritis and 
experimental autoimmune encephalomyelitis (EAE), an animal model of multiple 
sclerosis. The anti-inflammatory properties of this compound are similar to 
prednisolone, with the additional advantage of a reduced side effects profile (Lopez, et 
al., 2008; Miner, et al., 2007). Another potentially interesting GR ligand is Compound 
A (De Bosscher, et al., 2005) isolated from a desert shrub (Salsola tuberculatiformis). 
This compound was capable of efficiently transrepressing NF-κB-driven genes as well 
as incapable of activating GBS-mediated promoter activation.  Moreover, it was shown 
to be similar to dex in its ability to suppress inflammation in a zymosan-induced paw 
edema model in mice and to suppress the symptoms associated with EAE (De Bosscher, 
et al., 2005; van Loo, et al., 2009). Additionally, Compound A presented an improved 
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side effect profile compared to classical GCs with no hyperglycemia, hyperinsulinemia 
or a suppressive effect on the hypothalamic-pituitary-adrenal axis. A different study, 
however, despite observing improvements when treating EAE with low doses of 
Compound A, claimed that it induced high levels of apoptosis in several different type 
of cells and that doses only slightly higher than therapeutic doses were lethal to animals 
(Wust, et al., 2009). 
 
As described throughout chapter 1, GC regulation of transcription is now believed to be 
more complex than initially thought. The success of dissociated glucocorticoids still 
depends on more detailed and thorough studies, concerning for instance their anti-
inflammatory effects in vivo (using several different inflammation models),  as well as 
exploring the long list of side effects possibly associated with GR activity. Additionally, 
they should not be expected to only interact with GR. Are the new compounds 
interfering with other agents within the cells? Also are these new compounds capable of 
inducing novel mechanism of GR action which can lead to novel side effects obviously 
not being assessed? 
 
1.4.6. Alternative mechanisms of GCs action and gene induction for the anti-
inflammatory effects 
An increasing number of studies have cast doubt on this simple model of GC action, 
undermining the accepted dogma of the dichotomy between transrepression/anti-
inflammatory effects on one side and transactivation/side effects on the other. Hence it 
is indispensable to recognize the fact that GCs regulation of gene expression involves 
more complex and unclear mechanisms.  
 
First of all, it has been shown that GC can induce gene expression independently of the 
presence of palindromic GBS and GR dimerisation. For example, Signal Transducer 
and Activator of Transcription 5 (STAT5) is known to interact with GR and regulate 
expression of several genes in the absence of GBS (Smoak and Cidlowski, 2004). In 
fact, no GBS have been identified in some GC inducible genes, suggesting regulation in 
the absence of the dimerisation that can occur through cooperative interactions with 
transcription factors or binding of GR to half-sites (Groner and Shemanko, 2002). More 
evidence of GR-induced transcription in the absence of dimerisation comes from studies 
performed by Pearce’s group. Using several different GR dimerisation mutants they 
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showed that promoters with multiple GR binding sites, such as the one from 
phenylethanolamine N-methyltransferase, are still capable of being activated by the 
mutants, sometimes even better than the GR-wt (Adams, et al., 2003). Isolated GBS 
identified from promoters of GC-induced genes were also tested by Meijsing and 
colleagues for their ability to respond to GR mutants (Meijsing, et al., 2009). Again, 
some GBS were shown to respond to dex in the presence of GRdim.  In an interesting 
approach So and co-workers determined that the exact DNA sequence bound by GR, 
although extremely conserved for each individual GBS, varied extensively around a 
consensus, enhancing the complexity of GR transcriptional regulation (So, et al., 2007). 
This will be discussed in more detail later on. It appears that in many cases GC-
induction of transcription requires composite GC responsive regions (GRR) and that the 
GR hardly ever works alone (Clark, 2007; Kassel and Herrlich, 2007).  All the above, 
raises the question of how using reporters containing one or more copies of GBS to 
predict GR ability to dimerise and activate gene expression can lead to erroneous 
conclusions. For instance, GBS ability to respond to dex might actually be occurring in 
the absence of GR dimerisation. 
 
Secondly, more recent studies with GRdim mice have shown that not all anti-
inflammatory effects are independent of GR dimerisation since GCs did not treat all the 
inflammatory processes analysed in these mice. Additionally, these mice still presented 
side effects associated with GC treatment such as inhibition of bone formation (Kleiman 
and Tuckermann, 2007). 
 
Finally, there is evidence that GC can inhibit the inflammatory response through 
mechanisms which occur at post-transcriptional or translational levels (Clark, 2007). 
Also there are several potential anti-inflammatory genes, including IκBα, lipocortin-1, 
tristetraprolin (TTP), IL-10, glucocorticoid-induced leucine zipper (GILZ) and IL-1 
receptor antagonist, which are also transcriptionally induced by GCs and have been 
suggested to be relevant for their anti-inflammatory response (Clark, 2007; Newton, 
2000; Newton and Holden, 2007). Another gene transcriptionally upregulated by GCs 
and now known to play an important part in control of inflammation pathways is the 
dual specificity phosphatase 1 (DUSP1). The characterization of this protein and its 
impact in regulating inflammation will be scrutinized in the next sections. 
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1.5. Mitogen activated protein kinases and the inflammatory response 
MAPK signal transduction pathways are among the most widespread mechanisms of 
cellular regulation. All eukaryotic cells possess multiple MAPK pathways and each one 
can be activated through distinct sets of stimuli, such as hormones, mitogens, 
inflammatory cytokines and environmental factors. In recent years, it has emerged that 
several of these MAPK pathways in addition to the NF-κB are pivotal to the 
inflammatory response. 
 
Activation/inactivation of this group of proteins relies on a simple but effective 
mechanism of phosphorylation/dephosphorylation, respectively, of specific short 
activation motifs. After activation, the MAPK cascades continue by sequential 
phosphorylation of different substrates including transcription factors. MAPK such as 
JNK, MAPK p38 and ERK are involved in the regulation of the immune system, more 
specifically of the inflammatory response (Zhang and Dong, 2005). They play a crucial 
role in the regulation of inflammatory gene expression by acting at both transcriptional 
and post-transcriptional levels and are activated by pro-inflammatory stimuli. Whilst 
JNK regulates the activation of AP-1 (Whitmarsh and Davis, 1996), p38 is directly 
involved in regulation of transcription through transcription factors such as myocyte 
enhancer factor 2C (MEF-2C), ATF2 and NF-κB (Ono and Han, 2000; Schmitz, et al., 
2001; Treisman, 1996; Vermeulen, et al., 2003). MAPK p38 is also known to be 
involved in the post-transcriptional regulation of pro-inflammatory genes (Clark, et al., 
2003). 
 
1.6. Dual specificity phosphatase family 
MAPKs are known to be inactivated by tyrosine, serine/threonine and dual-specificity 
phosphatases. In mammalian cells the dual-specificity phosphatases (DUSPs) are a large 
family of which around 10 members are primarily responsible for inactivating MAPKs 
(Camps, et al., 2000). These 10 members can also be referred to as MAPK phosphatases 
(MKPs). This group of proteins share common features but can be subdivided according 
to characteristics such as substrate specificity, subcellular localization and structural 
organization of their genes (Dickinson and Keyse, 2006). They act upon MAPK by 
dephosphorylating both threonine and tyrosine residues of the Thr-X-Tyr activation 
motif (Keyse, 2000; Tamura, et al., 2002). This mechanism of inactivation represents a 
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rather efficient mode of modulating and controlling the MAPK pathways giving a 
central role for this family of proteins in the control of the inflammatory response. 
 
1.7. Dual specificity phosphatase 1  
Dual specificity phosphatase 1 is the founder of this large family of which at least 10 
different proteins were identified in mammals. DUSP1 is an inducible nuclear 
phosphatase first described as an immediate early response gene inducible by oxidative 
and heat shock stress (Keyse and Emslie, 1992). Regarding its substrate specificity 
DUSP1 may in some situations inhibit ERK (Camps, et al., 2000; Keyse, 2000), though 
it exerts its inactivating role preferentially upon JNK and p38 (Franklin and Kraft, 
1997). 
 
1.7.1. Regulation of DUSP1 by GCs and inflammatory or stress stimuli 
GCs were reported to induce the sustained and rapid expression of DUSP1 in different 
types of cells, from HeLa cells (Imasato, et al., 2002; Lasa, et al., 2002) to mast cells 
(Kassel, et al., 2001), macrophages (Chen, et al., 2002b) and osteoblasts (Engelbrecht, 
et al., 2003). This expression is GR-dependent and typically occurs within one hour 
(Lasa, et al., 2002). Additionally, the GR antagonist RU486 is able to block this 
expression. DUSP1 expression is also induced by pro-inflammatory stimuli, such as IL-
1 or LPS, in a strong though rapid and transient fashion. A dependency on p38 and/or 
JNK and NF-κB and ATF for this outcome was shown, suggesting that it might be a 
reflection of a feedback loop, responsible for the control of MAPK signalling (Carayol, 
et al., 2006; Hu, et al., 2007; Lasa, et al., 2002; Xu, et al., 2004; Zhao, et al., 2005).  
Reinforcing the concept of a tight control of the strength and duration of the 
inflammatory response is the fact that the expression of DUSP1 can be induced in a 
cooperative manner by both pro-inflammatory stimuli and GCs (Bhattacharyya, et al., 
2007; Issa, et al., 2007; Lasa, et al., 2002; Toh, et al., 2004). Even though the 
transcription factors involved in this upregulation have not been identified so far, it is 
hard to interpret these data in terms of the molecular mechanism, if one considers the 
negative effect that GR has on pro-inflammatory transcription factors such as NF-κB 
and AP-1. 
 
Stress stimuli also play a role in DUSP1 regulation, by inducing a rapid and strong 
increase of its expression. In some cases there appears to be an increase in transcription 
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dependent upon chromatin modification (Ho, et al., 2007; Li, et al., 2001). More than 
one study has also implicated ATF2 in this upregulation and in fact this transcription 
factor binds to the DUSP1 promoter (Breitwieser, et al., 2007; Hayakawa, et al., 2004; 
Teng, et al., 2007).  
 
The molecular mechanism underlying the GC-upregulation of DUSP1 gene remains 
unexplained. The requirement for GR to dimerise has been assessed in two independent 
studies. COS-7 cells, which do not express endogenous GR, were transfected with a 
murine 2 kb DUSP1 promoter construct and vectors expressing a wild type GR or a 
dimerisation defective GR (Ala458 → Thr458: GRdim). Following treatment with dex, it 
was shown that GRdim was not able to activate the reporter gene, unlike the wild type 
GR (Kassel, et al., 2001). On the contrary, bone marrow derived macrophages which 
only express GRdim, were still able to produce significant levels of DUSP1 protein upon 
treatment with LPS and dex (Abraham, et al., 2006). The contradictory information 
referring to the GR dimerisation dependency in the upregulation of DUSP1 still needs to 
be clarified before one can draw any conclusions.  
 
Also, dex and RU24858 (a prototypical dissociated ligand defective at classical GBS-
dependent transactivation) induced the expression of DUSP1, implying that the 
induction of DUSP1 might not be dependent on palindromic GBS and the classical 
mechanism of transactivation (Chivers, et al., 2006). While the studies described in this 
thesis were carried out, Okret and colleagues were investigating the promoter of human 
DUSP1 gene for elements involved in GC response and suggested that a 
CCAAT/enhancer binding protein beta (C/EBP-β) binding site as the crucial sequence 
for this regulation in A549 cells (Johansson-Haque, et al., 2008). According to them, 
GR was not binding directly to DNA but tethering with C/EBP-β in order to activate 
transcription of DUSP1. A different study implicated AP-1 and CREB in the 
upregulation of DUSP1 by GCs in human umbilical vein endothelial cells and they also 
discarded the hypothesis of GR directly binding DNA (Furst, et al., 2008).  
 
Evidence that DUSP1 gene expression can be regulated at the level of transcriptional 
elongation has also been reported. DUSP1 is upregulated by thyrotropin-releasing 
hormone (TRH) and epidermal growth factor (EGF) in rat GH4C1 pituitary cells. In the 
absence of stimulus, DUSP1 is constitutively expressed but a strong block of 
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transcriptional elongation occurs in exon 1, which is only overcome in the presence of 
TRH or EGF (Ryser, et al., 2002; Ryser, et al., 2001). Additional studies have in fact 
shown that in unstimulated conditions,  RNA pol II, NELF and DSIF associate with the 
proximal promoter of DUSP1 and elongation is paused (Fujita, et al., 2007). This 
inhibitory effect is overcome by recruitment of P-TEFb to DUSP1 gene after 
stimulation with TRH. P-TEFb causes dissociation of NELF/DSIF complex and 
increases the interaction of DSIF-RNA pol II interaction downstream of the elongation 
block site, enhancing the transcription process. This could be reversed by the addition of 
DRB, which as explained before inhibits P-TEFb activity. A different study elucidated 
that NELF presence is required to block the DUSP1 full expression since, knocking 
down NELF increased the expression of this phosphatase gene in unstimulated cells 
(Fujita, et al., 2009). Interestingly, knocking down NELF had different effects on 
DUSP1 gene expression depending on the stimulus analysed. NELF seemed to be 
required for DUSP1 gene induction after induction by TRH, whereas the gene 
expression induced by EGF was not altered in the absence of NELF. These studies 
highlight the importance of DUSP1 regulation of transcription through mechanisms 
downstream of RNA pol II recruitment.  
 
Moreover it is interesting to note that DUSP1 promoter has a high content of CpG 
islands, which have been associated with destabilization of nucleosome assembly, 
facilitating the binding of transcription factors and the transcriptional machinery prior to 
any stimulation. Sp1 seems to be involved in the recruitment of RNA pol II to these 
promoters (Ramirez-Carrozzi, et al., 2009; Sims, et al., 2004). Interestingly, DUSP1 
proximal promoter has been shown to bind Sp1 and Sp3 in the uninduced state (Ryser, 
et al., 2004). 
 
Post-transcriptional regulation of DUSP1 has been suggested to involve TTP, a zinc 
finger protein, which binds to adenosine/uridine-rich elements (ARE) regions. Knock 
out TTP dendritic cells presented an increase in DUSP1 mRNA levels (Bros, et al., 
2010). TTP has been shown to bind to the DUSP1 3’UTR in 3T3-L1 preadipocytes and 
in dendritic cells. Using a reporter gene system where the 3’UTR of the DUSP1 mRNA 
was cloned in the 3’UTR region of the reporter luciferase gene, it was shown that TTP 
was able to reduce the expression of the reporter gene in human embryonic kidney 
(HEK)293 and RAW264.7 cells (Emmons, et al., 2008; Lin, et al., 2008).  Two other 
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RNA binding proteins, HuR and nuclear factor 90 (NF90), were found to bind the 
3’UTR of DUSP1 mRNA in HeLa cells, increasing its stability and association with the 
translation machinery after H2O2 treatment (Kuwano, et al., 2008). 
 
Additionally, DUSP1 can be regulated at a post-translational level. DUSP1 is turned 
over by the ubiquitin-proteasome system and in fact, its levels are significantly 
increased in the presence of proteasomes inhibitors (Brondello, et al., 1999; Chen, et al., 
2005; Kassel, et al., 2001; Price, et al., 2007; Shi, et al., 2006). ERK has been shown to 
phosphorylate DUSP1 both in vitro and in vivo with a resulting increase in the half life 
of the protein of two to three fold (Brondello, et al., 1999; Sohaskey and Ferrell, 2002). 
A novel mechanism of control of DUSP1 by GCs was hypothesized by Kassel and co-
workers. Upon activation of mast cells, DUSP1 is degraded by the proteasome. 
However subjecting the cells to a prolonged treatment with GCs diminishes the 
proteosomal degradation of DUSP1 (Kassel, et al., 2001). Also, though the mechanism 
is still not understood, it seems that JNK can also phosphorylate DUSP1 whereas in this 
case it favours its degradation (Sohaskey and Ferrell, 2002). p38 has been shown to 
phosphorylate DUSP1 in vitro, but more studies are needed to understand the biological 
importance of this event (unpublished data mentioned in Li, et al., 2009) .  
 
Recently DUSP1 has also been suggested to be regulated by a novel mechanism where 
this phosphatase is acetylated, possibly by histone acetyltransferase p300, following 
TLRs activation. This did not affect its stability or intrinsic phosphatase activity, but 
instead increased its affinity for p38 thereby indirectly increasing its activity (Chi and 
Flavell, 2008). 
 
1.7.2. Anti-inflammatory effects of DUSP1 
The powerful anti-inflammatory properties of GCs are generally accepted to be the 
result of the phenomenon described as transrepression in which the GR interferes with 
the ability of AP-1 and NF-kB to induce the transcription of several pro-inflammatory 
genes. Widening of this concept is now taking place. 
 
MAPK p38 is responsible for the stabilization of pro-inflammatory mRNAs that possess 
ARE within their 3’-UTR. COX-2, IL-1α, IL-1β, IL-3, IL-6, IL-8, TNFα and vascular 
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endothelial growth factor are among that group of pro-inflammatory mediators (Clark, 
et al., 2003). This mechanism of the immune response control can be considered as 
important and common as the transcriptional regulation exerted via NF-κB. Many of the 
same genes that are positively regulated at a post-transcriptional level by p38 are also 
repressed at the same level by GCs (Clark and Lasa, 2003). Moreover, GCs can 
interfere with the p38-dependent mRNA stabilization of pro-inflammatory genes (Lasa, 
et al., 2001). The hypothesis is that this occurs by GC-dependent induction of DUSP1, 
which subsequently inhibits p38, leading to the destabilization of the inflammatory 
mRNAs and therefore to a negative control of the inflammatory response. Only one 
study linking all these events has been done for IL-6 mRNA stabilization (Quante, et 
al., 2008). One may also argue that the impact of DUSP1 upregulation can go even 
further if it is considered that p38, though through an unclear mechanism, can influence 
the transcriptional activity of NF-κB (Saccani, et al., 2002; Saha, et al., 2007; 
Vermeulen, et al., 2003) and also that the phosphorylation of c-Jun decreases when GCs 
upregulate DUSP1 (Wu, et al., 2006; Zhou, et al., 2007), which might suggest a 
consequence in the formation and function of AP-1 dimer. Therefore the upregulation of 
DUSP1 by dex would interfere with p38 and JNK, consequently inhibiting the action of 
NF-κB and AP-1 which as a final outcome will resemble the effects of transrepression. 
In fact recent data have suggested the dependency on DUSP1 for the inhibition of NF-
κB activity (Bladh, et al., 2009; King, et al., 2009; Wang, et al., 2008b). For example, 
the dex-mediated repression of TNFα-induced NF-κB-dependent transcription was 
significantly reversed by siRNA against DUSP1 (King, et al., 2009). 
 
The anti-inflammatory properties of GCs have been linked to DUSP1 activity in several 
types of cells. RNAi-mediated knockdown of DUSP1 expression in epithelial cells 
increased levels of phosphorylated p38 and JNK, and prevented dex from inhibiting 
expression of the pro-inflammatory adhesion molecule E-selectin. Overexpression of 
DUSP1 had the opposite effect (Furst, et al., 2007; Wadgaonkar, et al., 2004). In airway 
smooth muscle cells GCs inhibition of inflammatory mediator growth related oncogene 
(GRO)-α was shown to be dependent on JNK inactivation by DUSP1 (Issa, et al., 
2007). Dex was also shown to inhibit the production of monocyte chemoattractant 
protein 1 and the consequent migration of microglial cells to the site of inflammation by 
upregulating DUSP1 and interfering with p38 and JNK (Zhou, et al., 2007). 
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A few studies were done to evaluate if some compounds with anti-inflammatory action 
were dependent on DUSP1 for their effects. In an interesting study using RAW264.7 
macrophages different synthetic glucocorticoids were shown to induce DUSP1 in a 
manner that correlates with their relative anti-inflammatory potencies (Zhao, et al., 
2005). Endogenous endocannabinoids are released after brain injury and a recent study 
has shown that their effect of protecting neurons from inflammatory damage is 
dependent on DUSP1 upregulation and inactivation of MAPK signalling 
(Eljaschewitsch, et al., 2006). Astragali Radix, an oriental medicine thought to act as an 
immuno-regulator has been shown to operate through DUSP1 induction and consequent 
inactivation of p38 and ERK (Ryu, et al., 2008). Amino-acid L-glutamine protects mice 
from endotoxic shock through DUSP1 upregulation. Treatment with glutamine led to an 
inhibition of MAPK activity and an increase in DUSP1 mRNA and protein levels. 
siRNA experiments showed that knocking down DUSP1 abolished the glutamine ability 
to inactivate p38 and JNK and to protect against endotoxic shock (Ko, et al., 2009). 
Aurothiomalate is an anti-rheumatic drug which has recently been shown to inhibit 
COX-2, IL-6 and matrix metalloproteinase 3 (MMP-3) expression in human 
chondrocytes and cartilage. At the same time the levels of phosphorylated p38 were 
reduced whilst DUSP1 expression was increased. When using siRNA interference 
against DUSP1 it was shown that the ability of this compound to downregulate COX-2, 
IL-6 and MMP-3 and to dephosphorylate p38 was impaired (Nieminen, et al., 2010; 
Nieminen, et al., 2008). 
 
It is also relevant that DUSP1 seems important to the properties of the endogenous 
stress hormone cortisol (Bhattacharyya, et al., 2007). This study used a conditional 
deletion of GR in the myeloid lineage of mice. These mice were highly susceptible to 
LPS-induced endotoxic shock, which was shown to be dependent on p38 activity. In GR 
depleted macrophages treated with dex, DUSP1 was not induced and p38 was active, 
whereas in wild type macrophages DUSP1 was induced and p38 inactivated. Also, since 
they observed that LPS challenge resulted in the release of cortisol, it is likely that 
DUSP1 plays a role in the immunosuppressive effects of endogenous GCs that allow to 
control inflammatory responses taking place in macrophages. 
 
Several studies carried out in different labs using DUSP1-/-  macrophages and DUSP1-/- 
mice bring additional information about the importance of this phosphatase to the 
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regulation of the inflammatory process (Chi, et al., 2006; Frazier, et al., 2009; Hammer, 
et al., 2006; Salojin, et al., 2006; Wang, et al., 2007b; Wang, et al., 2008a; Zhao, et al., 
2006). When compared to wild type macrophages the same type of cells isolated from 
knockout mice exhibited prolonged JNK and p38 activation and presented a substantial 
increase in the levels of pro-inflammatory genes. DUSP1-/- mice were highly susceptible 
to endotoxic shock when challenged with LPS and this was paired with a dramatic 
increase in the serum levels of pro-inflammatory cytokines such as IL-6 and TNFα 
(Wang, et al., 2007b; Wang, et al., 2008a).  The same lab has also shown that DUSP1 
was involved in controlling the inflammatory response to Gram-positive bacteria. A 
more recent set of experiments carried out by the same group investigated the role of 
DUSP1 in host defence against live Gram-negative bacterial infection (Frazier, et al., 
2009). DUSP1 null mice susceptibility to accelerated mortality after Escherichia coli 
infection as well as to sepsis caused by cecal ligation and puncture was severely 
increased compared to wild type mice. Additionally, unlike wild type mice, DUSP1-/- 
mice did not respond to antimicrobial therapy for Gram-negative sepsis. Salojin and co-
workers also showed that collagen induced arthritis is more severe in the knockout mice 
(Salojin, et al., 2006). Interestingly the levels of the powerful anti-inflammatory 
cytokine IL-10 were also substantially increased. This suggests that this cytokine is 
probably negatively regulated in a DUSP1 dependent manner. Additionally, the fact that 
this increase does not protect against the hypersensitivity of these mice to endotoxic 
shock might suggest that this effect is dependent on DUSP1 or that this expression 
occurs too late in the course of events leading to septic shock. Once again, evidence 
reaffirms DUSP1 as an important negative regulator given that in its absence there is an 
exaggerated inflammatory response.  
 
Making use of the cutaneous air pouch model Abraham and co-workers showed that GC 
anti-inflammatory properties were impaired in DUSP1 knockout mice (Abraham, et al., 
2006). Using bone marrow macrophages from these mice it was confirmed that DUSP1 
is in fact necessary for the inhibition of both p38 and JNK through GCs action. Briefly, 
GCs effects on inflammatory mediators can be completely dependent on DUSP1, for 
example IL-1α; completely independent, for instance colony stimulating factor 2 
(CSF2); or partially dependent in the case of COX-2 among others. It is suggested that 
the anti-inflammatory action of GCs in a single cell type can operate through either 
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DUSP1-dependent or independent mechanisms. This study implicates DUSP1 as a 
central character in the anti-inflammatory effects of GCs in vitro and in vivo.  
 
One recent study brought some possibly contradictory data by showing that DUSP1-/- 
though highly sensitive to endotoxic shock were still sensitive to dex, suggesting that 
the anti-inflammatory properties of GC were still preserved in the absence of DUSP1 
(Maier, et al., 2007). One point of overlap in both studies is that in DUSP1-/- cells the 
dephosphorylation of p38 through dex action was impaired up to 8 hours. This might 
increase the interest in understanding if other DUSPs might play a role in the anti-
inflammatory properties of GCs and if in the absence of the DUSP1 they substitute for 
its contribution especially at later time points. Another consideration is that the studies 
used different type of cells and also that different models of inflammation were used in 
both studies. 
 
Obviously this is an issue still in need of more studies. Nonetheless, common to all the 
studies realised so far are the observations that DUSP1 knockout mice compared to the 
wild type are highly susceptible to LPS challenge, present an increase in the levels of 
pro-inflammatory cytokines and mediators and display higher sensitivity to endotoxic 
shock. Therefore DUSP1 seems to give a protective effect to exacerbated inflammatory 
responses. The current knowledge about this MAPK phosphatase indicates that it might 
be part of a novel mechanism of negative regulation of the inflammatory response by 
GCs. However, this mechanism remains unclear and numerous questions remain to be 
answered. Therefore it is necessary to further study how the expression of DUSP1 is 
regulated by GCs in order to understand the real importance and extent of its action.  
 
1.7.3. DUSP1 role in the side effects and resistance to GC treatment  
The benefits of steroid treatment for inflammatory diseases are sometimes 
overshadowed by the extensive list of undesired side effects. Considering DUSP1 as a 
vital character within the net of inflammatory gene regulation driven by GCs one might 
also evaluate whether it contributes in some way to the deleterious effects of this 
therapy.  
 
One of the most common side effects displayed by patients in GC-therapy is 
osteoporosis. This is thought to arise due to a decrease in osteoblast proliferation and 
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differentiation, survival and activity as well as an increase in osteoclast activity. DUSP1 
has also been implicated in the regulation of osteoblast proliferation, which is thought to 
be a process underlying osteoporosis. Inhibition of osteoblast proliferation was shown 
to correlate with an upregulation of some genes, including DUSP1, by dex (Leclerc, et 
al., 2004; Phillips, et al., 2006). Two different studies suggest ERK is the main MAPK 
responsible for the control of osteoblast proliferation and propose that the GC-inhibition 
of osteoblast proliferation is a result of GC-upregulation of DUSP1 which subsequently 
inactivates ERK (Engelbrecht, et al., 2003; Horsch, et al., 2007). A phosphatase 
inhibitor protected osteoblasts from GC-induced apoptosis and protected rats from GC-
induced osteoporosis (Conradie, et al., 2007; Hulley, et al., 2002). 
 
It has already been shown that this dual-phosphatase is critical for the metabolic 
homeostasis, given that mice lacking DUSP1 present resistance to diet-induced obesity 
(Wu, et al., 2006). In 3T3-L1 adipocytes DUSP1 was shown to work as an inhibitor of 
insulin-induced glucose uptake through the deactivation of p38 (Bazuine, et al., 2004). 
Therefore, even if 3T3-L1 adipocytes from mice treated with dex presented an increase 
in the levels of resistin (an adipocytokine that impairs glucose tolerance) and a decrease 
in the levels of adiponectin  (known to potentiate insulin sensitivity), it seems metabolic 
disturbances result from several mechanisms, some of which might include DUSP1 
(Fasshauer and Paschke, 2003).  
 
DUSP1 was also one of the genes upregulated in human lens epithelial cells as shown in 
two different studies (Gupta, et al., 2005; James, et al., 2005), though there is still not 
enough experimental evidence to establish a model explaining how this protein 
contributes to cataracts. 
 
Another significant problem with GC therapy is the inability of some patients to 
successfully respond to this treatment (Ito, et al., 2006). As referred to before several 
molecular mechanisms have been put forward to explain GC-insensitivity. Now it 
seems DUSP1 could be involved in some of them.  It is interesting that GC-resistance 
has been linked to the inability of GCs to inhibit MAPK pathways, since the use of 
MAPK inhibitors restored the ability of samples from patients to respond to GCs 
(Barnes and Adcock, 2009; Goleva, et al., 2009; Irusen, et al., 2002; Li, et al., 2004; 
Tsitoura and Rothman, 2004). Different studies have consistently shown inability of 
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GCs to downregulate levels of JNK or p38 phosphorylation in samples from GC-
resistant patients comparing to samples from GC-sensitive patients (Bantel, et al., 2002; 
Loke, et al., 2006; Sousa, et al., 1999). If DUSP1 plays a central role in the anti-
inflammatory effects of GCs by shutting down the MAPK pathways, the resistance 
presented by these patients could be a consequence of impairment in the expression or 
activity of DUSP1. This could be a direct effect of inability of DUSP1 to deactivate the 
MAPKs or it might be a result of GR phosphorylation by MAPK that is also known to 
occur coupled to impairment in GR activity (Itoh, et al., 2002; Rogatsky, et al., 1998). It 
would be interesting to explore the expression and activity of DUSP1 in the context of 
GC-insensitivity. In a study investigating the genes differently regulated between 
peripheral blood cells from GC-sensitive and –resistant asthma patients DUSP1 did not 
qualify as one (Hakonarson, et al., 2005). However one has to argue that not only 
mRNA levels but also protein expression and activity has to be evaluated in order to 
gather all the information required to exclude DUSP1 as a cause of resistance. However, 
given that there are numerous differences between human individuals it is likely that 
more than one factor will be associated with GC-resistance. Interestingly, a recent study 
has suggested the involvement of this phosphatase in GC-insensitivity. Briefly, this 
study involving patients with severe asthma has shown that in alveolar macrophages 
insensitive to GC-treatment p38 activity was increased and this was correlated with 
decreased expression of DUSP1 (Bhavsar, et al., 2008). Additionally, an independent 
study showed that T-cells were unresponsive to dex when pre-treated with cytokines IL-
2 and IL-4, which correlated with a reduction of GR translocation into the nucleus and 
DUSP1 expression. Sensitivity to GCs could be reversed by treatment with interferon-γ, 
which was associated with an increase in GR translocation to the nucleus and in the 
levels of DUSP1 expression (Goleva, et al., 2009). 
 
It would even be very interesting to evaluate if defects in DUSP1 expression and 
activity could be on the basis of some inflammatory diseases or at least lead to an 
increased susceptibility to develop one. 
 
1.8. Glucocorticoid receptor and regulation of transcriptional activation 
GCs positively regulate DUSP1 gene and therefore the description of how GR can 
influence transcription will focus on mechanisms of positive induction rather than 
repression of gene expression, another important feature of GR action. 
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1.8.1. GR-GBS 
GR binds to GGTACANNNTGTTCT, a DNA consensus sequence consisting of two 
inverted and imperfect repeats of hexanucleotide TGTTCT separated by the spacer, an 
element of any 3 nucleotides (Beato, et al., 1989). Functional GR binding sites can be 
found at variable distances from the TSS (John, et al., 2008; So, et al., 2007). By 
analysing functional GBS from several GC-induced genes, So and colleagues, found 
that there is considerable variation between functional GBS of GC-responsive genes of 
a given organism, as exemplified by GBS present in the Bcl2l1, Bteb1 and Peli1 loci of 
H. sapiens (Fig. 1.3). In contrast there is considerable evolutionary conservation 
between functional GR binding sites of orthologous genes as illustrated by a GBS 
present in the Bcl2l1 genes of H. sapiens and M. musculus (Fig 1.3). A GBS consensus 
was determined containing only 5 invariant residues, defined by GNACANNNNG (Fig. 
1.3) (So, et al., 2007). One of the hexanucleotides is normally more conserved than the 
other, which can influence the mechanism of binding for the GR. GR binds to the 
palindromic sequence as a homodimer and to single hexanucleotides as a monomer. The 
affinity for the binding as a dimer is one order of magnitude higher than the affinity for 
the binding as a monomer (Alroy and Freedman, 1992; Drouin, et al., 1992; Hard, et al., 
1990; Perlmann, et al., 1990; Segard-Maurel, et al., 1996). Binding develops by 
interaction of GR with the more conserved hexanucleotide followed by binding of the 
second monomer to the second hexanucleotide, which then stabilizes the GR-DNA 
complex (Dahlman-Wright, et al., 1991; Drouin, et al., 1992; Tsai, et al., 1988). At the 
same time, it has been shown that binding of GR to the imperfect palindromic sequence 
involves an allosteric effect exerted by the DNA itself on the receptor. Upon binding 
there is a conformational change in the DBD of the receptor, a reorientation of its D 
loop, favouring the interaction with the second GR monomer and stabilizing the dimer 
and the DNA contacts (Lefstin and Yamamoto, 1998). Ser459 and Pro493 are involved 
in this conformational change, since mutations of these residues lead to a constitutive 
dimerisation interface, which induces dimerisation of GR on a nonspecific DNA 
(Stockner, et al., 2003; van Tilborg, et al., 2000). Another interesting feature is the fact 
that GR binding has been shown to always occur in DNAse I hypersensitive sites, which 
can be constitutive or GC-inducible (John, et al., 2008).  
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Figure 1.3. GBS  
A. GBS consensus matrix weight adapted from So et al 2007 B.  Example of GBS from the human (Hs.) and 
mouse (Mm.) promoters of Bcl2l1, Bteb1 and Peli1. All of them obey to the consensus GNACANNNNG 
with 5 invariant base pairs, whereas the remaining residues vary extensively between different promoters. 
Each individual GBS is highly conserved between human and mouse. 
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The 3 bp spacer element is also important. Artificially changing the spacer to 2 or 4 bp 
in the GBS from mammary tumour virus- long terminal repeat (MMTV-LTR) and TAT 
promoters lead to a dramatic decrease in the affinity of the GR to bind and impaired the  
transcriptional induction (Chalepakis, et al., 1990; Dahlman-Wright, et al., 1991). Also, 
the spacer sequence itself can impact on the transcriptional activity of GR-GBS, since 
GBS that differ only in the spacer residues displayed different responses to dex in the 
presence of wild type GR and other GR defective mutants. In fact, the exact sequence of 
the GBS likely dictates different responses to dex, differences that were correlated with 
conformational changes induced by allosteric effects of the DNA on the GR (Meijsing, 
et al., 2009). The DNA sequence is apparently not just a docking site for the GR to bind 
but potentially “stores” information concerning how the GR is going to bind and how it 
is going to activate transcription. Basically, it is involved in dictating the regulatory 
mechanism that the GR will adopt in that particular gene. 
 
GR interaction with GBS is not a static event, but actually a dynamic phenomenon. For 
example, chaperones Hsp90 and p23 can be recruited to the sites where GR is binding 
GBS and are involved in promoting or destabilizing the complexes. Transcription factor 
cycling can allow sensing environmental changes, such as GC concentration. It has been 
shown that GR residence times influence the transcriptional output, suggesting that the 
rate of rapid exchange provides a means to tune transcriptional levels. In the “hit and 
run” model for the mechanism of GR action, the receptor is described as binding 
transiently to DNA (“hit”) inducing a more accessible chromatin structure for other 
transcription factors to bind and then is displaced from the GBS (“run”) (Freeman and 
Yamamoto, 2002; McNally, et al., 2000; Meijsing, et al., 2007; Rigaud, et al., 1991; 
Stavreva, et al., 2004).  A recent study has actually shown that ultradian hormone 
release induces cyclic GR-mediated transcriptional regulation (Stavreva, et al., 2009). 
Briefly, these pulses of GR induced transcription are correlated with GR rapidly 
exchanging between binding sites and by GR interaction with chaperones, allowing GR 
activity to be regulated depending on the concentration of available hormone. This 
constant GR displacement and assessment of the hormone levels allows for a tight 
modulation of promoter activation.  
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1.8.2. Glucocorticoid responsive regions (GRR) 
GR does not normally act alone but interacts with other transcription factors and 
cofactors to induce transcription. Therefore, GBS are normally embedded in composite 
regulatory regions of DNA. These regions can be designated as glucocorticoid 
responsive regions (GRR) and contain sequence binding motifs for the GR and for other 
transcription factors involved in the response to GCs. In fact, bioinformatics analysis 
has shown that binding sites for certain transcription factors (eg, C/EBP, Octamer-
binding transcription factor 1 [Oct-1]) are normally enriched in the vicinity of GBS 
(Phuc Le, et al., 2005; So, et al., 2007). Transcription depends on the presence of these 
sequences (cis-elements), on their accessibility for the transcription factors to bind, on 
the interaction of the transcription factors and cofactors (trans-elements) and on the 
expression and activity of these trans-elements. The right combination of these 
elements allows for transcription to occur by remodelling of the chromatin and effective 
recruitment of the transcriptional machinery.  
 
The set of GC-responsive genes can vary depending on the cell type, the developmental 
stage and the environmental context. Relying on composite regulatory elements to 
induce gene expression increases the plasticity in GC modulation of transcriptional 
activity. Activation of a specific gene will not only depend on the presence of the GR, 
but also on the expression and activity of additional transcription factors. Some 
transcription factors will only be present in specific tissues or at specific development 
stages, or will require activation by different signalling pathways. This obviously allows 
the GC to modulate gene expression in a more meticulous and precise way and reflects 
why not all the GC-induced genes are active in the presence of GC. A good example is 
the regulation of cytosolic PEPCK by the glucocorticoids. This gene is regulated in a 
tissue specific manner since it is upregulated by GCs in the liver and kidney, but 
inhibited in adipose tissue. This requires the presence of tissue specific elements to 
interact with GR. For example the two GR binding sites identified in the promoter are 
not able to mediate transcription on their own. Additional sequences containing binding 
sites for accessory proteins are also required, proteins including hepatic nuclear factor-3 
(HNF-3) and C/EBP (Hanson and Reshef, 1997; Sugiyama, et al., 1998). The regulation 
of carbamoylphosphatase synthetase (CPS) is another example. This gene is only 
expressed in hepatocytes and transient transfections of the GRR from CPS promoter 
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only resulted in activation of the reporter gene in hepatoma cells but not in fibroblasts 
(Christoffels, et al., 1998). 
 
1.8.3. Glucocorticoid interacts with other transcription factors to induce 
transcription 
An isolated GBS can be bound to GR and induce expression of reporter genes. However 
transcriptional induction can also occur in the presence of i) multiple half GR binding 
sites ii) GBS and additional transcription factors binding sites iii) binding sites for only 
GR or the cooperative transcription factor (tethering mechanism) (Fig. 1.4). Examples 
of different molecular mechanisms involving GR driven transcription will be described. 
 
GR multimerization can induce transcription. Here, GR monomers bind to the DNA and 
interact without the involvement of D loop of DBD, which is required for 
homodimerisation (Liu, et al., 1996). One example was observed in the MMTV-LTR 
where three half GR binding sites distributed within 40 bp were able to respond to GCs 
(Perlmann, et al., 1990) with the same fold as the palindromic GBS present further 
upstream. However these half GBS bound to GR need additional cooperating factors, in 
this case Oct-1 and NF-I. Another example of GRR containing half GBS and additional 
transcription factor binding sites was shown in the mouse phenylalanine hydroxylase 
gene. Here, one enhancer has been characterized which contains three half GR sites 
spread along 80 bp, but also binding sites for HNF1 and C/EBP which are required for 
activation by GCs (Faust, et al., 1996). 
 
The rat TAT locus contains an enhancer responsible for the response to dex that 
involves not only the binding of GR to a palindromic GBS but also the binding of 
C/EBP and HNF5 (Grange, et al., 1991). As previously mentioned, GR and Oct-1 
cooperate to activate the MMTV-LTR promoter. The binding of GR to a GBS was 
required for the binding of Oct-1 to its binding site which in turn was required for the 
transcriptional activation to occur (Bruggemeier, et al., 1991; Miksicek, et al., 1987). 
Other examples of similar cooperation occur at the promoter of somatostatin and 
PEPCK, where GR and CREB display a cooperative DNA binding to GBS and CRE, 
respectively (Imai, et al., 1993; Liu, et al., 1994). There are now several examples of 
composite glucocorticoid responsive regions with a variety of GR partners which 
 
59 
 
Chapter 1- Introduction 
 
 
 
 Simple GBS
GR binds as homodimer to GBS 
 
 
 Multiple half  GR sites
Several GR monomers bind 
independently of  dimerization; normally 
additional transcription factors binding 
sites are required and present nearby
 
 
 
 
 
 
Tethering 
GR does not directly bind DNA but 
interacts with a bound transcription 
factor; the reverse has been reported.
Composite regulatory region:
• GBS and other transcription factors 
that can directly or not interact
 
 
 
 
 • Heterodimers where the GR and 
another transcription factor bind DNA 
and interact with each other
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.4. GR interaction with transcription factors. 
Different modes of GR interaction with transcription factors to induce transcription.   
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include NF-I, C/EBP and Sp1 for the type IIA phospholipase A2 gene (Massaad, et al., 
2000), C/EBP and forkhead box (FOX)A/HNF3 for the CPS gene (Christoffels, et al., 
1998) and FOXO1 for the muscle RING finger 1 gene (Waddell, et al., 2008). 
 
As previously described, GR interferes with AP-1 ability to induce transcription. 
Interestingly, it has been shown that depending on the AP-1 dimer composition, GR 
binding to a nearby GBS can in fact stimulate its transcriptional activity, as shown on 
the mouse proliferin promoter. For instance, dimers composed by c-Jun/c-Jun have their 
transcriptional activity increased whereas the transcriptional activity of c-Jun/c-Fos 
heterodimers is repressed (Diamond, et al., 1990). A recent study has suggested an 
explanation for this fact. Based on previous data that showed nTrip6 (nuclear isoform of 
the thyroid hormone receptor-interacting protein 6) acted as a cofactor for AP-1 and was 
essential for the transrepression of AP-1 by GR by functioning as a tethering platform. 
Diefenbacher and colleagues have shown that nTrip6 was the key for the GR selectivity 
for AP-1 different dimers. The explanation is that nTrip6 does not interact with Jun 
family members or ATF2 but specifically interacts with the Fos family members. 
Therefore, GR which depends on nTrip6 to transrepress AP-1, is only able to repress the 
activity of dimers containing Fos members. Additionally, GR can also interfere with the 
activity of c-Jun:ATF2 dimers but at a different level, possibly by inhibiting JNK 
activity by inducing DUSP1, and indirectly inhibiting the activation of this dimer 
(Diefenbacher, et al., 2008). 
 
A different model of cooperation between GR and partners was shown in the promoter 
of α-amylase 2 gene in mouse. Here the binding sites for GR and pancreas transcription 
factor 1 (PTF1) factor are 100 bp from each other and proteins are thought to interact 
due to a loop in the DNA (Semsey, et al., 2005; Slater, et al., 1993). 
 
GR and STAT5 have also been reported to cooperate to induce gene activation, 
specifically in the promoter of β casein. One study provided evidence that the 
synergistic upregulation of this gene by GC and prolactin involved STAT5 and GR 
binding in a composite regulatory region, and that GR was binding to half GR binding 
sites (Lechner, et al., 1997). A different study showed that this upregulation could also 
occur by a mechanism involving GR tethering with STAT5 monomers since this could 
happen in the presence of STAT5 binding sites only (Stoecklin, et al., 1997). It was 
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later confirmed that both mechanisms can occur depending on the amount of activated 
GR present (Doppler, et al., 2001). Confirming the independence of GR 
homodimerisation for this process, STAT5 was equally associated with GR in 
immunoprecipitation experiments using extracts made from mammary glands of wild 
type or GRdim mice and the level of β casein protein expression was similar in wild type 
or GRdim samples (Reichardt, et al., 2001a). The same type of synergy dependent on 
tethering mechanisms has been shown to happen between GR and chicken ovalbumin 
upstream promoter transcription factor (COUP-TF)II (De Martino, et al., 2004) and 
between GR and Oct-1/2, though in this last case it is GR which binds to the DNA and 
then tethers Oct-1/2 (Wieland, et al., 1991). The α-macroglobulin gene was shown to be 
synergistically upregulated by GR and STAT3, through a composite regulatory region 
involving binding of STAT3, AP-1 and Oct-1 and tethering of GR (Lerner, et al., 2003). 
 
A well studied case of GR heterodimerisation occurs at the promoter of γ-fibrinogen in 
Xenopus laevis. The GR and XENOPUS: glucocorticoid receptor accessory factor 
(XGRAF) bind immediately adjacent and interact with each other to upregulate 
transcription. The ability of each factor to bind DNA increases when the partner is 
already bound (Morin, et al., 2001). This mimics the cooperative effect occurring with 
the binding of the GR homodimer: the binding of the first protein promotes the binding 
of the second one and this promotes the stabilization of the DNA-protein complex. 
There are two additional GR half sites upstream of the GR half site described above that 
when present increase the response to dex (Morin, et al., 2000). It is not known if the 
GR binds as a trimer, where one subunit interacts with XGRAF, forming a complex 
with higher transcriptional activity or whether the two additional GR half sites work by 
increasing the local receptor concentration and therefore increasing the likelihood of GR 
to bind to the other GR half site and interact with XGRAF. 
 
The enhancer from the rat TAT promoter contains a palindromic GBS which confers a 
15-fold response to dex. Surprisingly, a GR half site 50 bp from the GBS increases this 
response to 30-fold but is completely inactive when alone (Jantzen, et al., 1987). The 
half site could be used to increase the concentration of GR in the region increasing the 
probability of binding to the palindromic GBS. However in most of the cases it is not 
possible to exclude that the GR binding the half GR site is interacting with other 
transcription factors or cofactors to potentiate transcription, especially if one consider 
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that this specific enhancer activity also depends on the binding of C/EBP and HNF5 
(Grange, et al., 1991). What seems to be clear from all the different molecular 
mechanisms described here is that GR rarely acts alone and composite, complex nets of 
glucocorticoid responsive regions seem to be involved in GC-gene induction.  
 
1.8.4. GR interacts with cofactors and influences chromatin remodelling 
Initiation of transcription by GR requires not only its translocation into the nucleus and 
binding to DNA, but also depends on chromatin remodelling, such as displacement of 
nucleosomes and activation signals such as histone acetylations and specific 
methylations. For these purposes GR relies on interaction with several cofactors, which 
influence its transcriptional activity. This starts with the group of proteins complexed 
with GR in the cytoplasm, such as Hsp90, which induce the correct folding on the 
receptor allowing it to be bound by its ligand and consequently undergo a structural 
transformation that exposes the nuclear localization signal and allows the translocation 
of the GR into the nucleus. Cofactor-dependent steps continue once inside the nucleus 
leading to changes in chromatin structure and recruitment of the transcriptional 
machinery. GR cofactors include chromatin remodelling complexes (e.g. SWI/SNF, 
alteration/deficiency in activation/Spt-Ada-Gcn5-acetyltransferase ADA/SAGA), HATs 
(e.g. CBP/p300, p160 coactivator family), methyltransferases (e.g. coactivator-
associated arginine methylatransferase 1, CARM-1) and general transcription factors 
(e.g. components of DRIP complex) (Fig. 1.5) (Jenkins, et al., 2001). The cofactors 
have been identified by their ability to bind the GR directly, normally to the AF-1 or 
AF-2 domain, and alter its transcriptional activity. One of the first GR cofactors 
identified was the complex SWI/SNF. This ATP-dependent chromatin remodelling 
complex interacts directly with AF-1 and potentiates the activity of GR  in mammalian 
and yeast cells (Wallberg, et al., 2000). The importance of SWI/SNF for GR-induced 
regulation was also suggested by studies where cells deficient on SWI/SNF presented a 
decrease in GR mediated transcription (Muchardt and Yaniv, 1993; Yoshinaga, et al., 
1992). A different study estimated that around 40 % of GR-induced genes require the 
normal function of SWI/SNF (John, et al., 2008). One of the best studied examples of 
GR-coactivator interaction in the basis for transcriptional activation is the model for 
regulation on the MMTV-LTR promoter. When integrated in cellular chromosomes, 
this promoter contains six nucleosomes and its activation by GCs is dependent on a 
structural change in chromatin. GR was able to bind to the unchanged chromatin, but
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 Figure 1.5. GR interaction with cofactors. 
The activation of transcription requires GR interaction with several cofactors with different enzymatic 
activities. GR cofactors include chromating remodelling complexes (e.g. SWI/SNF), histone 
acetyltransferases (e.g. CBP/p300, p160 coactivator family), histone arginine methyltransferases (e.g. 
CARM-1) and general transcription factors mediating the interaction with RNA pol II (e.g. components of 
DRIP complex). Adapted from Perissi and Rosenfeld 2005. 
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other transcription factors involved in the response, such as Oct-1 and NF-I required 
structural changes in the position of nucleosomes to effectively bind. GR interaction 
with SWI/SNF was shown to be required for the chromatin remodelling and for the 
binding of NF-I (George, et al., 2009; Schoneveld, et al., 2004). Additionally, the 
interactions between GR and chromatin remodelling cofactors seem to be important for 
the dynamic GR “hit and run” model. The GR stably binds the promoter when this is 
present as free DNA or with chromatin, but it is displaced from chromatin when in the 
presence of chromatin remodelling complexes, suggesting the importance of the latter 
for the dynamic interaction of GR with DNA. The remodelling operated by GR and 
SWI/SNF on the MMTV-LTR promoter is followed by GR displacement (Fletcher, et 
al., 2002; McNally, et al., 2000; Rayasam, et al., 2005). 
 
Cofactors from the p160 family (steroid receptor coactivator 1, SRC1; GRIP1 and 
p300/CBP-interacting protein, p/CIP) can also act as GR cofactors to induce 
transcription. The elements of this family interact with AF-2 domain when the GR is 
bound to an agonist, but not when it is bound to an antagonist or lacks its ligand. This 
suggests that the interaction depends on the conformation of the receptor, which is 
influenced by the presence and type of ligand (Hong, et al., 1997). These factors do not 
directly bind DNA but interact with GR and seem to allow the recruitment of other 
cofactors such as CBP/p300 and CARM1. It was suggested that they act by remodelling 
chromatin through their acetylase activity and by serving as adaptors linking the AF-2 
domain of GR with other factors and the transcriptional machinery (Hong, et al., 1999; 
Jenkins, et al., 2001; Rogatsky, et al., 2002; Schoneveld, et al., 2004). Interestingly, 
GRIP1 (also known as transcriptional intermediary factor 2, TIF2) has been shown to 
interact with GR and other nuclear receptors and lead to activation but also repression of 
transcription (Cho and Kim, 2009; Hong, et al., 1997; Rogatsky, et al., 2001).  
 
CARM1 methylates Arg17 and Arg26 of histone H3 and cooperates with both p160 
family members and HATs such as CBP/p300 to enhance gene transcription. CARM1 
methyltransferase activity has been shown to be required for GC-induced gene 
expression. CARM1 can associate with the promoters of these genes, such as MMTV-
LTR, by binding to GRIP1, SRC1 or p-CIP, which in turn are bound to GR (Barr, et al., 
2009; Chen, et al., 2000; Ma, et al., 2001). Also knocking down CARM-1 significantly 
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decreased the transcriptional activity of GBS from GILZ and FKBP promoter 
(Meijsing, et al., 2009).  
 
As previously mentioned, CBP/p300 can act as a GR cofactor and bind directly to the 
receptor (Kamei, et al., 1996). However, it can also interact indirectly through p160 
family members or CARM-1. This complex can remodel chromatin through its histone 
acetylase activity but it can also act by acetylating transcription factors, by directly 
binding components of the transcriptional machinery or by recruiting other cofactors 
(Perissi and Rosenfeld, 2005). 
 
1.8.5. GR phosphorylation status influences its transcriptional activity 
GR can be modified by phosphorylations which ultimately influence its transcriptional 
activity by affecting GR ligand and DNA binding, subcellular localization, interactions 
with other proteins and its half-life. Phosphorylations of the human GR include Ser113, 
Ser141, Ser203, Ser211, Ser226 and Ser404, all in the AF-1 domain and all with 
equivalent phosphorylations in the mouse and rat GR (Ismaili and Garabedian, 2004). 
Phosphorylations are carried out by two main kinases families: MAPK and cyclin-
dependent kinases (CDKs). Phosphorylation of Ser203 is present at basal conditions and 
increases with addition of hormone whereas phosphorylation of Ser211 is dependent on 
hormone presence. Both Ser211 and Ser203 residues can be phosphorylated by CDKs 
and these specific phosphorylations are normally associated with enhanced 
transactivation of GBS containing promoters (Blind and Garabedian, 2008; Chen, et al., 
2008; Krstic, et al., 1997). For example TAT and GILZ promoters have been shown to 
preferentially be bound by Ser211 and Ser226 phosphorylated GR. Ser226 
phosphorylation is attributed to MAPK such as JNK and possibly p38 but it is normally 
associated with inhibition of its transactivation effects, the same being true for the 
phosphorylation of Ser404 by GSK 3β (Beck, et al., 2009; Ismaili and Garabedian, 
2004). Phosphorylation of Ser211 is accepted as the main hallmark of transcriptional 
activity for the receptor, and it seems that ultimately this increased transactivity requires 
that the relative phosphorylation of Ser211 is above that of Ser226 (Chen, et al., 2008). 
PKA phosphorylation has been suggested in vitro and overexpression of this kinase 
leads to enhanced GC activation of MMTV-LTR reporter gene, but more evidence is 
still required (Beck, et al., 2009). Phosphorylation of GR can affect its ability to 
mediate transcription. In fact its phosphorylation seems to be a mode of regulation that 
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allows to confer selectivity for specific promoters. First, studies revealed that there was 
only a minor reduction on transactivation of a reporter gene regulated by the MMTV 
promoter when GR serines were mutated to alanines. But surprisingly mutating the 
phosphorylation sites significantly decreased the activation of a reporter gene regulated 
by simple GBS, which become the first evidence that phosphorylating GR impacts its 
transcriptional activity in a promoter specific manner (Ismaili and Garabedian, 2004). 
One possible explanation for this promoter specific impact is that phosphorylations 
modify GR-cofactor interaction. A proposed mechanism suggests that GR 
phosphorylation of for example Ser211 promotes its interaction with DRIP/mediator 
complex subunit 14 (MED14) which is required for the upregulation of a specific set of 
genes. However inability of phosphorylating GR at Ser211, did not interfere with its 
ability to transactivate genes which are not DRIP/MED14 dependent (Chen, et al., 
2008; Hittelman, et al., 1999).  
 
1.9. Evolution and GRR 
The recent elucidation of mammalian genomes has shown that a similar set of genes is 
present in most mammalian species, giving basis to the hypothesis that it is in fact the 
differences in gene regulation and gene expression that mainly lie in the frontier 
between different species. The evolution of several different mechanisms of 
transcriptional regulation allows compensating for a considerable small pool of 
available genes in the genomes (Levine and Tjian, 2003; Wray, et al., 2003). At the 
same time, conservation of gene expression is thought to result from conservation of 
gene regulation mechanisms.  Molecular evolution has been the basis for many new 
approaches to study and understand gene regulation. The regulation of DUSP1 gene 
expression by glucocorticoids was the topic of the present thesis. To pursue this, a 
phylogenetic footprinting approach has been used as a tool to identify cis-regulatory 
elements in the 5’region of mouse and human DUSP1 genes. To clearly explain what is 
the basis for this approach, an overview of events acting on the evolution of cis-
regulatory regions, of how evolution can be used to identify cis-regulatory elements and 
of evolution of glucocorticoid responsive regions will be given first. 
 
Molecular evolution occurs primarily by alteration of the DNA sequence. This can have 
two major effects: on one hand it can change the protein coding sequence if the changes 
occur in the coding region of a gene; on the other hand it can affect the spatial, temporal 
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and or quantitative parameters of gene expression, if it occurs in non-coding functional 
DNA. Studying evolution of coding sequences is simplified comparing to the non-
functional. First, the regions of coding DNA are easily identified. Secondly, the coding 
nucleotide sequence is translated into an amino acid (a.a.) sequence according to a 
universal genetic code. This means that variations on the gene sequence can directly be 
correlated with changes in the protein a.a. sequence. The effects of changes in a.a. 
sequence on protein structure and function can often be predicted or determined by 
relatively straightforward biochemical approaches.  
 
In contrast, the study of non-coding functional sequence evolution does not have a 
reasonably defined approach or common vocabulary. The problem starts with the 
identification of such sequences. The information available so far indicates there are not 
universal structural features for cis-regulatory regions and it is not possible to determine 
what fraction of a locus is functional. There is not an explicit limit for how far upstream 
or downstream of a gene regulatory regions can be found. Cis-regulatory regions have 
been found up to 1 Mb away from the core promoter of the target gene (Lettice, et al., 
2002). They can be located in intronic regions of the target or an unrelated gene or even 
in different chromosomes (Nardone, et al., 2004). Obviously, this variation in distance 
and position of cis-regulatory regions complicates the task of first identifying them and 
secondly studying their evolution. 
 
As previously addressed, cis-regulatory regions contain binding sites for transcription 
factors. There are software programs that predict putative binding sites for transcription 
factors within the sequence of interest. However, these sites, of normally 6-15 bp, can 
actually vary around a consensus sequence allowing for a certain degree of degeneracy. 
This redundancy in the specificity of transcription factors for the DNA again makes it 
difficult to identify functional sequences even with informatics tools. Moreover there is 
redundancy in families of transcription factors with overlapping binding specificities for 
the different members, for example the AP-1 family members (Karin, et al., 1997). 
Additionally, sequences of binding sites can degenerate when transcription factors bind 
as dimers, which can normally occur with different partners. For example the GR itself, 
binds as a homodimer to two hexanucleotides, however one of them is found conserved 
more often than the other. Direct cooperation between transcription factors further 
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complicates the equation; one transcription factor binding site can modulate the 
properties of a nearby or relatively distant one.  
 
Many potential binding sites are in fact non-functional and not bound in vivo, whereas 
at the same time binding of transcription factors to the correct set of nucleotides but in 
inappropriate genomic locations can occur dissociated from transcriptional activation 
(Biggin and McGinnis, 1997; Li and Johnston, 2001). Discerning between functional 
and non-functional DNA is not an easy task.  The impact of evolution throughout time 
can actually mask the cis-regulatory regions making their identification and 
evolutionary study extremely difficult. 
 
The study of evolution of gene regulatory mechanisms is a fairly recent field 
(Dermitzakis, et al., 2005; Miller, et al., 2004). Most of the concepts are based on a 
popular theory, the neutral theory of molecular evolution, which was proposed by 
Kimura in 1983 (Kimura, 1983). Briefly, most of the sequence divergence observed 
between species results from mutations that have minor or no functional impact 
(neutral), allowing for their perpetuation. Conversely, mutations in functional DNA will 
have a negative impact in the function, will be deleterious for the organism and 
selection will therefore act to eliminate them, a process known as purifying selection. 
Sequence conservation between species is then correlated with sequences under 
evolutionary constraint and is thought to be a good indicative of functional DNA. This 
is the basic concept for phylogenetic footprinting, an approach used to identify cis-
regulatory regions discussed later on. Yet, even though information starts to accumulate 
the basic concepts relating function and evolution of non-conding regions are not clearly 
defined. 
 
1.9.1. Evolution of cis-regulatory regions 
The fundamental function of cis-regulatory regions of a gene is to integrate the 
information concerning the status of the cell at any given moment and to influence the 
expression of the corresponding gene accordingly. Enhancers are part of these cis-
regulatory regions and are involved in gene activation. They are characterized by 
specific features that make them suitable for selection to act. They can be located 
upstream, downstream or within regions transcribed and regulation normally results 
from the contribution of different modules, which might increase the probability of new 
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variations to be maintained. Variation mainly arises through mutation upon which 
evolution act.  
 
There are at least three possible models to describe the evolution of cis-regulatory 
regions (Strahle and Rastegar, 2008). In the first scenario, a new cis-regulatory region 
can arise by accumulation of mutations over a region of a few hundred base pairs 
creating a module of functional transcription factor binding sites (A in Fig. 1.6). In a 
second hypothesis, pre-existing cis-regulatory regions can be altered by mutations (B in 
Fig. 1.6). This can create new transcription factor binding sites or delete existing ones, 
which might change the activity of the module. In the third model (C in Fig. 1.6), it is 
not the sequence (cis) but the transcription factors (trans) binding the sequence which 
are affected. It can be referred to as evolution in trans and it is assumed that evolution 
acted first on the gene expressing that transcription factor. It can involve mutations 
affecting the transcription factor, by changing its expression profile, its DNA-binding 
domain or domains responsible for important protein-protein interactions (Wray, et al., 
2003). For example, a transcription factor can start being expressed in a cell type where 
it previously was not and activate an enhancer which previously was silent. The reverse 
can also occur. Several experiments have shown that altering the expression of a 
transcription factor will impact the expression of its targets (Alberts, 2002; Gilbert, et 
al., 2003). Variations in trans are highly pleiotropic and can have a broader impact than 
variations in cis, making them probably under a higher selective pressure. 
 
Variation can arise through several different types of mutations. Single nucleotide 
mutations can create or eliminate binding sites. Small insertion or deletion (indel) 
events can generate variation by creating or disrupting binding sites and/or changing the 
spacing between existing ones. Microsatellite repeat arrays can expand or contract, 
changing the space between functional cis-elements and altering the number of 
functional sites (Rockman and Wray, 2002). Transposition events can also cause 
significant rearrangements in the DNA, generating new binding sites or disrupting 
existing ones. In fact it has been shown that some experimentally characterized cis-
regulatory elements originated from transposable elements, such as a highly conserved 
neuronal enhancer of the proopiomelanocortin gene (Jordan, et al., 2003; Santangelo, et 
al., 2007). However, these new insertions or deletions might not immediately create a 
new cis-acting element but provide the raw material upon which selection will act.  
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Figure 1.6. Models for evolution of cis-regulatory regions 
 
 
 
 
 
 
A.  New binding sites in the proximity of other non-functional binding sites arise by accumulation of 
spontaneous mutations leading to the formation of a new cis-regulatory region. B. The function of pre-
existing cis-regulatory regions is altered by creation of new transcription factor binding sites or deletion of 
existing ones. C. Changes do not occur in the DNA sequence but in the transcription factors (trans) binding 
the sequence. Evolution acted first in the gene expressing that transcription factor. It can involve mutations 
affecting the transcription factor, by changing its expression profile, its DNA-binding domain or domains 
responsible for important protein-protein interactions. E.g., a transcription factor can start being expressed in 
a cell type where it previously was not and activate an enhancer which was previously silent. 
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Variations can also arise from gene duplications, which mean the additional element is 
now under a different selection constraint (Betran, et al., 2002). Variability in the 
sequence of cis-elements does not always have an impact in gene expression. Point 
mutations or indels between transcription factor binding sites might not alter the 
protein-protein interactions and some mutations within the binding sites are neutral and 
can be maintained. Even eliminating whole binding sites might be neutral if the locus 
contains other copies with redundancy in function (Wray, et al., 2003). 
 
1.9.2. Phylogenetic approaches to find regulatory regions 
Identification of cis-regulatory DNA regions within a gene can be accomplished; 
nonetheless it is far from a simple and straightforward task.  
The identification of regulatory regions involved in a specific response is simpler if 
DNA binding motifs are known for the transcription factors involved in that response. 
For example, searching for binding sites for the glucocorticoid receptor could help 
tracing glucocorticoid responsive regions. Still, just searching for similar sequences to 
the transcription factor binding site can be complicated; a massive number of matches 
for such a small sequence can be encountered, but most will in fact be non-functional. 
One way of improving this is to consider that transcription factors do not work alone, 
and therefore the binding sites identified in regions where clusters of several 
transcription factor binding sites are present are more likely to be functional. 
Additionally, including information about sequence conservation of the motifs can 
remarkably increase the rate of success in finding cis-regulatory elements (Narlikar and 
Ovcharenko, 2009). 
 
Using cross species sequence comparisons to identify functional sequences relies on the 
basic principles described by Kimura in the neutral theory of molecular evolution 
(Kimura, 1983). Hence, a popular approach to investigate regulatory regions is the use 
of “phylogenetic footprinting”. Within the non-coding regions of DNA there are 
segments of highly conserved sequences between species that receive the name of 
phylogenetic footprints. These islands of conserved sequences have been shown to 
contain cis-regulatory elements, where the sequence conservation reflects conservation 
of function in many studied genes (Wagner, et al., 2004). For example, comparison of 
human-rodent sequences can be used to identify highly conserved regions and evaluate 
if binding sites for the transcription factor of interest can be found there. Alternatively, 
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if one does not have a particular transcription factor to study, species comparisons can 
be used to identify regions of highly sequence conservation that can be tested for their 
function and where transcription factor binding sites can then be identified and their 
significance evaluated (Gibbs, et al., 2004). 
 
Sequence conservation of functionally important cis-elements is the primary assumption 
of phylogenetic footprinting. Whilst in most cases it has been proved to be true for 
protein-coding sequences, this assumption is far from being the rule when non-coding 
sequences are regarded. It is true that there are many examples of where this type of 
approach has been successfully used to identify regulatory regions (Elnitski, et al., 
1997; Loots, et al., 2000; Nobrega, et al., 2003; Pennacchio, et al., 2006; Prabhakar, et 
al., 2006). Still, it should not be forgotten that sequence conservation across species 
does not always imply functionality of the region (Cooper and Brown, 2008; Nobrega, 
et al., 2004). Conservation of nucleotides can be a product of chance or regions might 
have lost the evolutionary constraint recently enough not to be significantly different in 
sequence from orthologous functional regions. In an interesting study, Nobrega and 
colleagues deleted two regions of 1.5 and 0.8 kb of non-coding DNA from the mouse 
genome which contained 1243 non-coding sequences conserved between humans and 
rodents (70 % identity in a minimum of 100 bp segments). Mice were viable and only 
minor expression differences were seen for the genes around the same regions.  
 
Conversely, functional DNA might not be found in regions of highly conserved 
sequences.  A considerable number of cis-regulatory regions have been found in the 
globin gene complex, however not all of them are conserved between human and mouse 
(Hughes, et al., 2005; King, et al., 2005). New binding sites can arise by chance at a 
later point after species divergence or real binding sites can degenerate sufficiently to 
still maintain the specificity for the transcription factors but losing the high sequence 
similarity between species. It should not be expected that all cis-regulatory regions are 
under the same constraint and conserved between species. First, because there are many 
cases where the same gene is differently expressed for example in human and mouse, 
which can be related to divergence in at least some cis-regulatory sequences (Valverde-
Garduno, et al., 2004). Second, there are cases where the same pattern of gene 
expression is maintained by a different set of cis-regulatory regions in different species 
(Ludwig, et al., 2005; Oda-Ishii, et al., 2005). In fact, species evolution itself is greatly 
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derived by changes in the mechanisms of transcriptional regulation, which obviously 
will limit the use of phylogenetic footprinting. Evolution is a constant process and 
functional regions can be created or erased throughout time making the frontiers of 
evolutionary constraint harder to define. 
 
1.9.3. Using evolutionary conservation to identify GBS and GRR 
Yamamoto’s group developed a study to understand the organization and function of 
GBS present in GC regulated genes (So, et al., 2007). They assessed the sequence 
conservation, architecture and genomic positions of functional GBS within and between 
species. GBS appeared to be distributed evenly upstream and downstream of the gene 
they regulate. Their findings allowed to understand that the actual DNA sequence of 
functional GBS spread along the genome, varies immensely and has only 5 invariant 
base pairs of the 15 comprising the motif. Interestingly, the sequence of each individual 
GBS is highly conserved between different species indicating evolutional conservation 
(Fig. 1.3). As shown before, GR normally acts in cooperation with other transcription 
factors as part of a GRR. In agreement with that model, GBS appeared to be embedded 
in GRR that retain specific architectural features including the mentioned GBS as well 
as binding sites for additional transcription factors. Sequence conservation in the 
flanking sequences of the GBS could be seen up to 2 kb of distance. They detected 
enrichment of putative binding sites for known partners of GR such as AP-1, Sp1, and 
C/EBP in the regions surrounding the GBS. They also showed that GR occupancy at 
GBS seemed to correlate with transcriptional response.  
 
A second study allowed to further characterize functional GBS and GRR (So, et al., 
2008). They identified matches to the GBS consensus in promoters of GC-induced 
genes and assessed whether sequence conservation between mouse-human was enough 
to predict GBS functionality. Strikingly, the level of sequence conservation correlated 
directly with the probability of GR binding to that sequence. Briefly, the higher the 
number of residues conserved between human and mouse GBS the higher the 
probability of GR to bind to it. This probability reached 100 % when 15 out 15 bp were 
conserved. Interestingly, the same GBS sequence (GGAACAGAATGTTCA) was 
present in both Adamts 19 and DUSP1 loci of the mouse (the latter is referred to as 
GBS-29 in this thesis). Only the DUSP1 sequence was conserved between human and 
mouse and recognised by GR in mouse cells. This emphasises the importance of the 
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context where the GBS is present. This could in part correlate with the finding that 
functional GBS are present in highly conserved DNA regions containing binding sites 
for other transcription factors (So, et al., 2007). 
 
In summary, several important conclusions can be drawn by the data collected from 
these two studies. GBS sequences matching the consensus GNACANNNNG will be 
present in GRR where the GR binds. The exact sequence of each functional GBS 
present throughout the genome varies extensively and conforms to the above consensus; 
however each individual functional GBS is highly conserved between species in 
position, sequence and orientation. In fact, conservation of sequence correlates directly 
with occupancy by the GR and consequent transcriptional activity. The surrounding 
context of a GBS seems to be highly preserved between species in sequence and 
architecture reflecting the need for binding sites of additional transcription factors 
cooperating with GR. Evolution seemed to favour the preservation of sequence, 
orientation and position of modules involved in response to GCs.  
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1.9.4. Aims 
Even with the limitations mentioned above, phylogenetic approaches come across as 
powerfull techniques to trace regulatory regions. Additionally, sequence conservation 
has been correlated with functional glucocorticoid responsive regions, as discussed 
above. Therefore the use of evolutionary sequence conservation in the form of 
phylogenetic footprinting to study the regulation of the GC-responsive gene DUSP1 
was regarded as a feasible and reliable tool. The main aim of this thesis was to elucidate 
the molecular mechanism by which GCs can upregulate DUSP1 gene expression. 
Understanding how the GCs modulate DUSP1 gene expression, one of the effectors of 
its anti-inflammatory properties, can in the future improve the way inflammation is 
controlled. 
 
The work was developed in order to: 
• Identify regions in the DUSP1 promoter mediating the response to 
glucocorticoids; 
• Identify possible partners of GR; 
• Evaluate the dependency for GR dimerisation; 
• Compare all the above molecular mechanisms and features between human and 
mouse. 
 
As a starting point, a phylogenetic approach using two species, mouse (Mus musculus; 
Mm.) and human (Homo sapiens; Hs.) was conducted to orientate the search for 
glucocorticoid responsive regions within the DUSP1 5’ region of those two species. 
More precise details regarding the parameters used will be given in the first chapter of 
results. 
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2. Chapter 2 - MATERIALS and METHODS 
 
2.1. Materials 
 
2.1.1. General 
All reagents were purchased from Sigma-Aldrich Co. (UK) apart from the items listed 
below: 
• Agarose, ‘SeeBlue® Pre-Stained Standard’, ‘ZeroBlunt® PCR Cloning Kit’, ‘One 
Shot® TOP10 competent cells’ and salmon sperm DNA were from Invitrogen (USA); 
• Acrylamide 30% (w/v)/bis-acrylamide 0.8% (w/v) was from Severn Biotech Ltd 
(UK); 
• DTT was from Alexis Corporation (UK); 
• ‘QuikChange® II XL site directed mutagenesis kit’, ‘QuikChange® site directed 
mutagenesis kit’ and pBluescript KS+ plasmid from Stratagene (UK); 
• Yeast extract and Tryptone were from Biogene (UK); 
• Agar was from Difco (USA); 
• ‘QIAquick® Gel Extraction Kit’, ‘QIAprep® Spin Miniprep kit’, ‘Superfect 
Transfection Reagent’ and ‘QIAamp RNA Blood kit’ were from Qiagen Ltd (UK); 
• ‘UltraMobius 1000 Plasmid Kit’and dog and rat genomic DNA were from Novagen 
(UK); 
• ‘Wizard® SV Gel and PCR clean-up system’, ‘Dual Luciferase® Reporter Assay 
System’ Kit, 100bp DNA Ladder, Passive Lysis Buffer, Loading Buffer, pRL-TK, 
pGL3-Basic, pGL3-Promoter and pGL4.26 reporter vectors and PureYield™ Plasmid 
Midiprep System were from Promega (UK); 
• ‘Cryovials’ were from Simport (Canada); 
• ‘Microspin S-200 HR’ columns, Microspin G-25 columns’, ‘Enhanced 
chemiluminescence (ECL) Western Blotting Detection Reagents’ kit, Poly (dI-dC).Poly 
(dI-dC), [γ-32P]-dATP and Protein A-sepharose were from GE Healthcare (UK); 
• Polyscreen ® PVDF Transfer membrane was from Perkin Elmer Life sciences (UK) 
• Molecular biology enzymes were from New England BioLabs (UK); 
• Immobilized Streptavidin (6% beaded agarose) was from Pierce (USA); 
• MasterAmpTM PCR Optimization Kit was from Epicentre Technologies (USA); 
• SYBRGreen I was from Molecular Probes (USA); 
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• Mouse and human genomic DNA were from Clontech (USA); 
• SYBR Premix Ex Tap was from Lonza Biologics (UK); 
• One-Step RT qPCR Mix was from Eurogentec (Belgium); 
• Rotor-Gene 3000 was from Corbett Research Ltd, (Australia); 
• Sonicator: VCX130 was from Sonics (Switzerland); 
• TaqMan probes GAPDH Mm 99999915_g1 and DUSP1 Mm00457274_g1 were 
from Applied Biosystems (USA). 
 
2.1.2. Antibodies 
 
Table 2.1.  List of antibodies used for the different techniques. 
Name Species Source 
C/EBP-β Rabbit polyclonal Cell Signaling (USA) 
GR (8992X) Rabbit polyclonal Santa Cruz (USA) 
FOXO3a Rabbit polyclonal 
Gift from Prof. E. Lam 
(Imperial College) 
Rabbit IgG horseradish peroxidise 
conjugated 
Swine polyclonal DAKO (UK) 
Rabbit IgG (ChIP) Rabbit Santa Cruz (USA) 
p50 (C-19X) Goat polyclonal Santa Cruz (USA) 
p65 (F-6X) Mouse monoclonal Santa Cruz (USA) 
 
2.2. Methods 
 
2.2.1. Tissue Culture 
Dulbecco’s Modified Eagle’s medium (DMEM), Foetal Bovine Serum (FBS) and 
trypsin-EDTA were from PAA (Austria). 
 
2.2.1.1. General Maintenance 
Human cervical epithelial carcinoma (HeLa) cells, mouse embryonic fibroblasts (MEFs) 
and COS-7 (monkey kidney fibroblasts) cells were cultured in DMEM supplemented 
with 10 % (v/v) FBS and maintained in a humidified atmosphere with 5 % CO2 at 37 
ºC. All cell culture work was carried out in a class II laminar flow cabinet.  
 
2.2.1.2. Transient transfection of HeLa cells using ‘Superfect’ reagent 
HeLa cells were seeded in six-well plates at a density of 1.5 x 105 cells/well. The 
following day cells in each well were transfected with 200 ng of the indicated DUSP1 
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reporter/Firefly construct, 100 ng of pRenilla-TK plasmid and 700 ng of pBluescript 
(total of 1 µg DNA/well). The volume was brought up to 100 µl by adding DMEM and 
5 µl of Superfect reagent was added. This was mixed by vortexing and left at room 
temperature for 10 min allowing the Superfect-DNA complexes to form. After washing 
cells with sterile phosphate buffered saline (PBS: 120 mM NaCl, 2.7 mM KCl, 3.6 mM 
Na2HPO4, 2.8 mM NaH2PO4), 500 µl of DMEM supplemented with 10 % (v/v) FBS 
were added to each well along with 105 µl of the Superfect-DNA mixture. The cells 
were left to incubate for 3 hours at 37 ºC, after which they were washed with sterile 
PBS. 3 ml of DMEM supplemented with 10 % (v/v) FBS was added to each well. To 
proceed with luciferase assays dex (final concentration 100 nM) or vehicle (0.1% 
EtOH) were added. Following 20 hours of incubation at 37 ºC, cells were harvested 
using 200 µl of passive lysis buffer (supplied with the Dual Luciferase® Reporter Assay 
System’ Kit) and actively lysed by 2 rounds of freezing/thawing. 
 
2.2.1.3. Transient transfection of COS-7 cells using ‘Superfect’ reagent 
Vectors expressing GR-wt and GRdim (Ala458 → Thr458: a dimerisation-defective 
mutant) were a gift from Dr. A. Cato (Institute of Toxicology and Genetics, Karlsruhe, 
Germany). The procedure described in 2.2.1.2 was used except for the following: COS-
7 cells were transfected with 200 ng of the appropriate DUSP1/Firefly construct, 100 ng 
of pRL-CMV plasmid and 700 ng of pBluescript or 200 ng of the appropriate 
DUSP1/Firefly construct, 100 ng of pRL-TK, 650 ng of pBluescript and 50 ng of GR-
wt or GRdim expression vectors in a total of 1 µg DNA/well for reporter gene assays. For 
subsequent nuclear extraction and use in EMSA, COS-7 cells were transfected with 50, 
100 or 200 ng of GR-wt or GRdim expression vectors and pBluescript vector to a total of 
1 µg DNA/well.  
 
2.2.1.4. Transient transfection of MEFs cells using ‘Superfect’ reagent 
MEFs were seeded at 4 x 105 cells/well in six-well plates the day prior to transfection. 
The procedure for transient transfection was the same as described in 2.2.1.2. 
 
2.2.1.5. Stable Transfection of HeLa cells using ‘Superfect’ reagent 
HeLa cells were seeded in six-well plates at a density of 1.5 x 105 cells/well. The 
following day cells in each well were transfected with 200 ng of pGL3B(Hyg)-Hs.4.8kb 
reporter construct and 800 ng of pBluescript (total of 1 µg DNA/well). The volume was 
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brought up to 100 µl by adding DMEM and 5 µl of Superfect reagent was added. This 
was mixed by vortexing and left at room temperature for 10 min allowing the Superfect-
DNA complexes to form. After washing cells with sterile PBS, 500 µl of DMEM 
supplemented with 10 % (v/v) FBS were added to each well along with 105 µl of the 
Superfect-DNA mixture. The cells were left to incubate for 3 hours at 37 ºC, after which 
they were washed with sterile PBS. 3 ml of DMEM supplemented with 10% (v/v) FBS 
was added to each well and cells were allowed to recover and propagate for 48 h. Cells 
were then trypsynized and seeded at 1.0 x 105 cells/well in DMEM supplemented with 
10 % (v/v) FBS and 300 µg/mL of hygromycin (the selection antibiotic). A negative 
control with the same amount of cells not transfected was also set up. Cells were 
selectively grown in medium containing hygromycin, which was changed every two 
days. After all the cells in the negative control were dead and clumps of cells could be 
observed in the transfected wells, cells were trypsynised, pooled and were allowed to 
propagate always in selective medium. Stocks were kept in liquid nitrogen. 
 
For luciferase assays, cells were seeded at 1.5 x 105 cells/well in a 6-well plate with 
DMEM supplemented with 10 % (v/v) FBS (unless otherwise described) and the next 
day were treated with either dex (100 nM) or vehicle (0.1 % EtOH). Following 6 hours 
of incubation at 37 ºC, cells were harvested using 200 µl of passive lysis buffer and 
actively lysed by 2 rounds of freezing/thawing. 
 
2.2.1.6. Luciferase Assay  
Cell lysates were centrifuged for 15 s at 13 000 rpm. 20 µl of each cleared lysate was 
loaded into a luminometer 96-well plate. Firefly and Renilla luciferase activity were 
measured with ‘Dual Luciferase® Reporter Assay System’ Kit according to 
manufacturer’s instructions. 
 
2.2.2. Cloning of DUSP1 reporter fragments 
All primers were purchased from MWG-Biotech and all the constructs generated were 
verified by sequencing reactions carried out with the same company. 
 
2.2.2.1. Polymerase Chain Reaction (PCR) 
DUSP1 reporter fragments were generated using the templates and primers in Table 2.2. 
The PCR reaction mix containing 500 ng of template, 100 pmol of each primer , 2 U of 
81 
 
Chapter 2 – Materials and Methods 
Vent Polymerase and 10 µl of 2 x buffer from the MasterAmpTM PCR Optimization kit 
was set up in a final volume of 20 µl. The PCR conditions were as follows: an initial 
denaturation step of 5 min at 95 ºC was followed by 30 cycles of 30 s at 95 ºC, 1 minute 
at 55 ºC and 1 minute at 72 ºC and a final extension step of 10 min at 72 ºC. 
 
Table 2.2.  List of templates and primers used to generate the DUSP1 reporter constructs 
Construct Template Primer Sequence 
CGGGTACCTGGGATTCTAATCCAGGCAG 
pGL3B-Hs-4.8kb Human genomic DNA CGACGCGTGTGCTCTTTGTCTGTTCTCGG 
GGACGCGTTCTGTGGTTACAGAGACCAG 
pGL3B-Hs-2.7kb Human genomic DNA CGACGCGTGTGCTCTTTGTCTGTTCTCGG 
GGGGTACCACAAATCAAGTCGGTATGCAGTG 
pGL3B-Hs-1.7kb pGL3B-Hs-2.7kb CGACGCGTGTGCTCTTTGTCTGTTCTCGG 
GGGGTACCAGTTGCCACTGGTGATACAGCTCG 
pGL3B-Hs-1.5kb pGL3B-Hs-2.7kb CGACGCGTGTGCTCTTTGTCTGTTCTCGG 
GGGGTACCTTGTGGCCGGCTTCTGTTCC 
pGL3B-Hs-1.1kb pGL3B-Hs-2.7kb CGACGCGTGTGCTCTTTGTCTGTTCTCGG 
GGGGTACCGAGTTTGCTTGCTCACACTTTC 
pGL3B-Hs-0.7kb pGL3B-Hs-2.7kb CGACGCGTGTGCTCTTTGTCTGTTCTCGG 
pGL3B-Mm-4.5kb Mouse genomic DNA 
GGACGCGTTGGGCTCCTGGCCCAGGCTCAAC 
GGCTCGAGGCGGTTCTCCAGAAAAAGTCGGTC 
pGL3B-Mm-1.5kb Mouse genomic DNA 
GCGGGTACCAAATTTGAAGTTGGTATGCAGTTTG 
GCGGGTACCGTTGAGGTCCTCAGCTGAATAAGTAG 
GGGGTACCGGTGGCGCAATGTTTATG pGL3P-GRR-1.3-
Hs. 
pGL3B-Hs-
2.7kb CGACGCGTAACACTTGGGAAGACC 
GGGGTACCGGTGGCGCAATGTTTATG pGL3P-GRR-1.3-
Hs.(-1366/-1245) 
pGL3P-GRR-
1.3-Hs. GGACGCGTCCCCCTGGACAGCGGAGCC 
GGGGTACCGGTGGCGCAATGTTTATG pGL3P-GRR-1.3-
Hs.(-1366/-1254) 
pGL3P-GRR-
1.3-Hs. GGACGCGTCAGCGGAGCCTGCTGCAGC 
GGGGTACCGAAACCGCAGAATG pGL3P-GRR-1.3-
Hs.(-1350/-1237) 
pGL3P-GRR-
1.3-Hs. CGACGCGTAGTGACGGCCCCCTGGACA 
GGGGTACCTCCCCCAGGAGGGGAGGAA pGL3P-GRR-1.3-
Hs.(-1366/-1287) 
pGL3P-GRR-
1.3-Hs. CGACGCGTGGTACACAAACATAAAC 
GGGGTACCGAAACCGCAGAATG pGL3P-GRR-1.3-
Hs.(-1350/-1263) 
pGL3P-GRR-
1.3-Hs. CGACGCGTGCTGCAGCGACGCGAC 
GGGGTACCTCCCCCAGGAGGGGAGGAAA pGL3P-GRR-1.3-
Hs.(-1366/-1263) 
pGL3P-GRR-
1.3-Hs. CGACGCGTGCTGCAGCGACGCGAC 
GGGGTACCAGTTGCCACTGGTGATACAGCTCG pGL3P-GRR-1.3-
Hs.(-1426/-1297) 
pGL3B-Hs-
2.7kb CGACGCGTCATAAACATTGCGCCACC 
GGGGTACCAGTTGCCACTGGTGATACAGCTCG pGL3P-GRR-1.3-
Hs.(-1426/-1237) 
pGL3B-Hs-
2.7kb CGACGCGTAGTGACGGCCCCCTGGACA 
GGGGTACCAGTTGCCACTGGTGATACAGCTCG pGL3P-GRR-1.3-
Hs.(-1426/-1185) 
pGL3B-Hs-
2.7kb CGACGCGTAACACTTGGGAAGACC 
GGGGTACCGGTGGCGCAATGTTTATG pGL3P-GRR-1.3-
Hs.(-1366/-1185) 
pGL3B-Hs-
2.7kb CGACGCGTAACACTTGGGAAGACC 
GGGGTACCAGTTGCCACTGGTGATACAGCTCG pGL3P-GRR-1.3-
Hs.(-1426/-1096) 
pGL3B-Hs-
2.7kb CGACGCGTAACAGAAGCCGGCCACAAC 
GGGGTACCGGTGGCGCAATGTTTATG pGL3P-GRR-1.3-
Hs.(-1315/-1185) 
pGL3B-Hs-
2.7kb CGACGCGTAACACTTGGGAAGACC 
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pGL3P-GRR-1.3-
Mm 
Mouse 
genomic DNA 
GGGGTACCTTGCAAAGAGGAAGAAACC 
CGACGCGTATGACTACAGGGTAGG 
pGL3P-GRR-1.3-
Mm(-1509/-1029) 
Mouse 
genomic DNA 
GGGGTACCGAAAAGGCAGCAGCTGTAAC 
CGACGCGTACACCTGGGAAGACCGAAATG 
pGL3P-GRR-4.6-
Hs. 
Human 
genomic DNA 
CGACGCGTCCACTCAGGCCTACCTTGAG 
CGGGTACCTGGGATTCTAATCCAGGCAG 
pGL3P-GRR-4.6-
Mm. 
Mouse 
genomic DNA 
GCGGTACCTGGGCTCCTGGCCCAGGCTCAAC 
GCACGCGTCCTTTAAGGCTCACCCTGATGG 
pGL3P-GRR-4.6-
Cfa. 
Dog genomic 
DNA 
GCGACGCGTACTTAACCCATCTTGAGGGGC 
GCGGGTACCCTGGGATTCTAACCCAGGCAG 
pGL3P-GRR-4.6-
Rn. 
Rat genomic 
DNA 
GCGACGCGTTTTCTGGCCCACTCT 
GCGGGTACCCTACGCTCCTGGCCC 
pGL3P-GRR-29-Hs. Human genomic DNA 
GCGGTACCGACTGCACAGAGCTGATGACTCGGC 
GCACGCGTAAGGCATTTGAAACAAGAACAACCC 
pGL3P-GRR-29-
Mm. 
Mouse 
genomic DNA  
GCGGTACCGAACTCACAGGGCCTGTGACTCAGGG 
GCACGCGTAAGGACCTTGGAAGATGAAGAAGGAG 
pGL3P-GRR-29-
Cfa. 
Dog genomic 
DNA 
GGTACCACTGCACAGGGCAGATGACTCGCAG 
GGACGCGTAAAAGCATTTTAAGCTGAAGAATAGCCTATG 
pGL3P-GRR-29-
Rn. 
Rat genomic 
DNA 
GGTACCGAACTCACAGGGCCTGTGACTCAGG 
GGACGCGTAAGGACATATGAAGTTGAGGAAGTAGATG 
pGL3P-GRR-1.3-
CFa. 
Dog genomic 
DNA 
GGTACCATCCCATCCCCCCTGCCCGCGGAGAG 
GGACGCGTAGGGCGGGCCTCCGGGGCGGGGGAGGGCGG 
pGL3P-GRR-1.3-
Rn. 
Rat genomic 
DNA 
GGTACCCCCCTTGCAAAGAGGAAGAAACGCCAG 
GGACGCGTCATGACTACGGGGTAGGCCGTGAGCC 
Hs.4.6GRR-(-4834/-
4430) pGL3P-Hs-4.6 
CGGGTACCTGGGATTCTAATCCAGGCAG 
GCACGCGTGGGACAGAGCTAGCTGCC 
Hs.4.6GRR-(-4834/-
4530) pGL3P-Hs-4.6 
CGGGTACCTGGGATTCTAATCCAGGCAG 
GCACGCGTTTGAGAGGCAAGAGCCCAG 
Hs.4.6GRR-(-4740/-
4369) pGL3P-Hs-4.6 
GCGGTACCTTCGTTACAAAAGTTACA 
CGACGCGTCCACTCAGGCCTACCTTGAG 
Hs.4.6GRR-(-4635/-
4369) pGL3P-Hs-4.6 
GCGGTACCGGTTTGGACACACAGCTC 
CGACGCGTCCACTCAGGCCTACCTTGAG 
Hs.4.6GRR-(-4740/-
4459) pGL3P-Hs-4.6 
GCGGTACCTTCGTTACAAAAGTTACA 
GCACGCGTTTACAAACAGATCTCC 
Hs.4.6GRR-(-4740/-
4495) pGL3P-Hs-4.6 
GCGGTACCTTCGTTACAAAAGTTACA 
GCACGCGTCCCACAGAGCTGTGTCAT 
Hs.4.6GRR-(-4705/-
4430) pGL3P-Hs-4.6 
GCGGTACCTTCAAATCATTCAGAGTCA 
GCACGCGTGGGACAGAGCTAGCTGCC 
Hs.4.6GRR-(-4666/-
4430) pGL3P-Hs-4.6 
GCGGTACCACTCCACCTTCCAAAG 
GCACGCGTGGGACAGAGCTAGCTGCC 
pGL4-HsGBS-
1.3Oligo - 
CGAAACGCAGAATGTTCCTGACTCGGCACCCC 
TCGAGGGGTGCCGAGTCAGGAACATTCTGCGGTTTCGGTAC 
pGL4-MmGBS-
4.6Oligo - 
CCTCCTTAGGATGTTCTGAACACAGTGTGACTTTGGACAAGC 
TCGAGCTTGTCCAAAGTCACACTGTGTTCAGAACATCCTAAGGAG 
pGL4-HsGBS-
4.6Oligo - 
CACGGTTAGAATGTTCTGAACACTGTGTGACTTTGGACAGAC 
TCGAGTCTGTCCAAAGTCACACAGTGTTCAGAACATTCTAACCGT 
pGL4-MmGBS-
29Oligo - 
CCGGGGAAGGGAACAGAACATTCGGCCCCAGGC 
TCGAGCCTGGGGCCGAATGTTCTGTTCCCTTCCCCGGGTAC 
pGL4-HsGBS-
29Oligo - 
CTGGGAAAGGGAACAGAATGTTCAGCGCTAGAC 
TCGAGTCTAGCGCTGAACATTCTGTTCCCTTTCCCAGGTAC 
pGL4-HsGRR-24 Human genomic DNA 
GCGGTACCATGGGGAAAGAGAGGCTCAG 
GCCTCGAGAGCCTGGGTTATTTCAGAGG 
pGL4-HsGRR-28 Human genomic DNA 
GCGGTACCATGATCACCCTTCTTATGG 
GCCTCGAGTTCAGCATTATTGAGAAGTTG 
pGL4-MmGRR-28 Mouse genomic DNA 
GCGGTACCATGGTGCTTGTTGATGCCG 
GCCTCGAGTTCAGCATTATTGAGAAGTTG 
pGL4-MmGRR-24 Mouse genomic DNA 
GCGGTACCATGGGAACCAGAGAGAG 
GCCTCGAGAGCCTGGTCATTTAAGGGG 
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2.2.2.2. Cloning into pCR®-Blunt vector 
After addition of SYBRGreen and loading buffer (0.25 % xylene cyanol, 0.25 % 
bromophenol blue, 30 % glycerol), the PCR product was ran on an 1.5 % agarose Tris-
Borate-EDTA (TBE: 45 mM Tris, 45 mM boric acid, 1 mM EDTA) gel for 1 h at 80 V, 
excised and recovered using the ‘QIAquick Gel Extraction Kit’ according to the 
manufacturer’s instructions. The PCR product was then cloned into pCR®-Blunt vector 
using the ZeroBlunt® PCR Cloning Kit’ as suggested by the manufacturer. 1 µl of 
ligation product was transformed into ‘One Shot® TOP10 competent cells’ by heat 
shock. Cells were left to recover 1 h at 37 ºC in Luria-Bertani broth [LB: 1 % (w/v) 
NaCl, 0.5 % (w/v) yeast extract, 1 % (w/v) tryptone] without antibiotic before being 
plated onto LB-agar (LB + 1.5 % (w/v) agar) plates containing 50 µg/ml kanamycin and 
grown overnight. Several individual colonies were picked and grown at 37 ºC overnight 
in 4 ml of LB containing kanamycin. ‘QIAprep® Spin Miniprep kit’ was used to isolate 
plasmid DNA and restriction digestions with Eco RI were performed to identify positive 
clones containing the insert. 
 
2.2.2.3. Sub-cloning into pGL3P vector 
All fragments were cloned in the restriction site for Kpn I (5’) and MLu I (3’). 
DUSP1 reporter fragments were recovered from pCR®-Blunt by restriction digestion 
with Kpn I and Mlu I and sub-cloned into pGL3P, which had been previously linearized 
using the same restriction enzymes and dephosphorylated (dephosphorylation by 
incubation with 2 U of Shrimp Alkaline Phosphatase [SAP] for 1 hour at 37 ºC followed 
by inactivation of the enzyme by incubation at 70 ºC for 10 min). The ligation was 
performed overnight at 16 ºC using 4 U of T4 DNA Ligase. Transformation and growth 
of bacteria followed as previously described, except for the use of ampicillin (100 
µg/ml) as antibiotic. Plasmid DNA was isolated from several clones and digested with 
Kpn I and Mlu I to confirm the presence of the insert.  
 
2.2.2.4. Sub-cloning into pGL4.26 vector 
All fragments were cloned in the restriction site for Kpn I (5’) and Xho I (3’). 
DUSP1 reporter fragments were recovered by restriction digestion from pGL3P vector 
constructs with Kpn I and Xho I and sub-cloned into pGL4.26. The subsequent 
procedure was the same as described in the previous section.  
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2.2.2.5. Insertion of hygromycin cassette into pGL3B-Hs.4.8kb for stable 
transfection 
To perform stable transfection of pGL3B-Hs.4.8kb an antibiotic resistance for 
mammalian cells was introduced into the same vector. The hygromycin resistance 
cassette was removed from pGL4.26 by restriction digestion using Sal I and Bam HI 
and the product of the digestion was run on an agarose gel and the fragment 
corresponding to the hygromycin cassette was gel purified. The same enzymes were 
used to digest pGL3B-Hs.4.8kb., which was subsequently dephosphorylated using SAP 
(as previously described). The hygromycin cassette and the cut pGL3B-4.5kb-Hs. were 
ligated using 4 U of T4 DNA Ligase at 16 ºC overnight. Transformation was followed 
by growing of single colonies in LB with ampicilin. Glycerol stocks of a positive clone 
were kept. 
 
2.2.3. Site-directed Mutagenesis  
DUSP1 mutant constructs were generated using ‘QuikChange site directed mutagenesis 
kit’ or ‘QuikChange RII XL site directed mutagenesis kit’, depending on the size of the 
template construct. Manufacturer’s instructions were followed and the primers are listed 
in Table 2.3. 
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Table 2.3.  List of primers used to generate the mutant DUSP1 reporter constructs  
Construct Primer sequence 
pGL3P-GRR-1.3.Hs.-GBSm1 GAGGAAACCGCAGAACCCTCCTGACTCGGCACC 
pGL3P-GRR-1.3.Hs.-GBS2m GCAGGCTCCGCGGGCCAGGGGGCCGTCACTACG 
pGL3B-Mm.1.5kGBS1m GAAGAAACCGCAGAACCCTCCTGACTCGGCACC 
pGL3P-GRR-1.3.Hs.-SNP GTTTATGTTTGTGTACCCAGCGCGTCGCGTCGC 
pGL3P-GRR-1.3.Hs.-Sp1m CCTGACTCGGCACCCGAATTCGTGGCGCAATGTTTATG 
pGL3P-GRR-1.3.Hs.-CEBPm  CTCGGCACCCGGGCGGGTGGGATCCTGTTTATGTTTGTG 
pGL3P-GRR-1.3.Hs.-FOXm1 GGGCGGGTGGCGCAATAGGCCTGTTTGTGTACCCAGCG 
pGL3P-GRR-1.3.Hs.-FOXm2 CGCAATGTTTATGGGGGTGTACCTAGCGC 
pGL3P-GRR-1.3.Hs.-FOXm3 CGGGTGGCGCAATGTCCATGTCCGTGTACCCAGCGC 
pGL3P-GRR-1.3.Hs.-FOXm4 GGTGGCGCAATAGGCCTGGGGGTGTACC 
pGL3P-GRR-1.3.Hs.-AP1m  GCAGAATGTTCCTAAATCGGCACCCGGGC 
pGL3P-GRR-1.3.Hs.-ATFm GCTGTCCAGGGGGCCTAAGCTACGCGTGCTAGC 
pGL3P-GRR-1.3.Hs.-GMEBm GTTTGTGTACCTAGAGAGTCGAGTCGCTGCAGCAGG 
pGL3P-GRR-1.3-Mm.>Hs1 ACTCCGTGGTGTTGCAGCAGGCTCCGCTGCCTACCCTGTAG 
pGL3P-GRR-1.3-Mm.>Hs2 GTTTGTGTATCCAACTCGTCGCGTCGCTGCGGCGGACTCACTGC 
pGL3P-GRR-1.3-Mm.>Hs3 GTTTGTGTATCCAACTCGTCGCGTCGCTGCAGCAGGCTCCGCTGC 
pGL3P-GRR-1.3-Mm.>Hs4 GTTTATGTTTGTGTACCTAGCGCGTCGCGTCGCTGC 
pGL3P-GRR-4.6-Hs.-GBS-
4.6.1m CACTGTTAAGGGTTTGGGGGCACAGCTCACACAATGC 
pGL3P-GRR-4.6-Hs.-GBS-
4.6.2m1 CTGACTACGGTTAGAACCCTCTGAACACTGTGTGACTTTG 
pGL3P-GRR-4.6-Hs.-GBS-
4.6.2m2 CGGTTAGAATGTTCTGAGGGCTGTGTGACTTTGG 
pGL3P-GRR-4.6-Hs.-GBS-
4.6.2m3 GTTAGAATGTTCTGAACACTGCCCGACTTTGGACAGATTGC 
pGL3P-GRR-4.6-Hs.-GBS-
4.6.3m CAGAGAGGTTAGGCAATCCCCCCAAAGTCACACAG 
pGL3P-GRR-29-Mm.GBSm GTGTTGGGAAAGGGAGGGGAACCCTCAGCGCTAGAAGAG 
pGL3P-GRR-29-Hs.>Mm. GGGGAAGGGAACAGAATGTTCAGCGCCAGGCAGGAAAGA 
pGL3P-GRR-4.6-Hs.>Mm. GAATGTTCTGAACACAGTGTGACTTTGGACAG 
pGL3P-GRR-4.6-Mm.>Hs. GGATGTTCTGAACACTGTGTGACTTTGGACAAG 
pGL3P-GRR-1.3.Hs.-CEBP-J-H CGGCACCCGGGCGGGCAGTGTGATGTTTATGTTTGTG 
pGL3P-GRR-1.3.Hs.>Mm. CCTGACTCGGCACCCCTTCAGAGTGGTGCAATGTTTATGTTTGTG 
pGL3P-GRR-1.3.Hs.-CEBP-CA CGGCACCCGGGCGGGCAGCGCAATGTTTATGTTTGTG 
pGL3B-Mm.4.5kb-GBS4.6.2∆ GCAGCTGGTACCACACTGACTCCTGGACAAGTTGCTTAACCTCTC 
pGL3B-Mm.4.5kb-GRR-1.3m GAAGAAACCGCAGAACCCTCCTGACTCGGCAC 
pGL3B-Mm.4.5kb-GRR-1m AGGTGTGATGAGTGGGGTTCCCCCCACAGAGTGGCG 
pGL3B-Hs.4.8k- GBS4.6.2∆ CTCACACAATGCTGACTACGGTGGACAGATTGCCTAACCTCTCTG 
pGL3B-Hs.4.8k GRR-1.3mut GAGGAAACCGCAGAACCCTCCTGACTCGGCACC 
pGL3P-Hs.-GRR1.3m α GCTGCAGCAGGCCCATGGGTCCAGGGGGCC 
pGL3P-Hs.-GRR1.3m β CGCGTCGCTGCAAGGCCTTCCGCTGTCCAGG 
pGL3P-Hs.-GRR1.3m γ GCGCGTCGCGTCCCATGGGCAGGCTCCGCTG 
pGL3P-Hs.-GRR1.3m δ GTACCCAGCGCGTAGGCCTGCTGCAGCAGGC 
pGL3B-Hs.1.7kb-ATFm1 CCTGGCAGGGCGGGTCCCGGGACCGCCCCGTCAC 
pGL3B-Hs.1.7kb-ATFm2 CCAGCTCCGAGGCTGATCCCGGGTCCCCCTCTGG 
 
2.2.4. Small-scale preparation of plasmid DNA – (minipreps) 
The ‘QIAprep® spin Miniprep Kit’ was used to obtain DNA minipreps. Briefly, single 
colonies picked from an LB-agar plate containing the appropriate selection antibiotic 
were grown at 37 ºC overnight in 4 ml of LB with the same antibiotic. 3 ml from each 
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culture was centrifuged at 13 000 rpm for 1 min. The pellet of bacteria was resuspended 
and bacteria were lysed under alkaline conditions followed by neutralization. After 10 
min of centrifugation at 13 000 rpm the plasmid DNA was selectively adsorbed onto the 
membrane of a spin column in the presence of high salts. Several washes were 
performed to remove the salts and plasmid DNA was eluted using 40 µl of the elution 
buffer provided. DNA concentration was measured by the absorbance at 260 nm (1 A260 
unit =50 µg/mL dsDNA) 
 
2.2.5. Large-scale preparation of plasmid DNA – (maxipreps) 
The ‘UltramobiusTM 1000 plasmid Kit’ was used to obtain DNA maxipreps. Briefly, 100 
ml of LB containing the appropriate selection antibiotic was inoculated with 1 ml of 
culture of bacteria containing the appropriate vector. This was left to incubate overnight 
at 37 ºC, with gentle agitation. Bacteria were then pelleted by centrifugation at 6 000 x g 
for 15 min. The medium was removed and plasmid DNA was prepared by alkaline lysis 
of the bacteria, followed by neutralization, centrifugation to remove cellular debris and 
genomic DNA, and anion exchange chromatography of the supernatant. Plasmid DNA 
was then eluted from the columns using the elution buffer provided, and precipitated 
using isopropanol. The pellet of DNA obtained was washed with 70 % ethanol, before 
being resuspended in 100 to 500 µl of Tris-EDTA buffer (TE: 100 mM Tris-HCl pH 7.5 
and 10 mM EDTA pH 8.0) depending on its size. DNA concentration was measured by 
the absorbance at 260 nm. 
 
2.2.6. Generating glycerol stocks 
800 µl of freshly grown bacterial culture was mixed with 200 µl of sterile 100 % 
glycerol in sterile ‘Cryovials’. After vortexing, vials were left for 2 minutes in dry ice 
and then stored at -70 ºC. 
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2.2.7. Electrophoretic Mobility Shift Assays (EMSA) / Supershifts 
 
2.2.7.1. Oligos used in EMSA 
 
Table 2.4.  List of oligos used in EMSA as probes or competitors.  
Oligo 
designation Oligo sequence 
A TCCCCCAGGAGGGGAGGAAACCGCAGAATGTTCCTGACTC 
Am1 TCCCCCAGGAGGGGAGGAAACCGCAGAACCCTCCTGACTC 
B GGCACCCGGGCGGGTGGCGCAATGTTTATGTTTGTGTACC 
Bmut GGCACCCGGGCGGGTGGGATCCTGTTTATGTTTGTGTACC 
FOXm1 GGCACCCGGGCGGGTGGCGCAATAGGCCTGTTTGTGTACC 
FOXm3 GGCACCCGGGCGGGTGGCGCAATGTCCATGTCCGTGTACC 
C CAGCGCGTCGCGTCGCTGCAGCAGGCTCCGCTGTCCAGGG 
D CCGCAGAATGTTCCTGACTCGGCACCCGGGCGGGTGGCGC 
E AATGTTTATGTTTGTGTACCCAGCGCGTCGCGTCGCTGCA 
E-SNP AATGTTTATGTTTGTGTACCTAGCGCGTCGCGTCGCTGCA 
F GCAGGCTCCGCTGTCCAGGGGGCCGTCACTGGGACTCAGG 
Fmut GCAGGCTCCGCTGTCCAGGGGGCCTAAGCTGGGACTCAGG 
I GGGTGGCCAGCGAAATCCCCTCCCCCAGGAGGGGAGGAAA 
GBScon CAATCTCTGCGGTACAGGATGTTCTAGCTACTTTA 
CEBPcon TGCAGATTGCGCAATCTGCA 
CEBPcon/mut TGCAGAGACTAGTCTCTGCA 
GBS-4.6.2 ATCTGTCCAAAGTCGGGCAGCCCTCAGAGGGTTCTAAC 
GBS-4.6.2m GTTAGAATGTTCTGAACACTGTGTGACTTTGGACAGAT 
B-CAmut GGCACCCGGGCGGGCAGCGCAATGTTTATGTTTGTGTACC 
 
 
2.2.7.2. Preparation of nuclear extracts from HeLa cells or COS-7 cells 
Confluent HeLa cells from two 150 cm2 were incubated with dex (100 nM) or vehicle 
(0.1 % EtOH) for 1 or 2 hours. The cells were washed twice with PBS and centrifuged 
at 5000 rpm for 5 min. The cell pellet was resuspended in 400 µl of cold buffer A (10 
mM Hepes pH 7.9, 10 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 0.01 
mg/ml Aprotinin and 10 µM E64) and left to incubate on ice for 30 min to allow the 
cells to swell. Nonidet 40 (NP-40; 0.5 %) was then added and strongly mixed. The cell 
lysate was centrifuged for 5 min at 3000 rpm and washed twice with cold buffer A to 
pellet the nuclei. Nuclei were resuspended in 100 µl of cold buffer C (20 mM Hepes pH 
7.9, 400 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 0.01 mg/ml Aprotinin 
and 10 µM E64) and allowed to clump by incubating 30 min at 4 °C on a shaker. 
Nuclear debris were eliminated by centrifugation at 13000 rpm for 15 min and the 
supernatant transferred to a new tube. The protein concentration was measured using the 
Bradford method and aliquots of the nuclear extracts were stored at -80 °C. 
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Nuclear extract from COS-7 cells were recovered from two 6-well plates for each of the 
different conditions. 20 hours after transfection cells were stimulated with vehicle (0.1 
% EtOH) or dex (100 nM) for 1 hour. The same procedure described to prepare nuclear 
extract from HeLa cells was followed, by reducing the volumes of buffers and solutions 
used to half. 
  
2.2.7.3. EMSA 
The appropriate DNA oligos were end-radiolabelled with [γ32P]-ATP using T4 
polynucleotide kinase and purified by centrifugation through G-25 columns. The 
binding reaction contained 8 µg of HeLa cells nuclear extract, 250 mM KCl, 50 mM 
Tris pH 7.5, 5 mM DTT, 1 mM EDTA, 15 % (v/v) glycerol and 4 µg of poly(dI-dC) in a 
total volume of 19 µl. The probe (0.1 pmol) was subsequently added and the reaction 
was incubated on ice for 20 min. When performing competition assays molar excesses 
of competitors (10 x, 50 x or 100 x) were incubated with protein and binding buffer for 
10 min on ice prior to addition of probe and incubation for a further 20 min. For the 
supershift assays the 20 min of incubation with the probe were preceded by 10 min with 
1 µl of the antibody or 1 µl of Mouse IgG1 or 1 µl rabbit non-immune serum. The 
complexes formed were resolved in a 6 % (w/v) polyacrylamide gel in 0.5 x TBE. After 
pre-running the gel for 1 h samples were loaded with the addition of 2 µl of 10 x 
agarose loading buffer and the gel was run for 3 hours at 150 V. After being dried the 
gel was phosphorimaged. 
 
2.2.8. Oligo Pull-down Assay 
 
2.2.8.1. Preparation of nuclear extracts from HeLa cells 
As described in section 2.2.4.2 for EMSAs. 
 
2.2.8.2. Incubation 
Briefly, 50 µg of nuclear extract from HeLa cells treated with vehicle (0.1 % EtOH) or 
dex (100 mM) for 1 hour were incubated with 90 pmol of biotinylated oligo (purchased 
with 3’ biotin modification), binding buffer (5 mM Hepes pH 7.8, 75 mM NaCl, 1 mM 
DTT, 5 mM EDTA, 10 mM MgCl2, 10 % glycerol), 1 µg of poly(dI-dC) and BSA 
(1mg/ml) in a total volume of 100 µl and incubated for 1 hour at 4 ºC. For competition 
purposes the nuclear extracts were incubated with the biotinylated oligo in the presence 
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of 20 x molar excesses of competitor oligos. Streptavidin beads were pre-incubated with 
BSA (1mg/ml) in binding buffer for 1 hour at 4 ºC with shaking. Beads were washed 
twice and resuspended in binding buffer. Addition of beads was followed by 1 hour of 
incubation at 4 ºC with gentle mixing every now and then. Samples were washed 6 
times in binding buffer and were resuspended in 25 µl of 2 x SDS sample buffer (250 
mM Tris-HCL pH 6.8, 4 % (w/v) SDS, 20 % (v/v) glycerol, 200 mM DTT, 0.02 % 
Bromophenol Blue) after the last wash. After 5 min at 95 ºC and centrifugation at 13000 
rpm for 10 min, the samples were subjected to western blot. 
 
2.2.8.3. Western Blot 
Samples were run on a stacking/separating gel electrophoresis system (stacking gel: 125 
mM Tris-HCL pH 6.8, 0.1 % (w/v) SDS, 5 % (w/v) Acrylamide; separating gel: 380 
mM Tris-HCl ph 8.8, 0.1 % (w/v) SDS, 8 % (w/v) Acrylamide). ‘SeeBlue® Pre-Stained 
Standard’ was used as a protein size marker and Tris/Glycine/SDS (25 mM Tris-base, 
192 mM glycine, 0.1 % (w/v) SDS) as running buffer. The gel was run at 100 V for 2 
hours. The separating gel layer was transferred into a PVDF membrane, which had been 
previously soaked in 100 % methanol, rinsed with distilled water and soaked in transfer 
buffer (25 mM Tris-base, 192 mM glycine, 20 % (v/v) methanol). A transfer stack 
(sandwich) was assembled with the gel and membrane between six sheets of 
Whatman® 3MM paper and this was placed in a transfer cassette between two sponges. 
The cassette was placed inside a transfer tank with transfer buffer and the proteins were 
transferred from the gel to the membrane by electrophoresis at 100 V for 1 h at 4 ºC. 
The membrane was blocked in 5 % milk in PBS/0.1 % Tween-20 (PBS-Tween) for 1 
hour and then incubated overnight with GR antibody (1:2000) in 5 % milk in PBS-
Tween. Swine anti-rabbit IgG horseradish peroxidise conjugated (1:2000) in 5 % milk 
in PBS-Tween was used in the second incubation for 1 hour. After each incubation 
membrane was washed 3 times for 10 min periods in PBS-Tween. Detection of proteins 
was done by enhanced chemiluminescence using the ‘ECL Western Blotting Detection 
Reagents’ kit according to manufacturer’s instructions. 
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2.2.9. DUSP1 mRNA measurements 
 
2.2.9.1. Isolation of total RNA from MEFs 
Cells were seeded at a density of 6 x 105 per well in six-well plates the day prior to the 
RNA extraction. After dex or vehicle stimulation for the appropriate time, cells were 
washed in PBS and harvested. ‘QIAamp RNA Blood kit’ was used to extract total 
cellular RNA, according to the manufacturer’s instructions. Briefly, cells were lysed in 
a buffer containing a highly denaturing detergent, after which lysates were homogenised 
by centrifugation through shredder columns and added to spin columns. After several 
washes the RNA retained in the column was eluted with 40 µl of RNAse-free water. 
Quantification of RNA was done by spectrophotometry at 260 nm (1 A260 unit = 40 
µg/mL RNA) and samples were stored at -20 ºC. 
 
2.2.9.2. Q-PCR to confirm DUSP1 induction by dex 
Quantification of mRNA levels was determined by quantitative real-time PCR (qPCR) 
using One-Step RT qPCR Mix, TaqMan probes GAPDH Mm 99999915_g1 and 
DUSP1 Mm00457274_g1 and the Rotor-Gene 3000. PCR mix was performed in a total 
volume of 10 µl. Amplification conditions consists of an initial reverse transcriptase 
step of 30 min at 48 ºC, and 10 min denaturation at 95 ºC followed by 45 cycles of 3 s at 
95 ºC and 30 s at 60 ºC. DUSP1 mRNA levels were analysed using the Delta Delta C(T) 
method (Livak and Schmittgen, 2001). DUSP1 mRNA levels were normalized against 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels. 
 
2.2.10. Chromatin Immunoprecipitation Assay 
HeLa cells were seeded at a density of 3 x 106 cells in 10 cm dishes. MEFs were seeded 
at a density of 4 x 106 cells in 10 cm dishes. The following day, cells were treated with 
either dex (100 nM) or vehicle (0.1 % EtOH) for 30 min. Fixation of the cells was 
performed in 1 % formaldehyde for 10 min at room temperature. Fixed cells were then 
quenched with 125 mM Tris pH 7.5 and washed with ice-cold PBS. Cells were 
subsequently lysed in lysis buffer 1 (50 mM Tris pH 8.0, 2 mM EDTA pH 8.0, 0.1 % 
NP-40, 10 % glycerol and protease inhibitor cocktail). Nuclei were recovered by 
centrifugation at 3 000 rpm and resuspended in lysis buffer 2 (50 mM Tris pH 8.0, 0.5 
mM EDTA pH 8.0, 1 % SDS). Nuclei were sonicated (4 x 12 s with 10 s intervals on 
ice, 20 % power for HeLa cells or 5 x 5 s with 10 s intervals on ice, 25 % power for 
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MEFs, sonics VCX130) to obtain an average DNA length of 500 to 1500 bp, then 
clarified by centrifugation at 13 000 rpm for 5 min. Equal aliquots were used for 
individual ChIP reaction (typically, cells collected from one 10 cm dish were used for 4 
IPs). Each aliquot was diluted 10 x using dilution buffer (50 mM Tris pH 8.0, 5 mM 
EDTA pH 8.0, 200 mM NaCl, 0.5 % NP-40 and protease inhibitor cocktail) and pre-
cleared by incubation with 80 µl of protein A-sepharose freshly saturated with salmon 
sperm DNA for 2 h at 4 ºC. Immunoprecipitation was done overnight with either 2 µg 
of anti-GR antibody or 2 µg of normal rabbit IgG used as negative control. Immune 
complexes were collected by incubation with 30 µl of protein A for 30 min at 4 ºC, 
followed by 2 min centrifugation at 13 000 rpm. Aliquots of each supernatant – 
designated input – were kept separate from the IPs. Immune complexes were washed 
four times with washing buffer (20 mM Tris pH 8.0, 2 mM EDTA pH 8.0, 0.1 % SDS, 
1 % NP-40, 500 m M NaCl) and three times with TE. Complexes were extracted from 
the beads for 15 min at room temperature, using extraction buffer (TE containing 2 % 
SDS). After centrifugation for 1 min at 13 000 rpm, supernatants were collected. Cross-
links of input and IP samples were reversed by incubation at 65 ºC for 4 h. DNA was 
purified using QIAquick PCR purification kit following manufacturer’s protocol. 
Quantitative real time PCR was performed using SYBR Premix Ex Taq. PCR mix was 
performed in a total volume of 20 µl contained either 5 µl IP or 6 µl input DNA, 200 
nM final concentration of each primer and SYBR Premix Ex Taq. The PCR conditions 
used for amplification consisted of 45 cycles of denaturation (5 s at 95 ºC) followed by 
annealing/extension (30 s at 60 ºC). To ensure the absence of primer dimers or non-
specific products PCR products were verified by melting curve analysis and agarose gel 
electrophoresis. 
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Table 2.5.  Sequences of primers used for Q-PCR with ChIP samples. 
Primer pair designation Sequence 
Hs.FKBP TAACCACATCAAGCGAGCTG GCATGGTTTAGGGGTTCTTG 
Mm.FKBP GTTCAGCTGTGCAATCCAGA AGGGTGTTCTGTGCTCTTCAA 
Hs.GRR-1.3 -A GCGCAGGCGAAAACACACAA CGACGCGCTAGGTACACAAACA 
Hs.GRR-1.3-B ACCGCAGAATGTTCCTGACTC ACCGCAGAATGTTCCTGACTC 
Mm.GRR-1.3 CACGGAGTTGGATACACAAACA CAAGAGCTAAGAGAGGCCAAAG 
Hs.GRR-4.6-A CAAACAGATCTCCATGCTCAGAACTG CTCCACCTTCCAAAGATAAACACTG 
Hs.GRR-4.6-B GGAAGAAAATGAGAGGAACTCC CACAGAGCTGTGTCATCCTGTC 
Mm.GRR-4.6 CACACAGTTCTCGATCAGGCCTG CACTCACCCCTAAAGATAAGCACTG 
Hs.ChIP9 (negative control) GCCGGTGTGACTTAATGAGATCAG CTTTTCAGGCCTCTATTATACTTGCC 
Mm.ChIP9 (negative control) GCCAGAATGACTTTGTAGCATGGA GCTTTGTCACCCCTCCTAAACTTATC 
Hs.GRR-29 CTCATCAGGGTGAGCTGATGAC GACAGGCCAGGGCTCGCTTCTCA 
Mm.GRR-29 CTTAGGGTGAAGTGACATC CTTTGAGCTCACTTCCTCTTTTTGTG 
Hs.GRR-24 AGGCTCCTGGCCCCACATTGAA ATTGCGACCCCTGTTCCTCCATGC 
MmGRR-24 GTGCCTGGCTCTGCATCGAAAATGGAA TGGCTCAGACACTGCTGTCCCCTCT 
Hs.GRR-28 CAGAAGAGTGCGCAGAGAAG CTGGTCCAGGGAGTGAAAG 
Mm.GRR-28 GCTTCCCAGATGTGCCAAG CCAAACCTTGAGCCAGAGCAGTG 
 
2.2.11. Statistical Analysis 
Statistical analysis was performed employing GrapPad Prism 4.03. One-way ANOVA 
with bonferroni post test was used or, when appropriate one sample t-test. 
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3. Chapter 3 - Identification of Glucocorticoid Responsive Regions (GRR) in the 5’ 
region of DUSP1 gene 
 
The central purpose of the work described in this thesis was to identify GRR in the 5’ 
region of the DUSP1 gene. Sequence conservation has been used successfully to trace 
cis-regulatory regions. Here the use of sequence conservation to predict function in the 
DUSP1 5’ region will be tested.  
This first chapter will focus on explaining how a phylogenetic approach was designed to 
answer this question. The experimental design, methodology and treatment of the data 
will be described. Using this approach it was possible to study the involvement of 3 
different GBS located far upstream of the TSS of the human and mouse DUSP1 genes. 
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3.1. DUSP1 mRNA expression is similar in mouse and human  
Glucocorticoids have been shown by this lab and others to induce expression of the 
DUSP1 gene in several types of cells. In order to directly compare the levels of DUSP1 
gene expression between human and mouse, fibroblasts or macrophages from both 
species were challenged with dex (100 nM) or vehicle (0.1 % EtOH) for different time 
periods. Total RNA was extracted and mRNA measured by real time quantitative PCR 
(work performed with Roberta Perelli). DUSP1 mRNA levels were normalized against 
GAPDH. In macrophages there was a strong upregulation of DUSP1 mRNA level 
which peaks at one hour (Fig. 3.1). In fibroblasts there was also a rapid upregulation of 
DUSP1 mRNA expression which in this type of cells was more sustained. The pattern 
of DUSP1 mRNA up-regulation observed was similar between the two species. When 
the same pattern of expression of a given gene is maintained between species it is likely, 
albeit not certain, that the molecular mechanism of regulation is also preserved between 
species. This would result from conservation throughout evolution of the cis and trans-
regulatory elements necessary to maintain this expression. Additionally, the same 
mRNA measurements were performed in HeLa cells, the cell type where dex-
upregulation of DUSP1 was first demonstrated (Lasa, et al., 2002) and the chosen one 
to perform most of the studies described throughout this thesis. 
 
3.2. A phylogenetic approach as a tool to identify functional GRR 
GR is typically known to bind as a dimer to sequences of 15 bp designated as GR 
binding sites consensus sequences (GBS). These sequences are classically inverted 
repeats of TGTTCT separated by any three nucleotides. However an extensive study has 
shown that GR can bind to sequences that diverge considerably from the classical 
consensus (So, et al., 2007). Only 5 of 15 positions are absolutely conserved between 
GR binding sites, and a more relaxed consensus binding site can be represented as 
GNACANNNNG. GR regulation of transcription is also known to involve interaction 
with several other transcription factors. Therefore glucocorticoid responsive regions 
(GRR) can be defined as regions of DNA containing not only GBS but also binding 
sites for other transcription factors involved in the response to GCs. 
 
As previously described in chapter 1 there are three main propositions arising from the 
studies developed by Yamamoto’s group that allow to identify functional GRR: 
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Figure 3.1. GCs induce a similar pattern of DUSP1 mRNA expression in mouse and human  
Mouse macrophages, mouse fibroblasts, human macrophages and human fibroblasts were treated with dex 
(10 nM) or vehicle (0.1 % EtOH) for the indicated times. HeLa cells were treated with dex (100 nM) or 
vehicle (0.1% EtOH) for the indicated times. DUSP1 mRNA expression was measured by quantitative 
PCR. Data represents mean fold change of DUSP1 mRNA in response to dex, normalized against 
GAPDH, the house keeping gene chosen. Means and S.E.M. from three independent experiments are 
shown. Work performed in collaboration with Roberta Perelli. 
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1. All GRR contain matches to the loose consensus GNACANNNNG, which was 
defined by their studies; 
2. GBS can vary extensively between each other, hence the relaxed GBS consensus 
defined in that study; however they are highly conserved in sequence, 
orientation and position when it comes to the same individual GBS present in 
orthologous regions from different species. This reflects conservation of 
function and is associated with GR occupancy; 
3. Flanking sequences of the GBS tend to also be conserved; this is explained by 
the need to maintain binding sites for additional transcription factors cooperating 
with GR for the transcriptional activation.  
 
Based on these premises a phylogenetic approach was set up in order to identify GRR in 
the 5’ region of the DUSP1 gene and test the hypothesis that GBS conservation itself is 
enough to predict regulatory function and GR binding at individual genes, first proposed 
by Yamamoto and co-workers (So, et al., 2008).  
 
To identify putative GRR approximately 30 kb of 5’ flanking sequence of mouse and 
human DUSP1 genes were analysed. 56 matches to the consensus sequence 
GNACANNNNG were found in the human sequence, 88 in the mouse (Fig. 3.2A). The 
predicted occurrence of this motif in DNA of random composition is approximately two 
per kb, suggesting that many of the matches are not functionally significant. These 
“hits” were then filtered for sequences that were conserved between the mouse and 
human DUSP1 loci in position, orientation and sequence (at least 8 of 15 identical 
residues across the GR binding site). This greatly reduced the number of hits to 10 (Fig. 
3.2B). Coordinates of these GBS, their sequence and comparison between species can 
be seen in more detail in Table 3.1. Finally, this set of “hits” was filtered for conserved 
motifs that were located within extended regions of sequence conservation (≥ 65 % 
sequence identity over at least 100 bp), as defined by the Vista algorithm (Couronne, et 
al., 2003) (Fig. 3.2C and D). This led to the identification of six candidate GRRs. One 
putative GRR is located close to the TSS (GRR-0.2) and has not yet been investigated 
in detail (see Discussion in Chapter 5). GRR-4.6 contains three closely spaced GBS 
motifs. GRR-29 is included in this analysis even though the GBS is not, strictly 
speaking, conserved between mouse and human. The complicated sequence 
relationships within these GR binding sites are discussed in more detail later on. 
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 Figure 3.2. Search for GBS consensus in the 5’ region of human and mouse DUSP1 genes 
A. 30 kb upstream of the TSS of the human (Hs) and mouse (Mm) DUSP1 genes were searched for 
matches to the GNACANNNNG consensus. Matches in the sense strand in black and antisense in red. 56 
and 88 matches were found in the human and mouse, respectively. B. Matches which are conserved 
between the human and mouse DUSP1 loci in position, orientation and sequence. C. Matches which were 
located within extended regions of sequence conservation (≥65 % sequence identity over at least 100 bp).  
* represent three separated GBS. D. Alignment of the 30 kb upstream of the DUSP1 TSS of human and 
mouse using default settings of the Genome Vista browser (http://genome.lbl.gov/vista). Shaded peaks of 
strong conservation are indicated. Putative GBS matching the criteria are indicated below by referring to 
their distance in kb from the TSS. 
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Table 3.1. – GBS sequences, coordinates and species comparison.  
 
GBS Sequence Coordinate Strand 
Hs 
vs 
Mm 
Hs 
vs 
Rn 
Hs 
vs 
Cfa
Hs. AGAACATTCGGCCCC -28963 
-29 
Mm. AGAATGTTCAGCGCT -26854 
s 10 11 8 
Hs. AGAACATCTGGAAGG -27724 
-28 
Mm. GGCACATCTGGGAAG -25850 
as 11 11 12 
Hs. GGAACATTCTGCCCC -24401 
-24 
Mm. GGAACATTCTGCCCT -24450 
as 14 14 15 
Hs. AGGACAGTGGGACAC -15546 
-16 
Mm. AGGACAATGAGACTC -15256 
as 12 11 6 
Hs. TGGACACACAGCTCA -4625 
-4.6.1 
Mm. TGAACATGCAGCTGG -4297 
s 10 8 13 
Hs. TGAACACTGTGTGAC -4582 
-4.6.2 
Mm. TGAACACAGTGTGAC -4256 
s 14 14 15 
Hs. TGGACAGATTGCCTA -4565 
-4.6.3 
Mm. TGGACAAGTTGCTTA -4239 
s 12 12 13 
Hs. TGTACAGTGCGTCTA -2294 
-2.3 
Mm. AGTACAGCTGGTACC -1781 
as 8 9 9 
Hs. GGAACATTCTGCGGT -1340 
-1.3 
Mm. GGAACATTCTGCGGT -1182 
as 15 15 15 
Hs. CGGACAGCAGGGCGG -233 
-0.2 
Mm. GGGACAGGAGGGTGG -249 
s 12 11 - 
 
human (Homo sapiens; Hs.), rat (Rattus norvegicus; Rn.), mouse (Mus musculus; Mm.), dog (Canis 
familiaris; Cfa.);  - :  Not present; s- sense; as- antisense. 
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The functional role of each GBS was evaluated and will be described throughout this 
and the following chapters. First, the experimental design of the studies carried out will 
be described as well as the procedure to generate the required tools. 
 
3.3. Experimental design 
Briefly, the approach was to clone different fragments from the 5’ region of the DUSP1 
gene from different species and to test their ability to activate transcription in the 
presence of dex in HeLa cells. This can be divided in four different strategies: 
 
1. Use of heterologous promoters to study function of sequences located far from 
the DUSP1 TSS; 
 
2. Use of heterologous promoters and native promoter constructs to study function 
of regions less than 5 kb from the DUSP1 TSS; 
 
3. Functional analysis of GR binding sites in isolation; 
 
4. Additionally, DNA-binding studies were performed using different techniques, 
namely electrophoretic mobility shift assays, oligo pull-down assays and 
chromatin immunoprecipitation assays, to study the interaction of GR and other 
transcription factors with specific DNA sequences identified in the DUSP1 5’ 
region.  
 
Great emphasis was put on the functional assays throughout the development of this 
work. Therefore the next sections will briefly describe the generation of DUSP1 
reporter constructs and mutants and the procedure of transiently transfecting HeLa cells 
with the reporter constructs, to evaluate their responsiveness to dex.  
 
3.3.1. Generating the tools for the functional assays 
 
3.3.1.1. Choosing the vector 
Fragments were cloned in 3 different vectors: pGL3B, pGL3P and pGL4.26, all of them 
containing a modified Firefly luciferase coding region, which was the chosen reporter 
gene, optimized for monitoring transcriptional activity in eukaryotic cells. 
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pGL3-Basic (pGL3B), which contains no functional mammalian promoter was used 
when fragments containing the native proximal promoter of DUSP1 were cloned. 
pGL3-Promoter (pGL3P) which contains an SV40 minimal promoter upstream of the 
luciferase open reading frame, was the first choice to subclone fragments from the 5’ 
region of the DUSP1 gene. The SV40 promoter in fact contains a large number of 
putative binding sites for transcriptional factors including AP1, Sp1, ATF and C/EBP 
(Table 3.2), all of which have been shown to be involved with GR in regulation of 
transcription. As later discussed in section 4.6.4, there was some evidence that 
additional binding sites present in the SV40 promoter were interfering in some cases 
with the activity presented by the constructs. Therefore it was decided to utilize a 
second vector to confirm the results obtained. The pGL4 luciferase reporter vectors 
series was designed to reduce the number of putative binding sites for transcription 
factors in the vector backbone. The chosen vector was pGL4.26, which contains only a 
TATA box upstream of the luciferase open reading frame and for simplicity reasons 
will from now on be referred to only as pGL4. It is worth saying that, excluding the 
issues described in section 4.6.4, none of the other fragments tested showed any 
difference of responsiveness to dex whether cloned in pGL3P or pGL4. pGL4 was also 
used to clone short oligos containing isolated GBS, in order to assure there was no 
interference of the additional binding sites for transcriptional factors shown to cooperate 
with GR present in the SV40 early promoter. 
 
3.3.1.2. Cloning fragments from the 5’ region of the DUSP1 gene into reporter 
gene vectors 
Primers were designed against sequences approximately 250 bp upstream and 
downstream of putative GBS in the human (Homo sapiens; Hs.) DUSP1 locus. In some 
cases primer sites had to be shifted slightly because of high or low GC content or 
repetitive sequences. Corresponding mouse (Mus musculus; Mm.), rat (Rattus 
norvegicus; Rn.), and dog (Canis familiaris; Cfa.) primers were designed on the basis of 
the sequence alignment. Because of internal insertions or deletions, PCR products from 
human, mouse, rat and dog genomic amplification were not identical in size. One 
exception to this scheme was GRR-29. In this case the alignment was based on the 
mouse DUSP1 locus and primers were based on previously published primer sequences 
(So, et al., 2008). 
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Table 3.2. – Example of putative transcription factors binding sites within the SV40 early promoter 
predicted using Matrix inspector 
Family Further information Position 
OCT1 Octamer-binding factor 1 41 – 55 48 – 52 
AP1 Activator protein 1 56 – 66 141 – 151 
ZBP 
Core promoter-binding protein 
(CPBP) with 3 Krueppel-type zinc 
fingers 
70 – 92 
86 – 108 
91–113 
SP1 Stimulating protein 1, ubiquitous zinc finger transcription factor 
72 – 86 
84 – 98 
93 – 107 
105 – 119 
115 – 129 
126 – 140 
CEBP CCAAT/enhancer binding protein 232 – 246 
CREB cAMP response element binding factor 278 – 298 
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The generation of pGL3P-GRR-29-Rn will be presented here as an example. For further 
details refer to the methods section. All the fragments were cloned into pGL3P using the 
Kpn I (5’) and Mlu I (3’) restriction sites (the same for pGL3B and Kpn I / Xho I for 
pGL4). The DNA fragment was amplified from rat genomic DNA using the primers 
described in Table 2.2. PCR products resulting from the amplification using different 
PCR buffers were obtained (Fig. 3.3A). PCR product from lane B was recovered from 
the gel and cloned into pCR®-Blunt vector, recommended for cloning fragments with 
blunt extremities. The product of the ligation was transformed into competent cells and, 
after plating the bacteria on LB-agar plates containing kanamycin, six clones where 
selected and grown. Plasmid DNA was digested with Eco RI to identify clones 
containing the insert (Fig. 3.3B). Clones A-F were sequenced by MWG-biotech.  
Plasmid DNA from the positive clone A was restriction digested with Kpn I and Mlu I. 
pGL3P vector was digested with the same enzymes, and subsequently 
dephosphorylated. The restriction digestion product was recovered from the gel and 
sub-cloned into pGL3P vector. Transformation and selection of clones in ampicillin 
followed. Positive clones were confirmed by restriction digestion with Kpn I and Mlu I 
(Fig 3.3C). Clone A was maxipreped and glycerol stocks were kept. 
 
3.3.1.3. Generating mutants of the DUSP1 reporter constructs 
DUSP1 mutant constructs were generated by site-directed mutagenesis. For details not 
described here please refer to the methods section. pGL3P-GRR-29-Hs.>Mm generation 
will be described as an example.  PCR was performed using pGL3P-GRR-29-Hs as a 
template and the primers (Table 2.3) containing the mutation to be introduced. The 
presence of PCR product was confirmed on a gel (Fig. 3.3D). After transformation into 
competent bacteria, positive clones were selected by growth in ampicillin containing 
LB. Plasmid DNA was sent to sequence to confirm the introduction of the mutation and 
the integrity of the remaining sequence.  
 
3.3.2. Reporter-gene assays in HeLa cells 
When I first started using the luciferase reporter assays, an optimized system of 
transient transfection, dex-challenge and luciferase measurements in HeLa cells was 
already well established in the laboratory. Therefore there was no need for further 
optimizations.  
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 Figure 3.3. Example of cloning and mutagenesis: Cloning GRR-29-Rn. fragment into pGL3P and 
generating the mutant pGL3P-GRR-29-Hs.>Mm. 
A. GRR-29-Rn fragment of around 500 bp was amplified by PCR using rat genomic DNA as a template 
and the primers described in table 2.2. A-H indicate lanes containing PCR products generated using 
different buffers. The 500 bp band of the 100 bp ladder (m) is indicated by the arrow in all pictures. B. 
This fragment was cloned into pCR-Blunt vector. Positive clones were identified by restriction digestion 
with EcoRI and were sent to sequencing to confirm the presence of the correct sequence. A-F indicate 
different clones. C. The desired fragment was excised from the pCR-Blunt by restriction digestion with 
Kpn I and Mlu I and cloned into pGL3P vector. Positive clones were identified by restriction digestion 
with the same enzymes. A-F indicates different clones. D. Site-directed mutagenesis was performed 
according to the manufacturer’s directions. The mutation was inserted by PCR using as a template 
pGL3P-GRR-29-Hs and the primers described in table 2.3. The sample was run on an agarose gel to 
confirm the presence of product (arrow on the right). After transformation and selection of clones, 
samples were sent to sequencing to confirm the presence of the mutation.  
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DUSP1/Firefly luciferase constructs were co-transfected with Renilla-TK plasmid as a 
control for transfection efficiency. Briefly, HeLa cells were seeded at 1.5 x 105 
cells/well in 6-well plates. Cells were always kept in DMEM containing 10 % (v/v) 
FBS. The following day cells were transfected using Superfect, with 200 ng of the 
DUSP1/Firefly luciferase plasmid, 100 ng of pRL-TK plasmid and 700 ng of 
pBluescript (to complete a total of 1 µg DNA/well). Each construct was transfected in 
triplicates. After removing the transfection mix, fresh medium containing either dex 
(100 nM) or vehicle (0.1 % EtOH) was added to the cells, which were then incubated 
for 20 hours. After harvesting of the cells the luciferase activities were measured. 
 
3.3.2.1. Processing the data from the functional assays 
Except where noted, each construct was tested in at least three independent experiments. 
For each construct Firefly luciferase activity was normalized to Renilla luciferase to 
account for variations in transfection efficiency. The fold response to dex of each 
construct was then calculated. It was noted that fold responses of individual constructs 
varied between experiments, as illustrated with pGL3P and its derivative pGL3P-
Hs.GRR-1.3 in 4 independent experiments (Fig. 3.4A). If the activity of pGL3P was 
increased from one-fold to two-fold from one experiment to the other, then all the 
constructs present would also double their activity. As a result of this phenomenon, the 
standard error of the mean for the fold response was large. Much of the error appeared 
to be due to variable responses of the SV40 early promoter itself. If data were 
normalized against the fold induction presented by pGL3P in each experiment, fold 
responses to dex appeared far more reproducible and experimental error was clearly 
reduced (Fig. 3.4B). This method of normalisation was applied throughout so as to 
prevent overestimation of dex responses and minimise any contribution in activity from 
elements other than the fragments from the 5’ region of the DUSP1 gene tested. The 
same method of normalisation was applied to constructs based on pGL4, even though 
the intrinsic dex response of this vector was minimal and varied between experiments to 
a lower extent. pGL3B always displayed luciferase measurements below the 
background, therefore it was considered as completely unresponsive. The values of fold 
induction by dex not normalized against the empty vector were used to perform the 
statistical analyses. One-way ANOVA with Bonferroni post test was performed to 
compare the activity presented by different constructs. 
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Figure 3.4. Fold response to dex normalized against pGL3P 
Comparison between fold responses to dex normalized or not against pGL3P. A. Top graph contains data 
from 4 independent experiments where pGL3P and pGL3P-Hs.GRR-1.3 were tested. Fold responses to 
dex were calculated. Two last bars represent the mean and SEM of the four experiments. B. Bottom graph 
contains the same data but this time normalized against the pGL3P fold response. 
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3.4. Study of GRR located far upstream of the DUSP1 TSS 
 
3.4.1. Conservation of function in GRR-24 
The human-mouse sequence conservation analysis identified a putative GBS located 24 
kb upstream of the DUSP1 TSS.  This GBS differs by only one nucleotide between 
human and mouse and is actually highly conserved between 16 different species of 
placental mammals (Fig. 3.5A and B). A fragment of roughly 500 bp harbouring this 
GBS was amplified from human and mouse genomic DNA and cloned upstream of the 
TATA box in pGL4 (work performed with the assistance of Nasren Paktiawal, an MSc 
student under my supervision). Transient transfection of HeLa cells with 200 ng of each 
DUSP1 reporter construct or pGL4 and 100 ng of pRL-TK plasmid was followed by 20 
hours of stimulation with dex (100 nM) or vehicle (0.1 % EtOH). Cells were then 
harvested and the luciferase activities measured. Both human and mouse sequences 
were able to drive transcription with similar fold responses to dex (Fig. 3.5C). A 
construct known to respond to dex was included as control. Therefore conservation of 
the GBS sequence (14/15 bp) allowed to identify a functional GBS in both promoters. 
Nonetheless, it is worth mentioning that the fold response to dex of this region is 
somewhat weak comparing to the positive control, which is another GRR described 
later on. 
 
The use of reporter gene analyses to identify glucocorticoid responsive regions allows 
to determine whether a segment of DNA has enough information for the GR to 
orchestrate transcription. Yet this does not necessarily prove that these cis-elements are 
functional in the physiological context of a living cell. Chromatin immunoprecipitation 
allows to assess the binding of GR to the DUSP1 locus in a living cell, and the 
occupancy by the receptor in the identified GRR would establish a functional role for 
this region in a less artificial context. 
 
ChIP experiments were performed to establish the recruitment of GR to both the human 
and mouse GRR-24 in vivo. Technical details can be found in the materials and methods 
chapter. Both in HeLa cells and mouse fibroblasts (Figure 3.5D) a dex dependent 
recruitment of GR to a region of the FKBP51 locus was observed, which was used as a 
positive control because it has previously been reported to recruit this receptor. No 
enrichment was observed when primers for a region of the DUSP1 locus which contains 
108 
 
Chapter 3 - Identification of GRR in the 5’ region of the DUSP1 gene 
 
B
 A
 
GG A A CA T T CT G C CC C
GG A A CA T T CT G C CC T
*
GBS-24-Hs.
GBS-24-Mm.
 GRR-24
 GBS-24
 
 C
**
*
n.s.
Fold response to dex
pGL4-GRR-24-Hs.
pGL4
-Mm.
0 2 4 6 8 10 12 14 16 18
pGL4-GRR-4.6-Hs.(pos. control) 
 
 
 
 
 
 
 
 
 
 
 
D 
%
 in
pu
t
- + - +
FKBP GRR-24
IgG
α-GR
Hs.
Mm.
dex
0
0,2
0,4
0,6
0,8
0
0,05
0,15
0,25
%
 in
pu
t
%
 in
pu
t
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Human and mouse GRR-24 are responsive to dex 
A. Sequence of human and mouse GBS-24; * indicates residues not conserved and bold the 5 invariant 
residues of a GBS consensus. B. Multiz alignment of GRR-24 of 16 species of placental mammals (UCSC 
Genome Browser) C. Human and mouse GRR-24 were cloned in pGL4. pGL4-GRR-4.6 was included as 
a positive control. HeLa cells were transiently transfected with 200 ng of constructs and 100 ng of pRL-
TK plasmid. Cells were treated for 20 h with dex (100 nM) or vehicle (0.1 % EtOH), harvested and 
luciferase activities measured. For each construct, Firefly luciferase activity was normalized to Renilla 
luciferase activity. Fold response to dex was calculated and normalized against the response of the empty 
vector pGL4. Means and S.E.M. from three independent experiments are shown. Statistical comparisons 
are against pGL4. **, p<0.01; *, p<0.05; n.s., not significantly different. D. GR recruitment was assessed 
by ChIP. HeLa cells or mouse fibroblasts were treated with vehicle (0.1 % EtOH) or dex (100 nM) for 30 
min. Samples were then chromatin immunoprecipitated with either IgG (white columns) or anti-GR 
antibody (black columns). Q-PCR was used to detect the immunoprecipitated DNA fragments and 
measurements were done in triplicates. The enrichment of specific chromatin fragments was determined 
as a proportion of the initial material present (input). Data represent one experiment representative of two 
(mouse fibroblast) or three (HeLa) independent experiments. Work in C was performed with the 
assistance of Nasren Paktiawal. 
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no matches to GBS and is conserved between mouse and human were used (data not 
shown). In both type of cells the recruitment of GR to GRR-24 was
observed. The ability of this region to upregulate transcription in the presence of dex 
correlates with the ability of the same region to bind GR in vivo. Nonetheless, as 
previously observed this region displayed a modest response to dex and ability to recruit 
GR when compared to the other functional GRR described throughout this thesis. 
 
3.4.2. Absence of function in GRR-28 
Approximately 28 kb upstream of the DUSP1 TSS another GBS was pinpointed where 
11 of the 15 bp comprising a GBS are conserved between mouse and human (Fig. 
3.6A). An alignment of multiple mammal species across this region indicates the GBS 
is not highly conserved (Fig. 3.6B). A fragment of around 500 bp containing this GBS 
was amplified from mouse and human genomic DNA and cloned into pGL4 (work 
performed with the assistance of Nasren Paktiawal). Transient transfections performed 
as before revealed that neither of the constructs was responsive to dex (Fig. 3.6C). A 
construct known to respond to dex was included as control. 
 
The recruitment of GR to this region was studied by ChIP using the same procedure as 
formerly described. Both in HeLa cells and mouse fibroblasts (Fig. 3.6D) a dex 
dependent recruitment of GR to a region of the FKBP51 locus was observed and 
negative control behaved as expected (data not shown). No recruitment of GR to GRR-
28 was observed. Inability of this region to activate transcription was correlated with the 
absence of GR binding to the same region. Interestingly, the GBS present in this region 
is an example of a transcription factor binding site where sequence conservation 
between human and mouse is not a product of functional conservation. 
 
3.4.3. Evidence for species-specific usage of GRR-29 
A previous study has identified several hundred functional GRR in the genome on the 
basis of sequence conservation between mouse and human (So, et al., 2008). One of 
these is located 27 kb upstream of the mouse DUSP1 TSS and contains a near perfect 
palindromic version of the GBS consensus (Fig. 3.7A). In mouse C3H10T1/2 
mesenchymal stem-like cells GR was shown to be recruited to this site, and a 
transcriptional response to dex was dependent on the GBS sequence. The corresponding
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Figure 3.6. Human and mouse GRR-28 are not responsive to dex 
A. Sequence of human and mouse GBS-28. * indicate residues not conserved and bold the 5 invariant 
residues of a GBS consensus. B. Multiz alignment of GRR-28 of 17 species of placental mammals (UCSC 
Genome Browser) C. Human and mouse GRR-28 were cloned in pGL4. pGL4-GRR-4.6 was included as 
a positive control. HeLa cells were transiently transfected with 200 ng of constructs and 100 ng of pRL-
TK plasmid. Cells were treated for 20 h with dex (100 nM) or vehicle (0.1 % EtOH), harvested and 
luciferase activities measured. For each construct, Firefly luciferase activity was normalized to Renilla 
luciferase activity. Fold response to dex was calculated and normalized against the response of the empty 
vector pGL4. Means and S.E.M. from three independent experiments are shown. Statistical comparisons 
are against pGL4. n.s., not significantly different. D. GR recruitment was assessed by ChIP. HeLa cells or 
mouse fibroblasts were treated with vehicle (0.1 % EtOH) or dex (100 nM) for 30 min. Samples were then 
chromatin immunoprecipitated with either IgG (white columns) or anti-GR antibody (black columns). Q-
PCR was used to detect the immunoprecipitated DNA fragments and measurements were done in 
triplicates. The enrichment of specific chromatin fragments was determined as a proportion of the initial 
material present (input). Data represent one experiment representative of two (mouse fibroblast) or three 
(HeLa) independent experiments. Work in C was performed with the assistance of Nasren Paktiawal. 
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Figure 3.7. GBS-29 
A. Sequence of mouse (Mm.), human (Hs.), rat (Rn.) and dog (Cfa.) GBS-29. Red boxes indicate the 
mouse GBS as a base sequence and * indicates the GBS residues not conserved between mouse and the 
other species. Black boxes indicate the human GBS as a base sequence and • indicates the GBS residues 
not conserved between human and mouse. 5 invariant base pairs of GBS  are in blue. B. Multiz alignment 
of GRR-29 of 13 species of placental mammals (UCSC Genome Browser). 
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motif in the human DUSP1 locus is located 29 kb upstream of the TSS due to internal 
insertions and/or deletions. This region will therefore be referred to as GRR-29.  The 
mouse GBS-29 sequence contains matches to Yamamoto’s consensus on both strands 
(blue in Fig. 3.7A). Multi-species alignment across this region reveals that  the GBS is 
not highly conserved between placental mammals (Fig. 3.7B). Though the similarity of 
this GBS between the four species presented here is evident, it is complex to describe 
given that the differences arise not just from simple changes in base pairs but from the 
consequent shifts in position of the GBS. The sequence alignment in figure 3.7A is 
extended to several adjacent 5’ and 3’ residues to establish that differences in precise 
GBS position are not simply a result of misalignment. First, the mouse GBS will be 
considered as the “base” sequence (outlined in red box in Fig 3.7A) since it was the first 
one to be identified. Although having only one base pair different, the rat element lacks 
the GBS consensus in the bottom strand. The dog element differs by 3 nucleotides and 
lacks the GBS on the top strand. The human sequence which differs by 3 nucleotides 
lacks both the GBS seen in the mouse element. Instead, the human has acquired a “new” 
top strand GBS in a slightly shifted position. If this human GBS is now considered as a 
“base” sequence (outlined in black in Fig. 3.7A) there are actually 5 different residues in 
the mouse sequence.  GRR-29 is therefore a complex element which does not perfectly 
fit the criteria used in this study: conservation of GNACANNNNG sequence, position 
and orientation between mouse and human. Nevertheless, this element was also studied 
because the mouse element had already been shown to function and recruit GR in 
C3H10T1/2 cells, and because there is clear conservation of putative GR binding sites 
within this region (So, et al., 2008). After all this GBS was firstly identified based on 
GBS conservation, however different criteria were used in that study.  
 
In the same study the ability of the mouse region to respond to dex was tested in mouse 
C3H10T1/2 cells but the human sequence was not tested. Here, dex responses of 
orthologous GRR-29 of different species were assessed. A fragment of approximately 
500 bp centred on GBS-29 was cloned from mouse, rat, dog or human genomic DNA 
and inserted upstream of the SV40 minimal promoter in the Firefly luciferase reporter 
vector pGL3P. HeLa cells were transiently transfected and stimulated with dex as 
described before. The mouse construct displayed a strong response to dex, and this was 
dependent on the presence of the GBS given that a mutant in which both ACA triplets 
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Figure 3.8. Mouse GRR-29 is responsive to dex whereas the human orthologous region is not 
A. Human, mouse, rat and dog GRR-29 were cloned in pGL3P. Mutants were generated by site-directed 
mutagenesis. Hs.>Mm. is the human GRR with the mouse GBS. MmGBSm is the mouse GRR with the 
ACA and TGT triplets of GBS mutated. B. GBS-29 (italicized) is a short oligonucleotide containing the 
human or mouse GBS-29 element and a few conserved flanking residues cloned in pGL4. HeLa cells 
were transiently transfected with 200 ng of constructs and 100 ng of pRL-TK plasmid. Cells were treated 
for 20 h with dex (100 nM) or vehicle (0.1 % EtOH), harvested and measured for chemiluminescence. For 
each construct, Firefly luciferase activity was normalized to Renilla luciferase activity. Fold response to 
dex was calculated and normalized against the response of the empty vector pGL3P or pGL4. Means and 
S.E.M. from three independent experiments are shown. Statistical comparisons are against the empty 
vector pGL3P or pGL4 unless otherwise indicated ***, p<0.001; **, p<0.01; *, p<0.05; n.s., not 
significantly different. 
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were mutated to GGG (Mm.GBSm) was unable to respond (Fig. 3.8A). The rat 
construct was also responsive to dex. Surprisingly, the human construct was completely 
unresponsive to dex, whereas the dog GRR-29 mediated a very weak response. To 
evaluate whether the difference observed could be attributed to the difference in GBS 
sequence, a mutant of the human construct was generated harbouring the mouse GBS 
(Fig. 3.8A). This construct, though displaying a small increase in the fold response to 
dex when compared to the wild type, was still unable to fully activate transcription as 
the  mouse construct. This indicates that other sequences outside the GBS are crucial for 
the response observed. Oligos containing the isolated GBS from mouse or human were 
cloned in pGL4, which contains only a TATA box and was designed to minimize the 
occurrence of additional transcription factor binding sites within the vector backbone. 
The mouse GBS (GBS-29-Mm.; Fig. 3.8B) was highly responsive to dex whereas the 
human (GBS-29-Hs.) was inert. Combined, the results indicate that not only the human 
GBS is not functional, but its surrounding sequences offer a context which does not 
favour activation of transcription, even in the presence of a functional GBS like the 
mouse one.  
 
The binding of GR to this region in human and mouse cells was evaluated by ChIP 
(work performed by Dr. Carmen Tchen). GR recruitment for the positive control was 
shown in both HeLa cells and mouse fibroblasts (Fig. 3.9). A strong dex-dependent 
recruitment of GR to GRR-29 region was observed in mouse fibroblasts, whereas the 
presence of the receptor was not detected in the same region in HeLa cells. Therefore it 
was possible to establish a direct link between the ability of the GRR to activate 
transcription in response to dex and its the ability to recruit GR in vivo. 
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Figure 3.9. GR is recruited to mouse GRR-29 but not to human GRR-29  
GR recruitment was assessed by ChIP. HeLa cells or mouse fibroblasts were treated with vehicle (0.1 % 
EtOH) or dex (100 nM) for 30 min. Samples were then chromatin immunoprecipitated with either IgG 
(white columns) or anti-GR antibody (black columns). Q-PCR was used to detect the immunoprecipitated 
DNA fragments and measurements were done in triplicates. The enrichment of specific chromatin 
fragments was determined as a proportion of the initial material present (input). Data represent one 
experiment representative of two (mouse fibroblast) or three (HeLa) independent experiments. Work 
performed by Dr. Carmen Tchen. 
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3.5. DISCUSSION 
 
DUSP1 upregulation by GCs has been shown to occur in mouse and human cells (Clark, 
2007) and in the present study it was established that the mRNA expression pattern is 
similar between the same types of cells from the two species. DUSP1 gene seems to be 
regulated by GCs in a similar way in both species and it would not be surprising if the 
molecular mechanism for the GCs upregulation of this phosphatase was conserved 
between species. This chapter described the study of three putative GRR located far 
away from the TSS and identified based on a phylogenetic approach. If any of these 
regions is an enhancer it should be able to increase the utilization of heterologous 
promoters and it should function in either orientation or location upstream or 
downstream relative to the promoter (Lewin, 2004). This allows subcloning these 
regions upstream of a heterologous promoter and investigating their ability to respond 
to dex. However it will not be possible to investigate their activity in the context of the 
whole DUSP1 locus given that it would be unfeasible to clone 30 kb fragments. Issues 
concerning the use of reporter gene assays, the study of distal promoter elements and 
the layout of the phylogenetic approach used here will be discussed.  
 
3.5.1. A phylogenetic approach as a tool to identify functional GRRs 
It has been shown before that human and mouse seem to share cis-regulatory elements 
within the genome, and this has been shown specifically for glucocorticoid regulated 
regions. In a genomic study it was established that when a specific sequence of an 
individual GBS is conserved in four mammalian species analysed, it correlates with 
conservation of functional elements throughout evolution (So, et al., 2007). This 
conservation is also extended to flanking sequences of the GBS, comprising 
transcription factor binding sites also involved in the molecular mechanism of 
transcriptional regulation by GCs. Based on these facts, a phylogenetic approach was 
used to identify functional GRR and GBS within the 5’ region of the human and mouse 
DUSP1 genes. The analysis started by finding matches of the consensus 
GNACANNNNG within that region. 
 
A first question worth discussing is how to establish the physical boundaries when 
searching for cis-elements involved in regulating a gene, which can be a complicated 
task. The nearest confirmed 5’ neighbour gene of the human and mouse DUSP1 loci is 
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endoplasmic reticulum and Golgi intermediate compartment protein 1 (ERGIC1), 
located 63.3 kb distant in human and 45.8 kb in mouse. From the 3’ the nearest 
confirmed neighbour gene is neuralised-like protein 3/related E3 ubiquitin ligase 3 
(NEURL3 or LINCR), 76.6 kb distant in the human and 63.8 kb in the mouse. This 
means that in theory the search for GRR possibly involved in regulating DUSP1 gene 
would involve a potential area of more than 100 kb. And this is already excluding that 
sometimes regulatory elements are embedded in intronic sequences from the same gene 
or flanking genes. In this specific case there is no information in literature indicating 
GCs regulate the transcription of ERGIC1 gene. There are two studies from the same 
group relating GCs and NEURL3. However two reasons indicate GRR in its proximity 
should not be involved in its regulation: first NEURL3 is downregulated by GCs and 
second, this happens at the mRNA level but there is no evidence whether this is a 
transcriptional or post-transcriptional mechanism (Smith, et al., 2002). Since GCs are 
not involved in the upregulation of these genes, functional GRR identified in the 
flanking regions of DUSP1 locus would likely be involved in regulation of DUSP1, but 
does not exclude that a cis-element involved in the regulation of this gene can be 
present in the domains of adjacent genes.  
 
The search element contains only 5 invariant base pairs meaning that its information 
content is rather low. The search was arbitrarily limited to the 30 kb upstream of 
DUSP1 TSS. This 30 kb upstream of the TSS of both human and mouse DUSP1 gene 
were scanned for matches of the consensus GNACANNNNG. These were abundant and 
evenly distributed throughout the 30 kb illustrating that there are many putative sites for 
GR to bind to. Given that this is a fairly loose consensus it is predictable that most of 
the matches found are actually randomly present in DNA and are not functional. 
Therefore the “hits” were further selected for matches conserved in position, orientation 
and sequence between mouse and human DUSP1 loci and finally the ones embedded in 
regions of highly conserved sequence were selected. This filtering process significantly 
decreased the number of “hits” to investigate. Obviously this type of approach is 
subjected to errors and will be associated with false negative and false positive “hits”. 
Real examples of both were identified and will be later discussed. Also it should be 
noticed that it is highly likely that other GBS in human and mouse DUSP1 cis-
regulatory regions are functional but not conserved between both species. Evolution is 
an ongoing process and more than 100 million years of divergence between human and 
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mouse would have created or “erased” cis-regulatory elements that ultimately allow to 
maintain similar patterns of DUSP1 gene expression. There were 88 and 56 matches to 
the consensus GBS in the mouse and human 30 kb of the DUSP1 5’ region analysed. It 
would be a nearly unfeasible task to analyse them all, and therefore the phylogenetic 
approach offers a mostly reliable manner of selecting which ones to test.  
 
3.5.2. Artificial reporter assays and the type of promoter to use 
Reporter constructs designed to study the regulatory activity of cis-elements, normally 
contain a minimal promoter, upstream of which the element being studied is subcloned. 
Cloning far upstream elements close to a basal promoter should not pose a problem 
given that enhancers do not depend on the distance to the basal promoter for their 
activity; however it cannot be excluded that real enhancers might depend on other distal 
elements to be functional or might require specific basal promoter architecture for the 
interactions to occur. This means that the selection of the basal promoter used is 
important. 
 
The vector chosen to clone DUSP1 promoter fragments was pGL3P, which contains the 
SV40 early promoter. The issue of what vector/promoter to choose is debatable. The 
integrity and type of promoter can define interaction with distant cis-regulatory 
elements. Therefore it can be argued that the best option would have been to engineer a 
vector with the DUSP1 promoter and then clone upstream of it the different DUSP1 
potential enhancer elements analysed. The SV40 promoter however is similar to the 
DUSP1 proximal promoter: TATA-less, with high GC content and several sites for Sp1. 
The overall architecture seems to be preserved. Another possibility would have been to 
use the simplest vector possible, for example pGL4. This would be to assure that the 
presence of a promoter, even the DUSP1 promoter, does not interfere with the potential 
activity of the cis-element tested, either by inhibiting it or by artificially enhancing it. 
Even if using the DUSP1 promoter there would be the issue of the distance between the 
two elements not reflecting the real distance in the genome. Though it is true the 
distance from an enhancer to the basal promoter is not important, bringing distant 
elements close to the basal promoter could in theory create an artificial cooperation 
between two elements which in physiologic conditions would never be in proximity. 
Hence, there is not a correct answer when choosing the promoter. Still, in the future, it 
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could be interesting to use the DUSP1 promoter to evaluate the activity of the functional 
GRRs identified. 
 
Additionally there are alternatives to this approach. For example Pike and colleagues 
used cells stably transfected with a full-length vitamin D receptor bacterial artificial 
chromosome (BAC) clone-luciferase reporter gene to study the regulation of the vitamin 
D receptor gene (Zella, et al., 2010). Another approach would be to use genetic tools to 
directly delete or mutate elements in the context of the endogenous mouse DUSP1 locus 
or carry out deletion assays with reporter gene constructs in transgenic animals. 
Obviously these approaches are labour intensive and technically demanding, as well as 
costly.  
 
Reporter assay systems in cell culture systems are obviously a powerful and simple 
technique to identify enhancers; however, as discussed above, these systems pose 
several issues regarding the artificiality associated with them. In this case, establishing 
the binding of GR to the regions able to respond to dex became an essential argument 
for validation of the reporter assays. It was extremely reassuring that the ChIP data were 
always in agreement with the data from the reporter assays for all the regions tested. If a 
region can respond to dex in a reporter assay it has to involve the presence of GR. 
However if a region is not able to respond to dex, but contains putative GBS, it can 
reflect two different situations: a) cooperation downstream of DNA binding, in which 
GR binds DNA but is unable to cooperate with additional transcription factors/cofactor; 
b) cooperation at the level of DNA binding, in which GR does not bind DNA because it 
is unable to cooperate with transcription factors required for that to happen. All the 
identified regions unresponsive to dex, including some described later on, were always 
associated with the absence of GR binding. Given that the regions not able to respond to 
GR still contain the conserved GBS but do not bind GR it appears that divergence 
between mouse and human regulatory elements has occurred in binding sites for 
additional transcription factors that are required to recruit GR to the region. 
 
3.5.3. Identification of functional and non functional conserved GBS 
The first element tested was a GRR located 24 kb upstream of the TSS. This region 
contains a GBS with only one residue different between human-mouse sequences and it 
is in fact highly conserved between mammal species. Given the relationship between 
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GBS conservation/functionality described above, these observations indicated this GBS 
as a major candidate for a GR occupied site able to regulate transcription. In fact, both 
the human and mouse GRR-24 were responsive to dex and GR was shown to be 
recruited to this region in both HeLa cells and mouse fibroblasts. Nevertheless, the 
strength of this response and GR recruitment was modest compared to the other GRR 
identified in this study. Still, this region is a good example of how GBS sequence 
conservation is predictive of GR occupancy and transcriptional function in human and 
mouse. 
 
The next region assessed was 28 kb from the promoter and contained a GBS with 11/15 
bp conserved between mouse-human sequences. Interestingly, the GBS is not highly 
conserved between 17 species of mammals, although 11 or 15 bp are also conserved in 
the dog and rat, respectively. In this case neither mouse nor human GRR were able to 
induce expression of the reporter gene, which was adequately correlated with inability 
to recruit GR in both mouse fibroblasts and HeLa cells. This is clearly an example of a 
false positive error resulting from the approach used to identify GRR. 
 
3.5.4. GBS-29 divergence of function 
The third GRR examined is located 29 kb upstream of the human DUSP1 TSS. This 
region had been previously identified in a study looking at human-mouse sequence 
comparisons for GC-regulated genes. Only the mouse GRR was described in 
Yamamoto’s paper and GR recruitment was only assessed in mouse C3H10T1/2 cells. 
In the present analysis, mouse GRR-29 was again shown to be responsive to dex, and 
this was associated with GR recruitment in mouse fibroblasts. Surprisingly, human 
GRR-29 was completely unresponsive to dex and this perfectly correlated with the 
inability to recruit GR to this region in HeLa cells. This is an interesting example where 
GBS sequence conservation between human-mouse was only indicative of function in 
the case of the mouse element. Interestingly, this GBS was not predicted using the 
phylogenetic approach described here. This approach screened for perfect matches of 
GNACANNNNG that were conserved in sequence, position and orientation between 
human and mouse DUSP1 loci. GBS-29 has complex sequence relationships described 
before. Briefly, mouse GBS-29 contains matches to the consensus in both strands, 
whereas the human contains only one match which is actually shifted in position and 
therefore does not match all the requirements determined for this analysis. In 
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Yamamoto’s study they used a GBS positional weight matrix defined using 79 GBS 
identified through ChIP microarray tiling experiments. This is the matrix which defined 
that only 5 bp are invariant within the 15 bp of a GBS. Instead of fixing the search at 
only the loose consensus (GNACANNNNG) they looked at successive 15-bp windows 
progressing across the 64 kb surrounding each target gene TSS and scored them against 
the matrix (all the 15 bp), and the sites falling within the 90th percentile were defined as 
GBS. The conservation was established by then directly pairing the 15 bp sequences of 
both human and mouse, and selecting for the ones that had 9-15 identical base pairs. In 
the case of GBS-29 there are 12 or 10 identical base pairs if you take the mouse or the 
human GBS as a base sequence, respectively. For this analysis there is no need for 
conservation of the 5 invariant base pairs, which was the main criterion in the approach 
described here. This explains why this GBS was predicted in their study but not in this 
one. The fact that this GBS was not predicted here raises the question of false negatives 
associated with the approach described here. At the same time Yamamoto’s approach 
was unable to detect other functional GBS detected by this approach (GBS-24, GBS-
1.3, GBS-4.6) which indicates that it is impossible to detect all functional GBS using 
just one approach given that in the end all the criteria used will be arbitrary. Regarding 
this there are alternative approaches that could have been used to identify cis-regulatory 
regions in DUSP1 loci.  
 
DNAse I hypersensitive site mapping is one example. GR is known to bind in DNAse I 
hypersensitive sites (John, et al., 2008). Therefore this technique could be used to 
screen for possible GR binding sites by searching for sites which display increased 
sensitivity to DNAse I activity. However this would be a laborious technique to perform 
especially if applied to a large stretch of DNA. Additionally, GR binds to DNAse I 
hypersensitive sites but not all DNAse I hypersensitive sites detected might be bound by 
GR. This approach would had the advantage of not having false negatives. Shotgun 
cloning of DNA fragments from the DUSP1 locus could also be used to identify 
functional GRRs. Here, overlapping 1 kb fragments across the locus could be amplified 
by PCR, cloned into pGL4 or pGL3P and then evaluated for their ability to respond to 
dex. Though an unbiased and feasible approach, this seems not to have a strong 
rationale and clearly is labour intensive. 
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Another systematic approach would have been to use ChIP-chip (chromatin 
immunoprecipitation-microarray). In this case the chromatin immunoprecipitation 
procedure is done as normal, but the final step of detection of the chromatin enriched 
fragments is done by hybridizing the samples onto the ChIP-chip tiling arrays. This sort 
of tiled arrays can be custom made and in this case could be design to include probes 
across the DUSP1 locus. Currently very popular is the approach of ChIP-sequencing. 
This associates the ChIP procedure with high throughput sequencing allowing to screen 
the whole genome for specific binding sites. However, this technique (as well as ChIP-
chip) is not normally used to look at just one locus but at a genomic scale. In fact ChIP-
seq approach has likely been done to look at GR binding sites within the genome, 
including DUSP1, but the data is not yet in the public domain. 
 
3.5.5. Concluding remarks 
The phylogenetic approach described here was associated with a false positive example, 
namely GRR-28. This was the first evidence to the fact that conserved GBS sequences 
present in regions of highly conserved sequence will not always correlate with 
conservation of function. A false negative example, GRR-29, was also illustrated. This 
mainly points to the fact that GBS sequence conservation per se, can be defined by 
extensively subjective criteria when it comes to studies looking at large regions of 
DNA. These approaches can be successful however filtering processes to avoid false 
positives will sometimes come at the cost of false negatives. Additionally, the fact that 
GRR-29 is only functional in mouse and not in human also raises the question of 
starting with propositions that should not be regarded as absolute rules. In this case the 
first chapter already allows answering one of the questions of this thesis and key 
proposition of the phylogenetic approach: conservation of GBS, per se, is not sufficient 
to predict functional conservation of GBS in the 5’ region of the DUSP1 gene. GBS 
conservation might be a good predictor of GR occupancy but it is not sufficient to 
always indicate that event. In So’s paper it is determined that this relationship between 
GBS conservation/GR binding is in fact only a likelihood (So, et al., 2008). More 
specifically the % of functional GBS increases with the number of conserved base pairs 
within the GBS analysed. DUSP1 one so far seems to be an interesting example of 
exceptions, conserved GBS that fall outside the % of likelihood of function 
conservation. So far, the use of human-mouse GBS conservation to identify functional 
GRR has produce 3 different outcomes: function in both species (GRR-24), in neither 
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(GRR-28) or just in the mouse (GRR-29). The ability of a region with a GBS to regulate 
transcription in response to dex is widely accepted to be associated with ability to 
recruit GR. This was always the case for all the regions studied here. The next chapters 
will describe two GRR which add more information about the use of sequence 
conservation to identify functional GBS and further confirm that human and mouse use 
different cis-regulatory elements to regulate DUSP1 gene expression. 
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4. Chapter 4 - Glucocorticoid Responsive Region -1.3 (GRR-1.3) 
 
The data described in the previous chapter brought to light that GBS sequence 
conservation was not an absolute predictor of functional conservation. This chapter will 
focus on the study of a particular GRR located 1.3 kb upstream of the TSS of DUSP1 
gene. It starts with studies using the human DUSP1 native promoter and sequential 
deletion mapping that lead to a fragment of 130 bp which is highly responsive to dex 
and contains the putative GBS. Studies to evaluate the functional conservation of this 
region between species were performed, as well as ChIP assays to evaluate the 
recruitment of GR in vivo.  The human GRR-1.3 was also studied in more detail which 
included mutagenesis studies to implicate this GBS in the response to dex, study of its 
ability to directly recruit GR and investigation of additional elements that might 
contribute to the response.  
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4.1. Mapping the 5’region of the human DUSP1 gene 
The other highly conserved GBS present in both human and mouse 5’ region of the 
DUSP1 gene were located 1.3 or 4.6 kb upstream of the TSS. Studying cis-regulatory 
elements located far from the core and proximal promoter of the corresponding gene is 
limited to the use of heterologous promoters. These two regions were within a range of 
distance from core and proximal promoter which is still feasible to clone whilst 
including the native promoter. Therefore it was decided to clone a fragment spanning 
from position -4834 to +211 from the human DUSP1 TSS. The fragment was inserted 
into pGL3B, a promoterless vector and will be designated as pGL3B-4.8kb-Hs. Other 
constructs were generated containing deletions of the initial 4.8 kb. DUSP1 reporter 
constructs were transfected into HeLa cells and assessed for their ability to respond to 
dex (work done in collaboration with Dr. Carmen Tchen). 4.8kb-Hs mediated a 
response of 25-fold to dex (Fig. 4.1). A first deletion (2.7kb-Hs) significantly impaired 
but did not abolish the response to dex. This decrease could result from the absence of 
the three putative GBS located around 4.6 kb upstream from the TSS. A second 
impairment of the transcriptional response to dex occurred when deleting the segment 
between -1.5 and -1.1kb. In this case, the loss of function can be hypothesised to result 
from the loss of the putative GBS-1.3 contained within the deleted segment. This last 
hypothesis was tested and the study of the GRR containing this GBS will be described 
in this chapter. 
 
4.2. Evidence for species-specific usage of GRR-1.3 
As described before, deleting a segment of the human 5’ region of the DUSP1 gene 
between -1.5 and -1.1 kb from the TSS lead to abrogation of the response to dex. A 
construct containing an equivalent fragment was cloned into pGL3P, as well as several 
fragments harbouring deletions from 5’ or 3’. Luciferase reporter analysis in HeLa cells 
allowed to identify a 130 bp fragment extending from -1366 to -1237 with respect to the 
TSS, which is sufficient to mediate a response to dex (work performed by Dr. Tchen; 
Fig. 4.2). This fragment will be designated from now on as GRR-1.3. 
 
Alignment of the human 130 bp GRR-1.3 with the orthologous sequence of the mouse 
(conserved base pairs in light gray) or the dog (conserved base pairs in dark gray) 
reveals a sequence conservation of 74 % and 78 %, respectively (Fig 4.3A). Mouse and 
rat GRR-1.3 are almost identical (not shown). 
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Figure 4.1. Deletion analysis of the human 5’ region of the DUSP1 gene.  
Fragments of the human DUSP1 5’ region were subcloned into the Firefly luciferase reporter construct 
pGL3B. GBS elements are indicated by vertical bars. GBS-4.6 comprises three closely spaced GBS 
elements known as GBS-4.6.1,-4.6.2 and -4.6.3. HeLa cells were transiently transfected with 200 ng of 
each reporter construct and 100 ng of a Renilla luciferase expression vector (pRL-TK). Cells were then 
treated for 20 h with vehicle (0.1 % EtOH) or dex (100 nM) followed by harvesting and measuring of 
luciferase activities. For each construct, Firefly luciferase activity was normalized to Renilla luciferase 
activity, and fold response to Dex was calculated.  Means and S.E.M. from three independent experiments 
are shown. Unless otherwise indicated, statistical comparisons are against pGL3B-Hs.-4.8kb. ***, 
p<0.001. Work performed in collaboration with Dr. Carmen Tchen. 
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Figure 4.2. Deletion analysis to identify a GRR 1.3 kb upstream of the human DUSP1 TSS.  
A genomic fragment extending from -1426 to -1096 with respect to the human DUSP1 TSS and various 
deletion derivatives of this fragment were subcloned into pGL3P. The region between -1366 to -1237 was 
identified as a minimal GRR and is hereafter known as GRR-1.3(indicated in red). HeLa cells were 
transiently transfected with 200 ng of each reporter construct and 100 ng of pRL-TK. Cells were then 
treated for 20 h with vehicle (0.1 % EtOH) or dex (100 nM) followed by harvesting and measuring of 
luciferase activities. For each construct, Firefly luciferase activity was normalized to Renilla luciferase 
activity. Fold response to Dex was calculated and normalized against the response of the empty vector 
pGL3P. Means and S.E.M. from three independent experiments are shown. Statistical comparisons are 
first against the empty vector pGL3P and second against the construct containing the minimal GRR-1.3(-
1366/-1237) which is hereafter referred to as pGL3P-GRR-1.3-Hs. ***, p<0.001; **, p<0.01; n.s., not 
significantly different. Work performed by Dr. Carmen Tchen. 
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Figure 4.3. Orthologous GRR-1.3 present different responses to dex.  
A. Alignment of human (Hs.), mouse (Mm.) and dog (Cfa.) GRR-1.3 sequences. B. Dog, human, mouse 
and rat GRR-1.3 fragments were subcloned into pGL3P. HeLa cells were transiently transfected with 200 
ng of each reporter construct and 100 ng of pRL-TK. Cells were then treated for 20 h with vehicle (0.1 % 
EtOH) or dex (100 nM) followed by harvesting and measuring of luciferase activities. For each construct, 
Firefly luciferase activity was normalized to Renilla luciferase activity. Fold response to Dex was 
calculated and normalized against the response of the empty vector pGL3P. Means and S.E.M. from three 
independent experiments are shown. Statistical comparisons are against the empty vector pGL3P. ***, 
p<0.001; **, p<0.01; n.s., not significantly different. 
pGL3b_4834. 
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Orthologous mouse, dog and rat sequences of the GRR-1.3 were cloned upstream of the 
SV40 minimal promoter in pGL3P. As previously shown the human construct displayed 
a strong response to dex, and the same was observed with the dog construct (Fig. 4.3B). 
Surprisingly, the mouse construct was inert to dex and the rat only displayed a very 
weak response. A second mouse GRR-1.3 fragment was cloned [GRR-1.3-Mm.(1509/-
1029)], which extends 303 bp 5’ and 53 bp 3’ of the first one. The purpose was to 
include most of the region of strong sequence conservation between mouse and human 
and guarantee that another transcription factor binding site important was not being left 
out (work performed with the help of Dr. Carmen Tchen and Chwen Tay). Although 
this new construct is weakly responsive to dex when compared to the empty vector or 
GRR-1.3-Mm.(-1206/-1082), it still displays an extremely modest response if compared 
with human GRR-1.3 (Fig. 4.4). Therefore it seems that this particular region, despite 
strong sequence conservation is functional in the human but only very weakly 
responsive in the mouse. 
 
4.3. GR recruitment assessed by ChIP 
Chromatin immunoprecipitation experiments were carried out to assess the recruitment 
of GR to both the human and mouse GRR-1.3 in vivo. In HeLa cells a dex dependent 
enrichment of GR was observed for GRR-1.3 as well as for the positive control (Fig. 
4.5). This was confirmed with an additional set of primers for GRR-1.3 (data not 
shown). In mouse fibroblasts there was no recruitment of GR to the same region (Fig. 
4.5).  The ability or inability of GRR-1.3 to activate transcription in functional assays 
correlates perfectly with the ability or inability of the same region to recruit GR in vivo. 
 
4.4. Identification of GBS in the GRR-1.3 
GBS-1.3 is 100 % conserved between human and mouse and in fact is highly conserved 
between 16 different placental mammals (Fig. 4.6A and Table 3.1 in Chapter 3), further 
suggesting its importance. 
 
To determine if the putative GBS was necessary for the transcriptional activation 
observed, a mutational analysis was performed. Using site-directed mutagenesis with 
the primers described in Table 2.3, the putative GBS was mutated in the context of 
pGL3P-GRR-1.3-Hs. In GBSm1 the highly conserved ACA triplet was substituted by
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Figure 4.4. The mouse and human GRR-1.3 have clearly different abilities to respond to dex  
 
 
 
 
Mouse and human fragments from the 5’ region of the DUSP1 gene were cloned into pGL3P. HeLa cells 
were transiently transfected with 200 ng of DUSP1 reporter constructs and 100 ng of pRL-TK plasmid. 
After 20 h of treatment with dex (100 nM) or vehicle (0.1 % EtOH) cells were harvested and the 
chemiluminescence was measured. For each construct, Firefly luciferase activity was normalized to 
Renilla luciferase activity. Fold response to Dex was calculated and normalized against the response of 
the empty vector pGL3P. Means and S.E.M. from three independent experiments are shown. Statistical 
comparisons are against the empty vector pGL3P unless otherwise indicated. ***, p<0.001; **, p<0.01; 
n.s., not significantly different. Work performed with help of Dr. Carmen Tchen and Chwen Tay. 
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Figure 4.5. GR is recruited to human GRR-1.3 but not to mouse GRR-1.3 
HeLa cells or mouse fibroblasts were treated with vehicle (0.1 % EtOH) or Dex (100 nM) for 30 min. 
Samples were then chromatin immunoprecipitated with either IgG (white columns) or anti-GR antibody 
(black columns). Q-PCR was used to detect the immunoprecipitated DNA fragments and measurements 
were done in triplicates. The enrichment of specific chromatin fragments was determined as a proportion 
of the initial material present (input). Data represent the means and SD of one experiment representative 
of two (mouse fibroblast) or three (HeLa) independent experiments. Work performed by Dr. Carmen 
Tchen. 
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Figure 4.6. Human GRR-1.3 response to dex depends on GBS-1.3, but this element alone is not 
sufficient 
 
 
 
 
 
 
 
A. Multiz alignment of GRR-1.3 of 17 placental mammals (UCSC Genome Browser) B. Mutational 
analysis of putative GBS-1.3. pGL3P-GRR-1.3Hs.GBSm1 and –GBSm2 contain a mutation on the 
putative GBS and were generated by site-directed mutagenesis. C. Analysis of GBS.1.3 in isolation  
GBS-1.3 (italicized) is a short oligonucleotide containing the GBS-1.3 element and a few conserved 
flanking residues cloned in pGL4. HeLa cells were transiently transfected with 200 ng of constructs and 
100 ng of pRL-TK plasmid. Cells were treated for 20 h with dex (100 nM) or vehicle (0.1 % EtOH), 
harvested and measured for chemiluminescence. For each construct, Firefly luciferase activity was 
normalized to Renilla luciferase activity. Fold response to dex was calculated and normalized against the 
response of the empty vector pGL3P or pGL4. Means and S.E.M. from three independent experiments are 
shown. Statistical comparisons are against the empty vector pGL3P or pGL4 unless otherwise indicated 
***, p<0.001; **, p<0.01; *, p<0.05; n.s., not significantly different. 
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GGG whereas in mutant GBSm2 the final conserved G was substituted by C.  Mutation 
in GBSm1 was shown to completely abrogate transcriptional activation by dex, whereas 
the second mutation severely impaired this response (Fig. 4.6B). These data suggest that 
the activity of GRR-1.3 depends on this GBS. 
 
This GBS is perfectly conserved between mouse and human (15/15 bp). Given that the 
mouse construct is inactive, it appears that this GBS is necessary for the response to 
dex, yet it is not sufficient. Therefore it was also interesting to test its power to drive 
transcription on its own. Hence, an oligo containing the GBS and adjacent conserved 
residues was cloned into pGL4. For comparison human and mouse GRR-1.3 were also 
cloned into this vector. The isolated GBS displayed a very low response to dex, though 
statistically significant in comparison with the empty vector (GBS-1.3 in Fig 4.6C). This 
vector exhibits a much lower basal activity compared with pGL3P, which probably 
explains why in this context the mouse GRR-1.3 exhibited a weak response to dex, 
which was similar to GBS-1.3 alone. Still the difference in response between human 
and mouse was maintained, since the first exhibited a much stronger response to dex 
than the second. In summary, the GBS is necessary for the response to dex. However 
when isolated it is only capable of orchestrating a very modest response to dex. To fully 
activate transcription it requires additional sequences, present in the human but not in 
the mouse GRR. 
 
4.5. Studying DNA-protein interactions 
Figure 4.7 shows the sequence of the human 130 bp GRR and its homology with the 
orthologous region from the mouse and dog. Additionally the sequences of the oligos 
used in EMSAs and the putative binding sites for transcription factors of interest are 
included. 
 
4.5.1. 130 bp GRR EMSA studies 
The binding of GR to this region was shown by ChIP. However, EMSAs were also 
performed. This type of assay allows to define the specific base pairs necessary for the 
GR-GBS interaction, to establish GR affinity for this sequence and compare it with its 
affinity for other known GBS. It might also be adapted to provide some information 
about the conformation of GR when bound to this site. Additionally, it could be used to
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gcccgcggagaggggaagaaaccgcagaatgttcctgactctgcaccctggcc ggatggcgcaatatttatgtttgtgtacctagcacgtcggcgccgccctcccccgccctcccccgccccggaggcccgccct  
tcccccag gaggggaggaaaccgcagaatgttcctgactcggcaccc gggc gggtggcgcaatgtttatgtttgtgtacctagcgcgtcg cgtcgc  tgcagcaggctccgctgtccagggggccgtcact  
ttgcaaag a   ggaagaaaccgcagaatgttcctgactcggcaccc cttcagagtggtgcaatgtttatgtttgtgtatccaactc  cg tggtgt  tgcggcggactca ctgcctaccctgtagtca t
   
GRR-1.3-Hs.
GRR-1.3-Cfa.
i GRR-1.3-Mm.
  
tcccccaggaggggaggaaaccgcagaatgttcctgactcggcacccgggcgggtggcgcaatgtttatgtttgtgtacccagcgcgtcgcgtcgctgcagcaggctccgctgtccagggggccgtcact SNP 
 
 
tcccccaggaggggaggaaaccgcagaatgttcctgactcggcacccgggcgggtggcgcaatgtttatgtttgtgtacctagcgcgtcgcgtcgctgcagcaggctccgctgtccagggggccgtcact GBS1 
 
tcccccaggaggggaggaaaccgcagaatgttcctgactcggcacccgggcgggtggcgcaatgtttatgtttgtgtacctagcgcgtcgcgtcgctgcagcaggctccgctgtccagggggccgtcact SP1 
 
tcccccaggaggggaggaaaccgcagaatgttcctgactcggcacccgggcgggtggcgcaatgtttatgtttgtgtacctagcgcgtcgcgtcgctgcagcaggctccgctgtccagggggccgtcact CEBP 
  
tcccccaggaggggaggaaaccgcagaatgttcctgactcggcacccgggcgggtggcgcaatgtttatgtttgtgtacctagcgcgtcgcgtcgctgcagcaggctccgctgtccagggggccgtcact FOXL1 
 
tcccccaggaggggaggaaaccgcagaaccctcctgactcggcacccgggcgggtggcgcaatgtttatgtttgtgtacctagcgcgtcgcgtcgctgcagcaggctccgctgtccagggggccgtcact FOXO 
 
tcccccaggaggggaggaaaccgcagaatgttcctgactcggcacccgggcgggtggcgcaatgtttatgtttgtgtacctagcgcgtcgcgtcgctgcagcaggctccgctgtccagggggccgtcact ATF 
 
tcccccaggaggggaggaaaccgcagaatgttcctgactcggcacccgggcgggtggcgcaatgtttatgtttgtgtacctagcgcgtcgcgtcgctgcagcaggctccgctgtccagggggccgtcact AP1 
 
gggtggccagcgaaatcccctcccccaggaggggaggaaaccgcagaatgttcctgactcggcacccgggcgggtggcgcaatgtttatgtttgtgtacctagcgcgtcgcgtcgctgcagcaggctccgctgtccagggggccgtcact NF-κB 
 
tcccccaggaggggaggaaaccgcagaatgttcctgactcggcacccgggcgggtggcgcaatgtttatgtttgtgtacctagcgcgtcgcgtcgctgcagcaggctccgctgtccagggggccgtcact GBS2 
 
 
 
tcccccaggaggggaggaaaccgcagaatgttcctgactcggcacccgggcgggtggcgcaatgtttatgtttgtgtacctagcgcgtcgcgtcgctgcagcaggctccgctgtccagggggccgtcact 
 
 
gggtggccagcgaaatcccctcccccaggaggggaggaaaccgcagaatgttcctgactcggcacccgggcgggtggcgcaatgtttatgtttgtgtacctagcgcgtcgcgtcgctgcagcaggctccgctgtccagggggccgtcactgggactcagg 
 
 
gggtggccagcgaaatcccctcccccaggaggggaggaaaccgcagaatgttcctgactcggcacccgggcgggtggcgcaatgtttatgtttgtgtacctagcgcgtcgcgtcgctgcagcaggctccgctgtccagggggccgtcactgggactcagg 
 
 
 
A B C
D E
ii 
iii 
I F
Figure 4.7. GRR-1.3 
i Sequence of the GRR-1.3 human promoter aligned with the mouse and dog orthologous regions. Pink or blue background represents the conserved bp. 
ii Sequence of the putative binding sites for the several transcription factors and SNP within the human GRR-1.3 (grey). Sites determined by Matrix Inspector or TESS. 
iii Sequence of the oligos A-F and I used as probes for EMSA to study the DNA-protein interactions within GRR-1.3. 
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evaluate where other transcription factors were binding within GRR-1.3 and whether 
any of them were regulated by dex. The 130 bp fragment was divided into shorter 
sequences of 40 bp to be used as probes in this assay (Fig. 4.8A). Oligos including up to 
20 bp upstream and downstream of the extremities of this unit were later used to 
perform some additional studies that focus on transcription factors whose putative 
binding sites are close to the ends. Initially the EMSA protocol was optimized regarding 
parameters such as protein concentration, probe concentration, type and concentration 
of non-specific competitor and concentrations of the components in the binding buffer 
(data not shown). 
 
Probes A-E were used in EMSA with nuclear extract from HeLa cells stimulated with 
vehicle (0.1 % EtOH) or dex (100 nM) for 1 hour (Fig. 4.8B). This time point was 
chosen because the endogenous DUSP1 gene is rapidly upregulated by dex, and 
expression reaches its peak by 1 hour (Lasa, 2002 and Fig. 3.1). Only very weak 
binding to probe D was detected but all other probes generated DNA-protein 
complexes. The complexes with probes A and B appeared to be increased by dex, but 
this observation was not reproducible (for example see Fig. 4.8C). Competition 
experiments were then carried out to investigate the sequence specificity of the 
interactions detected (Fig. 4.8C). Oligo A seemed to form a specific complex, which 
was efficiently competed by an excess of unlabelled oligo A, but not by other oligos. 
Since this complex was not competed by the overlapping oligo D, it may involve 
interactions within the first 20 bp of the oligo. Fragment B formed specific complexes 
that were competed by self and by oligo E. These complexes are likely to involve the 
region of overlap of oligos B and E, which contains a putative FOX binding site later 
described. Oligo C formed a single complex. There was competition when the 
unlabelled oligo C was added, however oligos such as A and E also competed for the 
formation of the complex. The specificity of this complex is therefore uncertain. 
Finally, oligo E formed two complexes (indicated by arrows), which were not well 
resolved in the competition experiment. Both complexes were competed by unlabelled 
oligo E, but not by the non-overlapping oligos A and D. They therefore show the 
characteristics of specific DNA-protein complexes. The upper complex was apparently 
competed by oligo B, and therefore probably involves the region of overlap between 
oligos B and E.  The lower complex was not altered by the introduction of oligo B or C 
as competitors, which might signify that a protein is binding at the centre of oligo E, in
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 Figure 4.8. DNA-Protein binding studies for probes A-E 
A. Scheme of EMSA probes. A-F and I represent the oligonucleotide fragments used as probes in 
protein binding assays and their position relatively to the 130 bp GRR-1.3. Ellipse represents putative 
binding sites detected by EMSAs. B. Determining the binding for probes A-E Each of the 
radiolabelled probes was incubated with nuclear extract from HeLa cells for EMSAs. The binding 
reaction was separated on a 6 % (w/v) acrylamide gel. 0: no nuclear extract; -: nuclear extract from cells 
treated with vehicle (0.1 % EtOH); +: nuclear extract from cells stimulated with dex (100 nM). C. 
Competition Assays for Probes A, B, C and E. Excess of competitor oligonucleotide (10 x to 100 x) 
was incubated with 8 μg of HeLa cells nuclear extract retrieved after treatment with dex. A 
radiolabelled probe was added to the reaction and separated on a 6 % (w/v) acrylamide gel. V– Cells 
treated with vehicle (0. 1% EtOH); D1- Cells stimulated with dex (100 nM) for 1 hour; D2- Cells 
stimulated with dex (100 nM) for 2 hours. Experiment representative of two independent experiments 
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other words the intact binding site is not contained in either oligo B or C. 
 
Overall GC induced complexes were not detected. More detailed studies of some of 
these complexes are described below.  
 
4.5.2. Evaluating the GR-GBS interaction through EMSA  
EMSAs were performed in order to assess the direct binding of GR to the GBS. The 
DNA-protein complex formed with oligo A, containing the GBS, was evaluated in order 
to understand if GR was involved. In the preliminary EMSA results, there appears to be 
only one DNA-protein complex when using oligo A as a probe (Fig. 4.8C). However 
one additional complex when using the same probe was sometimes present (Fig. 4.9A). 
Yet this was also present when using oligo AM1 (oligo A with the GBS mutated) and 
was equally present when using nuclear extract from untreated cells, suggesting it did 
not involve GR. Moreover the complex was not shifted by anti-GR antibody and was 
not competed by the GBS consensus in a specific way (data not shown). Additional 
modifications to optimize the procedure were done. Zn2+ was included in the binding 
buffer, as well as dex, the gel was run at 4 ºC and/or recombinant full-length GR was 
used instead of nuclear extract. However none of these attempts was successful in 
demonstrating the binding of the GR to the GBS. 
 
A different approach was tried in order to detect GR-DNA complexes in case the 
problem was related to insufficient quantity of GR in the nuclear extracts from HeLa 
cells. COS-7 cells were transfected with 50, 100 or 200 ng of GR-wt or GRdim 
expressing vectors. 20 hours later the cells were treated with vehicle (0.1 % EtOH) or 
dex (100 nM) for one hour and nuclear extracts were recovered. 50 ng of GR expressing 
vectors were shown to be sufficient for GR to drive a response to dex in these cells 
when performing functional assays described later (section 5.11). EMSA was performed 
using an oligo with a GBS consensus as a probe to optimize the approach and prove it 
was able to detect GR-DNA complexes. One complex was observed but since it is 
common to the lanes containing extracts from COS-7 cells not transfected with GR 
expressing vectors it does not involve GR (Fig 4.9B). Almost all the attempts revealed 
the same pattern. Figure 4.9C illustrates a result that was obtained only once. Again 
GBS consensus was used as a probe and nuclear extracts from COS-7 cells transfected
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A AM1 - DexProbe 
Figure 4.9.  GR binding was not detected by EMSAs 
A. EMSA with probe A and AM1. Radiolabelled probe A or AM1 (oligo A with GBS-1.3 mutated) was 
incubated with 8 μg of nuclear extract from HeLa cells treated with dex (100 nM). The binding reaction 
was separated on a 6 % (w/v); arrow indicates additional complex in comparison with the previous studies 
B. EMSAs with COS-7 cells nuclear extract COS-7 cells were transfected with 50, 100 or 200 ng of 
GR-wt or GRdim expressing vectors. The following day cells were treated with vehicle (0.1 % EtOH) or 
dex (100 nM) for 1 hour before the nuclear protein extraction. Probe GBS consensus was incubated with 8 
μg of COS-7 cells nuclear extract. For competitions excess of competitor oligonucleotide was incubated 
with nuclear extract first and then the probe was added to the reaction. The binding reaction was separated 
on a 6 % (w/v) acrylamide gel. C. EMSA with COS-7 cells and complex possibly involving GR. COS-
7 cells were transfected with 50 ng of GRdim vector. The following day cells were treated with vehicle (0.1 
% EtOH) or dex (100 nM) for 1 hour before the nuclear protein extraction. Probe GBS consensus was 
incubated with 8 μg of COS-7 cells nuclear extract. The binding reaction was separated on a 6 % (w/v) 
acrylamide gel. Arrow indicates complex possibly containing GR but not reproducible. GR - GR-wt 
expressing vector; GRdim - A485T (a dimerization-defective mutant) expressing vector; (-) nuclear extract 
from cells treated with vehicle; (+) nuclear extract from cells treated with dex; GBS- oligo with consensus 
GBS. A and B representative of more than 3 independent experiments and C representative of one single 
experiment. 
-+ - + - + + + + 
GBS50x 100x 
+ + + + - + - Dex 
GRdim (ng) 50 50 50 50 50
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with 50 ng of GRdim or no GR expressing vector were used. A complex of slower 
migration was only present when cells were transfected with the GRdim expressing 
vector, was more abundant if cells were treated with dex and was competed by GBS 
oligo. Unfortunately this was never observed again and this approach was abandoned.  
 
EMSAs were unsuccessful to show the GR-GBS interaction. It is likely that the 
complex generated has large dimensions and is unable to penetrate the gel and/or 
dissociates during electrophoresis. It was therefore worth trying an alternative 
technique. The choice was oligo-pull down assay and the studies carried out will be 
described in the next section. 
 
4.5.3. Evaluating the GR-GBS interaction through Oligo Pull-down assay 
Oligo pull-down has been used before to detect GR-GBS interactions in published 
literature and was the chosen technique (Baumann, et al., 2005; Essafi, et al., 2005; 
Novac, et al., 2006; Shibusawa, et al., 2003). This approach can be used to detect DNA-
protein interactions with the advantage that the integrity of the complexes does not have 
to be maintained when loading and running the gel, since only the presence of the 
specific protein is assessed in that final step. In this approach a biotinylated 
oligonucleotide is immobilised on streptavidin beads and used to pull down DNA-
binding proteins, which can then be detected by western blot. Several washes ensure 
only the specific protein interactions remain. In the first attempt to use this approach 50, 
100 or 200 µg of nuclear extract from HeLa cells treated with vehicle (0.1 % EtOH) or 
dex (100 mM) for 1 hour were incubated with 90 pmol of biotinylated GBS consensus 
oligo, binding buffer and 1 µg of poly(dI-dC) in a total volume of 100 µl and incubated 
for 1 hour at 4 ºC (Fig. 4.10A). Streptavidin beads were then added and incubated 
overnight at 4 ºC (for all the following experiments this incubation time was 1 h). 
Samples were then washed 6 times in binding buffer, resuspended in 2 x SDS sample 
buffer and GR protein was detected by western blotting. GR was present only when 
dex-treated nuclear extracts were used. However pull down of GR was also detected in 
the negative control containing no oligo, suggesting a non-specific interaction of the 
protein with the beads. Attempts were made to reduce the background in this assay. 
Different times of incubation, incubating the oligo with beads prior to incubation with 
nuclear extracts, more extensive wash, including Zn2+ in the binding buffer or the use of 
magnetic-streptavidin beads did not improve the results (data not shown).  
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Figure 4.10. Oligo Pull-down optimization and GR-GBS-1.3 interaction  
General procedure included incubation of biotinylated oligo with nuclear extract from HeLa cells and 1 µg 
of poly(dI-dC) in binding buffer (5 mM Hepes pH 7.8, 75 mM NaCl, 1 mM DTT, 5 mM EDTA, 10 mM 
MgCl2, 10 % glycerol) for 1 h at 4 ºC. Addition of streptavidin agarose beads to each sample was followed 
by 1 h incubation at 4 ºC. Samples were washed 6 times in binding buffer. GR protein was detected by 
western blot. A. Oligo pull-down without pretreatment of agarose beads. The general procedure was 
followed except for incubation with beads overnight instead. Agarose beads were not blocked. Different 
concentrations of nuclear extract from cells treated with vehicle (0.1 % EtOH) or dex (100 nM) were 
tested. B. Oligo pull-down with pretreatment of agarose beads. The general protocol was followed 
except for preincubation of beads with BSA (1 mg/ml) and nuclear extract from HeLa cells untreated for 1 
h at 4 ºC to block the non-specific binding. C. Oligo pull-down with pretreatment of agarose beads and 
titration of NE and oligo. The general protocol was followed except for preincubation of beads with BSA 
(1 mg/ml) for 1 h at 4 ºC to block the non-specific binding. Quantity of nuclear extract and biotinylated 
oligo were titrated. D. Binding of GR to GBS consensus and the GBS-1.3 (oligo A). The general 
procedure was used with 50 μg of NE from dex treatedcells, 90 pmol of biotinylated oligo, 20 x molar 
excesses of competitors. Beads were pretreated with BSA (1 mg/ml) for 1 h at 4 ºC. 
(-) nuclear extract from untreated cells; Dex- nuclear extract from cells treated with dex (100 nM) for 1 h; 
NE- nuclear extract; A - oligo A; CEBPcon - oligo with CEBP consensus binding site; GBScon – oligo 
with consensus GBS; inp - starting material consisting of 15 μg of NE. 
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µ µ  µ  
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Alternatively, beads were preincubated with BSA (1mg/ml) and nuclear extract from 
unstimulated cells for 1 hour to block non-specific binding (Fig. 4.10B). Under these 
conditions binding of GR was not detected in the negative control (absence of oligo). In 
the experiment shown in figure 4.10C the same blocking conditions with BSA were 
used and both quantity of nuclear protein extract and quantity of biotinylated oligo were 
titrated. Again, GR was not pulled down in the absence of biotinylated oligo.  
 
Finally the binding of GR to a GBS consensus oligo and oligo A was compared (Fig. 
4.10D). 20 x molar excesses of non-biotinylated oligos were included as competitors in 
binding reactions. GR was pulled down by a consensus GBS oligo and oligo A, and in 
each case a non-biotinylated self oligo competed for binding (lanes 3 and 4, 6 and 7). 
However the background binding of GR in the absence of oligo was again present (lane 
2). The picture on the right panel shows a different experiment where again GR was 
pulled down in the presence of biotinylated GBS consensus or oligo A, and this was 
competed by the self oligos (lanes 4 and 8) or by cross-competition between oligo A 
and oligo GBS consensus (lanes 5 and 9).  
 
This assay allowed to detect the interaction of GR with the GBS contained in the GRR-
1.3. Yet, it should be pointed that problems of non-specific protein binding and 
difficulty in handling small bead volumes result in issues of background and difficulties 
in reproducibility. However the recruitment of GR to this region has also been studied 
by ChIP in HeLa cells, which offers a reassuring confirmation of this interaction 
described.  
 
4.6. Exploring the human GRR-1.3 
The GRR contains a GBS vital for the response to dex, however its presence is not 
sufficient to induce transcription. This GRR was then extensively studied to identify 
additional elements contributing to its function. The first study described involves the 
investigation of a single nucleotide polymorphism (SNP) present in the human GRR-
1.3. 
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4.6.1. Investigating if the SNP contained in the 130 bp GRR alters its 
properties 
The human GRR-1.3 sequence contains a SNP in position -1285 that can be either a 
thymine or a cytosine. In order to elucidate if the change of this base pair interferes with 
the ability of some proteins to bind DNA, an EMSA was carried out. Nuclear extracts 
from HeLa cells treated with dex (100 nM) or vehicle (0.1 % EtOH) for 1 hour were 
used and oligo E (with T) or E-SNP (with C) were used as probes. There was no 
difference in complex formation between the two variant oligos, both in the absence and 
presence of dex treatment (Fig. 4.11A). To investigate whether the SNP influences the 
response to dex a functional assay was performed. GRR-1.3-Hs-SNP contains the C 
variant and was generated by site-directed mutagenesis using the primers described in 
Table 2.3. Both variants of the SNP responded equally to dex, suggesting that the 
change of this base pair does not influence the response (Fig. 4.11B). Also, no 
differences in the basal activity were detected (not shown). 
 
4.6.2. Additional transcription factors involved in DUSP1 induction by dex 
Analysis of the GRR 130 bp sequence using Matrix Inspector 
(http://www.genomatix.de) and Transcription Element Search System (TESS; 
http://www.cbil.upenn.edu) have shown there are putative binding sites for Sp1, FOX 
family of transcription factors, AP-1, ATF and C/EBP-β (Fig. 4.12A). GR positively 
interacts with Sp1 to regulate gene expression (Manoli, et al., 2005; Marinovic, et al., 
2002; Ou, et al., 2006; So, et al., 2007). GCs can induce the expression of C/EBP 
family members in different type of cells (Cram, et al., 1998; Hernandez, et al., 2003; 
Yang, et al., 2005). It also has been shown that members of this family cooperate with 
GR to activate transcription (Alam, et al., 1993; Arizmendi, et al., 1999; Faust, et al., 
1996; Grange, et al., 1991; Wyszomierski and Rosen, 2001). The FOXO subfamily is 
known to associate with multiple nuclear receptors including GR (Wijchers, et al., 
2006). Recently it has been described that binding of FOXO3 to its target site in GILZ 
gene promoter is required to achieve full activation by GCs (Asselin-Labat, et al., 
2005). GR can increase the transcriptional activity of AP-1 depending on the 
composition of the dimers (Diamond, et al., 1990). As referred to in chapter 1 members 
of the ATF family, in particular ATF2, have been implicated in the control of DUSP1 
expression. ATF proteins are therefore interesting candidates to regulate DUSP1 
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Figure 4.11. The SNP present in the Hs.GRR-1.3 does not alter the pattern of complexes obtained 
for EMSAs or the ability to transcriptionally induce the luciferase reporter 
 ob
 
  nding reaction was separated on a 6 % (w/v) acrylamide gel. 0 no nuclear extracts; (-) nuclear extract 
 
 
 
 
 
 
 
 
A. Determining if the SNP alters the DNA-protein complexes presented in EMSA. Radiolabelled 
pr e E (with a T in position -1285) or E-SNP (with a C in position -1285) was incubated with 8 μg of 
HeLa cells nuclear extract retrieved after stimulation with dex (100 nM) or vehicle (0.1 % EtOH). The 
bi
from cells treated with vehicle; (+) nuclear extract from cells stimulated with dex. Data representative of 
one single independent experiment. B. Functional analysis of the SNP contained in the Hs.GRR-1.3. 
pGL3P- Hs.GRR-1.3 contained the variant form of the SNP (C instead of T in position 1285) and was 
generated by site-directed mutagenesis. HeLa cells were transiently transfected with 200 ng of constructs 
and 100 ng of pRL-TK plasmid. Cells were treated for 20 h with dex (100 nM) or vehicle (0.1 % EtOH), 
harvested and the chemiluminescence analysis was performed. For each construct, Firefly luciferase 
activity was normalized to Renilla luciferase activity. Fold response to dex was calculated and normalized 
against the response of the empty vector pGL3P. Means and S.E.M. from three independent experiments 
are shown. Statistical comparisons are against the empty vector pGL3P unless otherwise indicated ***, 
p<0.001; n.s., not significantly different.  
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ATF 
SP1  ACCCGGGCGGGTGGC 
SP1m  ACCCGAATTCGTGGC 
 
AP1  CTGACTCG 
AP1m  CTAAATCG 
 
CEBP-β  CGGGTGGCGCAATGT 
CEBP-βm CGGGTGGGATCCTGT 
 
FOXL1  CGCAATGTTTATGTTTG 
FOXm1  CGCAATAGGCCTGTTTG 
GMEB  GCGCGTCGCGT 
GMEBm  GAGAGTCGAGT 
 
Figure 4.12. Putative binding sites for transcription factors in the Hs.GRR-1.3 
A. Representation of putative binding sites. Scheme representing the position of putative binding sites 
for Sp1, C/EBP-β, FOXL1, ATF, AP-1, GMEB and a GBS like sequence on the Hs.GRR-1.3. Sites 
determined using Matrix Inspector and TESS or by eye inspection (GMEB and GBS2). B. Mutations. 
Binding sites for the different transcription factors and the mutations introduced for EMSAs and 
functional assays. 
 
 
B 
GBS2  AGGCTCCGCTGTCCA 
GBS2m  AGGCTCCGCCCCCCA 
 
 
Hs.GRR-1.3 
GBS2 
FOXL1AP-1 
ATF  TCCAGGGGGCCGTCACT 
ATFm  TCCAGGGGGCCTAAGCT 
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expression in cooperation with GR (Breitwieser, et al., 2007; Hayakawa, et al., 2004; 
Li, et al., 2007; Teng, et al., 2007). Additionally, inspection by eye uncovered a match 
for a glucocorticoid modulatory element binder (GMEB) binding site. GMEB is known 
to associate with the modulation of GR transactivation properties (Chen, et al., 2004; 
Chen, et al., 2002a). Hence these groups of transcription factors have been associated 
with GC action before, suggesting possible cooperation with GR in gene expression 
control. Figure 4.12B displays the mutations introduced in the transcription factors 
putative binding sites for carrying out EMSAs and functional assays. A GBS related 
sequence containing 4 out of the 5 invariant bp was also detected and mutated 
(GBS2m). 
 
Functional assays were performed to analyse if mutations disrupting the binding site for 
a specific transcription factor have any effect on the induction of reporter gene 
expression by dex. Site-directed mutagenesis using GRR-1.3-Hs as a template and the 
primers described in Table 2.3 was used to generate new constructs GRR-1.3-Hs-
GBS2m, GRR-1.3-Hs-Sp1m, GRR-1.3-Hs-CEBPm, GRR-1.3-Hs-FOXm1, GRR-1.3-
Hs-AP1, GRR-1.3-Hs-ATFm and GRR-1.3-Hs-GMEBm with mutations in the putative 
binding site for the indicated transcription factor. Mutant constructs and wild type GRR-
1.3-Hs. responded equally to dex (Fig. 4.13). No change in the basal level of 
transcription was seen for any of the mutants. The ability of this GRR to induce 
transcriptional activation was not impaired by these seven different mutations, 
suggesting that none of these transcription factors is required for such effect.  
 
Nevertheless, more studies were carried out to exclude the involvement of some of these 
transcription factors, including more mutagenesis and DNA-protein interaction studies. 
The following sections focus on the study of C/EBP-β, FOX family of transcription 
factors, ATF and their possible involvement in the upregulation of DUSP1 gene. 
 
4.6.2.1. Investigating the involvement of C/EBP-β: it is not involved in a 
tethering mechanism with GR in HeLa cells 
The first approach was to evaluate if C/EBP-β was involved in EMSA complexes 
formed using probe B, which contained a putative C/EBP-β binding site. In order to 
address this, competition assays were performed using oligo B as a probe and nuclear
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Figure 4.13. Functional analysis of putative transcription factor binding sites within GRR-1.3-Hs.
Putative binding sites for GR, C/EBP-β, Sp1, FOX, AP1, ATF and GMEB were mutagenized in the 
context of pGL3P-GRR-1.3-Hs. and were generated by site-directed mutagenesis. HeLa cells were 
transiently transfected with 200 ng of constructs and 100 ng of pRL-TK plasmid. Following 20 h of 
treatment with dex (100 nM) or vehicle (0.1 % EtOH) cells were harvested and the chemiluminescence 
analysis was performed. For each construct, Firefly luciferase activity was normalized to Renilla 
luciferase activity. A value of 100 % was assigned to the transcriptional response to dex of GRR-1.3-Hs. 
and the response of each mutant was calculated with reference to this. Data and S.E.M. from three 
independent experiments are shown. Statistical comparisons are against pGL3P-GRR-1.3-Hs. ***, 
p<0.001; n.s., not significantly different. Work performed in collaboration with Dr. Carmen Tchen. 
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 con/mut 
C/EBP-β 
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Figure 4.14. Investigation of putative C/EBP binding site 
 putative binding site. Excess of competitor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. EMSA competitions to analyse C/EBP-β binding to the
oligonucleotide (10 x to 100 x) was incubated with 8 μg of HeLa cells nuclear extracts retrieved after 1 
hour stimulation with dex (100 nM). A radiolabelled oligo B was added to the reaction and separated on a 
6 % (w/v) acrylamide gel. B. Supershift for C/EBP-β. 8 μg of HeLa cells nuclear extracts retrieved after 
stimulation with dex (100 nM) were incubated with antibody against C/EBP-β or Mouse IgG as a control. 
Probe B was added subsequently. The binding reaction was separated on a 6 % (w/v) acrylamide gel. (-) 
cells stimulated with vehicle (0.1 % EtOH); (+) cells stimulated with dex (100 nM) for 1 hour; 0 no 
nuclear extract. C Mouse IgG used as a control; - no antibody added. Data representative of two 
independent experiments. 
ompetitor 
B Bmut 
(-)
A 
 
(+)
CEBP 
Ab
Mouse 
Ab
Mouse 
Ab
__ __CEBP 
Ab0
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extract from HeLa cells treated with dex (100 nM) for 1 hour (Fig 4.14A). An oligo 
with the same sequence as B but with a mutation that disrupts the putative C/EBP-β
binding site (Bmut), an oligo with the consensus binding site for C/EBP-β (C/EBP- 
βcon) and an oligo with the consensus site for C/EBP-β mutated (C/EBP-βcon/mut) 
were used as competitors. For competition assays the nuclear extract was first incubated 
with excess of competitors and subsequently the probe was added. This competition 
experiment suggests that C/EBP-β is probably not present in complexes formed by B. 
Neither C/EBP-βcon nor a mutated form of this oligo competed for binding, whereas 
competition occurred equally with wild type oligo B and a mutated version lacking the 
C/EBP-β consensus binding site. To confirm this, supershift experiments were 
performed once again using oligo B as a probe and nuclear extract from HeLa cells 
treated with vehicle (0.1 % EtOH) or dex (100 nM) for 1 hour (Fig. 4.14B). An 
antibody against C/EBP-β was used and mouse IgG was included as a control. The 
addition of either C/EBP-β antibody or control IgG did not lead to a supershift of the 
main complexes. This suggests the exclusion of C/EBP-β as a component of the 
complexes shown and confirms the competition assays.  
 
During my work on DUSP1 gene regulation a paper was published by Okret’s group in 
which it was claimed that DUSP1 upregulation by GCs in A549 is dependent on the 
binding of C/EBP-β to the promoter, which then recruits GR independently of direct 
DNA binding by GR (i.e., tethering) (Johansson-Haque, et al., 2008). The binding site 
for C/EBP-β described is the one contained in the GRR-1.3 and studied here. Mutating 
the highly conserved core site of the C/EBP-β binding site (GCAAT) did not impair the 
response to dex in HeLa cells (Fig. 4.13). To further confirm these results, and exclude 
the presence of an artefact caused by the vector used for cloning, the same mutant was 
generated in pGL4 (C/EBPβm). Additionally, the mutation used by Okret’s group to 
support their claims (C/EBPβ-J-H; Fig. 4.15A) was introduced into pGL4-GRR-1.3-Hs. 
Again the mutation previously tested in pGL3P (C/EBPβm; Fig. 4.13) did not impair the 
response to dex (Figure 4.15B). The Okret mutation significantly impaired but did not 
abolish the response to dex. The difference shown by the two mutants could perhaps be 
explained by the difference in the actual base pairs mutated, given that the mutation in 
C/EBPβ-J-H extends outside the C/EBPβ core binding site (Fig. 4.15A). Therefore a 
third mutant was generated and tested, in which only the TG outside the core binding 
site was mutated to CA (C/EBPβ-CA). Interestingly, this mutant exhibited the same fold  
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Figure 4.15. Mutation adjacent to the C/EBPβ core binding site slightly impairs the response to dex  
A. Human and mouse sequence of the region containing the putative C/EBPβ binding site and the 
different mutations introduced. C/EBPβ putative binding site is underlined and the core binding site is 
italicized; C/EBPβm: the same mutant tested in figure 4.13;  C/EBPβ-J-H contains the same mutation 
described in Okret’s paper; C/EBPβ-CA contains a mutation in the base pairs outside the core binding site 
also mutated in C/EBP-J-H; Hs.>Mm. is the GRR-1.3-Hs. with the mouse sequence of the region 
containing the C/EBPβ binding site. B. Mutants in the context of pGL4-GRR-1.3-Hs. were generated by 
site-directed mutagenesis. HeLa cells were transiently transfected with 200 ng of each reporter construct 
and 100 ng of pRL-TK. Cells were then treated for 20 h with vehicle (0.1 % EtOH) or dex (100 nM) 
followed by harvesting and measuring of luciferase activities. For each construct, Firefly luciferase 
activity was normalized to Renilla luciferase activity. Fold response to dex was calculated and normalized 
against the response of the empty vector pGL4. Means and S.E.M. from three independent experiments 
are shown. Statistical comparisons are against pGL4-GRR-1.3-Hs. ***, p<0.001; **, p<0.01; n.s., not 
significantly different. 
pGL3b_4834. 
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induction to dex as C/EBPβ-J-H. This decrease in response is therefore a result of 
s previously described the mouse GRR-1.3 is not responsive to dex whereas the 
o clarify whether there was a transcription factor binding around this area, EMSAs 
 summary, the experiments carried out in HeLa cells indicate that C/EBPβ is not 
shifts assays, it did not seem worthwhile to pursue this issue. 
changing base pairs outside the C/EBPβ binding site itself.  
 
A
human equivalent is. Because there are some base pairs differences adjacent to the 
C/EBPβ binding site between the two species, a new construct was generated where the 
mouse sequence residues were introduced in the human fragment (Hs.>Mm.; Fig. 
4.15A). Once again the construct was able to respond to dex in a similar way as the 
human GRR-1.3 (Fig. 4.15B).  
 
T
were performed using nuclear extract from HeLa cells treated for 1 h with dex (100 
nM). Oligo B was used as probe. As has previously been shown the complexes 
presented were competed by the same oligo unlabelled and by the oligo containing the 
C/EBPβm mutation, but not by an oligo containing a C/EBPβ consensus site (Fig. 
4.16A). An oligo containing the mutation in C/EBPβ-CA was also able to compete. To 
further confirm the inexistence of a complex dependent on the presence of these two bp, 
the oligo containing the CA mutation was used as probe (Fig. 4.16B). The exact same 
complexes are formed as when B is used as probe, and the same pattern for the 
competitions was observed. Mutation of the TG reduces the transcriptional activity to 
dex; however this cannot be linked with binding of a transcription factor to this 
sequence. 
 
In
involved in the response to dex by this fragment of the human 5’ region of DUSP1 
gene: there was no evidence of C/EBPβ binding to this putative binding site in nuclear 
extracts from HeLa cells (Figure 4.14); GR was shown to bind to an oligo containing 
the GBS but not the C/EBPβ binding site arguing against the tethering and indirect 
recruitment of GR (Figure 4.10); a mutant of the core C/EBPβ binding site did not 
impair the response to dex and the effect seen on the other two mutants seems to be a 
consequence of changing base pairs outside the core site (Fig. 4.15). Given that the 
reduction in transcriptional activity in the presence of the CA mutation was somewhat 
modest and there was no evidence for any transcription factor binding in the mobility 
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B B -CA C/EBPßm C/EBPß-con
(+)
(-) B -CA B
C/EBPßm C/EBPß-con
(+)
(-)
Probe B-CA
 
 
 
Figure 4.16. C/EBPβ-CA mutant does not interfere with the pattern of complexes observed in 
EMSA 
Radiolabelled probe B (panel on the left) or B-CAmut (probe B with the same mutation as in mutant 
Probe B
 
 
 
 
 
 
 
 
 
C/EBP-CA; panel on the right) was incubated with 8 μg of HeLa cells nuclear extracts retrieved after 
stimulation with dex [100 nM; lanes with (+)] or vehicle [0.1 % EtOH; lanes with (-)] for 1 h. For 
competit
 
 
ions excess of competitor oligonucleotide (10 x to 100 x) was incubated with nuclear extract first 
and then the probe was added to the reaction. The binding reaction was separated on a 6 % (w/v) 
acrylamide gel. Representative of at least two independent experiments. 
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4.6.2.2. Investigating the involvement of ATF in the DUSP1 induction by dex 
MSAs studies were also performed to evaluate if there were any DNA-protein 
comp  
.2.3. Exploring the involvement of FOX transcription factors in DUSP1 
duction by dex 
Matri
iately adjacent is the related sequence TGTTTG, which a later 
f this mutation interfered with the 
bility of proteins to bind in this region. Oligo B or FOXm3 (oligo B containing the 
same mutation introduced in mutant GRR-1.3.Hs.-FOXm3) were used as probes and
E
lexes in the region with a putative ATF binding site. Oligo F and Fmut containing
the putative binding site for ATF preserved or mutated, respectively, were used as 
probes and incubated with nuclear extract from HeLa cells retrieved after stimulation 
with dex (100 nM) or vehicle (0.1 % EOH) for 1 hour. Oligos F, Fmut, C/EBP-βcon or 
C were used as competitors. When using F as a probe, several complexes could be 
observed, though the slowest migrating complex was more abundant (Fig. 4.17). The 
complexes were not competed by the unrelated oligos but were competed by an excess 
of oligo F but not Fmut, suggesting that they are specific and dependent on the putative 
ATF binding site. When the probe was oligo Fmut the complexes were not formed, 
confirming their dependency on the ATF binding site. Further characterization of this 
site was not performed, since there was no correlation with an effect in the functional 
assays. 
 
4.6
in
x inspector identified a putative FOXL1 binding site with the core sequence 
TGTTTA. Immed
analysis revealed as a possible binding site for FOXO factors. In fact, many of the FOX 
transcription factors have very similar DNA binding specificity. It was thought 
advisable to mutate the second putative FOX site either alone or together with the first 
site mutation (Fig. 4.18A). These mutants were designated FOXm2 and FOXm3 and 
were generated by site-directed mutagenesis using the primers described in Table 2.3. 
FOXm2 presented the same level of induction as the wild type construct (Fig 4.18B). 
On the other hand there was a significant increase in the fold induction of the reporter 
gene by FOXm3 when compared to GRR-1.3.Hs. A possible explanation was that FOX 
transcription factor functions as a negative regulator of the glucocorticoid response, and 
that only the double mutation prevents its binding.  
 
EMSA studies were then performed to evaluate i
a
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Probe F Probe F mut
CEBPcon
(-)0
FmutF Fmut F
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
Competitor
Figure 4.17. Investigation of putative ATF binding site 
Determining the binding and competition assays for the probes F and Fmut containing the putative 
binding site for ATF. Radiolabelled probe F or Fmut (mutated in the putative binding site for ATF) was 
incubated with 8 μg of HeLa cells nuclear extracts retrieved after stimulation with dex (100 nM) or 
vehicle (0.1 % EtOH) for 1 h. For competitions excess of competitor oligonucleotide (10 x to 100 x) was 
incubated with nuclear extract first and then the probe was added to the reaction. The binding reaction was 
separated on a 6 % (w/v) acrylamide gel. 0 no nuclear extract. (-) cells treated with vehicle; all the other 
lanes correspond to treatment with dex. Experiment representative of at least 3 independent experiments. 
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A
p
F
c
mutations in FOXm1 and FOXm2. Mutations are shown in red.
B. Mutational analysis for the FOX mutants. The several FOX mutants were generated by site-directe
mutagenesis. HeLa cells were transiently transfected with 200 ng of constructs and 100 ng of pRL-TK
plasmid. Cells were treated for 20 h with dex (100 nM) or vehicle (0.1 % EtOH), harvested and th
chemiluminescence analysis performed. For each construct, Firefly luciferase activity was normalized t
Renilla luciferase activity. Fold response to dex was calculated and normalized against the response of th
empty vector pGL3P. Means and S.E.M. from three independent experiments are shown. Statistical 
comparisons are against pGL3P-GRR-1.3Hs. ***, p<0.001; **, p<0.01; *, p<0.05; n.s., not significantl
different. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
FOXL1 CGCAATGTTTATGTTTGTGTACCTAGCGCGTCG
FOXO   CGCAATGTTTATGTTTGTGTACCTAGC
 
 
F
 
igure 4.18. Fox transcription factors are not involved in the response to dex
. Sequences of four different FOX mutants. pGL3P-GRR-1.3.Hs.FOXm1 contains a mutation in the
utative binding site for FOXL1, FOXm2 contains a mutation in the putative binding site for FOXO
OXm3 contains a double mutation in the putative binding site for FOXL1 and FOXO, and FOXm4
ontains a double mutation in binding site for both FOX transcription factors by combining the single
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e 
y 
GCGTCG 
 
FOX mut 1 CGCAATAGGCCTGTTTGTGTACCTAGCGCGTCG 
FOX mut 2 CGCAATGTCCATGGGGGTGTACCTAGCGCGTCG 
FOX mut 3 CGCAATGTCCATGTCCGTGTACCTAGCGCGTCG 
FOX mut 4 GGCAATAGGCCTGGGGGTGTACCTAGCGCGTCG 
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Figure 4.19. The double mutation in FOXm3 interferes with the formation of a DNA-protein 
mplex in EMSAs but FOXO3a is not part of that complex  
. EMSAs competitions to compare the pattern of DNA-protein complexes for probe B and FOXm3 
 with mutation 3). Radiolabelled probe was incubated with 8 μg of HeLa cells nuclear extract. For 
mpetitions, excess of competitor oligonucleotide (10 x to 100 x) was incubated with nuclear extract first 
d then the probe was added to the reaction. The binding reaction was separated on a 6 % (w/v); nuclear 
tracts from cells treated with dex (100 nM) for one hour were used. – indicates no competitor added. 
presentative of three independent experiments. B. Supershift for FOXO3a. 8 μg of HeLa cells nuclear 
tracts retrieved after stimulation with dex (100 nM) or vehicle (0.1 % EtOH) were incubated with 
tibody against FOXO3a or rabbit non-immune serum as a control. Probe B was added subsequently. 
e binding reaction was separated on a 6 % (w/v) acrylamide gel. (-) cells treated with vehicle; (+) cells 
 with dex for 1 hour; 0 no nuclear extract. C rabbit non-immune serum used as a control; - no 
tibody or serum added. Representative of two independent experiments. 
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incubated with nuclear extract from HeLa cells treated with dex (100 nM) for 1 hour. 
 same oligos were used as competitors. The complexes presented with probe B were  
he same time 
hen this oligo was used as probe the complexes seen with probe B were not formed 
nd one extra complex was present, though it appeared non-specific. A possible 
terpretation was that the introduction of the double mutation resulted in the inability 
f some protein to bind DNA and consequently lead to the loss of the complex shown 
r the intact oligo.  
here were two main candidates from the FOXO family for playing a role in DUSP1 
gulation, FOXO1 or FOXO3, since there are several studies linking these two 
anscription factors to GC induced regulation (Kwon, et al., 2004; Smith, et al., 2010; 
ddell, et al., 2008; Zhao, et al., 2009). Supershift experiments were carried out to 
ermine if FOXO3a was part of the complex observed. Nuclear extracts from HeLa 
ells either untreated or treated with dex (100 nM) were used and incubated with 
ntibody against FOXO3a or rabbit non-immune serum as a control. Oligo B was used 
s probe and subsequently added. There was no supershift observed in any of the 
onditions tested (Fig. 4.19B). The complex abrogated by the mutation is not FOXO3 
ound to the DNA. 
arallel to this, Dr. Carmen Tchen showed that the fold induction of DUSP1 mRNA by 
ex is the same in HeLa cells with FOXO3a knocked out by siRNA as it is in the 
ontrol cells (data not shown).  
dditionally, further EMSAs with oligos B, FOXm3 and FOXm1 (oligo B containing 
r FOXL1 and FOXO by combining the single mutations in FOXm1 and FOXm2 (Fig. 
.18A). This new mutant did not present the same increase in transcriptional activity as 
The
competed by the self oligo but not by oligo FOXm3 (Fig. 4.19A). At t
w
a
in
o
fo
 
T
re
tr
Wa
det
c
a
a
c
b
 
P
d
c
 
A
the same mutation introduced in mutant GRR-1.3.Hs.-FOXm1) revealed that the 
FOXm1 mutation impaired complex formation (data not shown). Therefore no 
correlation exists between function and complex formation in EMSA. The increased 
fold induction with FOXm3 could have been a product of the base pairs introduced to 
disrupt the putative binding site, perhaps introducing a binding site for a different 
transcription factor, and not a product of the loss of the binding site itself. To test this, a 
new mutant was generated. FOXm4 has a double mutation of the putative binding sites 
fo
4
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FOXm3 (Fig. 4.18B). In fact the level of response to dex was slightly less than the one 
presented by GRR-1.3.Hs. Given that FOXm4 had a double mutation disrupting the 
same binding sites as FOXm3 but had a different effect on transcriptional activation, 
one can consider that the response shown for the latter was probably an artefact of the 
base pairs introduced. All these data put together cast some doubt about the FOX 
transcription factors playing a role in the transcriptional activation of DUSP1. Overall it 
seems fair to conclude that FOXO transcription factors are not critical for the dex 
response of this region. 
d to dex with the same fold as the GRR-1.3(-1366/-1237), contrary 
 constructs GRR-1.3(-1366/-1263) and GRR-1.3(-1366/-1287) that presented a 
 the response to dex, given that construct GRR-1.3(-
350/-1237) was still responsive. Construct GRR-1.3(-1350/-1263) confirms that 
 
4.6.3. Continuing the deletion mapping from the 130 bp fragment 
After excluding the transcription factors with putative binding sites in the GRR as 
participants in the response to dex, a new strategy was required to unveil the other 
elements involved. Therefore it was decided to proceed with the deletion mapping in 
order to evaluate if there could be smaller GRR-1.3 fragments still responsive to dex. 
Figure 4.20 contains the alignment of new deletion constructs, whose design was based 
on evaluating the requirement of the 5’ and 3’ extremities of the GRR-1.3.Hs. The 
constructs were cloned into pGL3P using the primers described in Table 2.2. Sequential 
deletions of the 3’ extremity reveal that GRR-1.3(-1366/-1245) and GRR-1.3(-1366/-
1254) still responde
to
decreased response to dex (Fig. 4.20). This indicated there was something important in 
the additional base pair interval -1263 to -1254. Additionally the first 16 bp of the 5’ 
end do not seem important for
1
though the 5’ first 16 bp are not vital, the 3’ region contains something required for the 
maximal response to dex. 
 
4.6.4. Identifying the 3’ sequence involved in response to dex 
To try and identify the 3’ sequence necessary to increase the response to dex four new 
constructs harbouring a series of 6 bp block mutations were generated (Fig. 4.21A). The 
mutations covered the region implicated by the deletion study described above. None of 
the mutations impaired the response to dex (Fig. 4.21B). This seems contradictory to the 
results observed with the deletion constructs.  
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Figure 4.20. A distal (3’) part of the GRR is required for the transcriptional response to dex of 
GRR-1.3 
Deletion constructs from GRR-1.3(-1366/-1237) (in red) were cloned into pGL3P. HeLa cells were 
transiently transfected with 200 ng of each DUSP1reporter construct and 100 ng of pRL-TK. Cells 
were then treated for 20 h with vehicle (0.1 % EtOH) or dex (100 nM) followed by harvesting and 
measuring luciferase activities. For each construct, Firefly luciferase activity was normalized to 
Renilla luciferase activity. Fold response to dex was calculated and normalized against the response 
of the empty vector pGL3P. Means and S.E.M. from three independent experiments are shown. 
Statistical comparisons are first against the empty vector pGL3P and second against pGL3P-GRR-
1.3(-1366/-1237). ***, p<0.001; **, p<0.01; *, p<0.05; n.s., not significantly different. 
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Response   
to Dex 
GTACCTAGCGCGTCGCGTCGCTGCAGCAGGCTCCGCTGTCCAGGGGGCCGTCACT GRR-1.3(-1366/-1237)    + 
GTACCTAGCGCGTCGCGTCGCTGCAGCAGGCTCCGCTG   GRR-1.3(-1366/-1254)    + 
GTACCTAGCGCGTCGCGTCGCTGCAGCA     GRR-1.3(-1366/-1263)    - 
 
 
GTACCTAGCGCGTCGCGTCGCTGCAGCAGGCCCATGGGTCCAGGGGGCCGTCACT α 
GTACCTAGCGCGTCGCGTCGCTGCAAGGCCTTCCGCTGTCCAGGGGGCCGTCACT β 
GTACCTAGCGCGTCGCGTCCCATGGGCAGGCCCCGCTGTCCAGGGGGCCGTCACT γ 
GTACCTAGCGCGTAGGCCTGCTGCAGCAGGCCCCGCTGTCCAGGGGGCCGTCACT δ 
 
gure 4.21. Block mutations of the 3’ region do not impair the response to dex  
Sequences of the 3’ region of three different deletion constructs of Hs.GRR-1.3 are shown. Activity to 
 is indicated. Base pair changes in mutants α, β, γ and δ are indicated in red and were generated in the 
ext of GRR-1.3(-1366/-1237) by site directed mutagenesis. B. HeLa cells were transiently transfected 
of each reporter construct and 100 ng of pRL-TK. Cells were then treated for 20 h with 
cle (0.1 % EtOH) or dex (100 nM) followed by harvesting and measuring of luciferase activities. For 
onstruct, Firefly luciferase activity was normalized to Renilla luciferase activity. Fold response to 
s calculated and normalized against the response of the empty vector pGL3P. Means and S.E.M. 
 three independent experiments are shown. Statistical comparisons are against Hs.GRR-1.3  ***, 
0.001; n.s., not significantly different. 
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Another approach used to identify the 3’ sequence involved in response to dex was to 
ngineer human-mouse hybrid constructs. The mouse GRR-1.3 fragment is 
GR  
e
, where substituted base pairs 
r ain f function was observed 
ad to loss of function whereas 
veral mutations of sequences of the same region did not interfere with the ability to 
activate transcription in response to dex. 
 
The minimal SV40 promoter in fact contains binding sites for several transcription 
factors including C/EBP and Sp1. To confirm that the loss of function following the  
deletion of the 3’ region was not an artefact, it was decided to sub-clone the relevant 
constructs into a different plasmid vector. As described before, the pGL4 luciferase 
reporter vectors series was deliberately generated to reduce the number of putative 
binding sites for transcription factors in the vector backbone. The chosen vector was 
pGL4.26, which contains only a TATA box upstream of the luciferase open reading 
frame. The constructs were sub-cloned in the Kpn I / Xho I restriction sites. Transien
ansfection was as previously reported. As described before, in the pGL3P context 
me deletions of the 3’ region of GRR-1.3(-1366/-1237) were not able to activate 
.7. NF-κB and IL-1 
-1 has a striking inflammatory power, controlling signalling cascades that have NF-
B as one of the downstream effectors (Stylianou and Saklatvala, 1998) and as 
reviously discussed IL-1 is known to induce DUSP1 expression. The data obtained 
om luciferase reporter assays also included the levels of basal transcription. One of the 
onstructs, containing a 129 bp fragment from the 5’ region of DUSP1 gene [pGL3P-
GRR-1.3(-1426/-1297)] did not respond strongly to dex. However the basal level for
e not 
responsive to dex. With the intent of reg g o R-1.3-Mm. was used as a 
plate and different 3’ regions were substituted by the orthologous human sequ nce. 
ainin  functi n, 
tem
Each mutant is schematically represented in figure 4.22A
a e indicated in light grey. For none of the mutants a g  o
(Fig. 4.22B). Paradoxically, deletions of the 3’ region le
se
t 
tr
so
transcription as the full 130 bp fragment (see Figure 4.20). One example is GRR-1.3(-
1350/-1263) lacking the final 3’ 27 bp and another is GRR-1.3(-1350/-1287) lacking the 
3’ last 50 bp. Surprisingly, these two deletion constructs were able to activate 
transcription with the same fold induction as the full 130 bp fragment when cloned into 
pGL4 (Fig. 4.23). Therefore it seems the difference in fold induction by dex presented 
by the constructs in pGL3P was an artefact.  
 
4
IL
κ
p
fr
c
162 
 
Chapter 4 – Glucocorticoid Responsive Region -1.3 (GRR-1.3) 
 
 
gcaatgtttatgtttgtgta cctagcgcgtcgcgtcgctgc agcaggctccgctgtccagggggccgtca ct  
gcaatgtttatgtttgtgta tccaactcgtcgtggtgttgc ggcggactcagctgcctaccctgtagtca ct  
         
gcaatgtttatgtttgtgta tccaactcgtcgtggtgttgc agcaggctccgctgcctaccctgtagtca ct  
gcaatgtttatgtttgtgta tccaactcgtcgcgtcgctgc ggcggactcagctgcctaccctgtagtca ct  
gcaatgtttatgtttgtgta tccaactcgtcgcgtcgctgc agcaggctccgctgcctaccctgtagtca ct  
gcaatgtttatgtttgtgta cccagcgcgtcgcgtcgctgc agcaggctccgctgcctaccctgtagtca ct 
GRR-1.3.-Hs.
GRR-1.3.-Mm.
-Mm>Hs1
-Mm>Hs3
-Mm>Hs4
-Mm>Hs2
A
B
pGL3P
GRR-1.3.-Hs.
GRR-1.3.-Mm.
-Mm>Hs1
-Mm>Hs2
-Mm>Hs3
-Mm>Hs4
Fold response to dex
0 1 2 3 4 5 6
n.s.
n.s.
n.s.
(A)
***
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22. Mouse-human hybrid constructs of GRR-1.3 do not gain response to dex  
A. Human and mouse sequence of the 3’ region of GRR-1.3; dark grey shaded residues indicate conserved 
residues between human-mouse GRR-1.3 sequence. Mouse-human hybrid (Mm>Hs) constructs were 
generated by introducing the mouse sequence (light grey shaded residues) into the human GRR-1.3. 
B. HeLa cells were transiently transfected with 200 ng of each reporter construct and 100 ng of pRL-TK. 
Cells were then treated for 20 h with vehicle (0.1 % EtOH) or dex (100 nM), followed by harvesting and 
ring of luciferase activities. For each construct, Firefly luciferase activity was normalized to Renilla 
luciferase activity. Fold response to dex was calculated and normalized against the response of the empty 
or pGL3P. Means and S.E.M. from three independent experiments are shown. Statistical comparisons 
are against pGL3P-GRR-1.3-Mm. ***, p<0.001; n.s., not significantly different; (A) this construct was 
only tested once. 
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pGL4-GRR-1.3(-1366/-1237)
pGL4
GRR-1.3(-1350/-1263)
0 1 2 3 4 5 6
Fold response to dex
GRR-1.3(-1366/-1287) n.s.
n.s.
***
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23. GRR-1.3  fragments with different sizes respond equally to dex when cloned in pGL4 
Fragments GRR-1.3(-1366/-1237) (in red), GRR-1.3(-1366/-1287) and GRR-1.3(-1350/-1263) were 
subcloned into pGL4. HeLa cells were transiently transfected with 200 ng of each reporter construct and 
100 ng of pRL-TK. Cells were then treated for 20 h with vehicle (0.1 % EtOH) or dex (100 nM) followed 
by harvesting and measuring of luciferase activities. For each construct, Firefly luciferase activity was 
normalized to Renilla luciferase activity. Fold response to dex was calculated and normalized against the 
response of the empty vector pGL4. Means and S.E.M. from three independent experiments are shown. 
Statistical comparisons are against pGL4-GRR1.3(-1366/-1237) ***, p<0.001; n.s., not significantly 
different. 
pGL3b_4834. 
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this construct was strongly increased when compared to other reporter constructs tested 
(Fig. 4.24A). On examination of the sequence of this fragment from the 5’ region of 
DUSP1 gene a putative NF-κB binding site was detected. Therefore an exploratory 
study was conducted to investigate if NF-κB could in fact bind to this site, if IL-1 had 
any influence in its binding and if it could in fact have a functional role in 
transcriptional activation.  
o determine the DNA-protein interactions in the region containing the NF-κB putative 
inding site EMSA was performed. Oligo I was used as a probe and incubated with 
 or dex treated cells were used. At the 
me time complex 4 and especially complex 2 were stronger when nuclear extract from 
-1 treated cells was used. A supershift using antibodies against p65, p50 or mouse 
G as a control was performed (Fig. 4.24C). It is possible to conclude that p65 was 
volved in complex 2 given the clear supershift, and also in complex 1 since the 
tensity of the band is weaker. There was no supershift for p50. However, there is 
me doubt as to whether this batch of p50 antibody works, and no positive control was 
cluded. Therefore it is not possible to exclude the presence of p50 in one or more of 
ose complexes. Obviously, to draw any conclusions it would be required to repeat the 
xperiment and see whether p50 is present in any of the complexes. 
urthermore it would be interesting to observe if IL-1 could induce DUSP1 reporter 
onstructs containing this site for NF-κB. In figure 4.25A GRR-1.3 (-1426/-1297) 
agment is aligned with two other constructs highly inducible by dex (work previously 
one and shown in figure 4.2). GRR-1.3 (-1426/-1185) fragment contains one extra NF-
B site downstream and GRR-1.3 (-1426/-1237) fragment contains the NF-κB site 
ommon to both the other fragments. Therefore these three constructs were chosen to 
valuate if IL-1 could induce transcription through NF-κB. HeLa cells were transiently
 
T
b
nuclear extract from HeLa cells untreated, treated with dex (100 nM) for 1 hour or 
reated with IL-1 (20 ng/mL) for 1 hour. Oligo A (that overlaps with oligo I though it 
oes not contain the NF-κB putative binding site) and an oligo with C/EBP-β consensus 
inding site (CEBPcon) were used as competitors. Four complexes were formed for all 
ifferent stimulation conditions (Fig. 4.24B). However complexes 1 and 3 were more 
t
d
b
d
abundant when nuclear extract from untreated
sa
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Figure 4.24. Identification of an NF-κB binding site 
ase reporter assay for the Hs.GRR-1.3 (-1426/-1297) luciferase co
1 
3 
4 
A.  Lucifer nstruct. Hs.GRR-1.3(-
/-1297) and Hs.GRR-1.3(-1366/-1237) fragments were cloned in the pGL3P. HeLa cells were 
t
ng/  
bi
stimulated with dex for 1 hour; IL-1: cells stimulated with IL-1 for 1 hour; 0 no nuclear extract; 
CEBPcon: oligonucleotide containing the consensus binding site for CEBP used as non-specific 
competitor; A – oligo A; 1-4 indicate the complexes formed. EMSAs are representative of one 
experiment. 
1426
ransiently transfected with 200 ng of constructs and 100 ng of pRL-TK plasmid. Cells were treated for 20 
h with dex (100 nM) or vehicle (0.1 % EtOH, “unt” in figure), harvested and measured for 
chemiluminescence. For each construct, Firefly luciferase activity was normalized to Renilla luciferase 
activity. The figure illustrates absolute luciferase activity values obtained from one experiment 
representative of four independent experiments. B. Determining the binding and competition assays 
for probe I containing the putative binding site for NF-κB. In EMSA radiolabelled probe I was 
incubated with 8 μg of HeLa cells nuclear extract retrieved after stimulation with dex (100 nM), IL-1 (20 
mL) or vehicle (0.1 % EtOH and 0.1 % PBS). For competitions excess of competitor oligonucleotide
(10 x to 100 x) was incubated with nuclear extract first and then the probe was added to the reaction. The 
nding reaction was separated on a 6 % (w/v) acrylamide gel. C. Supershift for NF-κB 8 μg of HeLa 
cells nuclear extract retrieved after stimulation with IL-1 (20 ng/mL) or vehicle (0.1 % PBS) were 
incubated with antibody against p65, p50 or mouse IgG. The probe I was added subsequently. The 
binding reaction was separated on a 6 % (w/v) acrylamide gel. V: cells treated with vehicle; Dex: cells 
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Figure 4.25. Fragments from the 5’region of DUSP1 that contain NF-κB binding sites do not 
respond to IL-1 
A. Putative binding sites for NF-κB. Representation of relative positions of Hs.GRR-1.3 (-1426/-1185), 
Hs.GRR-1.3 (-1426/-1237) and Hs.GRR-1.3 (-1426/-1297) containing one or two NF-κB binding sites. 
B. Treatment with dex and/or IL-1 of constructs selected based on their content of the NF-κB 
putative binding sites. HeLa cells were transiently transfected with 200 ng of constructs and 100 ng of 
pRL-TK plasmid. Cells were treated for 20 h with dex (100 nM), IL-1 (20 ng/mL) or vehicle (0.1 % EtOH 
and 0.1 % PBS), harvested and measured for chemiluminescence. Firefly luciferase activities were 
normalized against Renilla luciferase activities. The data represents the absolute values or the fold 
response to dex, IL-1 or dex+IL-1 from one single experiment. 
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transfected with 200 ng of DUSP1 reporter constructs and 100 ng of pRL-TK plasmid, 
llowed by 20 h of treatment with vehicle (0.1 % EtOH and 0.1 % PBS) or dex (100 
M) or IL-1 (20 ng/mL) or both stimuli combined. Dex induced the reporter gene for all 
onstruct  (Fig. 4.25B). However IL-1 did not induce a response 
r any o cts either alone or with dex. Therefore even if EMSAs 
dicate t there is a shift of NF-κB dimers 
om untreated to IL-1 treated c s is not enough t  transcription. 
 functional role of DNA-NF-κB complexes induced by IL-1 remains unclear. They 
ht operate in cooperation with othe elements and/or depend on chromatin 
ifications. 
fo
n
c s as previously shown
fo f the different constru
in here are NF-κB proteins binding there and 
fr ells thi o drive
 
The
mig
od
r 
m
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
168 
 
Chapter 4 – Glucocorticoid Responsive Region -1.3 (GRR-1.3) 
 
4.8 DISCUSSION 
 
4.8.1. Species divergence in GRR-1.3 usage 
A thorough search for matches of the consensus GNACANNNNG in the 5’ region of 
the mouse and human DUSP1 genes allowed the identification of several conserved 
GBS, including one located 1.3 kb upstream of the TSS. Deletion mapping of the 5’ 
proximal region of the human DUSP1 gene indicated the presence of an important 
lement within an interval containing this GBS. Further deletion analysis allowed 
equence was shown to be highly conserved between several mammal 
ecies. It was surprising that a fragment containing the orthologous mouse region and 
e perfectly conserved GBS was unable to respond to dex. At the same time the rat 
rthologous region was only weakly responsive to dex, whereas the dog GRR-1.3 
isplayed the same fold response as the human GRR-1.3. The ChIP data reinforced the 
ifferences observed in the reporter assays for the mouse and human GRR-1.3. It was 
ossible to correlate transcriptional activity with the ability to recruit GR in HeLa cells 
r inability to drive transcription with inability to recruit GR in mouse fibroblasts. This 
 the first example where GBS conservation is only predictive of function in the 
uman. This particular case adds as more evidence that GBS sequence conservation will 
ot always be predictive of function and GR occupancy.  
BS-1.3 alone presented a much lower transcriptional activity than the whole 130 bp 
uman GRR-1.3. This result put together with the differences in mouse and human 
RR transcriptional activity seems to logically indicate that additional sequences, 
hich are only present in the human GRR, are required for full activation of 
anscription. These might comprise binding sites for transcription factors which play a 
art in recruiting GR and might also cooperate with the receptor. 
4.8.2. GR-GBS direct interaction 
he direct binding of GR was assessed firstly by EMSA. The band shift assay studies 
ere unable to demonstrate the binding of GR to this GBS. It is possible that the 
omplex is not able to penetrate the gel or it dissociates during electrophoresis. Several 
ifferent experimental conditions were attempted, still no GR-DNA specific complex 
e
tracing a 130 bp fragment containing this GBS which mediates a response to dex. The 
GBS sequence is totally conserved between human, mouse, rat and dog (15/15 bp), and 
moreover this s
sp
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o
d
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was observed. In a recent paper from Meijsing et al., EMSAs with GR were 
ccessfully performed using a truncated form of the receptor containing just the DNA 
binding pressing vector has recently been 
rs, AP-1, ATF, C/EBP-β and 
MEB, among others. All of these were possible candidates for playing a part in the 
e to dex.  
Okret a nsive region spanning from -1380 to -1266 
su
 domain (Meijsing, et al., 2009). This GR ex
kindly provided by Meijsing and will in the future be used to perform EMSAs using the 
GBS-1.3 and other GBS involved in the regulation of DUSP1 gene as probes.  
 
As described, an oligo pull-down assay was also carried out and allowed to detect the 
direct interaction between GR and GBS-1.3. As mentioned previously this technique 
suffered from difficulties in reproducibility and background levels, mainly associated 
with limitations in handling small bead volumes and non-specific binding of GR to the 
streptavidin beads. The number of attempts necessary to confirm the data obtained is 
therefore more than the desired, which makes this technique rather time-consuming and 
laborious. However, it was reassuring that the ChIP data were in agreement, which 
helps to further increase the confidence of the data obtained with the oligo pull-down. 
 
4.8.3. Additional sequences required for full transcriptional activity of 
human GRR-1.3 
An extensive list of experiments was performed in order to try and pinpoint sequences 
and transcription factors involved in the response to dex, other than GBS-1.3 and GR. 
Bioinformatics analysis and inspection by eye of the 130 bp sequence revealed putative 
binding sites for Sp1, FOX family of transcription facto
G
upregulation of DUSP1 by GCs given that all have been linked before with GR and 
gene regulation. Each of these sites was mutated and evaluated in reporter assays. 
Disrupting any of the putative binding sites within the human GRR-1.3 did not totally 
abrogate its ability to mediate a transcriptional response to dex. These data in some 
cases in conjunction with the characterization of the binding site by EMSAs excluded 
these transcription factors as GR partners in this particular respons
 
nd colleagues described a GC-respo
with respect to the human DUSP1 TSS, identified in their studies using A549 cells.  
They proposed the response to dex was due to the presence of a C/EBP binding site 
where C/EBP was binding and recruiting GR through a tethering mechanism. The 
region identified overlaps with the 130 bp GRR-1.3 identified and the C/EBP binding 
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site mentioned is the one studied here. It is also worth mentioning GBS-1.3 was also 
present in the GRR fragment identified in their study, yet this binding site was 
completely overlooked and no mutagenesis on its sequence was performed. 
Interestingly, the C/EBP binding site was mutated here and no impairment of the 
response to dex was observed. More studies were performed based on the fact that the 
o mutants involved mutation of different base pairs. The studies described here went 
portant it is to consider that transcription factor binding site sequences can vary quite 
extensi
defined by Yamamoto et al. had not been used in the analyses carried 
t effects in 
ctivity when using site-directed mutagenesis, but would cause impairment of response 
tw
further to reveal that only when mutating two base pairs outside the core binding site for 
C/EBP there is an effect on the response to dex, and even so it is only partial. It is fair to 
say it is not the C/EBP binding site modulating the response to dex observed. If we 
consider that no C/EBP direct binding to this site was detected in the EMSAs shown 
here, and more interestingly the GR was shown to directly bind the GBS in the absence 
of the C/EBP binding site, it seems safe to conclude no tethering mechanism is 
operating in HeLa cells. It seems that the direct involvement of the GR was disregarded 
because the presence of the GBS itself was overlooked. This also raises the issue of how 
im
vely, particular the GR binding site. If the loose GBS consensus sequence 
GNACANNNNG 
out here, GBS-1.3 would probably have been disregarded. 
 
Foxm4, C/EBP-CA and C/EBP-J-H did not abrogate the response to dex, as observed 
when mutating the GBS, but partially impaired this response. Each of these mutations 
have a modest impact in the ability of GRR-1.3 to respond to dex, however it might be 
interesting in the future to combine these mutations and observe whether these have 
additive effects in activation of the reporter gene expression. Inability of finding at least 
one other binding site, in addition to the GBS, which when mutated abolishes the 
response to dex can indicate that there is more than one site involved. More than one 
element can be participating in recruiting/cooperating with GR but there can be 
redundancy in their activity, which would be reflected in minor or inexisten
a
when the GBS is alone and no other transcription factor binding site is present. 
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4.8.4. pGL3P and the SV40 promoter artefact 
The data obtained by deletion constructs of the human GRR-1.3 indicated the 
requirement of an additional sequence close to its 3’ extremity. Whilst pursuing this, it 
was found that cloning of these particular fragments in pGL3P was creating an artefact 
in the response to dex displayed by these constructs. pGL3P as described before 
contains an SV40 minimal promoter and this harbours in fact many putative 
transcription factors binding sites. These include binding sites for C/EBP, AP1 and Sp1 
which are known to interact with GR. Though it is only speculation, the disparity 
between the activity presented by the fragments when cloned in pGL3P or pGL4 is 
likely to be the result of interactions between transcription factors binding to GRR-1.3 
and to the SV40 promoter. Such interactions might be sensitive to spacing and therefore 
affected by 3’ deletions of GRR-1.3 but unaffected by site-directed mutagenesis. Hence 
the activity mediated by these deletion constructs when in the context of pGL3P was 
affected by these elements foreign to the DUSP1 fragments. A fragment of 80 bp seems 
in fact sufficient to activate transcription. Still, it remains unexplained which specific 
sequences within the human GRR-1.3 lead to an amplification of the response to dex. 
 
This becomes a lesson for this type of assays, demonstrating that these artificial systems 
re subject to flaws which should be considered.  
nd IL-1 
eatment will be described in the next chapter. 
a
 
4.8.5. NF-κB binding site in the proximity of GRR-1.3  
IL-1 is known to upregulate DUSP1 gene expression. A putative binding site for NF-κB 
in the proximity of the human GRR-1.3 was explored mainly to understand if it was 
involved in the high basal level shown by one of the constructs. The putative binding 
site for NF-κB was shown to be bound by NF-κB proteins, and IL-1 treatment of HeLa 
cells induced a shift in the complexes binding to this site. However, this was not 
correlated with activation of transcription since DUSP1 reporter constructs containing 
this site were not responsive to IL-1 stimulation. Therefore its importance remains 
unclear. Nonetheless it would be interesting to understand the molecular mechanism by 
which IL-1 regulates DUSP1. More studies involving reporter constructs a
tr
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4.8.6. Concluding remarks 
This chapter described an extensive collection of studies carried out to discover which 
other sequences besides GBS-1.3 were significant for the response to dex. EMSAs and 
mainly mutagenesis studies involving putative binding sites for transcription factors 
cooperating with GR and/or nucleotide differences between human-mouse GRR-1.3 
were not able to detect an explanation of the differences in activities for these two 
species. It is likely than more than one transcription factor binding site is playing a role 
and this can be coupled to some degree of redundancy, which makes it difficult to 
pinpoint the exact sequences. Nonetheless it was robustly demonstrated that this human 
cis-element recruits GR and activates transcription, whereas the mouse is not able to 
mediate transcription or recruit GR. These differences can only be linked to binding 
sites for accessory transcription factors which have diverged between human and mouse 
at some point in evolution. 
 
So et al defended that GBS sequence conservation between species correlates with 
function and GR occupancy of the given GBS (So, et al., 2007). As previously pointed 
ut, they in fact showed that human-mouse sequence conservation of GBS only 
were conserved between human and 
ouse, 17 were bound by GR (i.e., 85%). What is interesting is that they showed that 
the pre 15 of the 15 bp for 7 
o
increases the probability of this GBS to be functional (Fig. 4.26). For example, of the 20 
GBS tested where 14 out of the 15 base pairs 
m
sence of a GBS totally conserved between human-mouse (
different GBS) was always correlated with GR occupancy at that GBS in mouse cells. 
The GBS-1.3 element is extremely interesting because it consists of a clear exception to 
this observation: it is totally conserved between human-mouse however it is not 
recruiting GR in the context of the mouse genome, whereas it recruits GR in human 
cells and is highly responsive to dex in the specific context of the human GRR-1.3. 
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GBS conserved bases (mouse-human) 
 
 
 Figure 4.26. GBS conservation Graph adapted from the paper by S
 b 
correlation with GR occupancy 
o and colleagues where it was shown that GBS sequence conservation 
etween human and mouse was a good predictor of GR occupancy. Adapted from So et al. 2007 
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5. Chapter 5 – Glucocorticoid Responsive Region -4.6 (GRR-4.6) 
his chapter will describe the study of the last GRR identified by the phylogenetic 
pproach, GRR-4.6. Studies to evaluate the functional conservation of this region 
etween species and the role of the several GBS present were performed, as well as 
udies to assess the GR-GBS interactions. Native mouse and human DUSP1 promoter 
onstructs were used to evaluate the role of GRR-4.6 and GRR-1.3 in a more 
hysiological context as well as to directly compare the activity of the mouse and 
uman 5’regions of the DUSP1 gene.  
 
Having identified several GR on of human and/or mouse 
USP1, several studies were performed to evaluate all of the different GRR for their 
ility to regulate transcription when transfected into mouse cells, their ability to 
respond to pro-inflammatory stimuli and their ability to respond to dex in the presence 
of a GR harbouring a mutation in the dimerisation loop. An attempt to generate a stably-
tra
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nsfected line harbouring the Hs.4.8kb construct will also be described. 
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5.1. Differential usage of GRR-4.6 between species 
As described previously, a fragment containing the 4.8 kb upstream of the human 
ed 4.6 kb upstream from the human DUSP1 TSS 
as amplified from human genomic DNA and cloned into pGL3P. Constructs 
dex is clearly 
ifferent between species. 
.2. GR recruitment in vivo to GRR-4.6 
R recruitment to this region was assessed in HeLa cells and mouse fibroblasts (work 
erformed by Dr. Carmen Tchen). In both type of cells recruitment of the receptor to the 
KBP locus was shown (Fig. 5.2). In HeLa cells a strong recruitment of the receptor 
as observed when using primers amplifying GRR-4.6. GR was also recruited to the 
rthologous region in mouse fibroblasts. There are several ways of analysing ChIP data. 
ne alternative method is to calculate the fold enrichment of a chromatin fragment in 
R immunoprecipitates, corrected for the fold enrichment of the same fragment in 
ontrol (IgG) immunoprecipitates. By this measure dex increased the association of GR 
ith mouse GRR-4.6 by only 3.4-fold in mouse fibroblasts. For comparison, dex 
creased the association of GR with GRR-29 by 26.2-fold in the same cells, and 
creased the association of GR with GRR-4.6 by 15.1-fold in HeLa cells. In other 
ords the association of GR with mouse GRR-4.6 appeared real but relatively weak. In 
ciferase reporter assays there were significant differences in the strength of the 
anscriptional response to dex, however both human and mouse GRR-4.6 were able to 
ediate a response to dex. Therefore it is not surprising that both regions were able to
DUSP1 TSS mediated a 25-fold response to dex and this was impaired by deletion of 
the segment between -4.8 kb and -2.7 kb (Fig. 4.1). This interval contains three putative 
GBS located 4.6 kb upstream of the TSS and identified on the basis of sequence 
conservation. An obvious hypothesis was that the decrease in fold response to dex 
observed was a result of losing these GBS. This region was first studied using 
heterologous promoters to prove its functionality. A fragment of approximately 500 bp 
centred on the three putative GBS locat
w
harbouring the orthologous regions of mouse, rat and dog were also generated and 
transiently transfected into HeLa cells. Upon challenge with dex both human and dog 
constructs were able to mediate a strong induction of the reporter gene (Fig. 5.1). 
Surprisingly, the mouse and rat constructs mediated a relatively weak, though 
significant, response to dex. It seems this region is capable of inducing transcription in 
the cases of all four species studied, but the strength of response to 
d
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 Figure 5.1. Orthologous GRR-4.6 pr
 
 
 
transfected with 200 ng of each reporter construct and 100 
with vehicle (0.1 % EtOH) or dex (100 nM) follo
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For each construct, Firefly luciferase activity was normalized to Renilla luciferase activity. Fold respon
to dex was calculated and normalized against the response of the empty vector pGL3P. Means and S.E.
from three independent experiments are shown. Statistical comparisons are against the empty vector 
pGL3P. ***, p<0.001; **, p<0.01. 
 
esent different responses to dex. 
Dog, human, mouse and rat GRR-4.6 fragments were subcloned into pGL3P. HeLa cells were transiently 
ng of pRL-TK. Cells were then treated for 20 h 
wed by harvesting and measuring of luciferase activities. 
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ment representative of two (mouse fibroblast) or three (HeLa) independent experiments. Work 
formed by Dr. Carmen Tchen. 
re 5.2. GR is recruited to human GRR-4.6 and to mouse GRR-4.6 
recruitment was assessed by ChIP. HeLa cells or mouse fibroblasts were treated with vehicle (0.1 % 
H) or dex (100 nM) for 30 min. Samples were then chromatin immunoprecipitated with either IgG 
te columns) or anti-GR antibody (black columns). Q-PCR was used to detect the immunoprecipitated 
 fragments and measurements were done in triplicates. The enrichment of specific chromatin 
ments was determined as a propor
ri
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cruit GR in vivo. Once more, ability of a GRR to induce transcription is intrinsically 
lated to the ability of the same region to recruit GR. 
.3. Identificatio
RR-4.6 contains three closely spaced GBS identified on the basis of sequence 
onservation and designated as -4.6.1, -4.6.2 and -4.6.3 (Fig. 5.3A). One of these GBS, -
.6.2, contains not only two half GR biding sites but also a third one overlapping. GBS-
.6.1 and -4.6.3 are not conserved when comparing the sequence of 15 different species 
f placental mammals, whereas GBS-4.6.2 is highly conserved (Fig. 5.3B). 
o determine if any of the putative GBS was necessary for the transcriptional activation 
bserved with this GRR, mutational analyses were performed. Using site-directed 
utagenesis with the primers described in Table 2.3, putative GBS were mutated by 
hanging the triplets ACA or TGT to GGG or CCC, respectively (Fig. 5.3A). The three 
alf GR binding sites of GBS-4.6.2 were all mutated separately. Mutants of GBS-4.6.1 
nd -4.6.3 were shown to be highly responsive to dex (Fig. 5.3D), indicating that these 
utations of GBS-4.6.2 were shown to impair the response to dex, which means the 
he single base pair difference between human and mouse GBS-4.6.2 lies within the 
ree nucleotide “spacer” between the second and third GR half-sites (Fig. 5.3C). The 
acer is thought not to make specific contacts with the receptor, and is unconstrained in 
oth the original GR binding site consensus AGAACANNNTGTTCT and the revised 
onsensus GNACANNNNG. Yet, differences in spacer sequence can affect interactions 
f GR with transcription cofactors, suggesting an impact on receptor conformation 
eijsing, et al., 2009). To understand whether the sequence difference within the 
acer accounted for the difference in fold response to dex, the single base pair was 
utated in both human and mouse constructs. When the human construct contained the 
ouse GBS-4.6.2 (-Hs.>Mm. in Fig. 5.4A) no loss of function was observed. At the
re
re
 
5 n of an unusual composite GBS within GRR-4.6 
G
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two GBS were not necessary for dex-induced transcription. Surprisingly, all the three 
m
three half GR binding sites were necessary for induction of transcription. It is 
interesting to note that this correlates with GBS-4.6.1 and -4.6.3 not being conserved 
between 15 different species of placental mammals and GBS-4.6.2 being highly 
conserved. 
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gure 5.3. Human GRR-4.6 response to dex depends on atypical GBS-4.6.2  
. Human sequence of region containing the three closely spaced GBS. Mutations introduced are indicated 
 sequence. B. Multiz alignment of GRR-4.6 of 15 placental mammals (UCSC Genome Browser) 
. Sequence of GBS-4.6.2 for different species. Dn (Dasypus novemcintus; armadillo) D. pGL3P-GRR-
6–Hs. was mutated as indicated in A using site-directed mutagenesis. HeLa cells were transiently 
ansfected with 200 ng of constructs and 100 ng of pRL-TK plasmid. Cells were treated for 20 h with dex 
00 nM) or vehicle (0.1 % EtOH), harvested and luciferase activities measured. For each construct, Firefly 
ciferase activity was normalized to Renilla luciferase activity. Fold response to dex was calculated and 
rmalized against the response of the empty vector pGL3P. Means and S.E.M. from three independent 
periments are shown. Statistical comparisons are against pGL3P-GRR-4.6–Hs. ***, p<0.001; n.s., not 
gnificantly different. 
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igure 5.4. GBS-4.6.2 is not sufficient for the human GRR-4.6 maximal response to dex 
. Mouse GBS-4.6.2 was introduced in pGL3P-GRR-4.6-Hs. (-Hs.>Mm.) and human GBS-4.6.2 was 
troduced in pGL3P-GRR-4.6-Mm. by site-directed mutagenesis (-Mm.>Hs.). B. GBS-4.6.2 (italicized) 
 a short oligonucleotide containing the human or mouse GBS-4.6.2 element and a few conserved 
anking residues cloned in pGL4. HeLa cells were transiently transfected with 200 ng of constructs and 
0 ng of pRL-TK plasmid. Cells were treated for 20 h with dex (100 nM) or vehicle (0.1 % EtOH), 
rvested and measured for chemiluminescence. For each construct, Firefly luciferase activity was 
nd normalized against the 
F
A
in
is
fl
10
ha
normalized to Renilla luciferase activity. Fold response to dex was calculated a
response of the empty vector pGL3P or pGL4. Means and S.E.M. from three independent experiments are 
shown. Statistical comparisons are against the empty vector pGL3P or pGL4 unless otherwise indicated; 
***, p<0.001; **, p<0.01; *, p<0.05; n.s., not significantly different. 
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me time, no gain of function was observed when the human GBS-4.6.2 was 
tro ed in the mouse GRR (-Mm>Hs. in Fig. 5.4A). To evaluate the transcriptional 
ctivity of GBS-4.6.2 in isolation, oligos containing either human or mouse GBS-4.6.2 
ere cloned into pGL4. Both human and mouse GBS-4.6.2 were shown to be 
sponsive to dex, and it can even be said that the mouse one was slightly more 
sponsive (Fig. 5.4B). Taken together with the previous results, this clearly shows that 
e differences observed for the transcriptional activity of human and mouse GRR-4.6 
id not result from differences in the GBS sequence but from differences in the context 
 which they are embedded.  
.4. E uating
espite unsatisfactory results obtained with EMSA to evaluate the interaction of GR-
ligo containing GBS-4.6.2 was incubated with nuclear extracts from HeLa cells treated 
ith dex (100 nM) or vehicle (0.1 % EtOH) for one hour. A strong complex could be 
bserved under both conditions (Fig. 5.5A). The complex formation was competed by 
n excess of the same unlabelled oligo but not by an excess of an oligo containing 
utations of the three half sites in GBS-4.6.2 (the same as in GBS-4.6.2m1, 2 and 3), 
hich indicates the interaction observed depends on all or some of these base pairs. The 
omplex was not competed by an unrelated control oligo containing a C/EBP consensus 
tOH) were incubated with 
iotinylated oligos containing a GBS consensus sequence or GBS-4.6.2. Non-
iotinylated oligos were included in 20 x molar excess for competition purposes. GR 
as pulled down by a GBS consensus and the same unbiotinylated oligo competed for 
e binding (Fig. 5.5 B; lanes 3 and 4). GR was also pulled down by biotinylated GBS-
.6.2 (lane 6) and the competition could be observed in the presence of either non-
iotinylated GBS-4.6.2 or GBS con (lanes 7 and 8). Nearly no GR was pulled down in 
e absence of biotinylated oligo (lane 5). GR seems to interact with GBS-4.6.2 which is 
confirmed by the results obtained with ChIP assays. 
sa
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5 val  the GR-GBS interaction through EMSA and oligo pull-down 
D
GBS-1.3, the same procedure was attempted to study the interaction GR-GBS-4.6.2. An 
o
w
o
a
m
w
c
site. Yet, the complex was not competed by an excess of a consensus GBS sequence and 
it was not supershifted by anti-GR antibody. Therefore, it is safe to say the complex 
does not involve the binding of GR to GBS-4.6.2. 
 
As before, oligo pull down assays were also performed. Nuclear extracts from HeLa 
cells treated with dex (100 nM) or vehicle (0.1 % E
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Figure 5.5. Investigation of GR-GBS-4.6.2 interaction 
A. EMSA was performed using a probe containing the human GBS-4.6.2 but not the other GBS closely
located. Excess of competitor oligonucleotide (10 x to 100 x) was incubated with 8 μg of HeLa cel
nuclear extracts retrieved after 1 hour stimulation with dex (100 nM) or vehicle (0.1 % EtOH), prior 
addition of probe. For the supershift, 8 μg of HeLa cells nuclear extracts retrieved after stimulation with
dex (100 nM) were incubated with antibody against GR or rabbit non-immune serum as a control. Prob
was added subsequently. The binding reaction was separated on a 6 % (w/v) acrylamide gel. (-) cell
stimulated with vehicle (+) cells stimulated with dex for 1 hour; C rabbit serum used as a control. GBS
4.6.2m – mutation of the 3 half GR sites; GBScon – oligo with GBS consensus; CEBPcon - oligo wi
CEBP consensus binding site B. Biotinylated oligos containing GBS consensus or GBS-4.6.2 we
incubated with 50 µg nuclear extract from HeLa cells. 20 x molar excess of competitors was use
Streptavidin beads, pretreated with BSA (1 mg/ml) for 1 h at 4 ºC were added to each sample an
incubated for 1 h at 4 ºC. Samples were washed 6 times in 1 x binding buffer. GR protein was detected b
western blot.  (-) nuclear extract from cells treated with vehicle (0.1 % EtOH); all other lanes correspon
to nuclear extract from cells treated with dex (100 nM) for 1 h; inp - starting material consisting of 15 μ
of nuclear extract. 
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5.5. Deletion analysis of human GRR-4.6 to identify additional sequences 
porta or its maximal response to dex 
uman GRR-4.6 is highly responsive to dex, which depends on the presence of an 
typical GBS. However additional sequences are required for the full activation by dex. 
his follows the fact that the mouse orthologous region presents a modest GC-response 
hich cannot be attributed to the only base pair different between mouse-human GBS-
.6.2. 
 an attempt to further pinpoint the additional regulatory sequences necessary for the 
anscriptional activation driven by the human GRR-4.6, several deletion constructs 
ere generated and assessed for their ability to respond to dex. Starting from the 3’ end 
ere was no impairment of the response to dex when deleting from -4430 to -4369 but 
ere was a significant impairment when the segment from -4530 to -4430 was deleted 
ig. 5.6). Deletions from the 5’ end revealed an increase of the response to dex when 
eleting from -4834 to -4740, but this did not reach statistical significance. Further 
eletion from -4740 to -4635 impaired the response to dex. In theory a fragment from -
740 to 30 shou
834/-4 ). Based on this assumption more deletions were generated. A 3’ deletion 
dicated that the interval between -4459 and -4430 contains something relevant for the 
sponse to dex. Further deleting from -4459 to -4495 did not further decrease the 
om -4740 to -4705 lead to a decrease in the response to dex and an additional deletion 
om -4705 to -4666 further decreased the response. This indicates that there could be at 
ast two elements important in the interval between -4740 and -4666. Overall, there are 
veral sequences within GRR-4.6 involved in a maximal response to dex: at least one 
re
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ld be equivalent in response to dex to the full length GRR-4.6 (-
4
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response to dex, probably because no other important element was lost. A 5’ deletion 
fr
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le
se
in each of intervals -4740/-4705, -4705/-4666 and -4459/-4430. Additionally, a 
agment between -4740 to -4430 should be cloned to confirm the assumption that this 
 equivalent to the full length (-4834/-4369). This would exclude the possibility of 
aving two elements, one in each extremity, involved in the response to dex but 
dundant in function. 
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Figure 5.6. Deletion analysis of the human GRR-4.6 
Deletion fragments from GRR-4.6-Hs(-4834/-4369) were cloned into pGL3P. HeLa cells were transiently 
transfected with 200 ng of each DUSP1 reporter constructs and 100 ng of pRL-TK. Cells were then 
treated for 20 h with vehicle (0.1 % EtOH) or dex (100 nM) followed by harvesting and measuring 
luciferase activities. For each construct, Firefly luciferase activity was normalized to Renilla luciferase 
activity. Fold response to dex was calculated and normalized against the response of the empty vector 
pGL3P. A value of 100 % was assigned to the transcriptional response of GRR-4.6-Hs(-4834/-4369) and 
the response of each deletion fragment was calculated with reference to this. Means and S.E.M. from three 
independent experiments are shown. Statistical comparisons are against pGL3P-GRR-4.6(-4834/-4369) 
unless otherwise indicated. ***, p<0.001; **, p<0.01; *, p<0.05; n.s., not significantly different. 
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.6. Studies with human and mouse DUSP1 native promoters 
ext feasible step was to test their importance in the context of the DUSP1 native 
romoter. As previously shown, a fragment containing 4.8 kb of the human DUSP1 5’ 
gion exhibited a 25-fold response to dex. A similar construct with an internal 26 bp 
eletion of GBS-4.6.2 displayed a reduction of activity to around 10-fold, mirroring the 
ffect of deleting around 3 kb from construct Hs.-4.8kb to Hs.-1.7kb (Fig. 5.7). GBS-4.6 
sponse. Therefore the decrease in activity from fragment Hs.-4.8kb to fragment Hs.-
.7kb can be linked to the absence of this GBS. Mutating the ACA triplet of GBS-1.3 
quivalent to the mutation in GRR-1.3.Hs.-GBSm1 in Fig. 4.6) dramatically impaired 
e dex response of the 4.8 kb construct, as well as the 1.7 kb construct. Here, it seems 
at GRR-1.3 has a pivotal role for the maximal activity of fragment Hs.4.8kb.  
logous 5’ region of the mouse DUSP1 
ffect the response to dex.  
ne GBS is present around 1 kb from the mouse TSS (GBS-1.0 in Fig. 5.7). This is not 
onserved between mouse and human and is a near perfect palindrome with the 5 
variant base pairs in both strands (AGTACAGTTTGTCCC). In order to try and 
nderstand what is driving the response of the mouse 5’ region constructs this additional 
BS was mutated (GBS-1.0m in Fig. 5.7). In the context of both 4.5kb and 1.5kb 
onstructs this mutation did not impair the response to dex. As seen in studies with 
eterologous promoters, mouse GRR-1.3 and GRR-4.6 play little role in transcriptional 
sponses to GC. 
 
5
 
5.6.1. Confirming the role of GRR-1.3 and GRR.4.6 and respective GBS 
The roles of GRR-4.6 and GRR-1.3 were established using heterologous promoters. The 
n
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is likely to be the only element between -4.8 and -1.7 that is relevant to the GC 
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Parallel studies were carried out on the ortho
gene. First, a fragment of 4.5 kb from the mouse promoter displayed a much lower 
response to dex than the equivalent Hs.4.8kb (Fig. 5.7). Differences in the fragment size 
result from internal deletions and/or insertions.  Deleting around 3 kb from Mm.4.5kb to 
Mm.1.5kb caused no impairment in the response to dex. Also, deletion of GBS-4.6 or 
mutation of GBS-1.3 (the latter in the context of either Mm.4.5kb or 1.5kb) did not 
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ragments of human and mouse DUSP1 5’ region were subcloned into the Firefly luciferase reporter 
onstruct pGL3B. GBS elements are indicated by vertical bars. Wild type fragments are indicated by blue 
ars. GBS mutations were introduced by site-directed mutagenesis. GBS-4.6∆ comprises deletion of 4.6.2 
ut not of GBS-4.6.1 and -4.6.3. HeLa cells were transiently transfected with 200 ng of each reporter 
onstruct and 100 ng of pRL-TK. Cells were then treated for 20 h with vehicle (0.1 % EtOH) or dex (100 
) followed by harvesting and measuring of luciferase activities. For each construct, Firefly luciferase 
ctivity was normalized to Renilla luciferase activity, and fold response to dex was calculated. Means and 
.E.M. from three independent experiments are shown. Statistical comparisons are as indicated. ***, 
<0.001; n.s., not significantly different. 
GL3b_4834. 
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5.6.2. Studying the role of ATF binding sites close to the TSS 
At the same time these studies were being carried out, a paper by Nick Jones’s group 
identified an ATF binding site in the proximity of the mouse DUSP1 TSS. In the 
presence of a stress stimulus, such as anisomycin, this site was shown to be occupied by 
ATF in mouse fibroblasts (Breitwieser, et al., 2007). As previously mentioned, this 
transcription factor has also been linked to DUSP1 gene regulation in two different 
studies using siRNA against ATF2 in human embryonic kidney 293T and in CD4+ T 
cells (Li, et al., 2001; Teng, et al., 2007). AP-1 and CREB, which possess a similar 
DNA binding specificity as ATF, have also been proposed to be involved in 
upregulation of DUSP1 by GCs in human umbilical vein endothelial cells (Furst, et al., 
2008). Therefore it would be interesting to evaluate whether this functional ATF 
binding site could also be involved in regulation by dex.  
 
The sequence of the putative ATF site is highly conserved between human and mouse, 
suggesting functional conservation (Fig. 5.8A). Hence, this same site was mutated by 
te-directed mutagenesis in the context of the Hs.1.7kb and tested in HeLa cells. A 
es. To allow for the possibility that either site might contribute to the 
sponse to dex, the second site was also mutated either alone (Hs.1.7kb-ATFm2) or 
gether with the mutation of the other site (Hs.1.7kb-ATFm1/2). However all the 3 
utants were capable of responding to dex with the same strength as the wild type 
onstruct, indicating that this site is not involved in the up-regulation of DUSP1 by GCs 
ig. 5.8B).  
.7. Overview of basal activities presented by DUSP1 reporter constructs 
he basal activity of each fragment, i. e., the ability to drive transcription in the absence 
f treatment with dex, was also screened for the several constructs generated. This 
ould allow to identify potential enhancers that are potent in activating transcription 
ven in the absence of stimulus. Some data are shown as example. GRR-29 from all
si
different site around 50 bp from the one described was also detected by sequence 
inspection and it is also conserved between the two species (Fig. 5.8A).  ChIP data can 
reveal the region where a transcription factor is binding, but cannot easily resolve 
between sites that are close to one another (less than 200 bp apart). The ATF 
recruitment shown in Jones’s paper could in theory result from binding of ATF to either 
of these sit
re
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Figure 5.8. ATF binding sites in DUSP1 human promoter are not involved in response to dex 
A. Sequence of the human and mouse ATF binding sites. Core binding site underline and mutations 
introduced in red. Divergent base pairs between mouse and human are shaded. B. Mutations of ATF 
binding sites were introduced by site-directed mutagenesis in the context of pGL3B-1.7kb-Hs. HeLa cells 
were transiently transfected with 200 ng of each reporter construct and 100 ng of pRL-TK. Cells were 
then treated for 20 h with vehicle (0.1 % EtOH) or dex (100 nM) followed by harvesting and measuring of 
luciferase activities. For each construct, Firefly luciferase activity was normalized to Renilla luciferase 
activity and fold response to dex was calculated. Means and S.E.M. from three independent experiments 
are shown. Statistical comparisons are against pGL3B-1.7kb-Hs. n.s., not significantly different. 
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ur studied species is a good example of a region that is completely inactive in the 
bsence of dex (Fig. 5.9). GRR-4.6 of all four species appeared to modestly increase  
asa nscription seemed to cause a weak 
anscriptional act arly did not. However all 
ese activities see l activity displayed 
y Hs.GRR-1.3(-1 described in section 4.7. No 
ther construct pre ing in more detail. 
USP
 further increase its expression (Bhattacharyya, et al., 2007; Issa, et al., 2007; Lasa, et 
l., 2002; Toh, et al., 2004). This response has also been shown to occur in HeLa cells. 
nd mouse DUSP1 gene or any of the GRRs of both species included cis-regulatory 
lements relevant for this upregulation, they were transiently transfected into HeLa cells 
nd treated with IL-1 (20 ng/ml) or vehicle (0.1 % PBS). None of the constructs 
ediated any transcriptional increase in response to IL-1 (Fig. 5.10). This might 
dicate that IL-1 upregulation of DUSP1 gene depends on some regulatory sequences 
ot present in the first 5 kb of the promoter or within the fragments containing the 
 assess cis-regulatory regions whose properties depend on chromatin structure and 
odifications. Therefore it would be interesting to generate a stable line harbouring the 
agment 4.8kb-Hs and then evaluate its response to dex and other stimuli, for example 
-1. To achieve that a new construct was generated. The hygromycin resistance 
assette was removed from the pGL4 vector by restriction digestion using Bam HI and 
al I and inserted in the pGL3B-Hs.-4.8kb using the same restriction sites. HeLa cells 
ere then transfected with the new pGL3B(Hyg)-Hs.4.8kb and grown with the selective 
ntibiotic for several weeks. After that, colonies of cells were pooled together and 
ocks were kept. 
fo
a
b l tra . GRR-1.3 of the mouse, dog and rat 
tr ivation, whereas the human equivalent cle
th med rather insignificant in comparison to the basa
b 426/-1297). The study of this construct is 
o sented a basal activity worth mentioning or explor
 
5.8. Human and mouse DUSP1 reporter constructs are not responsive to IL-1 
D 1 is also upregulated by pro-inflammatory stimuli which can synergize with GCs 
to
a
To evaluate if any of the constructs containing the 5 kb upstream of the TSS of human 
a
e
a
m
in
n
GRRs. Additionally or alternatively it might mean that the response requires chromatin 
modifications that are not taken into account in transient transfection assays. 
 
5.9. Stable transfection of Hs.4.8kb 
In stable transfection the transfected DNA is incorporated into the genome. This allows 
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Figure 5.9. Analysis of basal activity of DUSP1 reporter constructs 
Fragments from the 5’ region of the DUSP1 gene were analyzed for their ability to drive the expression of 
the reporter gene in the absence of dex. Data refers to luciferase activity presented by constructs when in 
the presence of vehicle (0.1 % EtOH). Firefly luciferase activities were normalized against Renilla 
luciferase activities. Luciferase activities for each construct were normalized against the luciferase activity 
of the empty vector pGL3P. Means and S.E.M. from three independent experiments are shown. 
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ormalized against the response of the empty vector pGL3P. The figure illustrates data from one single 
riment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. Analysis of human and mouse DUSP1 reporter constructs response to IL-1 
Human and mouse GRR-1.3, -4.6 and -29 and DUSP1 native promoter fragments were tested for their 
ability to respond to IL-1. HeLa cells were transiently transfected with 200 ng of each reporter construct 
and 100 ng of pRL-TK. Cells were then treated for 20 h with vehicle (0.1 % PBS) or IL-1 (20 ng/ml) 
followed by harvesting and measuring of luciferase activities. For each construct, Firefly luciferase 
ctivity was normalized to Renilla luciferase activity. Fold response to IL-1 was calcu n
expe
a
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Cells were stimulated with dex (100 nM) or IL-1 (20 ng/ml) or both, but were found to
e unresponsive to all the stimuli, which was not always reproducible. Several 
onditions were tested with no improvements observed. One example was including 0.1 
 or 10 % (v/v) FBS in the media which effectively made no difference in the basal 
ctivity or the fold response to the stimulus (Fig 5.11). 
.10. Divergence in function of human and mouse fragments from the 5’ region of 
e DUSP1 gene is due to differences in cis-regulatory elements 
lements) but it also influences the transcription factors themselves (trans-elements). So 
r, all the reporter assays studying cis-elements from different species have been 
erformed in HeLa cells. Millions of years of evolution can in theory have changed the 
ecificity of the transcription factors involved in the responses studied. This would 
ean that the differences observed in the response to dex between the different species 
uman GRR-4.6 was responsive to dex and the mouse orthologous region displayed a 
eak but significant response (Fig. 5.12). Human GRR-1.3 mediated a clear response to 
ex whereas its mouse equivalent was completely inert. Human GRR-29 was 
nresponsive to dex, whilst the mouse GRR-29 mediated a rather weak but statistically 
gnificant transcriptional activity. Overall the pattern of transcriptional activity 
bserved in mouse fibroblasts was similar to the pattern observed in HeLa cells, though 
e fold induction to dex was somewhat smaller. Therefore it is fair to conclude the 
ifferences observed between mouse and human GRR transcriptional activity are due to 
ifferences in the sequence and not to evolutionary divergence of trans-acting elements. 
.11. Evaluating the effect of GRdim on the mouse and human DUSP1 reporter 
onstructs 
s described in chapter 1, a murine DUSP1 promoter construct was shown to be 
ependent on GR dimerisation for its activation by dex in COS-7 cells (Kassel, et al., 
001). In an opposing observation GCs could upregulate DUSP1 expression in a
 
b
c
%
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5
th
Evolution acts not only on the sequence of binding sites for transcription factors (cis-
e
fa
p
sp
m
could be a product of the human transcription factors (from HeLa cells) no longer being 
able to recognize the cis-regulatory elements of other species. To examine this 
possibility, human and mouse constructs for the GRR mediating species-specific 
responses to dex (GRR-29, -4.6 and -1.3) were transfected into mouse fibroblasts. 
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Figure 5.11. Stable transfection of pGL3B-Hs.4.8kb in HeLa cells 
Hygromycin resistance cassette was introduced in pGL3B-Hs.4.8kb. This new vector was stably 
transfected in HeLa cells. Stably transfected cells were seeded in the presence of 10 % or 0.1 % (v/v) 
FBS. The following day cells were treated with dex (100 nM) or IL-1 (20 ng/mL) or vehicle (0.1 % EtOH; 
0.1% PBS) for 6 hours. Cells were then harvested and luciferase activity was measured. Data represent the 
absolute values or the fold response to dex or IL-1 from single experiments in the presence of 0.1 % or 10 
% (v/v) FBS.  
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Figure 5.12. Human and mouse GRR respond equally to dex in mouse fibroblasts   
Mo e and human orthologous fragments of GRR-1.3, -4.6 and -29 were tested for their response to dex 
in m ts were transiently transfected with 200 ng of each reporter construct 
and 100 ng of pRL-TK. Cells were then treated for 20 h with vehicle (0.1 % EtOH) or dex (100 nM) 
followed by arvesting and measuring of luciferase activities. For each construct, Firefly luciferase
ity was normalized to Renilla luciferase activity. Fold response to dex was calculated and normalized
om three independent experiments 
a
o
 
us
ouse fibroblasts. Mouse fibroblas
 h  
 activ
against the response of the empty vector pGL3P. Means and S.E.M. fr
re shown. Statistical comparisons are against pGL3P and comparisons between mouse and human 
rthologous fragments are also shown. ***, p<0.001; **, p<0.01; n.s., not significantly different. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 - Glucocorticoid Responsive Region -4.6 (GRR-4.6) 
 
dimerisation-independent manner, given that dex, combined with LPS, was still able to 
gnificantly increase the expression of DUSP1 protein in bone marrow derived  
macrophages which only express GRdim (Abraham, et al., 2006). Furthermore a 
different study revealed that both dex and RU24858 (a prototypical dissociated ligand 
defective at classical GBS-dependent transactivation) were capable of inducing the 
expression of potentially anti-inflammatory genes, including DUSP1 and GILZ, 
implying the importance of non-typical GC-dependent gene expression (Chivers, et al., 
2006). GBS from cis-regulatory regions of different genes were also shown to respond 
differently to a GR dimerisation mutant, with increasing, decreasing or unchanged 
transcriptional activity (Meijsing, et al., 2009). These data emphasized the fact that GCs 
control of gene expression might occur independently of GR dimerisation. The 
contradictory information referring to the GR dimerisation dependency in the 
pregulation of DUSP1 needs clarification.  
of GR 
and employing a cell type that is very different from either HeLa cells or mouse 
fibroblasts. It is intended merely as a system for assessing the requirement for GR
imerisation. It is likely that little of value can be concluded about relative strengths of 
ifferent GRR in this system. 
irst, pGL3P-GRR-1.3Hs. was used to prove that transcriptional activity was dependent 
n GR and the presence of a GBS (work performed by Dr. Carmen Tchen). Cells were 
ansiently transfected with 200 ng of pGL3P, pGL3P-GRR-1.3.Hs. or pGL3P-GRR-
.3.Hs.GBS1m together with 100 ng of Renilla-CMV and 50 ng of vector expressing 
ild type GR. It is clear that only the combination of GR-wt expression and stimulation 
ith dex leads to expression of the reporter gene (Fig. 5.13A). Once again this induction 
 abolished when the GBS is mutated. Parallel to this, it was established that both GR 
roteins were expressed at comparable levels (work performed by Dr. Carmen Tchen; 
ig. 5.13B).  
 
si
u
 
To try and shed some light on this issue, the ability of a GR dimerisation mutant 
(A458T or GRdim) to activate transcription through the different mouse and human 
DUSP1 reporter constructs was evaluated. COS-7 cells, derived from monkey kidney, 
were used to carry out these experiments because they do not express endogenous GR. 
It should be noted that this is an artificial system depending on overexpression 
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gure 5.13. COS-7 cells transfection with GR expressing vectors 
To establish that DUSP1 constructs were only able to drive transcription in COS-7 cells when in the presen
dex, GR and GBS, constructs pGL3P-GRR-1.3-Hs and pGL3P-GRR-1.3-Hs.GBSm1 were transfected. COS-
ls were transfected with 200 ng constructs, 100 ng of pRL-CMV plasmid and 50 ng of GR-wt or
erisation/transactivation-deficient GR mutant (A458T=GR
 
 
 o
pe
 
 
 
 
 
 
 
 
 
 
 
 
 
Fi
A. ce 
of 7 
cel  
dim  h 
with  
co as 
ca  response of the empty vector pGL3P. Means and S.E.M. from three 
ind  Whole cell extracts from the transfected COS-7 cells were prepared and 
ran n an 8 % polyacrylamide gel. The gel was western blotted for GR and for tubulin as a loading control. 
Ex riment representative of two independent experiments. Work performed by Dr. Carmen Tchen. 
dim) expression vectors. Cells were treated for 20
dex (100 nM) or vehicle (0.1 % EtOH), followed by harvesting and chemiluminescence analysis. For each
nstruct, Firefly luciferase activity was normalized to Renilla luciferase activity. Fold response to dex w
lculated and normalized against the
ependent experiments are shown. B.
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everal constructs were then transfected in the presence of either GR wt or GRdim and 
eir response to dex assessed (work performed in collaboration with Dr. Carmen 
chen). Th tivity presented by each construct in the presence of GR-wt was set as 
00 % (d
ith reference to this. In the same experiment a reporter construct containing two 
onsensus GBS [pGL3P-(GBS)2] was also evaluated to establish that it was responding 
 dex in the presence of GR-wt but that its response was impaired when in the presence 
f GRdim (Fig. 5.14 first column on the left). The 4.8kb-Hs. fragment which contains 
RR-1.3 and GRR-4.6 was shown to be activated by both GR-wt and GRdim. Hs.GRR-
.3 alone was shown to respond to dex in the presence of both GR-wt and GRdim, 
hereas H RR-4.6 transcriptional activity was only slighted affected by the dim 
utation. n DUSP1 GC-upregulation is not 
ependent upon dimerisation of the receptor. 
egarding the mouse constructs, activation of a 1.7kb fragment equivalent to the one 
sted b  Kassell and co-workers, was shown to be impaired by the mutation in the GR 
dimerisation loop. The same fragment with a mutation in the GBS-1.3 also displayed 
impaired activity in the presence of GRdi . The transcriptional activity of a larger 
he constructs presented different fold responses to dex when transfected in COS-7 or 
eLa cells. For example, in COS-7 cells the mouse 4.5 kb fragment displayed a much 
ronger response to dex than the equivalent human 4.8 kb, the opposite of what 
appened in HeLa cells. Additionally, human GRR-4.6 had a lower transcriptional 
ctivity than human GRR-1.3. The decrease in activity between Mm.1.5kb and 
m1.5kbGBSm1 has actually been shown not to be statistically significant. This could 
e explained by tissue-specific differences, but this assay was not used to compare the 
ctivity of different regions but only the activity of each fragment in the presence of 
ifferent GR proteins. 
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1 otted line in Fig. 5.14) and the activity in the presence of GRdim was calculated 
w
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Thism  might indicate that in overall huma
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promoter fragment, Mm4.5kb, was also impaired by the dim mutation. This seems to 
indicate that the mouse proximal 5’ region is responding to dex through the use of 
unidentified GR binding sites where GR dimerisation is required. Interestingly, the 
transcriptional activity of GRR-29, the more important GRR identified so far in the 
mouse DUSP1 gene regulation, was completely unaffected by the dim mutation. 
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igure 5.14. Analysis of GR dimerisation dependency for the activity of human and mouse DUSP1
ter constructs 
OS-7 cells were transfected with 200 ng of DUSP1 reporter constructs, 100 ng of pRL-CMV plasmid and 50
-wt or dimerisation/transactivation-deficient GR mutant (A458T=GRdim) expression vectors. Cell
ere treated for 20 h with dex (100 nM) or vehicle (0.1 % EtOH), followed by harvesting and 
emiluminescence analysis. (GBS)2 contains two GBS from TAT promoter, which are dimerisation
ependent for activation by dex. For each construct, Firefly luciferase activity was normalized to Renilla
ciferase activity. Fold response to dex was calculated and normalized against the response of t
ector pGL3P (indicated above graph). A value of 100 % was assigned to the transcriptional respon
 is
 
 
 
 
 
 
 
 
 
e response to dex in the presence of GR-wt and GRdim for each construct; **, p<0.01; *, p<0.05; n.s., no
ficantly different. Work performed in collaboration with Dr. Carmen Tchen. 
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.12. DISCUSSION 
he phylogenetic approach allowed the identification of a GRR located 4.6 kb upstream 
f the DUSP1 TSS. Human GRR-4.6 was shown to mediate a strong response to dex, 
hereas the mouse orthologous region mediated a comparatively weak response to dex. 
bility to respond to dex was correlated with ability to recruit GR in both mouse and 
uman cells. This region contains three closely spaced GBS; however the maximal 
sponse to dex presented by the human GRR depends solely on GBS-4.6.2. This GBS 
as not only two half GR binding sites, but also a third one partially overlapping. 
terestingly, mutation of each half site independently was shown to impair the response 
 dex. This is a rather atypical GBS element, which has not been described before. The 
ifference in sequence between mouse and human GBS resides in only one base pair 
located in the spacer. As mentioned previously GR is believed to bind as a dimer, with 
each monomer binding to one half site. The three nucleotide spacer, which can have any 
of the four bases in each of its positions, was classically believed to not play an 
important part. Actually, Meijsing et al have recently shown that this element will 
influence the conformation of the GR, since different GR surfaces will interact and
produce different transcriptional activities in the presence of GBS which only differ at
ctually, GRR-4.6-Hs. has also been subcloned in pGL4 and gives a 10-fold response 
 dex (data not shown). Therefore additional sequences present in GRR-4.6-Hs 
crease the response to dex from 3-fold to 10-fold. The mouse GRR should not contain 
ese and/or might contain inhibitory sequences. It could also be interesting to mutate 
e different GBS in the mouse GRR-4.6 and confirm that the weak activity observed 
epends on the same GBS as in the human. 
he differences in response to dex between mouse and human orthologous regions 
namely GRR-4.6, -1.3 and -29 were shown to be maintained when the constructs were 
5
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the spacer sequence (Meijsing, et al., 2009). Nonetheless, in the case of GBS-4.6.2 this 
nucleotide difference is not responsible for the different activities presented by the 
human and mouse GRR-4.6, considering the studies where the GBS sequence was 
swapped between species. At the same time, when in isolation the mouse GBS-4.6.2 
exhibited a stronger response to dex (6-fold) than the human GBS (3-fold). This leads to 
the conclusion that both GBS can be functional, however the ability to induce a stronger 
response to dex of the human GRR lies in additional sequences present in that element. 
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transfected into mouse cells. This clearly indicates the differences in response observed 
epend on the differences in sequence (cis-element). The fact that the fold response to 
lements, known to shape the genomes. 
d
dex is clearly lower in this type of cells can perhaps be explained by tissue specific 
differences. 
 
5.12.1. GR-GBS-4.6.2 interaction 
Binding of GR to the GBS was assessed by pull-down assay. In spite of the discussed 
technical challenges presented by this technique, it could be interesting to also assess 
the ability of mouse GBS-4.6.2 to bind GR and mutate the GBS to evaluate which base 
pairs are important for the binding. 
 
This new atypical element comprised of three overlapping half GR binding sites 
deserves to be further investigated. It will be interesting to evaluate if three GR 
monomers are binding to it, the GR affinity to bind it compared to classical binding 
sites, what mutations in DNA interfere with the binding, the conformation of GR when 
bound to it. EMSAs will be performed with GR-DBD provided by S. Meijsing and 
would be interesting to carry out some crystallography studies to further understand the 
conformation of the whole complex. Obviously, the fact that only the GR DBD will be 
present might become a problem given that other GR surfaces might be required for 
interactions between the monomers or the binding itself. Albeit these same limitations 
can apply, it could be useful to perform some methylation interference in order to try 
and pinpoint the exact residues involved in the direct binding of GR. 
 
5.12.2. GBS-4.6.2 and SINES 
GBS-4.6.2 is part of a strong enhancer element and its sequence is highly conserved 
between species. Additionally to mouse, rat and dog this GBS has no more than one 
base pair difference between human and horse, cow, marmoset, rhesus monkey, 
chimpanzee and orang-utan. The armadillo presents differences in two residues, which 
disrupt the overlapping GR binding half site, but create a “new” one on the opposite 
strand (Fig. 5.3C). Deeper inspection of GBS-4.6.2 revealed a bit more about how its 
appearance is associated with DNA mobile e
 
Short interspersed elements (SINES) were firstly defined by the existence in the 
genome of a large number of relatively short sequences that are related to one another. 
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These elements are retroposons, from the nonviral superfamily, which were generated 
by an RNA-mediated transposition event involving RNA pol III activity (Lewin, 2004). 
SINES actually comprise 10-15% of the human genome and are normally associated 
with non-functional DNA. However they have been associated with evolution of gene 
xpression because when they are inserted in the genome they can create a new cis-
regu regulatory elements already present (Brosius, 
quence is. Hence, even if it is not possible to say 
hether the insertion of this SINE created the GBS or if further selection events lead to 
hereas the mouse orthologous fragment was weakly responsive. Moreover it allowed 
to c to dex of the mouse DUSP1 orthologous 5’ region 
BS. 
 appears that in the context of the native promoter GBS-1.3 is more crucial for the 
e
latory element or they can disrupt 
1999; Dewannieux and Heidmann, 2005). Interestingly, GBS-4.6.2 is partially derived 
from a MIR3 SINE, a retrotransposon known to predate the divergence of rodent and 
primate lineages (Jurka, et al., 2005). GBS-4.6.2 is highly conserved between 
mammalian species, as the SINE se
w
its formation, it seems obvious that its presence was selectively maintained. It seems 
this cis-regulatory element is an example of how insertion of SINES in the genome can 
lead to creation of new regulatory elements, which confers an increase in the selective 
pressure acting upon it. This phenomenon is designated as exaptation (Brosius, 1999).  
 
5.12.3. Constructs containing the human and mouse DUSP1 native 
promoters 
Having established the ability of GRR-1.3 and GRR-4.6 to respond to dex it was 
important to further try to understand its importance in the context of the native DUSP1 
promoter. First of all, these studies allowed to establish that a fragment from the 5’ 
region of the human DUSP1 gene, of around 5 kb, was highly responsive to dex, 
w
onfirm that this weak response 
did not require the presence of GBS-1.3 or GBS-4.6.2. On the other hand, mutation of 
GBS-4.6.2 was shown to impair the response to dex of the human fragment, although 
some response remained. This was likely due to the presence of GBS-1.3 given that a 
promoter fragment of 1.7 kb which contained only this GBS exhibited the same fold 
response to dex. Interestingly, when mutating GBS-1.3, even in the presence of GBS-
4.6.2, the effect in the response to dex is much more striking. The result obtained 
mimics the fold response seen with fragments that do not contain any of these two G
It
response to dex, or perhaps the ability of GRR-4.6.2 to activate transcription when at 
the real distance from the TSS requires some kind of interaction between the two GBS. 
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To understand what was driving the weak response seen with the mouse fragment, one 
GBS located 1 kb upstream of the TSS and consisting of a near perfect palindrome 
which is only present in the mouse locus was investigated. However no effect in the 
response to dex was seen when mutating this element. Human DUSP1 fragments 1.1 kb 
and 0.7 kb still displayed a weak response to dex. In fact, they presented roughly the 
same fold response to dex as mouse fragments 4.5 kb and 1.7 kb. There was one GBS 
also identified by the phylogenetic approach which has not yet been studied (Table 3.2). 
This GBS locates 233 bp from the DUSP1 TSS and has 12/15 bp conserved between 
human-mouse sequence. Perhaps the activity observed for these mouse and human 
fragments was due to the presence of this GBS. It would be interesting to investigate 
this in the future by mutating this GBS in these human and mouse fragments.  
 
5.12.4. ATF binding site in DUSP1 promoter  
As mentioned previously, literature has several examples of evidence relating ATF 
family members with DUSP1 gene regulation by GCs or other stimuli. ATF was 
erefore a logical candidate for a transcription factor acting as a partner of GR in the 
upregu
oter in mouse cells (Breitwieser, et al., 2007). The same binding site was 
th
lation of DUSP1 and worthy of investigation. ATF was shown to bind to the 
DUSP1 prom
evaluated here for its involvement in responding to dex in the context of a 1.7 kb 
fragment from the human DUSP1 locus, given that the site is highly conserved between 
human-mouse. Its presence was shown not to be required for the response to dex. 
However, because the site was first discovered in mouse and because we have shown 
here that a binding site sequence can be conserved between human-mouse and yet be 
functional in only one of them, it would be interesting to mutate it in the context of the 
mouse DUSP1 native promoter. 
 
5.12.5. Deletions and additional elements involved in the response of human 
GRR-4.6 to dex 
Deletion analyses of the human GRR-4.6 seemed to indicate there are potentially 
several sequences/transcription factors involved in achieving a maximal response to 
dex. The interval -4459/-4430, 3’ of the GBS-4.6.2 was analysed with Matrix Inspector 
for putative transcription factors binding sites and the “hits” obtained compared for 
species highly responsive to dex (human and dog) or for those weakly responsive 
(human and mouse). Two potential candidates found were C/EBP and FOX 
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transcription factors. When analysing the orthologous interval (-4459/-4430) of mouse 
and dog, the FOX is not present in the dog, suggesting this might not be relevant. The 
C/EBP site is also present in the dog, but it can also be found in the mouse region. This 
might suggest that this site is not important since it is common to all three species. 
However, the site could still be important: the difference in response to dex between the 
mouse and human could be due to other additional sites, since even in the human this 
interval is not the only one necessary for the maximal response to dex. The interval 
between -4740/-4666 was also analyzed but the only potentially interesting candidates 
found were Oct-1 and v-ets erythroblastosis virus E26 oncogene homolog 1 (Ets1). 
Again both binding sites are also present in the mouse sequence.  
 
As described in the previous chapter, searching for additional sequences involved in the 
respons d mutagenesis studies and also 
 the exact sites where proteins are binding to the DNA. 
ased on the differences in response to dex presented by the different orthologous 
regions
loss/gain of response to dex. However, given what happened with 
e to dex can be done using primarily deletion an
DNA-protein interaction studies; however this may not always be successful. This type 
of approach is laborious, especially in this case where there is an extensive region to 
cover. Therefore it was decided not to pursue any more investigations. In the future 
however it will definitely be interesting to identify the partners of GR in activating 
transcription through GRR-4.6. However it is worth mentioning that given the artefact 
encountered when performing deletion analyses of the human GRR1.3 in pGL3P, it 
would be wise to confirm the results obtained for the deletions of human GRR-4.6 in 
pGL3P by subcloning the fragments into pGL4. 
 
Moreover it would be wise to address the identification of accessory transcription 
factors using different approaches. It would be worth trying DNAse I footprinting, 
given that it would allow to map
B
 of different species, mouse-human hybrid constructs could also be generated 
and assessed for 
GRR-1.3 where several mutants and mouse-human hybrid constructs were generated 
with no success in identifying the accessory transcription factors, this approach might 
end the same way. 
 
It is also worth mentioning that the complex observed in EMSAs with GBS-4.6.2 as 
probe might be interesting to investigate. This complex was affected by mutation of the 
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three half GR binding sites. It can be a transcription factor binding close to GR. Using 
the Matrix Inspector to identify putative binding sites for transcription factors binding in 
this region, no plausible candidate was identified. It might be useful to use oligos with 
mutations in each half GR binding site individually and mutate different base pairs to 
more precisely pinpoint the residues involved in the complex. It could be interesting to 
evaluate if the same complex is present in the mouse GBS-4.6.2 sequence. Methylation 
interference can also be used to pinpoint the residues involved in the interaction with 
DNA. 
 
5.12.6. GR dimerisation dependency of DUSP1 gene regulatory regions 
volved in the response to dex 
atsky, et al., 2003) and the GRdim mice 
ill display some side effects of the GC treatment (Kleiman and Tuckermann, 2007). 
d here suggest that the ability to respond to dex of the 5 kb fragment 
ontaining the mouse DUSP1 native promoter is dependent on GR dimerisation, 
in
For a long time it was believed that it was possible to attribute the side effects of GC 
treatment to the mechanism of transactivation, and the anti-inflammatory effects solely 
to the process of transrepression. This was based on studies with GRdim transfected cells 
(Heck, et al., 1997; Heck, et al., 1994) or GRdim mice (Reichardt, et al., 1998; Reichardt, 
et al., 2001b; Tuckermann, et al., 1999). These studies have shown that inhibition of 
NF-κB and AP-1 and the inflammatory effects remained unchanged in the presence of 
the mutant GR, whereas the ability to induce gluconeogenic enzymes was 
compromised. More recently it has become evident that this was simplistic for several 
reasons. For instance, several GC-induced genes were not affected by this mutation 
(Abraham, et al., 2006; Adams, et al., 2003; Rog
st
DUSP1 is one interesting case, of an active contributor for the GC anti-inflammatory 
effects which has been associated with side effects such as osteoporosis (Conradie, et 
al., 2007; Engelbrecht, et al., 2003; Horsch, et al., 2007; Hulley, et al., 2002), is up-
regulated by dissociated GCs (screened based on their ability to induce transrepression 
but not transactivation) (Chivers, et al., 2006) and about whose ability to be induced by 
the GRdim there seems to be some conflicting data (Abraham, et al., 2006; Kassel, et al., 
2001). 
 
The results describe
c
confirming the data obtained by Kassel and colleagues using the same type of approach. 
The response to dex of the 4.5 kb and 1.5 kb fragments analysed was not dependent on 
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GBS-1.3 or GBS-4.6.2 but is likely to rely on other unidentified GBS which require GR 
dimerisation to drive transcription. Interestingly, the ability of mouse GRR-29 to drive 
transcription is completely independent of GR dimerisation. So far, GRR-29 is the 
mouse DUSP1 cis-regulatory element with the strongest response to dex identified. This 
might indicate that this element plays an important role in regulating the DUSP1 
endogenous gene. When analysing the levels of DUSP1 gene expression in mouse cells 
expressing only GRdim there was no significant difference comparing with cells 
expressing GR-wt, perhaps because this element does not require GR dimerisation 
(Abraham, et al., 2006). It is rather likely that there is more than just one element 
involve
cription. Therefore a GR dimerisation mutant might 
 be unresponsive to any of the stimuli tested. This issue is definitely worthy of 
rther investigations. A feasible option could be using the human hepatoma cell line, 
d in the response to dex and it is more and more evident that not all GBS require 
GR dimerisation to activate trans
impair the involvement of specific GRR for the response to dex, but because other 
elements are still operating, these impairments will be masked and DUSP1 endogenous 
gene will still be expressed.  
 
Regarding the human DUSP1 regulation, GRR-1.3 response to dex was equally strong 
in the presence of GR-wt or GRdim, whereas GRR-4.6 was slightly impaired in the 
presence of the mutant. Nevertheless, the 4.8 kb construct which contains these two 
regions was able to respond to dex in the presence of GRdim, even slightly stronger. This 
indicates there is no dependency on GR dimerisation for the human 5 kb fragment 
containing the DUSP1 native promoter to respond to dex. Given that this 4.8 kb 
fragment includes the two human GRR more strongly responding to dex, it is likely that 
human DUSP1 endogenous gene upregulation by dex does not require GR dimerisation 
Fig. 5.15 summarises the requirement of GR dimerisation for the dex-mediated 
transcription of the reporter gene through the different human and mouse constructs. 
The GC-upregulation of the endogenous human and mouse DUSP1 gene is likely to be 
independent of GR dimerisation (Fig. 5.15). To confirm this for the human gene, U2OS 
cell lines stably expressing GR-wt or GRdim were used, however the DUSP1 gene was 
found to
fu
HepG2/C3A, which do not express functional human GRα, but have been shown to 
express DUSP1 in response to several stimuli other than GC (Fruchter, et al., 2005; Liu, 
et al., 2003; Zhou, et al., 2003).  Transfection of different GR-expressing vectors could
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igure 5.15. Summary of GR-mediated molecular mechanism for the human and mouse DUSP1 
ene upregulation 
BS present in the context of a GRR (A) or a 5 kb fragment (B) containing the DUSP1 native promoter 
nd their response to dex in the presence of GR-wt or GR
F
g
G
a
P
dim, determined using reporter studies. C. 
ossible model to explain the upregulation of DUPS1 endogenous gene by GCs.  
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e performed in these cells and subsequently evaluate the expression of DUSP1 gene 
following dex treatment. 
 
Additionally it would be interesting to investigate the response to dex of the human and 
mouse DUSP1 reporter constructs, and the endogenous gene, in the presence of other 
different dimerisation mutants (Adams, et al., 2003) to further confirm the results 
obtained here with the A458T mutant. 
 
5.12.7. Concluding remarks 
This is an example where sequence conservation allowed to identify a GBS which is 
important for the human DUSP1 promoter response to dex, but not for the mouse 
DUSP1 promoter response. The activity of this enhancer was shown to be dependent on 
an atypical 3 half site GBS, which has not been described before. Again the maximal 
response to dex of this region depends on additional sequences for transcriptional 
binding sites which are only present in the human sequence. GR dimerisation is not 
critical for the response to dex of the fragment from the human DUSP1 5’ region that 
contains the native promoter. The response to dex of the orthologous region of the 
mouse requires GR dimerisation, but not the GRR located 29 kb upstream of the mous  
USP1 TSS. 
b
e
D
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6. Chapter 6 - Final Discussion 
 
Glucocorticoids are the drug of choice to fight inflammatory pathologies such as 
rheumatoid arthritis, asthma or systemic lupus erythematosis. It now appears that the 
molecular mechanisms underlying their ti-inflammatory and immunosuppressive 
effects are more diverse and complex than initially thought. Additionally to directly 
suppress the expression of inflammatory genes by the mechanism of transrepression 
through GR, it now starts to be accepted that GC-upregulation of several anti-
inflammatory effectors is critical for their neficial effects (Clark, 2007). DUSP1 is 
one of the genes induced by GCs and responsible for the inactivation of MAPK 
pathways (Clark, et al., 2008). The extent of the protective role of DUSP1 against 
exacerbated inflammatory r tely understood. Still, an 
creasing number of studies, especially studies with DUSP1-/- cells and mice, have 
rectly implicated this phosphatase in the anti-inflammatory properties of GCs. It has 
been shown how absence of DUSP1 results in exaggerated inflammatory responses in 
cells and mice, with high susceptibility to LPS, dramatic increase in levels of pro-
inflammatory cytokines a vity to endotoxic shock 
(Clark, 2007; Li, et al., 20 DUSP1 can in the future 
e a critical target for the modulation of inflammatory processes. This was the basis for 
e studies described here where it was attempted to understand in more detail the 
olecular mechanism by which GCs upregulate human and mouse DUSP1 genes. 
entification of GRR in mouse and human DUSP1 loci was successfully achieved. Five 
ifferent regions of human and mouse DUSP1 promoter were studied. These regions 
ontained highly conserved GBS (Table 6.1) and flanking sequences with 65 % 
onservation over at least 100 bp. These features have been shown to be predictive of 
R occupancy and transcriptional activation (So, et al., 2007; So, et al., 2008). 
unctional reporter gene studies and ChIP assays were carried out for all of them 
ummary in Table 6.1) to assess whether they were in fact responding to dex and 
cruiting GR. However, the study of these five conserved regions in the DUSP1 locus 
d to four different outcomes when the relationship between sequence/function 
onservation is concerned: function in both species (GRR-24), in neither (GRR-28), 
lely in human (GRR-1.3 and GRR-4.6) and solely in the mouse (GRR-29). 
 
an
be
esponses is not yet comple
in
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nd mediators and increased sensiti
09; Tchen, et al., 2009). Therefore, 
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Table 6.1. – Summary of functionality, GR recruitment and GBS conservation for the five GRR studied 
GR Hs. vs. Mm. GBS GRR species Functionality recruitment sequence conservation 
Hs. + + 
-1.3 
Mm. - - 
15 
Hs. ++ + 
-4.6 
Mm. + + 
10/14/12 
Hs. + + 
-24 
Mm. + + 
14 
Hs. - - 
-28 
Mm. - - 
11 
Hs. - - 
-29 
Mm. + + 
10 or 12* 
 
* Depends on whether the human or mouse GBS is set as the “base” sequence 
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It is not the first time that the use of different cis-regulatory regions accomplishes the 
same expression of the target gene. The ascid cyn iona 
intestina exp eobo owever 
they lack cis-regulatory sequence conservation. In fact gene regulation was maintained 
through a few vital transcription factor binding sites with no apparent constraint 
concerning their number, order, orientation and surrounding sequences (Oda-Ishii, et 
al., 2005). Another example was described for the regulation of the eve-skipped gene in 
the blastoderm e Drosophila. Substantially diverged enhancers are responsible 
for ma ntical and precise expression of this gene in four different 
Drosophila species (Ludwig, et al., 2005). Clearly, there is a high flexibility for cis-
regulatory regions arrangement and for how different modules and combinations of 
modules are allowed as long as the final outcom is preserved. This applies to the 
regulation of DUSP1 gene expression. Here, it was shown that mouse and human 
combin fere -regulatory regions to achieve the desired gene expression. 
terestingly, divergence in cis-regulatory sequence, localization and architecture can 
s provide the basis for 
ossible future changes in the expression patterns. 
nalysis of sequence conservation in the form of phylogenetic footprinting is 
onetheless a powerful technique to search an enormous length of non-functional DNA 
r cis-regulatory regions. There are too many putative binding sites surrounding the 
USP1 gene and searching for species conservation allows to define a feasibly tested 
t of candidates. Alternative approaches to the phylogenetic approach associated with 
porter gene assays were already discussed in chapter 3. 
he search for conserved GBS was restricted to the 30 kb upstream of the TSS.  I have 
ow extended the bioinformatics analysis and have searched for matches of the 
onserved GNACANNNNG in the proximity of the human and mouse DUSP1 gene 
sing the same criteria as before. The region from 30 kb upstream of the TSS until the 
ext gene (ERGIC1) does not contain any matches. On the other hand, the region from 
st after the 3’UTR of DUSP1 gene until the next neighbour gene (NEURL3) contains 
ve different conserved GBS (Fig. 6.1). Interestingly, there is one conserved GBS in the 
tronic region between exons two and three. Additionally, there are two conserved
ians Halo
ression of hom
thia roretzi and C
x gene Otx, hlis share the same development 
mbryo of 
intaining an ide
e 
nt cise dif
In
remain neutral if the final outcome is maintained, but nevertheles
p
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Figure 6.1. Extended search for GBS consensus 
Human (Hs) and mouse (Mm) DUSP1 5’ and 3’ regions, intronic regions and 3’UTR were searched for
matches to the GNACANNNNG consensus. Matches conserved in position, orientation and sequence
between human-mouse and embedded in regions of extended sequence conservation (≥65 % sequence 
identity over at least 100 bp) are indicated. The 6 GBS identified in the first search within the 30 kb of the
5’ region of DUSP1 gene are indicated in black. 8 additional GBS were found when extending the search
until the neighbour genes loci (in red). * one GBS identified in the intronic region between exons 2 and 3
** 2 closely spaced GBS located in the 3’UTR. Alignment of the human and mouse DUSP1 genes and
surrounding regions were performed using default settings of t
strong conservation are indicated. 
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GBS (14/15 bp) separated by only 11 bp in the 3’UTR of the DUSP1 gene. It will be 
teresting to evaluate their functionality in the response to dex. For instance it would be 
teresting to clone the 3’ UTR of human and mouse DUSP1 gene downstream of the 
ciferase coding region on the same vector that contain the Hs.-4.8kb or the Mm.-4.5 
kb and evaluate the response to GC treatment. 
 
The work described here illustrated how in the human-mouse DUSP1 loci, GBS 
sequence conservation and GRR position, orientation and sequence were not high 
predictors of functional conservation for the mentioned sequences. Statements such as 
“GBS conservation alone is sufficient to predict GR occupancy and the GBS function at 
induced genes” may not reflect in the best way the data which it refers to (So, et al., 
d with strong support, is that the % of GBS 
an sequence context was it able to be bound by 
study analysed human-mouse sequence 
 of the GBS for the mouse; it raises the 
ilar would the results be if the study would have been extended to 
an sequences and cells. Perhaps some of the functional GBS would have been 
an (as GBS-29 identified in that study can exemplify) and some GBS 
ouse) would have been functional in the human. 
x depending on whether they were isolated 
bedded in a specific context. This indicates the extreme importance of the 
ability of GR to drive transcription through GBS. 
for transcription factors cooperating with 
at can favour activation of transcription. 
ple human GBS4.6.2 activity increases from when it is isolated to when it is in 
ntext. At the same time the absence of those sequences or the presence of 
tivity of GBS-GR can also decrease the activity presented 
ple mouse GBS-29 which is highly active when alone or in 
in
in
lu
2008). In fact, what the So paper claims, an
which are functional, increases with the number of human-mouse conserved base pairs 
ithin the GBS analysed (So, et al., 2008). This in reality leaves space for exceptions, 
xamples falling in the % of GBS which are conserved but not functional. What is 
teresting is that 7 of the GBS tested contained 15/15 bp conserved and were all 
nctional and bound by GR. Here, an exception, GBS-1.3, was described. This GBS 
w
e
in
fu
contains 15/15 bp but only in the hum
GR and strongly respond to dex. So’s 
conservation but only tested the functionality
question of how sim
the hum
inert in hum
discarded as non-functional (in the m
 
GBS presented different fold responses to de
or em
surrounding sequences for the 
Additional sequences, possibly binding sites 
GR, appear to create a surrounding context th
For exam
the GRR co
sequences that inhibit the ac
by the GBS alone. For exam
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the mouse GRR, is only very weakly responsive when in the context of the human 
GRR. It is clear from all the different studies described here that for all the GBS tested, 
sequence context played an important part in transcriptional activation by dex. As 
described in chapter 1 GR interacts with several partners to induce transcription. The 
several GRR described here appear to contain binding sites for transcription factors that 
elp GR bind to the GBS. This is similar to the mechanism observed in the MMTV-
le 
ontaining mutations in the GR phosphorylation sites. A recent study has shown that a 
h
LTR promoter, where Oct-1 binding to its binding site was required for GR to bind to 
the GBS, which in turn was required for the binding of Oct-1 (Bruggemeier, et al., 
1991; Miksicek, et al., 1987). 
 
As previously mentioned in chapter 1, the same exact mouse GBS sequence is present 
in the DUSP1 (GBS-29) and Adamts 19 loci, however in mouse C3H10T1/2 cells it was 
only bound by GR in the former gene (So, et al., 2008). In this case the same GBS in 
the same species can be active or inactive probably depending on the context of the 
sequence. A similar situation was shown here, but this time the same GBS, GBS-1.3, 
was present in the human and mouse promoter and was only responsive and bound after 
dex treatment in the human promoter. Once again, the context influences the 
transcriptional outcome. 
 
This raises the question of using simple GBS to evaluate the response to different GR 
mutants (GRdim, GR phosphorylation mutants, etc) or to different GR ligands. The data 
obtained might not reflect the true transcriptional activity of that element when 
embedded in its real surrounding context. It would be interesting to test the response of 
the different GRR and GBS identified to other GR ligands and GR mutants for examp
c
GR triple mutant (Ser 203, Ser211, Ser226) was able to drive transcription through two 
GBS linked upstream of the thymidine kinase promoter but not through the MMTV-
LTR or two copies of the GBS from TAT promoter, suggesting a promoter specific 
dependency on GR phosphorylation (Avenant, et al., 2010). 
 
Screening dissociated compounds by using reporter genes with NF-κB and AP-1 
reporters and classical GBS might actually not be serving the purpose of separating 
gene repression from gene induction. There are now several examples of GC gene 
induction in the absence of classical transactivation and GR dimerisation (Adams, et al., 
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2003; Meijsing, et al., 2009; Smoak and Cidlowski, 2004). Obviously, it seems that 
some dissociated GCs will to some extent be able to upregulate gene expression and 
therefore their real effects can be more complex than the predicted. For example, it 
should be regarded that some dissociated ligands defective at classical GBS-dependent 
transactivation such as RU24858 were still able to induce DUSP1 expression (Chivers, 
et al., 2006). Moreover, GRR-1.3 was responsive to AL-438 and to two dissociated 
compounds similar to ZK216348 and AL-438, currently being studied in this lab (J. 
Martins and A. Clark unpublished data). Additionally, these two compounds are still 
capable of inducing DUSP1 gene expression in several types of cells (E. Joanny and A. 
lark, unpublished data). 
 these fragments. Transient transfection of reporter genes is 
ommonly used to identify important cis-regulatory elements in gene promoters. 
ion factors involved might 
ill bind the DNA but are not able to interact with cofactors due to their absence or due 
C
 
In a clear evidence for a tight regulation of the inflammatory response DUSP1 is 
upregulated by pro-inflammatory stimuli (Carayol, et al., 2006; Hu, et al., 2007; Lasa, 
et al., 2002; Xu, et al., 2004; Zhao, et al., 2005). This prompted me to evaluate the 
DUSP1 reporter constructs response to IL-1. All the different human and mouse GRR, 
as well as the 5 kb native promoter constructs, were found to be unresponsive to IL-1 
stimulation. A simple explanation is that cis-regulatory regions involved in the response 
to IL-1 are absent from
c
However, this method is associated with limitations when regulatory processes are 
related to chromatin context. This might be an explanation why all the fragments from 
both human and mouse DUSP1 loci were unresponsive to IL-1 stimulation. Perhaps the 
activation of DUSP1 promoter by this stimulus requires specific recruitment of 
cofactors involved in chromatin remodelling and histone modifications either prior or 
after the stimulus. It has been shown that DUSP1 promoter recruits CBP either in 
resting conditions or for example treatment with TRH (Ryser, et al., 2004). In fact, the 
DUSP1 promoter seems to be preactivated before induction. Perhaps this might involve 
creation of a specific chromatin structure required for binding of transcription factors 
involved in the IL-1 response. Alternatively, the transcript
st
to the lack of the correct chromatin disposition or activation signals. Shortly, 
preactivation of the promoter might be important for the upregulation by IL-1, and/or 
the nature of the proximal promoter could play a decisive part in this response. 
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GCs and pro-inflammatory stimuli cooperate to induce DUSP1 gene expression 
(Bhattacharyya, et al., 2007; Issa, et al., 2007; Lasa, et al., 2002; Toh, et al., 2004). The 
molecular mechanisms by which this occurs is intriguing. In the future, it would be 
interesting to elucidate what events and elements are important for such regulation. It is 
already known that RNA Pol II is constitutively recruited to the promoter and that 
DUSP1 transcription is regulated at the elongation level (Fujita, et al., 2009; Fujita, et 
al., 2007; Ryser, et al., 2001). It can be important to evaluate what changes occur in the 
chromatin (eg., histones acetylations and methylations, DNAse I hypersensitivity sites) 
not only after treatment with GCs, but also will IL-1. For example, it can be interesting 
to perform ChIP experiments to study H3 K10 phosphorylation, H3 K14 and H4 K5 
cetylation, modifications associated with transcriptional activation. Also, it could be 
 
a
worthy investigating whether the changes observed for these stimuli independently are 
just addictive or they actually differ when inflammatory and anti-inflammatory stimuli 
are present simultaneously. Modifications observed can also be analysed for their 
occurrence in the time scale of events and for the requirement for specific co-factors, for 
example the presence of SWI/SNF, NELF, P-TEFb. Given the differences observed 
here between the cis-regulatory regions of human and mouse, it would obviously be 
interesting to perform these experiments in both human and mouse cells. 
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The powerful anti-inflammatory effects of glucocorticoids
(GCs) have been known for more than sixty years, but their
molecular mechanisms are still incompletely understood and
hotly debated. The GC receptor (GR) was cloned in 1985 and
shown to be a transcription factor. Initially, the anti-inflamma-
tory actions of GCs were explained in terms of genes that were
up-regulated by the receptor. However, none of these putative
mediators seemed able to account for the spectrum of anti-in-
flammatory responses to GCs. The discovery of a negative regu-
latory function of GR then shifted the focus away from GC-in-
duced genes as anti-inflammatory mediators. In recent years,
attention has begun to move back toward the idea that the anti-
inflammatory response toGCs is partially dependent on thepos-
itive regulation of gene expression by GR.
Classical Model of Glucocorticoid Action
Synthetic GCs2 inhibit expression of many immune and
inflammatory mediators in several cell types. For this reason,
they are of great use as immunosuppressants and in the treat-
ment of chronic inflammatory diseases (1, 2), yet they can also
give rise to a number of side effects of varying severity (3). Both
the therapeutic and undesired effects of GCs are mediated by
GR, a member of a large family of transcription factors, the
nuclear hormone receptors. GR activates or inhibits gene
expression via mechanisms known as transactivation and tran-
srepression. According to the current paradigm, the side effects
of GCs are largely dependent on dimerization of GR, binding to
palindromic GC-response elements, and activation of expres-
sion of genes (for example, regulators of gluconeogenesis). On
the other hand, anti-inflammatory effects are thought to be
largely due to the dimerization-independent transrepression of
NF-B, AP-1, and other transcription factors that contribute to
pro-inflammatory gene expression (3–5). Hence, novel GR
ligands that selectively promote transrepression rather than
transactivation might retain anti-inflammatory effects but
cause fewer side effects (6, 7).
This model of GC action is based largely on the in vivo and in
vitro properties of dimerization-defective GR mutants (8). A
re-examination of this model (9, 10) has been prompted by
several recent findings. (i) Anti-inflammatory functions of GR
are not, as originally thought, independent of dimerization (8,
11). (ii) Activation of gene expression by GCs is not invariably
dependent on palindromicGC-response elements or on dimer-
ization of GR (9, 12–16). (iii) A growing number of anti-inflam-
matory mediators have been shown to be up-regulated by GCs
(9, 10). Among these factors are phosphatases that inactivate
MAPKs.
MAPKs and Phosphatases
In response to extracellular stimuli, MAPKs become acti-
vated via the phosphorylation of threonine and tyrosine resi-
dues within short activationmotifs. The activatedMAPKs then
modulate cellular responses by phosphorylating a variety of
substrates, including transcription factors and downstream
effector kinases. Activation of ERK frequently mediates prolif-
erative or anti-apoptotic responses, whereas JNK and p38
MAPK often mediate transcriptional and post-transcriptional
responses to stressful and/or pro-inflammatory stimuli (17).
Among other mechanisms, JNK phosphorylates and activates
the c-Jun component of AP-1 to induce transcription of many
inflammatory effectors. Stimulation of the p38MAPK pathway
results in the transient stabilization of many inflammatory
mediator mRNAs that contain destabilizing adenylate/uridy-
late-rich elements in their 3-untranslated regions (18). The
p38 pathway has also been implicated in regulation of NF-B
function, although the precise mechanism is disputed (19–21).
The timely inactivation of MAPKs is essential for the gener-
ation of appropriate cellular outcomes and for restoration of
responsiveness. Such inactivation can be carried out by tyro-
sine-specific, serine/threonine-specific, or dual specificity
(DUSP) phosphatases. The DUSP family includes 10 mem-
bers that catalyze dephosphorylation of both threonine and
tyrosine residues within MAPK activation motifs (22, 23).
These enzymes are also known as MAPK phosphatases.
The roles of DUSPs in cellular responses to external stimuli
are determined by their different patterns of expression, sub-
cellular localization, and substrate specificity. A few such as
DUSP2 appear rather cell type-restricted in expression,
whereas others are widely expressed. Some are constitutively
expressed, whereas others are inducible and contribute to neg-
ative feedback regulation of the MAPK pathways. Some, like
DUSP1 andDUSP4, are reportedly restricted to the nucleus and
may modulate cellular responses not only through inactivation
but also by nuclear sequestration of their substrates (24).
DUSP5–DUSP7 appear to be highly specific for dephosphoryl-
ation and inactivation of ERKs, whereas others are less selec-
tive. According to some reports, DUSP1 knock-out results in
disregulated p38MAPK and/or JNK but not ERK signaling (12,
* This minireview will be reprinted in the 2008 Minireview Compendium,
which will be available in January, 2009.
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Table 1 and additional references.
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25–28), whereas others describe increases in ERK activity in the
absence of DUSP1 (29–31). An unexplored possibility is that
substrate specificity might be modulated in a cell type-specific
manner by means of post-translational modification such as
phosphorylation or through interactions of MAPKs and their
phosphatase with scaffold proteins.
Regulation of DUSP Gene Expression by GCs and
Inflammatory Stimuli
Pro-inflammatory and stress stimuli typically induce rapid
and transient expression of DUSP1 mRNA. JNK and/or p38
MAPK signaling pathways, NF-B, and activating transcription
factor 2 have been implicated in such responses (32–38). Being
regulated by the same pathways that it suppresses, DUSP1 forms
part of a classical negative feedback loop to limit cellular responses
to noxious and pro-inflammatory stimuli. Hence, dusp1/mice
showed exaggerated (sometimes lethal) inflammatory responses
in experimentalmodels ofGram-negative orGram-positive sepsis
and allergic or autoimmune inflammation (25–28, 39, 40).
As summarized in supplemental Table 1, microarray and
other studies have shown GCs to up-regulate expression of
DUSP1 in several primary and transformed cells, including cells
of the myeloid lineage, vascular endothelial cells, eosinophils,
and ASMCs. Rather less consistently, other DUSPs have also
been identified as GC targets. The induction of DUSP1 is
dependent on GR and typically occurs rapidly (within one hour
or less). In contrast to inflammatory stimuli, GCs often induce
DUSP1 expression in a manner that is quantitatively moderate
but very sustained. GC-response elements of the DUSP1 gene
have not been identified, and conflicting conclusions have been
drawn concerning the requirement for GR dimerization (Fig. 1)
(12, 29). Strikingly, GCs can cooperate with inflammatory ago-
nists such as LPS and IL-1 to enhance and extend the expres-
sion of DUSP1 (34, 41–43). Other DUSPs have not yet been
described as responding in the same way. The cooperative con-
trol of DUSP1 expression by GCs and inflammatory agonists is
likely to be physiologically significant because of effects on the
duration of MAPK signaling. At the same time, such cooperat-
ivity is difficult to understand in the context of the classical
model of GC action, in which GR antagonizes the function of
pro-inflammatory transcription factors such as NF-B.
DUSP1 protein is rapidly turned over by the proteasome and
strikingly up-regulated in response to proteasome inhibitors
(44, 45). GCs may regulate DUSP1 protein levels in part by
modulating proteasome-mediated degradation (29). Because
this post-translational control is apparent only after prolonged
exposure to GCs, it is likely to be a secondary effect.
Role of DUSP1 in Anti-inflammatory Action of GCs
Cells of the myeloid lineage are central to the regulation of
innate immune and inflammatory responses and are important
targets for the anti-inflammatory effects of GCs. For example,
targeted knock-out of GR expression in the myeloid lineage
rendered mice highly sensitive to LPS-induced endotoxic
shock, which was dependent on p38 MAPK activity (41). The
syntheticGCdexamethasone induced the expression ofDUSP1
and inhibited p38 MAPK function in wild-type macrophages
but not in those lacking GR. Hence, endogenous GCs may pre-
vent lethal macrophage-mediated inflammatory responses in
part by inducing DUSP1 and inhibiting p38 MAPK. In rat
microglia (resident myeloid cells of the nervous system), dexa-
methasone inhibited the activation of JNK and p38 MAPK, as
well as the expression of monocyte chemotactic protein 1.
Again, indirect evidence suggested that these anti-inflamma-
tory effects of dexamethasone were mediated by DUSP1 (46).
Consistent with these findings, dexamethasone inhibited the
late phase of LPS-induced activation of JNK and p38 MAPK in
dusp1/ but not dusp1/ macrophages (12). The anti-in-
flammatory effects of dexamethasone in these knock-out mac-
rophages were partially impaired. Some inflammatory media-
tors such as inducible nitric-oxide synthase were equally
sensitive to dexamethasone-mediated inhibition in dusp1/ and
dusp1/ cells, whereas others such as IL-1 were down-regu-
latedbydexamethasone inanentirelyDUSP1-dependentmanner.
Several inflammatory mediators showed an impairment but not
loss of inhibitionbydexamethasone in the absenceofDUSP1, sug-
gesting that both DUSP1-mediated and DUSP1-independent
mechanisms operate together to regulate their expression.
GCs exert important anti-inflammatory effects on endothe-
lial cells, reducing the expression of adhesionmolecules and the
ability of leukocytes to infiltrate to sites of inflammation. In
human vascular endothelial cells, low doses of dexamethasone
inhibited tumor necrosis factor-induced p38 MAPK signaling
in a manner that was dependent on de novo gene expression,
blocked by sodium orthovanadate (an inhibitor of DUSP1 and
other phosphatases), and prevented by a DUSP1 antisense oli-
gonucleotide. The same antisense oligonucleotide impaired the
ability of dexamethasone to down-regulate the adhesion mole-
cule E-selectin. Most compellingly, in endothelial cells differ-
entiated from dusp1/ embryonic stem cells, the inhibitory
effect of dexamethasone on tumor necrosis factor-induced
E-selectin expression was reversed (47).
FIGURE1.BlackboxofDUSP-mediated responses toGCs. It is not known (i)
whether GC-mediated induction of DUSP1 is dependent on dimerization of
GR, (ii) towhat extent otherDUSPproteins are up-regulatedbyGCs, (iii) under
what circumstancesDUSP1 inhibits ERK signaling, (iv) at what level(s) DUSP1-
mediated inhibition of MAPKs influences gene expression, and (v) whether
DUSP1 contributes to side effects as well as anti-inflammatory effects of GCs.
TF, transcription factor.
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The anti-inflammatory effects of GCs on ASMCs, mast cells,
epithelial cells, and other targets in the lung are important in
the treatment of asthma.GC-mediated reduction of chemokine
expression by ASMCs may help to prevent the infiltration of
eosinophils and other cells that contribute to airway inflamma-
tion and remodeling.DUSP1was induced by dexamethasone in
ASMCs, and its incomplete knockdown by RNA interference
partially rescued the chemokine CXCL1 (CXC motif ligand 1)
from dexamethasone-mediated inhibition (42). Dexametha-
sone inhibited the migratory response of mast cells to stem cell
factor. Inhibition was accompanied by up-regulation of DUSP1
and inhibition of p38MAPK, but a causal relationship between
these effects has not yet been established (48).
These in vitro experiments suggest that expression ofDUSP1
may contribute to anti-inflammatory actions of GCs. Evidence
for such a role in vivo is equivocal so far, partly because the
exaggerated inflammatory responses of dusp1/ mice make
direct comparisons of GC efficacy difficult. In a simple experi-
mental model of acute, localized, macrophage-dependent
inflammatory responses, therapeutic effects of dexamethasone
were abrogated in dusp1/mice (12). The protective effects of
GCs were reportedly also impaired in dusp1/mice subjected
to endotoxic shock (cited as unpublished observations in Ref.
49). Another study did not make this comparison because of
differences in LPS sensitivity betweenwild-type and dusp1-null
mice (40). In experimental models of allergic airway inflamma-
tion, dusp1/ and dusp1/micewere equally sensitive to the
therapeutic effects of GCs (40). The anti-inflammatory effects
of GCs on mast cells may involve the induction of other phos-
phatases (40) and other negative regulators of pro-inflamma-
tory signaling pathways (9).
Themechanism(s) by which GC-induced DUSP1 expression
impairs inflammatory gene expression have not been defined in
detail. In theory, the blockade of JNK and p38MAPK signaling
could cause inhibition of AP-1 and NF-B. It has not been
shown whether GCs exert different effects on AP-1 and NF-B
reporter constructs inDUSP1/ andDUSP1/ cells. InHeLa
cells, the p38 MAPK pathway was required for stabilization of
cyclooxygenase-2 mRNA in response to IL-1 (50). Dexam-
ethasone induced expression of DUSP1 (but not other DUSPs)
and destabilized reporter mRNAs containing the cyclooxygen-
ase-2 3-untranslated region via phosphatase-dependent inhi-
bition of p38MAPK (34, 51). The implication is that dexameth-
asone induces DUSP1, down-regulates p38 MAPK, and
destabilizes mRNAs that contain p38 MAPK-sensitive adeny-
late/uridylate-rich elements. A recent publication has provided
evidence that GCs inhibit expression of IL-6 by such a mecha-
nism in ASMCs (52). Other transcriptional or post-transcrip-
tional mechanisms cannot be ruled out.
A small proportion of patients with chronic inflammatory
diseases do not show a robust anti-inflammatory response to
GCs and are often difficult to treat effectively (2, 53). If DUSPs
contribute to the anti-inflammatory action of GCs, it is possible
that defects in the expression or activity of DUSPs could con-
tribute to GC insensitivity. Consistent with this hypothesis,
persistent activation of p38MAPK and JNK has been described
in clinical samples from GC-resistant patients compared with
GC-sensitive controls (54–56). More recently, GC insensitivity
of alveolar macrophages was correlated with decreased expres-
sion of DUSP1 and increased activity of p38 MAPK in severe
asthma (57). It should be noted that GR activity may be
impaired by p38 MAPK (58–60); therefore, the chain of cause
and effect is difficult to establish (61). Do excessive inflamma-
tion and activation of p38 MAPK lead to impairment of GR
function and defective induction of DUSP1?Or does a defect in
the expression of DUSP1 permit unchecked p38MAPK activa-
tion and exaggerated inflammatory gene expression?
Role of DUSPs in Side Effects of GCs
Osteoporosis and consequent bone fractures are among the
most frequent side effects of prolonged exposure to oral GCs (3,
62). The major underlying cause is thought to be a decrease in
the survival and proliferation of osteoblasts. In primary osteo-
blasts and osteoblast cell lines, GCs induced DUSP1 expression
and inhibited ERK, which is essential for survival and prolifer-
ation (63–65). Immunodepletion and RNA interference exper-
iments suggested that DUSP1 is responsible for GC-mediated
inhibition of ERK (30). Sodium orthovanadate, an inhibitor of
DUSP1 and other phosphatases, prevented apoptosis of osteo-
blasts both in vitro and in vivo and protected rats from experi-
mental GC-induced osteoporosis (66, 67). Therefore, induction
of DUSP1 expression may contribute to one of the major side
effects of GCs, although this remains untested so far in
dusp1/mice.
Endogenous GCs oppose the actions of insulin on adipocytes
and other cells and are thought to contribute to insulin resist-
ance and diet-induced obesity (68, 69). Clinically, both endog-
enous GC excess and prolonged exposure to exogenous GCs
cause glucose intolerance and central obesity (3, 68, 69). The
up-regulation of gluconeogenic enzymes has been considered a
major cause of GC-induced diabetes (3), but this does not pre-
clude other mechanisms. In 3T3-L1 adipocytes, dexametha-
sone induced the expression of DUSP1 and DUSP2, inhibited
insulin-induced p38 MAPK activation, and impaired glucose
uptake. Overexpression of DUSP1 mimicked the inhibitory
effect of dexamethasone on glucose uptake (70). Interestingly,
both dusp1 knock-out and adipocyte-specific blockade of GC
signaling protected mice from diet-induced obesity (31, 71). In
the case of the dusp1 knock-out, elevated basal activity of
MAPKswas found in adipose tissue (31). Together, these obser-
vation suggest that there could be a link between the induction
of DUSPs in adipose tissue, the altered regulation of MAPK
signaling, and the metabolic syndrome caused by GC excess. It
would be interesting to test the metabolic responses of
dusp1/ and dusp1/mice to continued GC administration
or adrenalectomy.
Another common side effect of GCs is cataracts. Two inde-
pendent microarray studies of lens epithelial responses to GCs
have demonstrated up-regulation of DUSP1 (72, 73). It has
been speculated that DUSP1 (or other GC-induced signaling
molecules)might perturbMAPK function and cause changes in
epithelial cell proliferation or differentiation. As is the case for
most putative roles of DUSPs in GC side effects, strong exper-
imental evidence is lacking so far.
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DUSPs in Tumor Cell Responses to GCs
Disregulation of DUSPs has been described in several
tumors, but there is little consistency as to whether they are
silenced or overexpressed, reflecting the diverse roles of
MAPKs in the regulation of proliferation, differentiation, and
apoptosis (74). Similarly, the up-regulation of DUSPs by GCs
could have either pro- or anti-apoptotic consequences.
GCs are commonly used in the treatment of childhood acute
lymphoblastic leukemias (ALLs) and prostate cancers because
of their anti-proliferative or pro-apoptotic effects. GCs have
been found tomodulate expression of DUSPs in primary leuke-
mias or ALL cell lines, but with no consistent pattern (supple-
mental Table 1). RNA interference and overexpression experi-
ments in one ALL line did not support a role for DUSP1 in the
anti-proliferative response to GC (75). In prostate cancers
resistant to hormone treatment, expression of GR (76) and
DUSP1 (77) was low. Lentiviral expression of GR in a GC-re-
sistant prostate cancer cell line restored the capacity of a GC to
inhibit MAPK signaling and block proliferation (76), although
it is not known whether expression of DUSP1 was restored. To
summarize, there is not yet strong evidence that DUSPs medi-
ate therapeutic responses to GCs in these cancers.
On the other hand, DUSP1 is postulated to be an important
mediator of resistance of breast cancers to a variety of chemo-
therapeutic agents (78). Consistent with such a role, GC-in-
duced up-regulation of DUSP1 was associated with impaired
apoptotic responses of breast cancer cells to paclitaxel in vitro
and in vivo (79–81), and blockade of DUSP1 expression by
RNA interference prevented the anti-apoptotic effect of GC in
a breast cancer cell line (79).
Conclusions
There is growing but not yet conclusive evidence that
DUSPs, in particularDUSP1, contribute to biological responses
to GCs in several tissues. DUSP1 appears to function as an
important negative feedback regulator of MAPK signaling, and
GCs can be considered to modulate the sensitivity and/or
potency of this feedback loop.What this implies in terms of the
control ofDUSP1 gene expression by GCs and other agonists is
not yet clear. GC-induced expression of other DUSP family
members suggests that a degree of redundancy may exist in at
least some cells. Still less is known about the regulation of these
other phosphatases. Where the time course of induction is
slow, it may involve a secondary response to GC-mediated up-
regulation of other transcription factors.
It should be pointed out that changes inDUSP expression are
only one aspect of the highly complex cellular response to GCs.
This response also involves the induction of severalmodulators
of intracellular signaling in addition to the DUSPs (9, 10), inhi-
bition of transcriptional responses bymeans of transrepression
(82), and non-genomic actions of GCs that have not been
touched on here (5). It remains to be seen just how important a
contribution is made by the up-regulation of DUSPs, in what
cell types, and under what conditions.
A recent initiative in GC research has been to attempt to
uncouple the therapeutic and harmful consequences of GR
engagement, for example, by designing novel GR ligands that
selectively mediate transrepression rather than transactivation
(6, 7). Clinically valuable uncoupling may prove difficult to
achieve if transactivation is required for GC-induced expres-
sion of anti-inflammatorymediators such as DUSP1 and others
(9, 10) or if members of the DUSP family can contribute to both
harmful and beneficial effects of GCs.
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Glucocorticoid Regulation of Mouse and Human Dual
Specificity Phosphatase 1 (DUSP1) Genes
UNUSUAL CIS-ACTING ELEMENTS ANDUNEXPECTED EVOLUTIONARYDIVERGENCE*□S
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From the Kennedy Institute of Rheumatology Division, Imperial College London, 65 Aspenlea Road, Hammersmith,
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Anti-inflammatory effects of glucocorticoids (GCs) are partly
mediated by up-regulation of DUSP1 (dual specificity phospha-
tase 1), which dephosphorylates and inactivates mitogen-acti-
vated protein kinases. We identified putative GC-responsive
regions containing GC receptor (GR) binding site consensus
sequences that are well conserved between human and mouse
DUSP1 loci in position, orientation, and sequence (at least 11 of
15 positions identical) and lie within regions of extended
sequence conservation (minimum65% identity over at least 100
bp). These were located 29, 28, 24, 4.6, and 1.3 kb upstream
of the DUSP1 transcription start site. The homology-based
approach successfully identified four cis-acting regions that
mediated transcriptional responses to dexamethasone. How-
ever, there was surprising interspecies divergence in site usage.
This could not be explained by variations of theGRbinding sites
themselves. Instead, variations in flanking sequences appear to
have driven the evolutionary divergence in mechanisms of reg-
ulation of mouse and human DUSP1 genes. There was a good
correlation between the ability of cis-acting elements to respond
to GC in transiently transfected reporter constructs and their
ability to recruit GR in the context of intact chromatin.We pro-
pose that divergence of gene regulation has involved the loss or
gain of binding sites for accessory transcription factors that
assist in GR recruitment. Finally, a novel GC-responsive region
of the humanDUSP1 gene contains a highly unusual element, in
which three closely spaced GR half-sites are required for potent
transcriptional activation by GC.
DUSP1 (dual specificity phosphatase 1), orMKP-1 (mitogen-
activated protein kinase phosphatase 1), belongs to a family of
around 10 enzymes that inactivate MAPKs3 by catalyzing the
removal of phosphate groups from threonine and tyrosine res-
idues in the activation loops of those kinases (1). The preferred
substrates of DUSP1 are p38 and -MAPKs and JNKs, which
play critical roles in the expression of inflammatory mediators
at transcriptional and post-transcriptional levels (2, 3). In most
cells, the basal expression of DUSP1 is low, but it rapidly
increases in response to a wide variety of proinflammatory
stimuli, including the cytokines interleukin 1 and tumor necro-
sis factor, ligands of the Toll-like receptors, environmental
stresses like heat shock, oxidative or genotoxic stresses, andUV
light (4–6). The induction of DUSP1 by such agonists is depen-
dent on p38 MAPK and/or JNK, therefore creating a negative
feedback loop that shapes the signaling response to cell activa-
tion and prevents the unconstrained expression of inflamma-
torymediators (7–10). At first considered to have no phenotype
(11), DUSP1/ mice have subsequently been shown to over-
respond to inflammatory insults, such as administration of bac-
terial lipopolysaccharide (12–15), infectionwithGram-positive
bacteria (16), ischemia-reperfusion injury (17), and experimen-
tal induction of arthritis or anaphylaxis (14, 18). DUSP1 there-
fore emerges as an important regulator of immune homeosta-
sis, and its level of expression may have a critical impact on the
outcome of an inflammatory insult (4–6).
In several cell types, the expression of DUSP1 is also induced
by glucocorticoids (GCs), providing a mechanism by which
these powerful anti-inflammatory drugs can inhibit JNK and
p38 MAPK signaling (4, 19–21). GC-induced DUSP1 expres-
sion and consequent inhibition of MAPK signaling have been
implicated in the inhibition of proinflammatory gene expres-
sion by GCs in macrophages (22, 23), microglia (24), and vas-
cular endothelial cells (25). The induction of DUSP1 also con-
tributes to the cardioprotective effect of GCs (26) and the
inhibition by GCs of mucin and -defensin expression (27, 28).
In airway smooth muscle cells, GCs inhibited the expression of
CD38, interleukin-6, and the chemokine CXCL1 (CXC motif
ligand 1) at least partly via the induction of DUSP1 (29–31),
suggesting that DUSP1may contribute to therapeutic effects of
GCs in asthma. Consistent with this hypothesis, in severe or
GC-resistant asthma, GCs were defective in the induction of
DUSP1 and failed to inactivate JNK or p38MAPK (32–34). The
mechanism of control ofDUSP1 gene expression is fundamen-
tal to understanding the anti-inflammatory actions of GCs.
Furthermore, it is possible that defects in this regulation may
contribute to GC insensitivity, a major problem in the treat-
ment of chronic inflammatory diseases (35).
GCs activate transcription via the GC receptor (GR), a mem-
ber of the nuclear hormone receptor superfamily of transcrip-
tion factors. The canonical pathway of transcriptional activa-
* This work was supported by the Medical Research Council (United King-
dom) and the Arthritis Research Campaign (United Kingdom).
□S The on-line version of this article (available at http://www.jbc.org) contains
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3 The abbreviations used are: MAPK, mitogen-activated protein kinase; JNK,
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CCAAT/enhancer-binding protein; TSS, transcription start site; SINE, short
interspersed element; Dex, dexamethasone.
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tion involves dimerization of GR and binding to inverted
repeats of the half-site sequence AGAACAwith separation of 3
bp (36). In reality, the DNA binding specificity of GR is some-
what relaxed. Of the 15-bp idealized consensus binding
sequence AGAACANNNTGTTCT, only five (underlined) are
consistently present at authentic GR binding sites in chromatin
(37). Variations in the sequence of individual binding sites are
thought to subtly alter the conformation ofGR and influence its
interactions with transcriptional cofactors (38). GR dimeriza-
tion is mediated by the D-loop, a short, charged motif at the
knuckle of the second zinc finger. Mutation of a single residue
of theD-loop (Ala4583Thr substitution in humanGR) created
a mutant protein, known as GRdim, that did not efficiently
dimerize or activate transcription via consensus GC response
elements (39–41). However, someGC-induced genes were not
sensitive to this dimerization loop mutation (38, 42, 43), sug-
gesting that either dimerization is dispensable or other protein-
protein or protein-DNA interactions might stabilize the bind-
ing of GR dimers to certain sites.
In the context of chromatin, GR recognizes only a minute
fraction of potential binding sites that contain the relaxed con-
sensus sequence GNACANNNNG. It is thought that GR is
guided to appropriate sites in chromatin through interactions
with other DNA-bound transcription factors in a manner that
is dependent on localized chromatin remodeling (20, 37,
44–49). The cis-acting elements that mediate transcriptional
responses toGCs tend to be quite extended, containing binding
sites not only for GR but also for additional transcription fac-
tors with which GR cooperates. Functional GC-responsive
regions (GRRs) are very often conserved between orthologous
GC-regulated genes of distantly related species, such as mice
and humans, and the GR binding sites that they contain tend to
be highly similar in sequence (47). Strong evolutionary conser-
vation of the GR binding site and surrounding sequence is pre-
sumed to reflect common mechanisms for recruitment of GR
to DNA and subsequent activation of transcription. A conse-
quence is that novel, functional GRRs can be discovered by a
phylogenetic footprinting approach; in other words, the com-
parison of putative regulatory regions of orthologous GC-in-
duced genes and the identification of strongly conserved GR
binding site consensus sequences (GBS) that lie within regions
of high sequence similarity. We used this approach to try to
identify GC-responsive cis-acting elements of the human
DUSP1 gene.
EXPERIMENTAL PROCEDURES
Plasmids—Expression vectors for wild-type and dimeriza-
tion-defective (A458T mutant) GR were a gift of Andrew Cato
(Karlsruhe Institute of Technology). A U2OS cell line stably
expressing dimerization-defective GRwas generously provided
by Inez Rogatsky (Cornell University, Ithaca, NY). Human,
mouse, rat, and dogDUSP1promoter fragmentswere amplified
from genomic DNA and subcloned to pGL3b, pGL3p, or
pGL4.26 (Promega). Mutations of transcription factor binding
sites were introduced using QuikChange site-directed
mutagenesis kits (Agilent Technologies). Matrix Inspector
(available at theGenomatixWeb site) was used during design of
mutations to avoid inadvertent introduction of new transcrip-
tion factor binding sites. All mutations were checked by
resequencing.
Cell Culture, Transfection, and Luciferase Assays—HeLa,
mouse fibroblast, and COS-7 cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% (v/v) fetal
bovine serum in a humidified atmosphere of 5% CO2 at 37 °C.
Cells were transiently transfected using Superfect (Qiagen)
with 200 ng of firefly luciferase reporters as indicated plus 100
ng of Renilla luciferase expression vector and pBluescript (Agi-
lent Technologies) as carrier tomake the total quantity of DNA
up to 1g. Some experiments included 50 ng of vector express-
ing wild type GR or GRdim. Following transfection cells were
treated with vehicle (0.1% (v/v) EtOH) or Dex (100 nM unless
otherwise stated) for 20 h. Cells were harvested, and luciferase
activities were measured using the dual luciferase reporter
assay kit (Promega) and Microbeta luminometer (PerkinElmer
Life Sciences). Firefly luciferase activities were normalized
against Renilla luciferase.
Western Blotting—COS-7 cells were harvested by lysis in
SDS-PAGE loading buffer. Lysates were run on 8% SDS-poly-
acrylamide gels and transferred to polyvinylidene difluoride.
Western blottingwas performed by standardmethods. A rabbit
polyclonal antibody against GR was from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA). A mouse monoclonal antibody
against tubulin was from Sigma.
Chromatin Immunoprecipitation—HeLa cells or mouse
fibroblasts (3  106 cells/10-cm dish) were treated with either
vehicle (0.1% (v/v) EtOH) or 100 nMDex for 30min. A chroma-
tin immunoprecipitation assay was carried out using GR anti-
body (catalog number sc 8992X, Santa Cruz Biotechnology,
Inc.) or rabbit IgG (Santa Cruz Biotechnology, Inc.) as
described (50), with the exception that DNAwas purified using
the QIAquick PCR purification kit (Qiagen) after reversion of
cross-links. Quantitative PCR was performed using SYBR
Premix Ex Taq (Lonza) and Rotor-Gene 6000 thermal cycler
(Qiagen). Human primer pairs used were as follows: FKBP, 5-
taaccacatcaagcgagctg-3 and 5-gcatggtttaggggttcttg-3; GRR-
29, 5-ctcatcagggtgagctgatgac-3 and 5-gacaggccagggctcgcttc-
tca-3; GRR-28, 5-cagaagagtgcgcagagaag-3 and 5-ctggtccag-
ggagtgaaag-3; GRR-24, 5-aggctcctggccccacattgaa-3 and 5-
attgcgacccctgttcctccatgc-3; GRR-4.6, 5-ctccaccttccaaagataa-
acactg-3 and 5-caaacagatctccatgctcagacctg-3; GRR-1.3, 5-
gcgcaggcgaaaacacacaa-3 and 5-cgacgcgctaggtacacaaaca-3.
Mouse primer pairs were as follows: FKBP, 5-gttcagctgtgcaat-
ccaga-3 and 5-agggtgttctgtgctcttcaa-3; GRR-29, 5-cttagggt-
gaactgacatc-3 and 5-ctttgagctcacttcctgttttgtg-3; GRR-28, 5-
gcttcccagatgtgccaag-3 and 5-ccaaaccttgagccagagcagtg-3;
GRR-24, 5-gtgcctggctctgcatcgaaaatggaa-3 and 5-tggctcagac-
actgctgtcccctct-3; GRR-4.6, 5-ggaagaggatgcaaggagcact-3
and 5-ctgagcagctgtgtcctgtcatc-3; GRR-1.3, 5-caagagctaagag-
aggccaaa-3 and 5-cacggagttggatacacaaaca-3.
Preparation of Nuclear Extracts and Oligonucleotide Pull-
down (ABCD) Assay—HeLa cells were incubated with Dex (100
nM) or vehicle (0.1% (v/v) EtOH) for 1 h.Nuclear protein extract
was prepared as described (67). 50 g of HeLa nuclear extract
was incubatedwith 90 pmol of biotinylated oligonucleotide, 1
binding buffer (5 mMHepes, pH 7.8, 75 mMNaCl, 1 mM dithio-
threitol, 5 mM EDTA, 10 mM MgCl2, 10% glycerol), 1 g of
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poly(dI-dC), and BSA (0.1mg/ml) and incubated for 1 h at 4 °C.
For competition purposes, the nuclear extracts were incubated
with the biotinylated oligonucleotide in the presence of 20-fold
molar excesses of non-biotinylated competitor oligonucleo-
tides. Streptavidin-agarose beads (Perbio Science) were prein-
cubated with bovine serum albumin (1 mg/ml) and washed
twice in 1 binding buffer. The addition of beads to the sam-
ples was followed by 1 h of incubation at 4 °C. Pellets were then
washed six times in binding buffer, resuspended in 2 SDS
sample buffer, and boiled. The sampleswere subjected toWest-
ern blot. Oligonucleotides used were as follows (top strands
only shown): GRR-1.3, 5-tcccccaggaggggaggaaaccgcagaatgttc-
ctgactc-3; GBScon, 5-caatctctgcggtacaggatgttctagctacttta-3.
Statistics—Statistical analysis was performed using one-way
analysis of variance with Bonferroni post-test or, where appro-
priate, one-sample t test.
RESULTS
Similarities between Human and Mouse DUSP1 Genes—30
kb of the 5 region of the humanDUSP1 locus was aligned with
the orthologous mouse sequence (Fig. 1). The two sequences
were also scanned for matches to the GBS, GNACANNNNG
(37). Regions of strong sequence similarity between mouse and
human DUSP1 loci were identified, extending to at least 30 kb
upstream of the transcription start site. The human sequence
contained more than 50 and the mouse sequence more than 80
GBS. However, only nine GBS were conserved in position and
orientation between the two spe-
cies. GBS at approximately 1.3,
24, and 28 kb as well as three
closely spaced GBS at 4.6 kb with
respect to the transcription start site
were located within domains of
extended sequence similarity. Sev-
eral of these GBS were also con-
served in rat and dog DUSP1 loci
(supplemental Fig. 1) aswell as in theDUSP1 loci of othermam-
malian species. GBS at 2.3 and 16 kb were conserved
between mice and humans but were not located within
extended domains of sequence conservation and were not con-
sistently present in other mammalianDUSP1 loci (supplemen-
tal Fig. 1). This analysis identified regions around 1.3, 4.6,
24, and 28 kb as possible mediators of transcriptional
responses to Dex. GBS-29 of the human DUSP1 locus corre-
sponds to the site previously identified at27 kb of the mouse
DUSP1 locus (47). The complex sequence relationships within
this region are discussed in more detail below.
Identification of an Unusual GC-responsive Region 4.6 kb
Upstream of the Human DUSP1 Gene—To identify regulatory
elements of the human DUSP1 gene, we began by studying the
region immediately upstream of the transcription start site.
Transient transfection experiments were performed using
HeLa cells, in which DUSP1 was first identified as a GC-in-
duced gene (7). A fragment extending from 4834 to 211
with respect to the DUSP1 transcription start site mediated a
25-fold response toDex (Fig. 2). Deletion from4834 to2726
strongly impaired but did not ablate the response (compare first
and second bars). A second significant decrease in the transcrip-
tional response to Dex was observed on deletion between
1495 and 1095. These results suggested that at least two
discrete regions of the human DUSP1 5 region contribute to
transcriptional control by Dex.
The distal region was inspected first. Three closely spaced
GBSwere located4.6 kb upstreamof the humanDUSP1 tran-
scription start site, within a region that shows considerable
sequence similarity between human and mouse loci (Fig. 1). A
multiple species alignment across this region revealed that the
first and third GBS (GBS-4.6.1 and -4.6.3) were not strongly
conserved between distantly related mammals, whereas the
central motif (GBS-4.6.2) was highly conserved (Fig. 3A and
supplemental Fig. 1). GBS-4.6.2 is a complex element. It con-
tains not only a match to the consensus GNACANNNNG
sequence (indicated by asterisks in Fig. 3B) but also an overlap-
ping perfect half-site sequence AGAACA on the antisense
strand (indicated by the arrow in Fig. 3B). This unusual struc-
ture is well conserved, with no more than 1 nucleotide differ-
ence, in the mouse, dog, rat, horse, cow, marmoset, rhesus
monkey, chimpanzee, and orangutan DUSP1 loci. At the
DUSP1 locus of the armadillo Dasypus novemcintus (Dn.), a
2-nucleotide substitution destroys the overlapping half-site but
creates another on the sense strand (Fig. 3B).
A GRR-4.6 fragment, encompassing the region of sequence
conservation between human and mouse and containing GBS-
4.6.1, -4.6.2, and -4.6.3, mediated a 15-fold Dex response when
cloned upstream of the SV40 early promoter in the luciferase
FIGURE 1. Conservation of potential GR binding sites at human and mouse DUSP1 loci. 30 kb of human
genomic sequence 5 of theDUSP1 TSSwas alignedwith the orthologousmouse genomic sequence using the
default settings of theGenomeVista browser (65). Both sequenceswere scanned formatches to the redundant
GR binding site consensus sequence GNACANNNNG (GBS) (37). Matches that are conserved between the two
species are indicated below the alignments, and approximate coordinates are given with reference to the TSS
of the human sequence. See supplemental Fig. 1 for accurate coordinates of GBS elements.
FIGURE 2.Deletion analysis of the humanDUSP1 promoter. Fragments of
thehumanDUSP15 regionwere subcloned into the firefly luciferase reporter
construct pGL3b. Thepositions of GBS elements are indicatedby vertical bars.
GBS-4.6 comprises three closely spaced GBS elements known as GBS-4.6.1,
-4.6.2 and -4.6.3. 200 ng of each reporter construct and 100 ng of a Renilla
luciferase expression vector were transiently transfected into HeLa cells,
which were then treated for 20 h with vehicle (0.1% ethanol) or Dex (100 nM)
beforeharvesting andmeasuring luciferase activities. For each construct, fire-
fly luciferase activity was normalized to Renilla luciferase activity, and -fold
activation in response to Dex was calculated. In this and subsequent figures,
mean -fold responses S.E. from three independent experiments are shown.
***, p 0.001; **, p 0.01; *, p 0.05; n.s., not significantly different. Unless
otherwise indicated, statistical comparisons are against the largest construct,
pGL3b4834.
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reporter construct pGL3p (compare first and second bars in Fig.
3C). The response was not impaired by mutation of GBS-4.6.1
or -4.6.3, suggesting that these less well conserved sites are not
functional. In contrast, mutation of any of the three ACA trip-
lets of GBS-4.6.2 strongly impaired theDex response. Although
GBS-4.6.2 is well conserved between mammalian species, rat
and mouse GRR-4.6 fragments were only weakly responsive to
Dex (Fig. 3D). The orthologous dog fragment mediated a very
strong response. The 3-nucleotide spacer between half-sites in
a conventional GBS is not thought to make specific contacts
with GR, yet sequence differences within the spacer can exert
allosteric effects on the conformation and activity of the bound
receptor (38). We speculated that the single nucleotide differ-
ence between human andmouseGBS-4.6.2might contribute to
the difference in activity of the fragments within which these
sequences are embedded. However, introduction of the human
GBS-4.6.2 sequence into themouseGRR-4.6 fragment (Fig. 3D,
MmHs) caused no gain of activity. Conversely, introduction
of the mouse GBS-4.6.2 sequence into the human GRR-4.6
fragment did not impair the response to Dex (Fig. 3D, Hs 
Mm).
The SV40 early promoter in pGL3p contains binding sites for
Sp1 and AP-1 transcription factors, which may functionally
interact with GR (20). In the absence of any subcloned frag-
ment, this construct displayed a weak response to Dex, which
has been corrected for in all relevant figures. To test regulatory
activities of GBS elements in isolation from other transcription
factor binding sites, we used an alternative reporter construct,
pGL4.26, which contains only a TATA box upstream of the
luciferase open reading frame and has very low basal transcrip-
tional activity or intrinsic Dex responsiveness. In this back-
ground, both human and mouse GBS-4.6.2 oligonucleotides
were responsive to Dex. If anything, the mouse element
responded more strongly than the human. Together, these
results clearly show that differential responses of mouse and
human GRR-4.6 fragments are due not to the minor sequence
differences of the GR binding sites themselves but to differ-
ences of the surrounding sequence. HumanGRR-4.6 provides a
DNA environment that supports and/or amplifies the tran-
scriptional response to Dex, whereas mouse GRR-4.6 does not.
FIGURE 3. Characterization of a GC-responsive region 4.6 kb upstreamof
the human DUSP1 start site. A, Multiz alignment of GRR-4.6 of 28 mamma-
lian species at the UCSC Genome Browser (University of California, Santa
Cruz) (66). Thepositions ofGBS-4.6.1, -4.6.2, and -4.6.3 are indicatedbelow the
alignment.B, sequencesofGBS-4.6.2 of human (Homo sapiens;Hs.), rat (Rattus
norvegicus; Rn.), mouse (Mus musculus;Mm.), dog (Canis familiaris; Cfa.), cow
(Bos taurus; Bta.), horse (Equus caballus; Eca.), and armadillo (Dasypus novem-
cintus; Dn.). The conserved GBS sequence GNACANNNNG is indicated by
asterisks, and an additional GR half-site is denoted by an arrow. Differences
from thehuman sequence are highlighted. Sequences ofmutated versions of
GBS-4.6.2 are also shown. C, a 467-bp human genomic fragment centered on
GBS-4.6.2 was cloned upstream of the SV40 early promoter in pGL3p. Muta-
tions at GBS-4.6.1, -4.6.2, or -4.6.3 (as indicated in B) were introduced by PCR.
Dex responses were assayed as in Fig. 2 and normalized against the response
of the empty vector pGL3p. With the exception of pGL3p-GRR-4.6-GBS-4.6.2-
m2, all constructswere significantly different from theparental vector pGL3p.
Statistical comparisons against pGL3p-GRR-4.6 are indicated. D, orthologous
GRR-4.6 fragments from dog, human, mouse, and rat (Cfa., Hs.,Mm., and Rn.)
were cloned into pGL3p, and responses to Dexwere calculated as in C. Statis-
tically significant differences frompGL3p are indicated beside each construct,
and additional comparisons are as shown. E, short oligonucleotides contain-
ing human or mouse GBS-4.6.2 were subcloned into the firefly luciferase
reporter pGL4.26 (for simplicity indicated as pGL4 in the figure). Responses to
Dexwere calculated as in C. Statistically significant differences frompGL4 are
indicated beside each construct, and other statistical comparisons are as
indicated.
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Characterization of a GC-responsive Region 1.3 kb Upstream
of the Human DUSP1 Gene—Deletion of residues 1495 to
1095 of the humanDUSP1 promoter impaired the transcrip-
tional response to Dex (Fig. 2). An equivalent fragment medi-
ated a 4-fold response to Dex when cloned upstream of the
heterologous SV40 early promoter. Deletions from 5- and
3-ends led to the identification of a minimal GC-responsive
130-bp fragment extending from1366 to1237 with respect
to the transcription start site (Fig. 4). The minimal GC-respon-
sive fragment is hereafter referred to as GRR-1.3. On the anti-
sense strand, near the 5-end of this fragment, is the GBS-1.3
element that was identified on the basis of human/mouse
DUSP1 sequence alignment (Fig. 1). GBS-1.3 is very strongly
conserved amongDUSP1 loci of mammals (Fig. 5,A and B, and
supplemental Fig. 1). On the basis of conservation at 15 of 15
positions, this element would be predicted to be functional in
the dog, rat, andmouseDUSP1 loci (47). In fact, human anddog
GRR-1.3 fragments were similarly responsive to Dex, whereas
the rat fragment was very weakly responsive, and the mouse
fragment was inert in this assay (Fig. 5C). To confirm that GBS-
1.3 is necessary for transcriptional activation of the human
reporter by Dex, we introduced two different mutations of this
site: a substitution of the three highly conserved ACA residues
by GGG (m1) or a substitution of the final conserved G residue
by C (m2). The first of these mutations completely abolished
and the second severely impaired the response to Dex (Fig. 5C).
The highly conserved element GBS-1.3 was therefore abso-
lutely necessary yet apparently not sufficient for Dex-mediated
activation of transcription in the context of the pGL3p reporter.
FIGURE4. Identificationof aGC-responsive region1.3 kbupstreamof the
human DUSP1 start site. A genomic fragment extending from 1426 to
1096with respect to thehumanDUSP1TSS andvariousdeletionderivatives
of this fragment were subcloned into pGL3p. Responses to Dex were calcu-
lated as in Fig. 3C. The region 1366 to 1237 was identified as a minimal
GC-responsive region and is hereafter known as GRR-1.3. Statistical compar-
isons are first against the parental vector pGL3p and second against the con-
struct containing the minimal GC responsive region1366 to1237, which
is hereafter referred to as pGL3p-GRR-1.3-Hs.
FIGURE 5. Characterization of GRR-1.3. A, Multiz alignment of GRR-1.3 of 28mammalian species at the UCSC Genome Browser (66). The positions of GBS-1.3
is indicated below the alignment. B, alignment of human (Hs.), dog (Cfa.), andmouse (Mm.) GRR-1.3 sequences. The positions of putative C/EBP andGRbinding
sites (GBS-1.3) are shown below the alignment. GBS-1.3 (in italic type) is a short oligonucleotide containing the GBS-1.3 element and a few conserved flanking
residues.Nucleotide changes introduced into thehumanGRR-1.3 fragment to create theGBSm1andGBSm2are shown.C, dog, rat,mouse, andhumanGRR-1.3
fragments were subcloned into pGL3p, and responses to Dexwre calculated as in Fig. 3C. Differences from the parental vector pGL3p are shown to the right of
each bar, and other statistical comparisons are as indicated. D, human and mouse GRR-1.3 fragments or the oligonucleotide GBS-1.3 were subcloned into
pGL4.26 (shown as pGL4), and responses toDexwere calculated as in Fig. 3C. Differences from the parental vector pGL4 are shown to the right of each bar, and
other statistical comparisons are as indicated.
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A 24-bp oligonucleotide that contains GBS-1.3 and the sur-
rounding conserved bases (labeled as GBS-1.3 in Fig. 5B) sup-
ported a weak but statistically significant response to Dexwhen
placed upstream of the TATA box in pGL4.26 (Fig. 5D). In this
low background reporter construct, a similar weak response to
Dex was detected using the mouse GRR-1.3 fragment. The dif-
ferential responsiveness of mouse and human GRR-1.3 frag-
ments was maintained; human GRR-1.3 gave an almost 3-fold
stronger response than either mouse GRR-1.3 or the conserved
GBS-1.3 element. Therefore GBS-1.3 is able to mediate a weak
response to Dex that can be detected if the signal/noise ratio is
sufficiently high. A potent transcriptional response requires
sequences that lie outside of GBS-1.3 itself and differ between
mouse and human DUSP1 loci.
Differential Usage of GRR-4.6 and GRR-1.3 in Mouse and
Human DUSP1 Promoters—The contributions of GRR-4.6 and
GRR-1.3 were next tested in the context of intact DUSP1 pro-
moters rather than heterologous promoter constructs (Fig. 6).
The 5-kb human DUSP1 promoter was activated almost
25-fold by Dex. An internal deletion of 28 base pairs (removing
GBS-4.6.2 but leaving GBS-4.6.1 and -4.6.3 intact) reduced the
Dex response to 10-fold, similar to the effect of removing
more than 3 kb between positions 4834 and 1495. There-
fore, GBS-4.6.2 makes an important contribution to the
response of the 5-kb promoter construct, and there are unlikely
to be other relevant sites between4834 and1495.Mutation
of 3 bp of GBS-1.3 (equivalent to m1 in Fig. 5B) impaired the
response of the 5-kb promoter evenmore strikingly, to less than
5-fold. The same mutation also strongly impaired the response
of the1495 promoter construct. In the intact human DUSP1
promoter, GBS-1.3 appears to play a critical role.
A 5-kb mouse DUSP1 promoter yielded much weaker Dex
responses than the equivalent human promoter (note that size
differences of the two constructs are due to internal deletions
and/or insertions at mouse and human DUSP1 loci). The weak
response of the mouse construct was not significantly affected
by deletion of 3 kb from the 5-end (positions4495 to1533),
internal deletion of GBS-4.6.2, or mutation of GBS-1.3. The
shorter 1463 promoter fragment was also not significantly
affected by mutation of GBS-1.3. Entirely consistent with the
results using heterologous promoters, GBS-4.6 and -1.3 appear
to play little role in the regulation ofmouseDUSP1 gene expres-
sion by Dex.
Characterization of a GC-responsive Region 27 kb Upstream
of theMouse DUSP1Gene—This raised the question of how the
mouse DUSP1 gene is able to respond to Dex. On the basis of
genome-wide sequence comparisons, a GC-responsive region
was previously identified27 kb 5 to the mouse DUSP1 start
site (47). InDex-treatedmousemesenchymalC3H10T1/2 cells,
this region was occupied by GR. The corresponding region of
the human DUSP1 locus is 29 kb 5 to the start site (supple-
mental Fig. 1). For consistency, the human, mouse, and other
orthologous elements are referred to as GRR-29. Mouse
GRR-29 contains a symmetrical sequence element with two
nearly perfect matches to the half-site sequence AGAACA.
GBS matches are present on both strands (Fig. 7A). The corre-
sponding rat sequence differs by 1 nucleotide and has only the
top strand GBS. The dog sequence differs by 3 nucleotides and
has only the bottom strand GBS. The human sequence differs
from themouse by 3 nucleotides and contains a new top strand
GBS that is shifted with respect to the background alignment.
Although it is true to say that putative GR binding sites within
this region are conserved between mammalian species, this
statement does not do justice to the complex sequence relation-
ships that exist.
A 500-bp fragment centered on GBS-29 was amplified from
mouse genomic DNA and placed upstream of the SV40 early
promoter. As has been reported in C3H10T1/2 cells (47), this
fragment mediated a strong transcriptional response to Dex in
HeLa cells (Fig. 7B). Consistentwith previous observations (47),
mutation of the ACA triplets of GBS-29 ablated the Dex
response of this fragment (Mm-GBSm in Fig. 7B). Correspond-
ing rat, dog, and human fragments were amplified from
genomic DNA and tested in parallel. The rat GRR-29 fragment
was responsive to Dex, but the human fragment was inert and
the dog fragment only weakly responsive. To assess the relative
importance of GR binding site sequence and surrounding con-
text, mutagenesis was used to introduce the mouse GBS-29
sequence into the context of human GRR-29. This sequence
swap only slightly increased the activity of the human fragment
(GRR-29-Hs.Mm. in Fig. 7B). The activities of short oligonu-
cleotides containing human and mouse GBS-29 were then
tested, using pGL4 to minimize possible contributions from
transcription factor binding sites in the vector backbone (Fig.
7C). The human GBS-29 oligonucleotide did not respond to
Dex, whereas the mouse oligonucleotide responded very
strongly. In this case, differential responses to Dex appear to
arise from divergence of both GBS sequence and surrounding
context. The GRR-29 region of the human DUSP1 locus con-
FIGURE 6. Differential usage of GRR-4.6 and -1.3 in mouse and human
DUSP1 promoters. Site-directed mutagenesis was performed to introduce
mutations into thehuman (Hs.) reporter constructs pGL3b4834 and1495.
The 	4.6 mutation is a 28-bp internal deletion that removes GBS-4.6.2 but
leaves GBS-4.6.1 and -4.6.3 intact. Them1.3mutation is a 3-bp substitution of
GGG for the ACA motif triplet of GBS-1.3 (identical to m1 in Fig. 5B). Corre-
sponding deletion and point mutation constructs were generated for the
mouse (Mm.) DUSP1 promoter. The differences in size of mouse and human
promoter fragments are due to internal insertions and deletions at the two
DUSP1 loci. Responses toDexweredeterminedas in Fig. 2.n.s., not significant.
Divergent Glucocorticoid Responses of DUSP1 Genes
JANUARY 22, 2010•VOLUME 285•NUMBER 4 JOURNAL OF BIOLOGICAL CHEMISTRY 2647
 at Im
perial College London, on February 16, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
http://www.jbc.org/content/suppl/2009/11/23/M109.037309.DC1.html
Supplemental Material can be found at:
tains a non-functional GBS, but it also creates a DNA environ-
ment in which a powerfully responsive element, such as the
nearly perfect palindromic mouse GBS-29, cannot function
effectively.
Differences in Regulatory Activity of Mouse and Human Ele-
ments Are Related to Sequence and Not Cellular Environment—
Human GRR-1.3 and -4.6 were strongly Dex-responsive when
tested in HeLa cells, whereas the corresponding mouse
sequences were not. In principle, this difference in responsive-
ness could be influenced by cellular environment. In other
words, transcription factors that cooperate with GR tomediate
transcriptional responses may have altered in DNA binding
specificity during the evolutionary divergence of mice and
humans,makingmouse cis-acting elements “unfit” for function
in the environment of a human cell. Human and mouse ele-
ments were therefore assayed in mouse fibroblasts (Fig. 8).
HumanGRR-4.6 and -1.3 were relatively strongly responsive to
Dex, whereas the corresponding mouse fragments were weak
or inactive, just as inHeLa cells. HumanGRR-29was unrespon-
sive, whereas the corresponding mouse fragment gave a weak
but statistically significant response. Overall, we found exactly
the same pattern of species specificity in the mouse fibroblasts
as in the HeLa cells, demonstrating that differential responses
of mouse and human regulatory elements are at the cis rather
than the trans level; in other words, they are explained by
sequence differences rather than the cellular environment
(human or mouse) in which they are tested.
Recruitment of GR to Functional Elements of Endogenous
DUSP1 Genes—Chromatin immunoprecipitation experiments
were carried out to assess the recruitment of GR to different
regions of human and mouse DUSP1 loci in HeLa and mouse
fibroblast cells. InHeLa cells, therewasDex-dependent recruit-
ment of GR to GRR-1.3 and GRR-4.6 but not to GRR-29 (Fig.
9A). Similar recruitment at GRR-1.3 and GRR-4.6 was demon-
strated using alternative primer pairs (data not shown). In
mouse fibroblasts, therewasDex-dependent recruitment ofGR
at GRR-29 but none at GRR-1.3 and relatively little at GRR-4.6
(Fig. 9B). In both cases, recruitment of GR to a known binding
site of the FKBP51 gene served as a positive control. The ability
or inability of isolated cis-acting elements to respond to Dex in
transiently transfected cells was therefore in agreement with
the ability or inability of the same regions to recruit GR in intact
chromatin.
Dependence of Dex Responses on GR Dimerization—There is
controversy over whether GR dimerization is necessary for
induction of DUSP1 by Dex. In COS-7 cells (which do not
express endogenous GR), a mouse DUSP1 promoter was acti-
vated by wild type GR but not by the dimerization-defective
mutant GRdim (51), yet Dex retained the ability to up-regulate
DUSP1 protein in mouse macrophages expressing only GRdim
(22). To try to resolve this controversy, we tested whether
mutation of the GR dimerization loop influenced the Dex
responses of human and mouse DUSP1 promoter and GRR
reporters inCOS-7 cells. First, the pGL3p-Hs.GRR-1.3 reporter
FIGURE 7. Characterization of a GC-responsive region 29 kb upstream of
the human DUSP1 start site. A, alignment of GBS-29 sequences of mouse,
rat, human, and dog. This element was first described in the mouse DUSP1
locus (47); therefore, themouse is regarded as the base sequence, and differ-
ences from it are highlighted. Matches to the consensus GNACANNNNG on
the top or bottom strand are indicated by asterisks. B, dog, rat, mouse, or
human GRR-29 fragments were cloned into pGL3p. pGL3p-GRR-29-Mm.-
GBSm was created by mutagenizing both of the ACA triplets within the
mouse GRR-29 fragment to GGG. pGL3p-GRR-29-Hs.Mm.was generated by
mutagenizing the sequence GAACATTCGGwithin human GRR-29 to the cor-
responding mouse sequence, GAATGTTCAG. This 3-nucleotide change cre-
ates a palindromic element with GNACANNNNG matches on both strands.
Dex responses were calculated as in Fig. 3C. Differences from the parental
vector pGL3p are shown to the right of each bar, and other statistical compar-
isons are as indicated. C, short oligonucleotides containing human and
mouseGBS-29were cloned intopGL4. Responses toDexwere calculated as in
Fig. 3C. Differences from the parental vector pGL4 are shown to the right of
each bar, and other statistical comparisons are as indicated.
FIGURE 8. Species-specific transcriptional responses to Dex in mouse
fibroblasts. Dex responses of human andmouse GRR-29, -4.6, and -1.3 frag-
ments were tested in mouse fibroblasts and calculated as in Fig. 3C. Differ-
ences from the parental vector pGL3p are indicated above each column, and
pairwise comparisons of orthologous mouse and human fragments are also
shown. n.s., not significant.
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construct was used to establish that transcriptional activation
in response to Dex was dependent on GR (Fig. 10A, compare
columns 2 and 5) and an intact GR binding site (compare col-
umn 5with columns 4 and 6). It was then shown that GRdim and
wild type GR were expressed at similar levels in transfected
COS-7 cells (Fig 10B) but differed markedly in their ability to
activate a reporter construct (52) that contains two consensus
GR binding sites (Fig 10C, top).
Next it was shown that activation of a short mouse DUSP1
promoter construct was impaired by the dim mutation (Fig
10C), consistent with a previous publication that used a very
similar construct (51). The 5-kb mouse promoter fragment
behaved identically (data not shown). Mutation of GBS-1.3
made the reporter even more sensitive to perturbation of GR
dimerization. Together with the results presented in Fig. 6,
these data suggest that responses of the mouse proximal pro-
moter are largely mediated by a site or sites that are (i) distinct
from GBS-1.3 and (ii) strongly dependent on GR dimerization.
However, GRR-29, the most powerful GC-responsive region of
the mouse DUSP1 promoter that we or others have identified,
was insensitive to the dim mutation. Similar differential re-
sponses to wild type and mutant GR were observed across a
range of inputs of expression vector from 10 to 200 ng (data not
shown). These observations may explain the apparent discrep-
ancy between the previous reporter assays (51) and the
responses of the endogenousDUSP1 gene in macrophages that
express GRdim (22). The reporter construct simply lacked an
important regulatory element located far upstream of the tran-
scription start site and was therefore unrepresentative of the
endogenous gene.
The construct pGL3b-Hs.4834 contains the major GC-re-
sponsive regions that have been identified at the humanDUSP1
locus, namely GRR-1.3 and -4.6. In COS-7 cells, wild type GR
and GRdim activated this construct equally potently (Fig 10C).
The dimmutation did not affect the transcriptional response of
GRR-1.3 in isolation and only weakly impaired the response of
GRR-4.6. It is likely that transcriptional activation of the endog-
enous humanDUSP1 gene is unaffected by mutation of the GR
FIGURE 9. Recruitment of GR to functional GC-responsive regions. HeLa
cells (A) ormouse fibroblasts (B) were treatedwith vehicle (0.1% EtOH) or Dex
(100 nM) for 30 min, and then chromatin immunoprecipitation assays were
performed using either IgG (open columns) or an anti-GR antibody (filled col-
umns). Immunoprecipitated chromatin fragments were detected by quanti-
tative PCR, and enrichment of specific genomic fragmentswas calculated as a
proportion of the starting material. Measurements were made in triplicate.
The figure illustratesmeans S.D. fromsingle experiments, representative of
three (HeLa) or two (mouse fibroblast) independent experiments.
FIGURE 10.Mutation of the GR dimerizationmotif has distinct effects on
different regulatory elements. A, COS-7 cells were transfected with 200 ng
of pGL3p (open columns), pGL3p-GRR-1.3-Hs. (filled columns), or pGL3p-GRR-
1.3-Hs.-GBSm1 (shaded columns) and with 50 ng of a vector expressing wild
type GR or the corresponding empty vector. Responses to Dex were calcu-
lated as in Fig. 3C. B, in a parallel experiment, whole cell extracts were pre-
pared from transfected COS-7 cells andWestern blotted for GR or for tubulin
as a loading control. C, different reporter constructs were transfected into
COS-7 cells with wild type GR or GRdim expression vectors. A value of 100%
was assigned to the transcriptional response of each construct in the pres-
ence of wild type GR (open bars), and the response in the presence of GRdim
was calculated with reference to this (filled bars). Statistically significant dif-
ferences between the responses of wild type GR and GRdim are indicated.
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dimerization loop, but this has not yet been formally demon-
strated. We used a GRdim-expressing stable U2OS cell line (53)
to investigate transcriptional responses of the dimerization-de-
fective mutant but found the DUSP1 gene to be transcription-
ally silenced in these cells (data not shown).
DISCUSSION
Ahallmark ofmanyGC-responsive cis-acting elements is the
evolutionary conservation of not only GR binding sites them-
selves but also surrounding sequence and binding sites for
accessory transcription factors (37). Across the genome, this
conservation can be successfully used to identify novel ele-
ments (47). However, the phylogenetic footprinting approach
can produce surprising results when applied to individual
genes, as illustrated here.
We used the DUSP1 locus to test the hypothesis that “GBS
conservation alone is sufficient to predict GR occupancy
and . . . function at individual genes” (47). Human and mouse
GRR-1.3 and -4.6 are 70 and 65% identical in sequence and
contain GBS elements that are conserved at 15 of 15 or 14 of 15
positions, respectively. The hypothesis predicts that such
strong sequence conservation is correlated with conserved
function and GR occupancy. The human elements functioned
as GC-responsive sequences in either mouse or human cells
and were occupied by GR in Dex-treated HeLa cells. Unexpect-
edly, the correspondingmouse elements were either unrespon-
sive or very weakly responsive in HeLa cells and mouse fibro-
blasts and recruitedGRweakly or not detectably inDex-treated
mouse fibroblasts. A GBS is conserved at 29 kb upstream of
the transcription start site in mouse and human DUSP1 loci,
although its exact position with respect to the background
sequence alignment differs slightly. Here too, GBS conserva-
tion (loosely defined) was predictive of function and GR occu-
pancy in only one of the two species. Themouse elementmedi-
ated a response to Dex in either HeLa cells ormouse fibroblasts
and was occupied by GR in Dex-stimulated mouse fibroblasts.
The human element was unresponsive to Dex in either cell type
and not occupied by GR in Dex-stimulated HeLa cells. We also
investigated two other putative GC-responsive regions at 24
and 28 kb (supplemental Fig. 2). Both human and mouse
GRR-28 were unresponsive to Dex and failed to recruit GR in
Dex-stimulated HeLa cells or mouse fibroblasts. In contrast,
both human and mouse GRR-24 mediated significant tran-
scriptional responses to Dex and recruited GR in Dex-stimu-
lated HeLa cells and mouse fibroblasts. At a single locus, we
have therefore found examples of all four possible outcomes
where GBS and surrounding sequences were conserved
betweenmouse and human: function in both species (GRR-24),
in neither (GRR-28), selectively in mouse (GRR-29), or selec-
tively in human (GRR-1.3 and GRR-4.6).
The single nucleotide difference atGBS-4.6.2 is not sufficient
to account for the differential activity of mouse and human
GRR-4.6 fragments in mouse or human cells. GBS-1.3 is per-
fectly conserved between mice and humans, yet GRR-1.3 frag-
ments of the two species displayed very different activities,
whether tested in mouse or human cells. Elements that were
able to mediate transcriptional activation by Dex in transiently
transfected reporter constructs were also able to recruit GR in
the context of intact chromatin. We therefore propose that a
critical determinant in GC responsiveness is the absence or
presence of binding sites for transcription factors that assist in
the recruitment of GR. Loss or gain of such accessory sites
appears to have been a driving force in the evolutionary diver-
gence of transcriptional responses to GCs.
We have tried to identify sequence differences between
mouse and humanGRR-1.3 that might account for their differ-
ent activities. For example, a previous study (54) suggested that
in human pulmonary A549 cells, GR regulated DUSP1 expres-
sion via indirect tethering to a C/EBP site at 1308 with
respect to the TSS (indicated in Fig. 5B). Note that the minimal
functional GC-responsive fragment identified in that study
contained GBS-1.3. The putative C/EBP site was absent from
an oligonucleotide that efficiently bound GR in vitro (supple-
mental Fig. 3), implying that GR recruitment is direct rather
than indirect, and consistent with the deleterious effect of
mutations within GBS-1.3 (Fig. 5C). C/EBP consensus
sequences are significantly enriched in the vicinity of GR bind-
ing sites in chromatin (37, 48), and there are several docu-
mented examples of cooperation between the two transcription
factors (20). Therefore, we considered the hypothesis that
C/EBP assists GR recruitment to GRR-1.3 and that interspe-
cies differences in the vicinity of the C/EBP site contribute to
differences in function. However, a human to mouse sequence
swap across this region did not impair the response of human
GRR-1.3 toDex (m4 in supplemental Fig. 4); nor did amutation
of 5 bp at the core of the C/EBP site (m8 in supplemental Fig.
4). In fact, other thanmutations of GBS-1.3 itself (m1 andm2 in
supplemental Fig. 4), only two of an extensive set of mutations
(m6 and m7 in supplemental Fig. 4) significantly impaired the
response of human GRR-1.3 to Dex and even then only weakly.
It appears that the sequence differences that underlie the func-
tional differences of human and mouse GRR-1.3 are not dis-
crete or localized. Evolutionary loss or gain of more than one
transcription factor binding site may have contributed to the
divergence of function.
Closer inspection provides further insight into events that
have contributed to the evolution of DUSP1 genes. Approxi-
mately half of mammalian DNA is composed of repetitive
sequences (55, 56).Much of it is in the formofmobile elements,
such as short interspersed elements (SINEs), which are copied
and inserted into new genomic locations via reverse transcrip-
tion from short RNA polymerase III transcripts. They are often
regarded as mere genome parasites, but they may contribute to
the evolution of gene expression by creating or disrupting reg-
ulatory elements (56–60). Likemost non-codingDNA regions,
theDUSP1 5 region contains many SINEs and other repetitive
elements. In the GBS-4.6.2 sequence TGTTCTGAACA/CTG-
TGTGAC, the last nine residues (after the slash) are derived
from a MIR3 SINE, an ancient retrotransposon that predates
the divergence of mammalian clades (61) (supplemental Fig. 5).
GBS-4.6.2 therefore owes its existence to the insertion of a
mobile element. It cannot be known whether that retrotrans-
position event directly created the GBS or provided the raw
material from which the GBS later arose. Whichever of these
scenarios is correct, the strong conservation of the SINE
sequence acrossmanymammalian species implies that the gen-
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eration of a novel regulatory element conferred an advantage
and was subject to positive, purifying selection. This is an
apparent example of exaptation, the adoption of novel function
by a genetic element, which then comes under altered selective
pressure. Exaptation of regulatory functions by mobile ele-
ments including SINEs is thought to have been a major force
driving innovation in gene expression (58, 59). In this case, the
process appears to have created a particularly powerful and
unusual GR binding site whose function is dependent on three
closely spaced or overlapping half-sites. Future studies will aim
to discover howGR interacts with this site and which cofactors
it is able to recruit when bound.
It has been suggested that the anti-inflammatory effects of
GCs are independent of transcriptional activation by GR. This
argument is largely based on the properties of a knock-inmouse
strain that expresses only the dimerization-defective GRdim
mutant (62). GRdimwas unable tomediate up-regulation of glu-
coneogenic enzymes but still reduced expression of inflamma-
tory mediators (40). However, the properties of this mutant
now appear farmore complex than originally thought. The dim
mutation did not impair the regulation of certain GC target
genes in stably transfected U2OS cells (53), and the transcrip-
tional responses of individual GR binding sites were also differ-
entially affected by the mutation (38). For example, activation
of a tyrosine aminotransferase GBS was strongly impaired,
whereas activation of a palindromic GBS containing two per-
fect AGAACA half-sites was actually increased. Althoughmice
and humans employ different cis-acting elements to control
DUSP1 expression, the response to GC appears to be insensi-
tive to the dimmutation in both species. DUSP1 is amediator of
anti-inflammatory effects of GCs; therefore, it is unsafe to con-
clude from the properties of the GRdim knock-in mouse
whether or not anti-inflammatory effects of GCs are dependent
on activation of transcription.
Transcriptional responses to GCs are highly heterogeneous,
and a typical GC-regulated gene is difficult to define. However,
the DUSP1 gene is very unusual in many respects. We have
shown that, although there is strong evolutionary conservation
of several GR binding sites, mouse and human genes employ
different sets of cis-acting elements to achieve very similar
responses to Dex. Evolution clearly permits a degree of plastic-
ity in the molecular mechanisms of transcriptional regulation,
provided that the final outcome ismaintained. In bothmice and
humans, the activation of DUSP1 transcription appears to be
independent of GR dimerization or at least insensitive to the
mutation of a single residuewithin the dimerization loop. In the
case of the human gene, transcriptional activation is partly
mediated by a three half-sitemotif that is, as far as we are aware,
unique. Perhaps reflecting the unconventional nature of its
transcriptional control, DUSP1 can be up-regulated by novel
GR ligands (63) that are thought to be otherwise poor at medi-
ating transactivation (64).4Up-regulation of theDUSP1 gene by
GCs is also highly sensitive to cell density, whereas the response
of a reporter containing consensus GR binding sites is insensi-
tive to cell density.5 These observations suggest that it may be
possible to selectively modulate the GC response of theDUSP1
gene.
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